{"a416350e5da8a35128cc4ab5d293c85d48f3e53d": [["IntroductionAdvancements in recombinant DNA technology, genomics and immunology have greatly impacted the process of vaccine development.", [["DNA", "CELLULAR_COMPONENT", 40, 43]]], ["Genetic manipulation of microbes to adapt them as vectors for gene delivery offers a unique opportunity for vaccine design.", [["gene delivery", "TREATMENT", 62, 75], ["vaccine design", "TREATMENT", 108, 122]]], ["As more effective, novel and safe vaccines are sought for existing, emerging and reemerging diseases, viral and bacterial vectors are becoming an important immuno-prophylactic tool in the arsenal of modern medicine.", [["novel and safe vaccines", "TREATMENT", 19, 42], ["reemerging diseases", "PROBLEM", 81, 100], ["viral and bacterial vectors", "PROBLEM", 102, 129], ["modern medicine", "TREATMENT", 199, 214]]], ["The advantages of vectored vaccines include efficient antigen presentation and induction of both humoral and cell-mediated immunity.", [["cell", "ANATOMY", 109, 113], ["cell", "CELL", 109, 113], ["vectored vaccines", "TREATMENT", 18, 35], ["cell-mediated immunity", "TREATMENT", 109, 131]]], ["Among various vaccine vectors, adenoviral (Ad) vectors are being extensively investigated.", [["adenoviral", "ORGANISM", 31, 41], ["Ad", "ORGANISM", 43, 45], ["adenoviral (Ad) vectors", "DNA", 31, 54], ["adenoviral", "SPECIES", 31, 41], ["Ad", "SPECIES", 43, 45], ["Among various vaccine vectors", "TREATMENT", 0, 29], ["adenoviral (Ad) vectors", "TREATMENT", 31, 54]]], ["Since the first use of Ad expression vectors in the early 1980s, Ad vectors have shown great promise as vaccine vectors [1] [2] [3] [4] .", [["Ad", "ORGANISM", 23, 25], ["Ad", "ORGANISM", 65, 67], ["[1] [2] [3] [4]", "SIMPLE_CHEMICAL", 120, 135], ["Ad", "SPECIES", 65, 67], ["Ad expression vectors", "TREATMENT", 23, 44], ["Ad vectors", "TREATMENT", 65, 75], ["great promise as vaccine vectors", "TREATMENT", 87, 119]]], ["In addition, Ad vectors are being extensively explored for their applications in gene therapy [5] .", [["Ad", "ORGANISM", 13, 15], ["Ad", "SPECIES", 13, 15], ["Ad vectors", "TREATMENT", 13, 23], ["gene therapy", "TREATMENT", 81, 93]]], ["Ad vectors are also becoming a therapeutic tool for cancer therapy, by virtue of their own oncolytic nature.", [["cancer", "ANATOMY", 52, 58], ["cancer", "DISEASE", 52, 58], ["Ad", "ORGANISM", 0, 2], ["cancer", "CANCER", 52, 58], ["Ad", "SPECIES", 0, 2], ["Ad vectors", "TREATMENT", 0, 10], ["cancer therapy", "TREATMENT", 52, 66], ["cancer", "OBSERVATION", 52, 58]]], ["Several preclinical and clinical trials have demonstrated therapeutic potential of Ad vectors in the treatment of a variety of cancers [6] [7] [8] [9] .", [["cancers", "ANATOMY", 127, 134], ["cancers", "DISEASE", 127, 134], ["Ad", "ORGANISM", 83, 85], ["cancers", "CANCER", 127, 134], ["[6] [7] [8] [9]", "SIMPLE_CHEMICAL", 135, 150], ["Ad", "SPECIES", 83, 85], ["Ad vectors", "TREATMENT", 83, 93], ["a variety of cancers", "PROBLEM", 114, 134], ["variety", "OBSERVATION_MODIFIER", 116, 123], ["cancers", "OBSERVATION", 127, 134]]], ["Ad vectors are also being explored for genetic immunotherapy of tumors, as a clinical modality in conjunction with conventional chemo-and radiation-therapy [10] .Advantages of adenoviral (Ad) vectorsAd vectors offer several advantages as vaccine vectors and meet the most important criteria of an ideal vaccine vector in terms of efficacy, safety and stability [4] .", [["tumors", "ANATOMY", 64, 70], ["tumors", "DISEASE", 64, 70], ["Ad", "ORGANISM", 0, 2], ["tumors", "CANCER", 64, 70], ["adenoviral", "ORGANISM", 176, 186], ["Ad", "ORGANISM", 188, 190], ["Ad", "SPECIES", 0, 2], ["adenoviral", "SPECIES", 176, 186], ["Ad", "SPECIES", 188, 190], ["Ad vectors", "TREATMENT", 0, 10], ["genetic immunotherapy", "TREATMENT", 39, 60], ["tumors", "PROBLEM", 64, 70], ["conventional chemo", "TREATMENT", 115, 133], ["radiation-therapy", "TREATMENT", 138, 155], ["adenoviral (Ad) vectorsAd vectors", "TREATMENT", 176, 209], ["several advantages", "TREATMENT", 216, 234], ["vaccine vectors", "TREATMENT", 238, 253], ["an ideal vaccine vector", "TREATMENT", 294, 317], ["tumors", "OBSERVATION", 64, 70]]], ["Ad can infect a broad range of both actively dividing as well as post-mitotic quiescent mammalian cells.", [["cells", "ANATOMY", 98, 103], ["Ad", "ORGANISM", 0, 2], ["mammalian cells", "CELL", 88, 103], ["post-mitotic quiescent mammalian cells", "CELL_TYPE", 65, 103], ["post-mitotic quiescent mammalian cells", "TREATMENT", 65, 103], ["broad", "OBSERVATION_MODIFIER", 16, 21], ["post-mitotic quiescent", "OBSERVATION", 65, 87], ["mammalian cells", "OBSERVATION", 88, 103]]], ["Transgene expression with Ad vectors is usually robust and can be further enhanced by driving gene expression with strong heterologous promoters.", [["Transgene", "GENE_OR_GENE_PRODUCT", 0, 9], ["Ad", "ORGANISM", 26, 28], ["heterologous promoters", "DNA", 122, 144], ["Transgene expression with Ad vectors", "TREATMENT", 0, 36], ["strong heterologous promoters", "TREATMENT", 115, 144]]], ["Generation of various Ad vectors is fairly straightforward and the vectors can be easily grown to large scale in tissue culture.", [["tissue culture", "ANATOMY", 113, 127], ["Ad", "ORGANISM", 22, 24], ["tissue", "TISSUE", 113, 119], ["Ad vectors", "TREATMENT", 22, 32], ["the vectors", "TREATMENT", 63, 74], ["tissue culture", "TEST", 113, 127], ["various", "OBSERVATION_MODIFIER", 14, 21]]], ["Since Ad vectors are replication-defective, there is no serious threat of horizontal transmission.", [["Ad", "ORGANISM", 6, 8], ["Ad", "SPECIES", 6, 8], ["horizontal transmission", "PROBLEM", 74, 97], ["defective", "OBSERVATION", 33, 42], ["no", "UNCERTAINTY", 53, 55], ["serious", "OBSERVATION_MODIFIER", 56, 63], ["horizontal transmission", "OBSERVATION", 74, 97]]], ["The vector genome does not integrate into the host chromosome and mostly remains epichromosomal, thus making their use safe without a potential risk of insertional mutagenesis.", [["chromosome", "ANATOMY", 51, 61], ["host chromosome", "CELLULAR_COMPONENT", 46, 61], ["vector genome", "DNA", 4, 17], ["host chromosome", "DNA", 46, 61], ["epichromosomal", "PROBLEM", 81, 95], ["insertional mutagenesis", "PROBLEM", 152, 175], ["epichromosomal", "OBSERVATION", 81, 95], ["insertional mutagenesis", "OBSERVATION", 152, 175]]], ["Ad vectors induce strong immunity when administered via parenteral (subcutaneous, intravenous, intramuscular or intraperitoneal) or mucosal (oral or intranasal) routes.", [["subcutaneous", "ANATOMY", 68, 80], ["intravenous", "ANATOMY", 82, 93], ["intramuscular", "ANATOMY", 95, 108], ["intraperitoneal", "ANATOMY", 112, 127], ["mucosal", "ANATOMY", 132, 139], ["oral", "ANATOMY", 141, 145], ["Ad", "ORGANISM", 0, 2], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 82, 93], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 95, 108], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 112, 127], ["mucosal", "IMMATERIAL_ANATOMICAL_ENTITY", 132, 139], ["oral", "ORGANISM_SUBDIVISION", 141, 145], ["Ad", "SPECIES", 0, 2], ["Ad vectors", "TREATMENT", 0, 10], ["parenteral (subcutaneous, intravenous, intramuscular or intraperitoneal)", "TREATMENT", 56, 128], ["mucosal (oral or intranasal)", "TREATMENT", 132, 160], ["mucosal", "ANATOMY", 132, 139]]], ["The latter is often desired as most infections occur at mucosal surfaces.", [["mucosal", "ANATOMY", 56, 63], ["infections", "DISEASE", 36, 46], ["mucosal surfaces", "PATHOLOGICAL_FORMATION", 56, 72], ["most infections", "PROBLEM", 31, 46], ["mucosal surfaces", "OBSERVATION", 56, 72]]], ["Furthermore, Ad vectors appear to be safe for use in humans as human Ad (HAd) serotypes 4 and 7 have been used as live oral vaccines in military recruits in the USA for several decades without any known adverse effects [11] .Advantages of adenoviral (Ad) vectorsAlthough the mechanism of immune response against foreign antigens expressed by Ad vectors is not fully understood, it is thought to involve both humoral and cellular arms of the immune system [4] .", [["oral", "ANATOMY", 119, 123], ["cellular", "ANATOMY", 420, 428], ["immune system", "ANATOMY", 441, 454], ["Ad", "ORGANISM", 13, 15], ["humans", "ORGANISM", 53, 59], ["human", "ORGANISM", 63, 68], ["Ad (HAd) serotypes 4", "ORGANISM", 69, 89], ["oral", "ORGANISM_SUBDIVISION", 119, 123], ["adenoviral", "ORGANISM", 239, 249], ["Ad", "ORGANISM", 251, 253], ["foreign antigens", "GENE_OR_GENE_PRODUCT", 312, 328], ["Ad", "ORGANISM", 342, 344], ["cellular", "CELL", 420, 428], ["foreign antigens", "PROTEIN", 312, 328], ["humans", "SPECIES", 53, 59], ["human", "SPECIES", 63, 68], ["Ad", "SPECIES", 13, 15], ["humans", "SPECIES", 53, 59], ["human", "SPECIES", 63, 68], ["Ad", "SPECIES", 342, 344], ["Ad vectors", "TREATMENT", 13, 23], ["human Ad (HAd) serotypes", "TREATMENT", 63, 87], ["adenoviral (Ad) vectorsAlthough", "TREATMENT", 239, 270], ["immune response", "PROBLEM", 288, 303], ["foreign antigens", "PROBLEM", 312, 328], ["both", "ANATOMY_MODIFIER", 403, 407], ["humoral", "ANATOMY", 408, 415]]], ["Following Ad vector administration, foreign gene product-specific antibodies are elicited in var-ious experimental animal models [3, 12] .", [["Ad", "ORGANISM", 10, 12], ["foreign gene product", "PROTEIN", 36, 56], ["specific antibodies", "PROTEIN", 57, 76], ["Ad", "SPECIES", 10, 12], ["Ad vector administration", "TREATMENT", 10, 34], ["foreign gene product", "TREATMENT", 36, 56], ["specific antibodies", "TEST", 57, 76]]], ["These antibodies are primarily of the IgG2a isotype, indicating the predominance of Thl-type help.", [["IgG2a", "GENE_OR_GENE_PRODUCT", 38, 43], ["Thl", "GENE_OR_GENE_PRODUCT", 84, 87], ["antibodies", "PROTEIN", 6, 16], ["IgG2a isotype", "PROTEIN", 38, 51], ["These antibodies", "TEST", 0, 16], ["the IgG2a isotype", "PROBLEM", 34, 51], ["IgG2a isotype", "OBSERVATION", 38, 51]]], ["In addition, specific CD8+T cells also develop [13, 14] .", [["CD8+T cells", "ANATOMY", 22, 33], ["CD8", "GENE_OR_GENE_PRODUCT", 22, 25], ["CD8+T cells", "CELL_TYPE", 22, 33], ["specific CD8+T cells", "TEST", 13, 33]]], ["Ad vectors also induce a strong innate immune response [15] that presumably potentiates the subsequent humoral and cellular immune responses.", [["cellular", "ANATOMY", 115, 123], ["Ad", "ORGANISM", 0, 2], ["cellular", "CELL", 115, 123], ["Ad", "SPECIES", 0, 2], ["Ad vectors", "TREATMENT", 0, 10], ["cellular immune", "OBSERVATION", 115, 130]]], ["Furthermore, transduction of antigen presenting cells [16] by Ad vectors facilitates antigen presentation and prolongs the duration of immune response.Current status of Ad vector vaccinesMost vaccine studies using Ad vectors have been carried out with HAd serotype 5 (HAd5) as this expression system has been extensively used as a delivery vehicle in the majority of Ad vector-based gene therapy trials [17] .", [["cells", "ANATOMY", 48, 53], ["antigen presenting", "GENE_OR_GENE_PRODUCT", 29, 47], ["cells", "CELL", 48, 53], ["Ad", "ORGANISM", 62, 64], ["Ad", "ORGANISM", 169, 171], ["Ad", "ORGANISM", 214, 216], ["HAd serotype 5", "ORGANISM", 252, 266], ["HAd5", "GENE_OR_GENE_PRODUCT", 268, 272], ["Ad", "ORGANISM", 367, 369], ["antigen presenting cells", "CELL_TYPE", 29, 53], ["Ad", "SPECIES", 62, 64], ["Ad", "SPECIES", 169, 171], ["Ad", "SPECIES", 214, 216], ["antigen presenting cells", "PROBLEM", 29, 53], ["immune response", "PROBLEM", 135, 150], ["Ad vector vaccines", "TREATMENT", 169, 187], ["Most vaccine studies", "TEST", 187, 207], ["Ad vectors", "TREATMENT", 214, 224], ["a delivery vehicle", "TREATMENT", 329, 347], ["Ad vector", "TREATMENT", 367, 376], ["based gene therapy trials", "TREATMENT", 377, 402]]], ["HAd5 is the best characterized of all adenoviruses.", [["HAd5", "GENE_OR_GENE_PRODUCT", 0, 4], ["adenoviruses", "ORGANISM", 38, 50], ["HAd5", "PROTEIN", 0, 4], ["all adenoviruses", "PROBLEM", 34, 50], ["all", "OBSERVATION_MODIFIER", 34, 37], ["adenoviruses", "OBSERVATION", 38, 50]]], ["Several recent reviews have focused on the prospects of HAd5 vectors for vaccination [4, 18, 19] .", [["HAd5", "GENE_OR_GENE_PRODUCT", 56, 60], ["HAd5 vectors", "TREATMENT", 56, 68]]], ["A number of preclinical and clinical trials using HAd5 vectors as a vaccine are currently in progress [20] [21] [22] [23] [24] [25] [26] [27] .", [["HAd5", "ORGANISM", 50, 54], ["[20] [21] [22] [23] [24] [25] [26] [27]", "SIMPLE_CHEMICAL", 102, 141], ["HAd5 vectors", "TREATMENT", 50, 62], ["a vaccine", "TREATMENT", 66, 75]]], ["The notable among them are: (i) an HAd5 vector vaccine against Ebola virus (EV) that elicited protective immunity against challenge with EV in primates; (ii) an HAd5 vector vaccine expressing human immunodeficiency virus (HIV)-1) env gene that induced protective immunity against HIV in rhesus monkeys as well as in baboons, and neutralizing antibodies in monkeys; (iii) an HAd5 vector that expressed a protective antigen of anthrax and showed effective protection against anthrax challenge; and (iv) HAd5 vectors expressing severe acute respiratory syndrome (SARS) corona virus protein that elicited a specific immune response in rhesus macaques.", [["HAd5", "CHEMICAL", 35, 39], ["Ebola virus", "DISEASE", 63, 74], ["human immunodeficiency virus", "DISEASE", 192, 220], ["anthrax", "DISEASE", 425, 432], ["anthrax", "DISEASE", 473, 480], ["acute respiratory syndrome", "DISEASE", 532, 558], ["SARS", "DISEASE", 560, 564], ["HAd5", "GENE_OR_GENE_PRODUCT", 35, 39], ["Ebola virus", "ORGANISM", 63, 74], ["primates", "ORGANISM", 143, 151], ["HAd5", "GENE_OR_GENE_PRODUCT", 161, 165], ["human immunodeficiency virus (HIV)-1", "ORGANISM", 192, 228], ["env", "ORGANISM", 230, 233], ["HIV", "ORGANISM", 280, 283], ["rhesus", "ORGANISM", 287, 293], ["monkeys", "ORGANISM", 294, 301], ["baboons", "ORGANISM", 316, 323], ["monkeys", "ORGANISM", 356, 363], ["HAd5", "GENE_OR_GENE_PRODUCT", 374, 378], ["anthrax", "ORGANISM", 425, 432], ["anthrax", "ORGANISM", 473, 480], ["HAd5", "GENE_OR_GENE_PRODUCT", 501, 505], ["rhesus", "ORGANISM", 631, 637], ["macaques", "ORGANISM", 638, 646], ["env gene", "DNA", 230, 238], ["neutralizing antibodies", "PROTEIN", 329, 352], ["Ebola virus", "SPECIES", 63, 74], ["human", "SPECIES", 192, 197], ["immunodeficiency virus", "SPECIES", 198, 220], ["HIV", "SPECIES", 280, 283], ["rhesus monkeys", "SPECIES", 287, 301], ["monkeys", "SPECIES", 356, 363], ["rhesus macaques", "SPECIES", 631, 646], ["Ebola virus", "SPECIES", 63, 74], ["EV", "SPECIES", 76, 78], ["EV", "SPECIES", 137, 139], ["human immunodeficiency virus", "SPECIES", 192, 220], ["HIV", "SPECIES", 222, 225], ["HIV", "SPECIES", 280, 283], ["rhesus monkeys", "SPECIES", 287, 301], ["anthrax", "SPECIES", 473, 480], ["severe acute respiratory syndrome (SARS) corona virus", "SPECIES", 525, 578], ["rhesus macaques", "SPECIES", 631, 646], ["an HAd5 vector vaccine", "TREATMENT", 32, 54], ["Ebola virus", "PROBLEM", 63, 74], ["an HAd5 vector vaccine", "TREATMENT", 158, 180], ["human immunodeficiency virus", "PROBLEM", 192, 220], ["HIV in rhesus monkeys", "PROBLEM", 280, 301], ["neutralizing antibodies in monkeys", "PROBLEM", 329, 363], ["anthrax challenge", "TREATMENT", 473, 490], ["(iv) HAd5 vectors", "TREATMENT", 496, 513], ["severe acute respiratory syndrome", "PROBLEM", 525, 558], ["SARS) corona virus protein", "PROBLEM", 560, 586], ["severe", "OBSERVATION_MODIFIER", 525, 531], ["acute", "OBSERVATION_MODIFIER", 532, 537], ["respiratory syndrome", "OBSERVATION", 538, 558], ["rhesus macaques", "OBSERVATION", 631, 646]]], ["Ad vectors can also be used for passive immunotherapy as exemplified by a recent study [25] , demonstrating the production of a single-chain antibody directed against a protective antigen of Bacillus anthracis.Importance of vector immunity in immunizationDespite the above-mentioned advantages, clinical use of Ad vectors is severely hampered by the widely prevalent preexisting immunity against HAd5 in the majority of the human population [28, 29] .", [["HAd5", "CHEMICAL", 396, 400], ["Ad", "ORGANISM", 0, 2], ["Bacillus anthracis", "ORGANISM", 191, 209], ["Ad", "ORGANISM", 311, 313], ["HAd5", "GENE_OR_GENE_PRODUCT", 396, 400], ["human", "ORGANISM", 424, 429], ["single-chain antibody", "PROTEIN", 128, 149], ["Bacillus anthracis", "SPECIES", 191, 209], ["human", "SPECIES", 424, 429], ["Ad", "SPECIES", 0, 2], ["Bacillus anthracis", "SPECIES", 191, 209], ["Ad", "SPECIES", 311, 313], ["human", "SPECIES", 424, 429], ["Ad vectors", "TREATMENT", 0, 10], ["passive immunotherapy", "TREATMENT", 32, 53], ["a recent study", "TEST", 72, 86], ["a single-chain antibody", "TREATMENT", 126, 149], ["Bacillus anthracis", "PROBLEM", 191, 209], ["vector immunity", "TREATMENT", 224, 239], ["immunization", "TREATMENT", 243, 255], ["Ad vectors", "TREATMENT", 311, 321]]], ["The efficacy of HAd5 vectors is expected to be highly variable depending on the levels of preexisting vector immunity.", [["HAd5", "GENE_OR_GENE_PRODUCT", 16, 20], ["HAd5 vectors", "DNA", 16, 28], ["HAd5 vectors", "TREATMENT", 16, 28], ["preexisting vector immunity", "TREATMENT", 90, 117]]], ["Since Ad vectors are highly immunogenic, their first use also leads to development of strong humoral and cellular immunity [30] , which blocks subsequent use of the vector.", [["cellular", "ANATOMY", 105, 113], ["Ad", "ORGANISM", 6, 8], ["cellular", "CELL", 105, 113], ["Ad", "SPECIES", 6, 8]]], ["This is a potential problem in vaccination strategies that require repeated administration.", [["vaccination strategies", "TREATMENT", 31, 53], ["repeated administration", "TREATMENT", 67, 90]]], ["Suppressive effects of anti-HAd5 immunity are attributed to strongly neutralizing antibodies directed against viral capsid components [31, 32] and HAd5-specific CD8+ T cells [33] .", [["CD8+ T cells", "ANATOMY", 161, 173], ["anti-HAd5", "GENE_OR_GENE_PRODUCT", 23, 32], ["HAd5", "GENE_OR_GENE_PRODUCT", 147, 151], ["CD8", "GENE_OR_GENE_PRODUCT", 161, 164], ["neutralizing antibodies", "PROTEIN", 69, 92], ["viral capsid components", "PROTEIN", 110, 133], ["HAd5", "PROTEIN", 147, 151], ["CD8", "PROTEIN", 161, 164], ["T cells", "CELL_TYPE", 166, 173], ["anti-HAd5 immunity", "TREATMENT", 23, 41], ["strongly neutralizing antibodies", "PROBLEM", 60, 92], ["viral capsid components", "PROBLEM", 110, 133], ["HAd5", "TEST", 147, 151]]], ["Neutralizing antibodies lead to inactivation of free Ad vector, thus blocking transduction of the target cell, a prerequisite for antigen expression (Fig. 1) .", [["cell", "ANATOMY", 105, 109], ["Ad", "ORGANISM", 53, 55], ["cell", "CELL", 105, 109], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["target cell", "CELL_TYPE", 98, 109], ["Neutralizing antibodies", "PROBLEM", 0, 23], ["free Ad vector", "TREATMENT", 48, 62], ["target cell", "OBSERVATION", 98, 109]]], ["Neutralizing antibodies drastically reduce uptake of the Ad vector by cells, leading to poor transgene expression resulting in blunting of the transgene-specific immune response.", [["cells", "ANATOMY", 70, 75], ["Ad", "ORGANISM", 57, 59], ["cells", "CELL", 70, 75], ["Neutralizing antibodies", "PROTEIN", 0, 23], ["Ad", "SPECIES", 57, 59], ["Neutralizing antibodies", "TEST", 0, 23], ["poor transgene expression", "PROBLEM", 88, 113], ["transgene expression", "OBSERVATION", 93, 113], ["blunting", "OBSERVATION_MODIFIER", 127, 135], ["immune response", "OBSERVATION", 162, 177]]], ["Indeed, several studies have shown a drastic reduction in gene-transfer potential of HAd5 vectors in preimmune animal models [30, [34] [35] [36] .", [["HAd5", "GENE_OR_GENE_PRODUCT", 85, 89], ["HAd5 vectors", "DNA", 85, 97], ["several studies", "TEST", 8, 23], ["a drastic reduction", "TREATMENT", 35, 54], ["HAd5 vectors", "TREATMENT", 85, 97], ["preimmune animal models", "TEST", 101, 124], ["drastic", "OBSERVATION_MODIFIER", 37, 44], ["reduction", "OBSERVATION_MODIFIER", 45, 54]]], ["Specific CD8+ T-lymphocytes will eliminate the vector transduced cells and thus shorten the duration of antigen expression.", [["CD8+ T-lymphocytes", "ANATOMY", 9, 27], ["cells", "ANATOMY", 65, 70], ["CD8", "GENE_OR_GENE_PRODUCT", 9, 12], ["cells", "CELL", 65, 70], ["CD8+ T-lymphocytes", "CELL_TYPE", 9, 27], ["vector transduced cells", "CELL_LINE", 47, 70], ["Specific CD8", "TEST", 0, 12], ["T-lymphocytes", "PROBLEM", 14, 27], ["the vector transduced cells", "TREATMENT", 43, 70], ["T-lymphocytes", "OBSERVATION", 14, 27]]], ["In case of the individuals that are not pre-exposed to HAd5, the first use of HAd5 vectors will lead to development of strong anti-HAd5 immunity that will make their subsequent use less effective (Fig. 1 ).", [["individuals", "ORGANISM", 15, 26], ["HAd5", "GENE_OR_GENE_PRODUCT", 55, 59], ["HAd5", "GENE_OR_GENE_PRODUCT", 78, 82], ["anti-HAd5", "GENE_OR_GENE_PRODUCT", 126, 135], ["HAd5 vectors", "TREATMENT", 78, 90], ["strong anti-HAd5 immunity", "TREATMENT", 119, 144]]], ["This is a limitation of most of the live virus vector vaccines as many vaccine applications warrant more than one dose/booster of the vaccine in order to elicit protective immunity.Importance of vector immunity in immunizationPreexisting HAd5 immunity drastically reduces the immunogenicity of HAd5 vector vaccines in animals [24, 30, 37] as well as in human beings [18] .", [["HAd5", "CHEMICAL", 294, 298], ["HAd5", "GENE_OR_GENE_PRODUCT", 294, 298], ["human", "ORGANISM", 353, 358], ["human", "SPECIES", 353, 358], ["HAd5", "SPECIES", 238, 242], ["human", "SPECIES", 353, 358], ["the live virus vector vaccines", "TREATMENT", 32, 62], ["many vaccine applications", "TREATMENT", 66, 91], ["the vaccine", "TREATMENT", 130, 141], ["vector immunity", "TREATMENT", 195, 210], ["immunizationPreexisting HAd5 immunity", "TREATMENT", 214, 251], ["HAd5 vector vaccines", "TREATMENT", 294, 314]]], ["Furthermore, since the level of anti-HAd5 neutralizing antibodies varies widely in the human population, immune responses following vaccination with HAd5 vectors will be highly variable and largely unpredictable [19] .", [["anti-HAd5", "GENE_OR_GENE_PRODUCT", 32, 41], ["human", "ORGANISM", 87, 92], ["HAd5", "GENE_OR_GENE_PRODUCT", 149, 153], ["anti-HAd5 neutralizing antibodies", "PROTEIN", 32, 65], ["human", "SPECIES", 87, 92], ["human", "SPECIES", 87, 92], ["anti-HAd5 neutralizing antibodies", "TREATMENT", 32, 65], ["vaccination with HAd5 vectors", "TREATMENT", 132, 161]]], ["Therefore, a preliminary screening of target individuals would be necessary prior to using HAd5 vectors.Importance of vector immunity in immunizationIn order to circumvent the preexisting HAd5 immunity, several approaches are under investigation.", [["individuals", "ORGANISM", 45, 56], ["HAd5", "GENE_OR_GENE_PRODUCT", 91, 95], ["HAd5", "GENE_OR_GENE_PRODUCT", 188, 192], ["HAd5 vectors", "DNA", 91, 103], ["a preliminary screening", "TEST", 11, 34], ["target individuals", "PROBLEM", 38, 56], ["HAd5 vectors", "TREATMENT", 91, 103], ["vector immunity in immunization", "TREATMENT", 118, 149], ["the preexisting HAd5 immunity", "TREATMENT", 172, 201]]], ["These include priming with recombinant DNA prior to boosting with a HAd5 vector [37, 38] , mucosal delivery of HAd5 vectors [39] , microencapsulation of HAd5 vectors in inert polymers [40, 41] , engineering fiber-or hexon-chimeric HAd5 vectors [42] [43] [44] , use of Ad vectors based on rare HAd serotypes [28, 45] , or use of vectors derived from nonhuman Ad types [46] [47] [48] [49] .", [["mucosal", "ANATOMY", 91, 98], ["DNA", "CELLULAR_COMPONENT", 39, 42], ["mucosal", "MULTI-TISSUE_STRUCTURE", 91, 98], ["HAd5", "GENE_OR_GENE_PRODUCT", 111, 115], ["HAd5", "GENE_OR_GENE_PRODUCT", 153, 157], ["Ad", "ORGANISM", 268, 270], ["nonhuman", "ORGANISM", 349, 357], ["Ad", "ORGANISM", 358, 360], ["recombinant DNA", "DNA", 27, 42], ["HAd5 vector", "DNA", 68, 79], ["HAd5 vectors", "DNA", 153, 165], ["recombinant DNA", "PROBLEM", 27, 42], ["a HAd5 vector", "TREATMENT", 66, 79], ["mucosal delivery of HAd5 vectors", "TREATMENT", 91, 123], ["microencapsulation of HAd5 vectors in inert polymers", "TREATMENT", 131, 183], ["serotypes", "TEST", 297, 306]]], ["The focus of this review is on nonhuman Ad vectors and this will be discussed in the following sections.Nonhuman adenovirusesAdenoviruses have been isolated from a variety of animal species and birds [50] .", [["sections", "ANATOMY", 95, 103], ["nonhuman", "ORGANISM", 31, 39], ["Ad", "ORGANISM", 40, 42], ["adenoviruses", "ORGANISM", 113, 125], ["Adenoviruses", "GENE_OR_GENE_PRODUCT", 125, 137], ["Ad vectors", "TREATMENT", 40, 50], ["Nonhuman adenoviruses", "PROBLEM", 104, 125], ["Adenoviruses", "PROBLEM", 125, 137], ["animal species", "PROBLEM", 175, 189], ["variety", "OBSERVATION_MODIFIER", 164, 171]]], ["Based on their genome organization, serological properties and growth in cell culture, these viruses have been grouped into four distinct genera under the family Adenoviridae [51] .", [["cell culture", "ANATOMY", 73, 85], ["cell culture", "CELL", 73, 85], ["serological properties", "TEST", 36, 58], ["cell culture", "TEST", 73, 85], ["these viruses", "PROBLEM", 87, 100]]], ["Most mammalian adenoviruses, including all known HAd serotypes belong to the genus Mastadenovirus.", [["mammalian adenoviruses", "ORGANISM", 5, 27], ["HAd serotypes", "ORGANISM", 49, 62], ["Most mammalian adenoviruses", "PROBLEM", 0, 27], ["serotypes", "PROBLEM", 53, 62], ["adenoviruses", "OBSERVATION", 15, 27], ["genus Mastadenovirus", "OBSERVATION", 77, 97]]], ["Adenoviruses isolated from birds are classified under the genus Aviadenovirus.", [["birds", "ORGANISM", 27, 32], ["Adenoviruses", "PROBLEM", 0, 12], ["genus Aviadenovirus", "OBSERVATION", 58, 77]]], ["The genus Atadenovirus consists of unique viruses isolated from ovine, bovine, deer, possum as well as some bird isolates.", [["ovine", "ORGANISM", 64, 69], ["bovine", "ORGANISM", 71, 77], ["deer", "ORGANISM", 79, 83], ["ovine", "SPECIES", 64, 69], ["bovine", "SPECIES", 71, 77], ["deer", "SPECIES", 79, 83], ["ovine", "SPECIES", 64, 69], ["bovine", "SPECIES", 71, 77], ["deer", "SPECIES", 79, 83], ["unique viruses", "PROBLEM", 35, 49], ["genus Atadenovirus", "OBSERVATION", 4, 22], ["viruses", "OBSERVATION", 42, 49]]], ["These viruses are distinct from the genus Mastadenovirus as they lack a distinct early region 1 (El) transcriptional unit and have very high AT (adenine and thymidine)-rich genomes.", [["adenine", "CHEMICAL", 145, 152], ["thymidine", "CHEMICAL", 157, 166], ["adenine", "CHEMICAL", 145, 152], ["thymidine", "CHEMICAL", 157, 166], ["Mastadenovirus", "GENE_OR_GENE_PRODUCT", 42, 56], ["early region 1", "GENE_OR_GENE_PRODUCT", 81, 95], ["adenine", "SIMPLE_CHEMICAL", 145, 152], ["thymidine", "SIMPLE_CHEMICAL", 157, 166], ["early region 1 (El) transcriptional unit", "DNA", 81, 121], ["AT (adenine and thymidine)-rich genomes", "DNA", 141, 180], ["These viruses", "PROBLEM", 0, 13], ["the genus Mastadenovirus", "PROBLEM", 32, 56], ["adenine and thymidine)", "TREATMENT", 145, 167], ["viruses", "OBSERVATION", 6, 13], ["distinct", "OBSERVATION_MODIFIER", 18, 26], ["genus Mastadenovirus", "OBSERVATION", 36, 56], ["distinct", "OBSERVATION_MODIFIER", 72, 80], ["early", "OBSERVATION_MODIFIER", 81, 86], ["region", "OBSERVATION_MODIFIER", 87, 93], ["high", "OBSERVATION_MODIFIER", 136, 140]]], ["Most recently, a fourth genus Siadenovirus was proposed that includes viruses isolated from frog, other invertebrates and the virus causing turkey hemorrhagic enteritis [50] .", [["turkey hemorrhagic enteritis", "DISEASE", 140, 168], ["frog", "ORGANISM_SUBDIVISION", 92, 96], ["turkey hemorrhagic enteritis", "SPECIES", 140, 168], ["turkey hemorrhagic enteritis", "SPECIES", 140, 168], ["a fourth genus Siadenovirus", "PROBLEM", 15, 42], ["viruses", "PROBLEM", 70, 77], ["the virus", "PROBLEM", 122, 131], ["turkey hemorrhagic enteritis", "PROBLEM", 140, 168], ["hemorrhagic", "OBSERVATION_MODIFIER", 147, 158], ["enteritis", "OBSERVATION", 159, 168]]], ["Like most HAd, the majority of nonhumann Ad, chosen for vector design do not cause significant clinical or pathological signs in their natural host species.", [["HAd", "CANCER", 10, 13], ["nonhumann Ad", "ORGANISM", 31, 43], ["vector design", "TREATMENT", 56, 69], ["significant clinical or pathological signs in their natural host species", "PROBLEM", 83, 155], ["natural host species", "OBSERVATION", 135, 155]]], ["Since Ad infections are widespread, the majority of the adult population of the host species is seropositive to the most prevalent Ad serotypes.Nonhuman adenovirusesThe precedent for using nonhuman Ad as expression vectors primarily came from their no or low pathogenicity for their natural hosts and similarity of their structural and genomic organization with that of HAd5 in the case of the Mastadenovirus species.", [["Ad infections", "DISEASE", 6, 19], ["Ad", "ORGANISM", 6, 8], ["Ad", "ORGANISM", 131, 133], ["adenoviruses", "ORGANISM", 153, 165], ["nonhuman", "ORGANISM", 189, 197], ["Ad", "ORGANISM", 198, 200], ["HAd5", "GENE_OR_GENE_PRODUCT", 370, 374], ["Mastadenovirus species", "ORGANISM", 394, 416], ["HAd5", "DNA", 370, 374], ["Ad", "SPECIES", 6, 8], ["Ad infections", "PROBLEM", 6, 19], ["the host species", "PROBLEM", 76, 92], ["Nonhuman adenoviruses", "PROBLEM", 144, 165], ["low pathogenicity", "PROBLEM", 255, 272], ["the Mastadenovirus species", "PROBLEM", 390, 416], ["infections", "OBSERVATION", 9, 19], ["widespread", "OBSERVATION_MODIFIER", 24, 34], ["majority", "OBSERVATION_MODIFIER", 40, 48], ["adult", "OBSERVATION_MODIFIER", 56, 61], ["population", "OBSERVATION_MODIFIER", 62, 72], ["host species", "OBSERVATION", 80, 92], ["most prevalent", "OBSERVATION_MODIFIER", 116, 130]]], ["Various nonhuman Ad that are currently under investigation as gene expression vectors include bovine Ad serotype 3 (BAd3), canine Ad serotype 2 (CAd2), chimpanzee Ad serotype 1 (for example; simian adenovirus serotype 25, SAd25), ovine Ad seortype 7 (OAd7), porcine Ad serotypes 3 and 5 (PAd3, PAd5) and fowl Ad serotype 1, 8, 9 and 10 (FAd1, 8, 9, 10) (Table 1) .Nonhuman adenovirusesWith greater understanding of the biology of these nonhuman Ad and availability of suitable systems for vector rescue and propagation, replication-competent as well as replication-defective vectors have been constructed.", [["nonhuman", "ORGANISM", 8, 16], ["Ad", "ORGANISM", 17, 19], ["bovine", "ORGANISM", 94, 100], ["Ad serotype 3", "ORGANISM", 101, 114], ["BAd3", "GENE_OR_GENE_PRODUCT", 116, 120], ["canine Ad serotype 2", "ORGANISM", 123, 143], ["CAd2", "GENE_OR_GENE_PRODUCT", 145, 149], ["chimpanzee", "ORGANISM", 152, 162], ["Ad serotype 1", "ORGANISM", 163, 176], ["simian adenovirus serotype 25", "ORGANISM", 191, 220], ["SAd25", "ORGANISM", 222, 227], ["ovine Ad seortype 7", "ORGANISM", 230, 249], ["OAd7", "GENE_OR_GENE_PRODUCT", 251, 255], ["porcine Ad serotypes 3", "ORGANISM", 258, 280], ["5", "ORGANISM", 285, 286], ["PAd3", "GENE_OR_GENE_PRODUCT", 288, 292], ["PAd5", "GENE_OR_GENE_PRODUCT", 294, 298], ["fowl Ad serotype 1", "ORGANISM", 304, 322], ["nonhuman", "ORGANISM", 436, 444], ["Ad", "ORGANISM", 445, 447], ["replication-defective vectors", "DNA", 553, 582], ["bovine", "SPECIES", 94, 100], ["canine", "SPECIES", 123, 129], ["chimpanzee Ad serotype", "SPECIES", 152, 174], ["simian adenovirus serotype", "SPECIES", 191, 217], ["ovine", "SPECIES", 230, 235], ["porcine", "SPECIES", 258, 265], ["fowl Ad serotype", "SPECIES", 304, 320], ["canine Ad serotype 2", "SPECIES", 123, 143], ["chimpanzee Ad serotype 1", "SPECIES", 152, 176], ["simian adenovirus serotype 25", "SPECIES", 191, 220], ["fowl Ad serotype 1", "SPECIES", 304, 322], ["gene expression vectors", "TREATMENT", 62, 85], ["bovine Ad serotype 3 (BAd3)", "TREATMENT", 94, 121], ["canine Ad serotype 2 (CAd2)", "TREATMENT", 123, 150], ["chimpanzee Ad serotype", "TREATMENT", 152, 174], ["simian adenovirus serotype", "TREATMENT", 191, 217], ["ovine Ad seortype", "TREATMENT", 230, 247], ["porcine Ad serotypes", "TREATMENT", 258, 278], ["fowl Ad serotype", "TEST", 304, 320], ["vector rescue", "TREATMENT", 489, 502], ["replication", "TREATMENT", 520, 531], ["replication-defective vectors", "TREATMENT", 553, 582]]], ["Multiple sites for foreign gene insertion have been identified in the genomes of various nonhuman Ad (Fig. 2) .", [["nonhuman", "ORGANISM", 89, 97], ["Ad", "ORGANISM", 98, 100], ["Multiple sites", "PROBLEM", 0, 14], ["foreign gene insertion", "TREATMENT", 19, 41], ["foreign gene insertion", "OBSERVATION", 19, 41]]], ["In general, a two-plasmid strategy for homologous recombination in bacteria to generate the full-length recombinant Ad genome followed by transfection of a suitable El-complementing cell line ( Fig. 3 ) has been the mainstay of nonhuman Ad vector construction [52, 53] .", [["cell line", "ANATOMY", 182, 191], ["Ad", "ORGANISM", 116, 118], ["cell line", "CELL", 182, 191], ["Fig. 3", "CELL", 194, 200], ["nonhuman", "ORGANISM", 228, 236], ["Ad", "ORGANISM", 237, 239], ["Ad genome", "DNA", 116, 125], ["El-complementing cell line", "CELL_LINE", 165, 191], ["a two-plasmid strategy", "TREATMENT", 12, 34], ["homologous recombination in bacteria", "PROBLEM", 39, 75], ["a suitable El-complementing cell line", "TREATMENT", 154, 191], ["nonhuman Ad vector construction", "TREATMENT", 228, 259], ["cell line", "OBSERVATION", 182, 191]]], ["Chimpanzee Ad vectors can be rescued in El-complementing cell lines of human origin following cotransfection of a shuttle plasmid and the wild-type genomic DNA [46] .", [["cell lines", "ANATOMY", 57, 67], ["plasmid", "ANATOMY", 122, 129], ["Ad", "ORGANISM", 11, 13], ["cell lines", "CELL", 57, 67], ["human", "ORGANISM", 71, 76], ["DNA", "CELLULAR_COMPONENT", 156, 159], ["El-complementing cell lines", "CELL_LINE", 40, 67], ["shuttle plasmid", "DNA", 114, 129], ["wild-type genomic DNA", "DNA", 138, 159], ["human", "SPECIES", 71, 76], ["human", "SPECIES", 71, 76], ["Chimpanzee Ad vectors", "TREATMENT", 0, 21], ["a shuttle plasmid", "TREATMENT", 112, 129], ["cell lines", "OBSERVATION", 57, 67]]], ["For OAd7, a recombination strategy using a cosmid has also been used, in addition to the homologous recombination in bacteria.", [["OAd7", "GENE_OR_GENE_PRODUCT", 4, 8], ["OAd7", "DNA", 4, 8], ["cosmid", "DNA", 43, 49], ["a recombination strategy", "TREATMENT", 10, 34], ["a cosmid", "TREATMENT", 41, 49], ["the homologous recombination in bacteria", "PROBLEM", 85, 125]]], ["FAd vectors were developed by co-transfection of a shuttle plasmid and genomic DNA in a permissive cell line (Fig. 3) .Nonhuman adenovirusesNonhuman Ad vectors have been characterized in vivo.", [["plasmid", "ANATOMY", 59, 66], ["cell line", "ANATOMY", 99, 108], ["FAd", "GENE_OR_GENE_PRODUCT", 0, 3], ["DNA", "CELLULAR_COMPONENT", 79, 82], ["cell line", "CELL", 99, 108], ["Nonhuman adenoviruses", "ORGANISM", 119, 140], ["Nonhuman Ad vectors", "ORGANISM", 140, 159], ["FAd vectors", "DNA", 0, 11], ["shuttle plasmid", "DNA", 51, 66], ["genomic DNA", "DNA", 71, 82], ["permissive cell line", "CELL_LINE", 88, 108], ["FAd vectors", "TREATMENT", 0, 11], ["a shuttle plasmid", "TREATMENT", 49, 66], ["genomic DNA", "PROBLEM", 71, 82], ["a permissive cell line", "TREATMENT", 86, 108], ["Nonhuman adenovirusesNonhuman Ad vectors", "TREATMENT", 119, 159], ["permissive cell line", "OBSERVATION", 88, 108]]], ["Absence of virus neutralizing antibodies in human sera suggests that these viruses are not prevalent in the human population.", [["sera", "ANATOMY", 50, 54], ["human", "ORGANISM", 44, 49], ["sera", "ORGANISM_SUBSTANCE", 50, 54], ["human", "ORGANISM", 108, 113], ["virus neutralizing antibodies", "PROTEIN", 11, 40], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 108, 113], ["human", "SPECIES", 44, 49], ["human", "SPECIES", 108, 113], ["virus neutralizing antibodies in human sera", "TEST", 11, 54], ["these viruses", "PROBLEM", 69, 82], ["virus", "OBSERVATION", 11, 16], ["viruses", "OBSERVATION", 75, 82]]], ["Further, preexisting HAd5 antibodies in the sera of human or experimental animals did not cross-neutralize most nonhuman Ad [36, 48, 49] .", [["sera", "ANATOMY", 44, 48], ["HAd5 antibodies", "GENE_OR_GENE_PRODUCT", 21, 36], ["sera", "ORGANISM_SUBSTANCE", 44, 48], ["human", "ORGANISM", 52, 57], ["nonhuman", "ORGANISM", 112, 120], ["Ad", "ORGANISM", 121, 123], ["HAd5 antibodies", "PROTEIN", 21, 36], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["preexisting HAd5 antibodies", "TEST", 9, 36]]], ["In addition, these vectors efficiently transduce several human and nonhuman cells [46, 48, [54] [55] [56] , indicating their usefulness as alternative vectors for human as well as veterinary use.", [["cells", "ANATOMY", 76, 81], ["human", "ORGANISM", 57, 62], ["nonhuman", "ORGANISM", 67, 75], ["cells", "CELL", 76, 81], ["human", "ORGANISM", 163, 168], ["human and nonhuman cells", "CELL_TYPE", 57, 81], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 163, 168], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 163, 168], ["several human and nonhuman cells", "TEST", 49, 81]]], ["Below, we present a review of recent advances with each of these nonhuman Ad vectors.Bovine Ad vectorsTen Ad serotypes (1-10) have been isolated from cattle.", [["nonhuman", "ORGANISM", 65, 73], ["Ad", "ORGANISM", 74, 76], ["Bovine", "ORGANISM", 85, 91], ["Ad vectorsTen Ad serotypes", "ORGANISM", 92, 118], ["1-10", "ORGANISM", 120, 124], ["cattle", "ORGANISM", 150, 156], ["Bovine", "SPECIES", 85, 91], ["cattle", "SPECIES", 150, 156], ["Bovine", "SPECIES", 85, 91], ["cattle", "SPECIES", 150, 156], ["these nonhuman Ad vectors", "TREATMENT", 59, 84], ["Bovine Ad vectorsTen Ad serotypes", "TREATMENT", 85, 118]]], ["These are classified either under the genus Mastadenovirus or Atadenovirus based on their genome organization and ability to grow in cell culture.", [["cell culture", "ANATOMY", 133, 145], ["cell culture", "CELL", 133, 145], ["the genus Mastadenovirus", "PROBLEM", 34, 58], ["Atadenovirus", "TREATMENT", 62, 74], ["cell culture", "TEST", 133, 145], ["genus Mastadenovirus", "OBSERVATION", 38, 58]]], ["Bovine Ad serotype 3 (BAd3) is a Mastadenovirus isolated from the conjunctiva of a healthy cow [57] .", [["conjunctiva", "ANATOMY", 66, 77], ["Bovine", "ORGANISM", 0, 6], ["Ad serotype 3", "ORGANISM", 7, 20], ["BAd3", "ORGANISM", 22, 26], ["conjunctiva", "ORGAN", 66, 77], ["cow", "ORGANISM", 91, 94], ["Bovine", "SPECIES", 0, 6], ["cow", "SPECIES", 91, 94], ["Bovine Ad serotype 3", "SPECIES", 0, 20], ["cow", "SPECIES", 91, 94], ["Bovine Ad serotype", "TREATMENT", 0, 18], ["a Mastadenovirus isolated", "PROBLEM", 31, 56], ["conjunctiva", "ANATOMY", 66, 77]]], ["Complete nucleotide sequence and genomic map of BAd3 revealed a high level of similarity with HAd5 [58] .", [["nucleotide", "CHEMICAL", 9, 19], ["nucleotide", "CHEMICAL", 9, 19], ["BAd3", "GENE_OR_GENE_PRODUCT", 48, 52], ["BAd3", "DNA", 48, 52], ["Complete nucleotide sequence", "TEST", 0, 28], ["genomic map of BAd3", "TEST", 33, 52]]], ["The E3 region of BAd3 is smaller and less complex than the E3 of HAd5 [58] , and is not essential for virus replication in tissue culture [59] .", [["tissue culture", "ANATOMY", 123, 137], ["E3", "GENE_OR_GENE_PRODUCT", 4, 6], ["BAd3", "GENE_OR_GENE_PRODUCT", 17, 21], ["E3", "GENE_OR_GENE_PRODUCT", 59, 61], ["HAd5 [58]", "GENE_OR_GENE_PRODUCT", 65, 74], ["tissue", "TISSUE", 123, 129], ["E3 region", "PROTEIN", 4, 13], ["BAd3", "PROTEIN", 17, 21], ["E3", "PROTEIN", 59, 61], ["HAd5", "PROTEIN", 65, 69], ["virus replication", "PROBLEM", 102, 119], ["tissue culture", "TEST", 123, 137], ["E3", "OBSERVATION_MODIFIER", 4, 6], ["region", "OBSERVATION_MODIFIER", 7, 13], ["BAd3", "OBSERVATION", 17, 21], ["smaller", "OBSERVATION_MODIFIER", 25, 32], ["less", "OBSERVATION_MODIFIER", 37, 41], ["complex", "OBSERVATION_MODIFIER", 42, 49], ["not essential for", "UNCERTAINTY", 84, 101], ["virus", "OBSERVATION", 102, 107]]], ["A recent study compared the influence of various promoters for transgene expression in the E3 region of BAd3 [60] .", [["E3", "GENE_OR_GENE_PRODUCT", 91, 93], ["promoters", "DNA", 49, 58], ["E3 region", "DNA", 91, 100], ["A recent study", "TEST", 0, 14], ["various promoters", "TREATMENT", 41, 58], ["transgene expression", "TREATMENT", 63, 83]]], ["The murine cytomegalovirus (MCMV) immediate early promoter was more efficient for foreign gene expression in the E3-parallel orientation than other exogenous promoters such as phoshphoglycerate kinase (PGK) or human cytomegalovirus (HCMV) promoters.", [["phoshphoglycerate", "CHEMICAL", 176, 193], ["phoshphoglycerate", "CHEMICAL", 176, 193], ["murine cytomegalovirus", "ORGANISM", 4, 26], ["MCMV", "ORGANISM", 28, 32], ["E3", "GENE_OR_GENE_PRODUCT", 113, 115], ["phoshphoglycerate kinase", "GENE_OR_GENE_PRODUCT", 176, 200], ["PGK", "GENE_OR_GENE_PRODUCT", 202, 205], ["human cytomegalovirus", "ORGANISM", 210, 231], ["HCMV", "ORGANISM", 233, 237], ["murine cytomegalovirus (MCMV) immediate early promoter", "DNA", 4, 58], ["E3", "PROTEIN", 113, 115], ["exogenous promoters", "DNA", 148, 167], ["phoshphoglycerate kinase (PGK) or human cytomegalovirus (HCMV) promoters", "DNA", 176, 248], ["murine", "SPECIES", 4, 10], ["human", "SPECIES", 210, 215], ["murine cytomegalovirus", "SPECIES", 4, 26], ["MCMV", "SPECIES", 28, 32], ["human cytomegalovirus", "SPECIES", 210, 231], ["HCMV", "SPECIES", 233, 237], ["The murine cytomegalovirus", "TEST", 0, 26], ["foreign gene expression", "PROBLEM", 82, 105], ["human cytomegalovirus (HCMV) promoters", "TREATMENT", 210, 248], ["cytomegalovirus", "OBSERVATION", 11, 26]]], ["Development of El-complementing cell lines of bovine origin was an important requirement in order to generate replicationdefective BAd3 vectors since the HAd5 El-expressing human 293 cell line [61] did not support BAd3 replication [59] .", [["cell lines", "ANATOMY", 32, 42], ["293 cell line", "ANATOMY", 179, 192], ["El-complementing cell lines", "CELL", 15, 42], ["bovine", "ORGANISM", 46, 52], ["BAd3", "GENE_OR_GENE_PRODUCT", 131, 135], ["HAd5", "GENE_OR_GENE_PRODUCT", 154, 158], ["human", "ORGANISM", 173, 178], ["293 cell line [61", "CELL", 179, 196], ["BAd3", "GENE_OR_GENE_PRODUCT", 214, 218], ["El-complementing cell lines", "CELL_LINE", 15, 42], ["replicationdefective BAd3 vectors", "DNA", 110, 143], ["HAd5 El-expressing human 293 cell line", "CELL_LINE", 154, 192], ["BAd3", "PROTEIN", 214, 218], ["bovine", "SPECIES", 46, 52], ["human", "SPECIES", 173, 178], ["human", "SPECIES", 173, 178], ["El-complementing cell lines", "TREATMENT", 15, 42], ["replicationdefective BAd3 vectors", "TREATMENT", 110, 143], ["El-complementing cell lines", "OBSERVATION", 15, 42], ["bovine origin", "OBSERVATION", 46, 59]]], ["The El gene products of BAd3 were shown to complement E1A function of HAd5 as demonstrated by replication of an Eldeleted HAd5 vector in BAd3 infected MDBK cells [62] .", [["MDBK cells", "ANATOMY", 151, 161], ["BAd3", "GENE_OR_GENE_PRODUCT", 24, 28], ["E1A", "GENE_OR_GENE_PRODUCT", 54, 57], ["HAd5", "GENE_OR_GENE_PRODUCT", 70, 74], ["HAd5", "GENE_OR_GENE_PRODUCT", 122, 126], ["BAd3", "CELL", 137, 141], ["MDBK cells", "CELL", 151, 161], ["El gene products", "PROTEIN", 4, 20], ["BAd3", "PROTEIN", 24, 28], ["E1A", "PROTEIN", 54, 57], ["HAd5", "PROTEIN", 70, 74], ["Eldeleted HAd5 vector", "DNA", 112, 133], ["BAd3 infected MDBK cells", "CELL_LINE", 137, 161], ["MDBK", "SPECIES", 151, 155], ["The El gene products of BAd3", "TREATMENT", 0, 28], ["an Eldeleted HAd5 vector", "TREATMENT", 109, 133], ["infected MDBK cells", "PROBLEM", 142, 161], ["MDBK cells", "OBSERVATION", 151, 161]]], ["This trans-complementation, based on structural and functional homologies in the El genes of HAd5 and BAd3, led to the generation of complementing cell lines by transforming cells of bovine origin with HAd5 El [63, 64] .Bovine Ad vectorsSubsequently, replication-defective BAd3 with deletion in E1A and/or E3 were constructed by homologous recombination in E. coli BJ5183 [53] and rescued by transfecting El-complemeting bovine retina cells (VIDO R2, [63] ; FBRT HE1 [56, 64] ) (Fig. 3 ).", [["cell lines", "ANATOMY", 147, 157], ["cells", "ANATOMY", 174, 179], ["retina cells", "ANATOMY", 428, 440], ["HAd5", "GENE_OR_GENE_PRODUCT", 93, 97], ["BAd3", "GENE_OR_GENE_PRODUCT", 102, 106], ["cell lines", "CELL", 147, 157], ["cells", "CELL", 174, 179], ["bovine", "ORGANISM", 183, 189], ["Bovine", "ORGANISM", 220, 226], ["Ad", "ORGANISM", 227, 229], ["BAd3", "GENE_OR_GENE_PRODUCT", 273, 277], ["E1A", "GENE_OR_GENE_PRODUCT", 295, 298], ["E3", "GENE_OR_GENE_PRODUCT", 306, 308], ["E. coli", "ORGANISM", 357, 364], ["bovine", "ORGANISM", 421, 427], ["retina cells", "CELL", 428, 440], ["El genes", "DNA", 81, 89], ["HAd5", "DNA", 93, 97], ["BAd3", "DNA", 102, 106], ["complementing cell lines", "CELL_LINE", 133, 157], ["BAd3", "DNA", 273, 277], ["E1A", "DNA", 295, 298], ["E3", "DNA", 306, 308], ["El-complemeting bovine retina cells", "CELL_LINE", 405, 440], ["VIDO R2", "CELL_LINE", 442, 449], ["bovine", "SPECIES", 183, 189], ["Bovine", "SPECIES", 220, 226], ["E. coli", "SPECIES", 357, 364], ["bovine", "SPECIES", 421, 427], ["Bovine", "SPECIES", 220, 226], ["E. coli", "SPECIES", 357, 364], ["complementing cell lines", "TREATMENT", 133, 157], ["Bovine Ad vectorsSubsequently", "TREATMENT", 220, 249], ["deletion in E1A", "TREATMENT", 283, 298], ["E. coli BJ5183", "TEST", 357, 371], ["VIDO R2", "TEST", 442, 449], ["FBRT HE1", "TEST", 458, 466], ["cell lines", "OBSERVATION", 147, 157]]], ["In addition, bovine cell lines expressing El proteins of BAd3 have also been developed [64] .", [["cell lines", "ANATOMY", 20, 30], ["bovine", "ORGANISM", 13, 19], ["cell lines", "CELL", 20, 30], ["BAd3", "GENE_OR_GENE_PRODUCT", 57, 61], ["bovine cell lines", "CELL_LINE", 13, 30], ["El proteins", "PROTEIN", 42, 53], ["BAd3", "PROTEIN", 57, 61], ["bovine", "SPECIES", 13, 19], ["bovine cell lines", "TREATMENT", 13, 30], ["El proteins of BAd3", "PROBLEM", 42, 61], ["bovine cell lines", "OBSERVATION", 13, 30]]], ["More recently, BAd3 genome sequences involved in the virus packaging have been identified.", [["BAd3", "GENE_OR_GENE_PRODUCT", 15, 19], ["BAd3 genome sequences", "DNA", 15, 36], ["BAd3 genome sequences", "TEST", 15, 36], ["the virus packaging", "TREATMENT", 49, 68]]], ["This may be helpful in designing novel vectors with increased carrying capacity on the prece-dence of helper-dependent 'gutless' HAd5 vectors [65] .", [["HAd5", "GENE_OR_GENE_PRODUCT", 129, 133], ["helper-dependent 'gutless' HAd5 vectors", "DNA", 102, 141], ["novel vectors", "TREATMENT", 33, 46], ["increased carrying capacity", "PROBLEM", 52, 79]]], ["The ability to incorporate a heterologous protein in the C-terminus of minor capsid protein pIX protein of BAd3 [66] offers a unique opportunity to insert specific ligands in the viral capsid to improve or alter transduction by BAd3 vectors.Bovine Ad vectorsA number of studies have demonstrated the feasibility of generating a strong immune response against foreign gene products expressed by BAd3 vectors.", [["C", "CHEMICAL", 57, 58], ["pIX", "GENE_OR_GENE_PRODUCT", 92, 95], ["BAd3", "GENE_OR_GENE_PRODUCT", 228, 232], ["Bovine", "ORGANISM", 241, 247], ["Ad", "ORGANISM", 248, 250], ["BAd3", "GENE_OR_GENE_PRODUCT", 394, 398], ["heterologous protein", "PROTEIN", 29, 49], ["C-terminus", "PROTEIN", 57, 67], ["minor capsid protein pIX protein", "PROTEIN", 71, 103], ["BAd3", "PROTEIN", 107, 111], ["BAd3 vectors", "DNA", 228, 240], ["foreign gene products", "PROTEIN", 359, 380], ["BAd3 vectors", "DNA", 394, 406], ["Bovine", "SPECIES", 241, 247], ["Bovine", "SPECIES", 241, 247], ["a heterologous protein", "TEST", 27, 49], ["specific ligands", "TREATMENT", 155, 171], ["the viral capsid", "TREATMENT", 175, 191], ["foreign gene products", "TREATMENT", 359, 380], ["viral capsid", "OBSERVATION", 179, 191]]], ["Mucosal immunization of calves with a replication-competent BAd3 vector carrying bovine herpesvirus type 1 (BHV-1) glycoprotein gD in the E3 region induced neutralizing antibodies that conferred protection against BHV-1 challenge [67] .", [["Mucosal", "ANATOMY", 0, 7], ["BHV-1", "CHEMICAL", 214, 219], ["Mucosal", "ORGAN", 0, 7], ["calves", "ORGANISM", 24, 30], ["BAd3", "ORGANISM", 60, 64], ["bovine herpesvirus type 1", "ORGANISM", 81, 106], ["BHV-1", "ORGANISM", 108, 113], ["glycoprotein gD", "GENE_OR_GENE_PRODUCT", 115, 130], ["E3", "GENE_OR_GENE_PRODUCT", 138, 140], ["BHV-1", "ORGANISM", 214, 219], ["BAd3 vector", "DNA", 60, 71], ["bovine herpesvirus type 1 (BHV-1) glycoprotein gD", "PROTEIN", 81, 130], ["E3 region", "PROTEIN", 138, 147], ["neutralizing antibodies", "PROTEIN", 156, 179], ["calves", "SPECIES", 24, 30], ["bovine", "SPECIES", 81, 87], ["herpesvirus type 1", "SPECIES", 88, 106], ["BHV-1", "SPECIES", 108, 113], ["bovine herpesvirus type 1 (BHV-1", "SPECIES", 81, 113], ["BHV-1", "SPECIES", 214, 219], ["Mucosal immunization of calves", "TREATMENT", 0, 30], ["a replication", "TREATMENT", 36, 49], ["BHV", "TEST", 108, 111], ["glycoprotein gD in the E3 region", "TREATMENT", 115, 147], ["neutralizing antibodies", "TREATMENT", 156, 179]]], ["Comparison of replication-defective and replication-competent BAd3 vectors expressing BHV-1 gD showed a lower immune response was elicited with the replication-defective vector [68] .", [["BAd3", "ORGANISM", 62, 66], ["BHV-1 gD", "ORGANISM", 86, 94], ["BAd3 vectors", "DNA", 62, 74], ["BHV", "PROTEIN", 86, 89], ["1 gD", "PROTEIN", 90, 94], ["BHV-1", "SPECIES", 86, 91], ["replication", "TREATMENT", 14, 25], ["replication", "TREATMENT", 40, 51], ["BHV", "TEST", 86, 89], ["a lower immune response", "PROBLEM", 102, 125]]], ["It is important to note that these vectors carried the foreign gene under the adenoviral major late promoter.", [["adenoviral", "ORGANISM", 78, 88], ["foreign gene", "DNA", 55, 67], ["adenoviral major late promoter", "DNA", 78, 108], ["these vectors", "TREATMENT", 29, 42]]], ["Potentially, the problem of a lower immune response with a replication-defective vector could be overcome by driving the transgene expression with strong promoters, such as the HCMV or the simian virus 40 (SV40) early promoter.", [["HCMV", "ORGANISM", 177, 181], ["simian virus 40", "ORGANISM", 189, 204], ["SV40", "ORGANISM", 206, 210], ["replication-defective vector", "DNA", 59, 87], ["strong promoters", "DNA", 147, 163], ["HCMV or the simian virus 40 (SV40) early promoter", "DNA", 177, 226], ["simian virus", "SPECIES", 189, 201], ["HCMV", "SPECIES", 177, 181], ["simian virus 40", "SPECIES", 189, 204], ["a lower immune response", "PROBLEM", 28, 51], ["a replication-defective vector", "TREATMENT", 57, 87], ["the HCMV", "TREATMENT", 173, 181], ["the simian virus", "TREATMENT", 185, 201]]], ["Another study investigated the feasibility of generating an immune response against bovine viral diarrhea virus (BVDV) glycoprotein E2 in cotton rats using an E3-deleted BAd3 vector [69] .", [["bovine viral diarrhea", "DISEASE", 84, 105], ["E2", "CHEMICAL", 132, 134], ["bovine viral diarrhea virus", "ORGANISM", 84, 111], ["BVDV", "ORGANISM", 113, 117], ["glycoprotein E2", "GENE_OR_GENE_PRODUCT", 119, 134], ["cotton rats", "ORGANISM", 138, 149], ["E3", "GENE_OR_GENE_PRODUCT", 159, 161], ["BAd3", "GENE_OR_GENE_PRODUCT", 170, 174], ["E3-deleted BAd3 vector", "DNA", 159, 181], ["bovine", "SPECIES", 84, 90], ["viral diarrhea virus", "SPECIES", 91, 111], ["BVDV", "SPECIES", 113, 117], ["rats", "SPECIES", 145, 149], ["bovine viral diarrhea virus", "SPECIES", 84, 111], ["BVDV", "SPECIES", 113, 117], ["cotton", "SPECIES", 138, 144], ["Another study", "TEST", 0, 13], ["an immune response", "PROBLEM", 57, 75], ["bovine viral diarrhea virus", "PROBLEM", 84, 111], ["BVDV) glycoprotein E2 in cotton rats", "TREATMENT", 113, 149], ["an E3-deleted BAd3 vector", "TREATMENT", 156, 181]]], ["BVDV E2-specifc IgA and IgG responses were elicited following intranasal immunization with the vector.Bovine Ad vectorsSeveral studies examined preexisting immunity against BAd3 and its role in the subsequent use of BAd3 vectors in the cattle population [67, 70] .", [["E2", "CHEMICAL", 5, 7], ["BVDV", "ORGANISM", 0, 4], ["E2", "GENE_OR_GENE_PRODUCT", 5, 7], ["IgA", "GENE_OR_GENE_PRODUCT", 16, 19], ["IgG", "GENE_OR_GENE_PRODUCT", 24, 27], ["Bovine", "ORGANISM", 102, 108], ["Ad", "ORGANISM", 109, 111], ["BAd3", "GENE_OR_GENE_PRODUCT", 173, 177], ["BAd3", "GENE_OR_GENE_PRODUCT", 216, 220], ["BVDV E2", "PROTEIN", 0, 7], ["IgG", "PROTEIN", 24, 27], ["BAd3", "PROTEIN", 173, 177], ["BAd3 vectors", "DNA", 216, 228], ["BVDV", "SPECIES", 0, 4], ["Bovine", "SPECIES", 102, 108], ["cattle", "SPECIES", 236, 242], ["BVDV", "SPECIES", 0, 4], ["Bovine", "SPECIES", 102, 108], ["cattle", "SPECIES", 236, 242], ["BVDV E2", "TEST", 0, 7], ["IgG responses", "TEST", 24, 37], ["intranasal immunization", "TREATMENT", 62, 85], ["Bovine Ad vectorsSeveral studies", "TEST", 102, 134], ["BAd3 vectors", "TREATMENT", 216, 228]]], ["Replication-competent BAd3 vectors could induce protective immune responses in calves that had pre-existing BAd3-specific antibodies.", [["BAd3", "ORGANISM", 22, 26], ["calves", "ORGANISM", 79, 85], ["BAd3", "GENE_OR_GENE_PRODUCT", 108, 112], ["BAd3 vectors", "DNA", 22, 34], ["BAd3", "PROTEIN", 108, 112], ["specific antibodies", "PROTEIN", 113, 132], ["calves", "SPECIES", 79, 85], ["calves", "SPECIES", 79, 85], ["Replication", "TREATMENT", 0, 11], ["competent BAd3 vectors", "TREATMENT", 12, 34], ["pre-existing BAd3-specific antibodies", "PROBLEM", 95, 132]]], ["BAd3 vectors could also circumvent preexisting HAd5 immunity in a mouse model [36] .", [["BAd3", "GENE_OR_GENE_PRODUCT", 0, 4], ["HAd5", "GENE_OR_GENE_PRODUCT", 47, 51], ["mouse", "ORGANISM", 66, 71], ["BAd3 vectors", "DNA", 0, 12], ["mouse", "SPECIES", 66, 71], ["mouse", "SPECIES", 66, 71], ["BAd3 vectors", "TREATMENT", 0, 12]]], ["We recently reported that BAd3 is not prevalent in the human population, and that preexisting HAd immunity does not cross-neutralize BAd3 [56] .", [["BAd3", "GENE_OR_GENE_PRODUCT", 26, 30], ["human", "ORGANISM", 55, 60], ["HAd", "GENE_OR_GENE_PRODUCT", 94, 97], ["BAd3", "PROTEIN", 26, 30], ["human", "SPECIES", 55, 60], ["human", "SPECIES", 55, 60], ["not prevalent", "UNCERTAINTY", 34, 47]]], ["These studies demonstrated the potential of BAd3 vectors for gene transfer in humans even in the presence of HAd neutralizing antibodies.", [["BAd3", "GENE_OR_GENE_PRODUCT", 44, 48], ["humans", "ORGANISM", 78, 84], ["HAd", "GENE_OR_GENE_PRODUCT", 109, 112], ["BAd3 vectors", "DNA", 44, 56], ["HAd neutralizing antibodies", "PROTEIN", 109, 136], ["humans", "SPECIES", 78, 84], ["humans", "SPECIES", 78, 84], ["These studies", "TEST", 0, 13], ["BAd3 vectors", "TREATMENT", 44, 56], ["neutralizing antibodies", "PROBLEM", 113, 136]]], ["To further explore this possibility, it was important that BAd3 vectors efficiently transduce human cells.", [["cells", "ANATOMY", 100, 105], ["BAd3", "GENE_OR_GENE_PRODUCT", 59, 63], ["human", "ORGANISM", 94, 99], ["cells", "CELL", 100, 105], ["BAd3 vectors", "DNA", 59, 71], ["human cells", "CELL_TYPE", 94, 105], ["human", "SPECIES", 94, 99], ["human", "SPECIES", 94, 99], ["BAd3 vectors", "TREATMENT", 59, 71]]], ["The wild-type BAd3 could infect but did not grow in human cell lines [54, 59] .", [["cell lines", "ANATOMY", 58, 68], ["BAd3", "GENE_OR_GENE_PRODUCT", 14, 18], ["human", "ORGANISM", 52, 57], ["cell lines", "CELL", 58, 68], ["BAd3", "PROTEIN", 14, 18], ["human cell lines", "CELL_LINE", 52, 68], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57], ["cell lines", "OBSERVATION", 58, 68]]], ["Replication-defective BAd3 vectors efficiently express foreign gene/s in a variety of human as well nonhuman cells in culture [54, 56, 63] .", [["cells", "ANATOMY", 109, 114], ["BAd3", "GENE_OR_GENE_PRODUCT", 22, 26], ["human", "ORGANISM", 86, 91], ["nonhuman", "ORGANISM", 100, 108], ["cells", "CELL", 109, 114], ["BAd3 vectors", "DNA", 22, 34], ["foreign gene", "DNA", 55, 67], ["human as well nonhuman cells", "CELL_TYPE", 86, 114], ["human", "SPECIES", 86, 91], ["human", "SPECIES", 86, 91], ["Replication-defective BAd3 vectors", "TREATMENT", 0, 34], ["foreign gene/s", "PROBLEM", 55, 69]]], ["BAd3 entry into various cell types appears to be CAR-as well as integrin-independent [71] .", [["cell", "ANATOMY", 24, 28], ["BAd3", "GENE_OR_GENE_PRODUCT", 0, 4], ["cell", "CELL", 24, 28], ["CAR", "GENE_OR_GENE_PRODUCT", 49, 52], ["BAd3", "PROTEIN", 0, 4], ["CAR", "PROTEIN", 49, 52], ["various cell types", "OBSERVATION", 16, 34]]], ["In addition, tropism of BAd3 could be altered by switching the viral fiber knob with the HAd5 fiber knob [72] , thus indicating the involvement of receptor/s distinct from primary receptors of HAd5 in BAd3 internalization [71] .Canine Ad vectorsTwo serotypes of canine Ad (CAd) have been isolated.", [["BAd3", "CHEMICAL", 24, 28], ["BAd3", "GENE_OR_GENE_PRODUCT", 24, 28], ["HAd5", "GENE_OR_GENE_PRODUCT", 193, 197], ["BAd3", "GENE_OR_GENE_PRODUCT", 201, 205], ["Canine", "ORGANISM", 228, 234], ["Ad", "ORGANISM", 235, 237], ["canine Ad", "ORGANISM", 262, 271], ["CAd", "GENE_OR_GENE_PRODUCT", 273, 276], ["BAd3", "PROTEIN", 24, 28], ["primary receptors", "PROTEIN", 172, 189], ["HAd5", "PROTEIN", 193, 197], ["BAd3", "PROTEIN", 201, 205], ["Canine", "SPECIES", 228, 234], ["canine", "SPECIES", 262, 268], ["Canine", "SPECIES", 228, 234], ["canine", "SPECIES", 262, 268], ["the viral fiber knob", "TREATMENT", 59, 79], ["the HAd5 fiber knob", "TREATMENT", 85, 104], ["receptor/s", "PROBLEM", 147, 157], ["Canine Ad vectors", "TREATMENT", 228, 245], ["canine Ad (CAd", "TREATMENT", 262, 276]]], ["Both CAdl and CAd2 have been associated with mild upper respiratory tract infections in dogs.", [["upper respiratory tract", "ANATOMY", 50, 73], ["respiratory tract infections", "DISEASE", 56, 84], ["CAdl", "GENE_OR_GENE_PRODUCT", 5, 9], ["CAd2", "GENE_OR_GENE_PRODUCT", 14, 18], ["upper", "ORGANISM_SUBDIVISION", 50, 55], ["respiratory tract", "ORGANISM_SUBDIVISION", 56, 73], ["dogs", "ORGANISM", 88, 92], ["CAdl", "PROTEIN", 5, 9], ["CAd2", "PROTEIN", 14, 18], ["dogs", "SPECIES", 88, 92], ["mild upper respiratory tract infections in dogs", "PROBLEM", 45, 92], ["mild", "OBSERVATION_MODIFIER", 45, 49], ["upper", "ANATOMY_MODIFIER", 50, 55], ["respiratory tract", "ANATOMY", 56, 73], ["infections", "OBSERVATION", 74, 84]]], ["Effective live-modified vaccines are available for routine vaccination of dogs against both CAdl and CAd2, with an excellent safety record.", [["dogs", "ORGANISM", 74, 78], ["CAdl", "SIMPLE_CHEMICAL", 92, 96], ["CAd2", "SIMPLE_CHEMICAL", 101, 105], ["dogs", "SPECIES", 74, 78], ["Effective live-modified vaccines", "TREATMENT", 0, 32], ["routine vaccination of dogs", "TREATMENT", 51, 78]]], ["The complete genomic sequence of CAdl is known [73] .", [["CAdl", "DNA", 33, 37]]], ["An E3-deleted CAd vector expressing the capsid protein of canine parvovirus was generated by homologous recombination in bacteria [74] .", [["E3", "GENE_OR_GENE_PRODUCT", 3, 5], ["CAd", "GENE_OR_GENE_PRODUCT", 14, 17], ["canine parvovirus", "ORGANISM", 58, 75], ["E3-deleted CAd vector", "DNA", 3, 24], ["capsid protein", "PROTEIN", 40, 54], ["canine parvovirus", "SPECIES", 58, 75], ["canine parvovirus", "SPECIES", 58, 75], ["An E3-deleted CAd vector", "TREATMENT", 0, 24], ["the capsid protein of canine parvovirus", "PROBLEM", 36, 75], ["bacteria", "PROBLEM", 121, 129], ["canine parvovirus", "OBSERVATION", 58, 75]]], ["CAd2 is well characterized, and has been utilized for vector development.", [["CAd2", "CHEMICAL", 0, 4], ["CAd2", "GENE_OR_GENE_PRODUCT", 0, 4], ["CAd2", "PROTEIN", 0, 4], ["vector development", "TREATMENT", 54, 72], ["well characterized", "OBSERVATION_MODIFIER", 8, 26]]], ["The CAd2 genome carries an El-transcription region similar to HAd5.", [["CAd2", "GENE_OR_GENE_PRODUCT", 4, 8], ["HAd5", "GENE_OR_GENE_PRODUCT", 62, 66], ["CAd2 genome", "DNA", 4, 15], ["El-transcription region", "DNA", 27, 50], ["HAd5", "DNA", 62, 66], ["The CAd2 genome", "TREATMENT", 0, 15], ["an El-transcription region", "PROBLEM", 24, 50]]], ["Since El-deleted CAd2 vectors did not replicate in human Elcomplementing cell lines, an El-complemetnig canine kidney cell line (DK/El-28) was developed that expressed CAd2 El proteins [52, 75] .", [["Elcomplementing cell lines", "ANATOMY", 57, 83], ["kidney cell line", "ANATOMY", 111, 127], ["CAd2", "GENE_OR_GENE_PRODUCT", 17, 21], ["human", "ORGANISM", 51, 56], ["Elcomplementing cell lines", "CELL", 57, 83], ["El-complemetnig canine kidney cell line", "CELL", 88, 127], ["DK/El-28", "CELL", 129, 137], ["CAd2", "GENE_OR_GENE_PRODUCT", 168, 172], ["El-deleted CAd2 vectors", "DNA", 6, 29], ["human Elcomplementing cell lines", "CELL_LINE", 51, 83], ["El-complemetnig canine kidney cell line", "CELL_LINE", 88, 127], ["DK/El-28", "CELL_LINE", 129, 137], ["CAd2", "PROTEIN", 168, 172], ["El proteins", "PROTEIN", 173, 184], ["human", "SPECIES", 51, 56], ["canine", "SPECIES", 104, 110], ["human", "SPECIES", 51, 56], ["canine", "SPECIES", 104, 110], ["an El-complemetnig canine kidney cell line", "TEST", 85, 127], ["DK/El", "TEST", 129, 134], ["El proteins", "TEST", 173, 184], ["cell lines", "OBSERVATION", 73, 83], ["kidney", "ANATOMY", 111, 117], ["cell line", "OBSERVATION", 118, 127]]], ["Homologous recombination following co-transformation of a shuttle plasmid and CAd genomic DNA in E. coli BJ5183 was adapted for generating recombinant infectious clones (Fig. 3) .", [["plasmid", "ANATOMY", 66, 73], ["clones", "ANATOMY", 162, 168], ["DNA", "CELLULAR_COMPONENT", 90, 93], ["E. coli", "ORGANISM", 97, 104], ["BJ5183", "ORGANISM", 105, 111], ["clones", "CELL", 162, 168], ["shuttle plasmid", "DNA", 58, 73], ["CAd genomic DNA", "DNA", 78, 93], ["recombinant infectious clones", "CELL_LINE", 139, 168], ["E. coli", "SPECIES", 97, 104], ["E. coli", "SPECIES", 97, 104], ["Homologous recombination", "TREATMENT", 0, 24], ["a shuttle plasmid", "TREATMENT", 56, 73], ["CAd genomic DNA", "PROBLEM", 78, 93], ["E. coli BJ", "TEST", 97, 107], ["generating recombinant infectious clones", "PROBLEM", 128, 168], ["infectious", "OBSERVATION", 151, 161]]], ["A conditionally replicating CAd2 vector, the first oncolytic vector based on a nonhuman Ad, was successfully tested for its therapeutic application in canine osteosarcoma [76] .", [["osteosarcoma", "ANATOMY", 158, 170], ["canine osteosarcoma", "DISEASE", 151, 170], ["CAd2", "GENE_OR_GENE_PRODUCT", 28, 32], ["nonhuman", "ORGANISM", 79, 87], ["Ad", "ORGANISM", 88, 90], ["canine", "ORGANISM", 151, 157], ["osteosarcoma", "CANCER", 158, 170], ["CAd2 vector", "DNA", 28, 39], ["canine", "SPECIES", 151, 157], ["A conditionally replicating CAd2 vector", "TREATMENT", 0, 39], ["the first oncolytic vector", "TREATMENT", 41, 67], ["canine osteosarcoma", "PROBLEM", 151, 170], ["osteosarcoma", "OBSERVATION", 158, 170]]], ["With the availability of the information regarding the packaging sequence of CAd2 [77] , a system for generating helper-dependent vectors (with majority of the viral genome deleted) has been developed [78] .Canine Ad vectorsBased on the experience with commonly used live CAd vaccines, it was observed that these CAd vaccines were efficacious for the vaccination of dogs not only by the parenteral route but also by the mucosal route.", [["mucosal", "ANATOMY", 420, 427], ["Canine", "ORGANISM", 207, 213], ["Ad", "ORGANISM", 214, 216], ["dogs", "ORGANISM", 366, 370], ["mucosal route", "MULTI-TISSUE_STRUCTURE", 420, 433], ["helper-dependent vectors", "DNA", 113, 137], ["viral genome deleted", "DNA", 160, 180], ["Canine", "SPECIES", 207, 213], ["dogs", "SPECIES", 366, 370], ["Canine", "SPECIES", 207, 213], ["generating helper-dependent vectors", "TREATMENT", 102, 137], ["live CAd vaccines", "TREATMENT", 267, 284], ["these CAd vaccines", "TREATMENT", 307, 325], ["the vaccination of dogs", "TREATMENT", 347, 370]]], ["Replication-competent CAd vectors were expected to be useful in providing protective immunity in dogs and wild animals against a variety of pathogens including rabies.", [["rabies", "DISEASE", 160, 166], ["CAd", "ORGANISM", 22, 25], ["dogs", "ORGANISM", 97, 101], ["rabies", "ORGANISM", 160, 166], ["CAd vectors", "DNA", 22, 33], ["dogs", "SPECIES", 97, 101], ["rabies", "SPECIES", 160, 166], ["competent CAd vectors", "TREATMENT", 12, 33], ["pathogens", "PROBLEM", 140, 149]]], ["A replication-competent CAd2 vector expressing canine distemper virus (CDV) hemagglutinin or fusion protein in the E3 region under the control of a truncated HCMV promoter, resulted in significant seroconversion and protective immunity [79] .", [["CAd2", "GENE_OR_GENE_PRODUCT", 24, 28], ["canine distemper virus (CDV) hemagglutinin", "ORGANISM", 47, 89], ["E3", "GENE_OR_GENE_PRODUCT", 115, 117], ["HCMV", "ORGANISM", 158, 162], ["CAd2 vector", "DNA", 24, 35], ["canine distemper virus (CDV) hemagglutinin", "PROTEIN", 47, 89], ["fusion protein", "PROTEIN", 93, 107], ["E3 region", "PROTEIN", 115, 124], ["truncated HCMV promoter", "DNA", 148, 171], ["canine distemper virus", "SPECIES", 47, 69], ["canine distemper virus", "SPECIES", 47, 69], ["CDV", "SPECIES", 71, 74], ["HCMV", "SPECIES", 158, 162], ["A replication", "TREATMENT", 0, 13], ["competent CAd2 vector", "TREATMENT", 14, 35], ["canine distemper virus", "PROBLEM", 47, 69], ["CDV) hemagglutinin", "TREATMENT", 71, 89], ["fusion protein in the E3 region", "TREATMENT", 93, 124], ["a truncated HCMV promoter", "TREATMENT", 146, 171], ["significant seroconversion", "PROBLEM", 185, 211], ["distemper virus", "OBSERVATION", 54, 69], ["E3", "ANATOMY", 115, 117], ["HCMV promoter", "OBSERVATION", 158, 171], ["significant", "OBSERVATION_MODIFIER", 185, 196], ["seroconversion", "OBSERVATION", 197, 211]]], ["Intranasal vaccination with this vector induced significant levels of CDVspecific immunity in seronegative puppies but a poor immune response was elicited in the puppies preexposed to CAd2.", [["CAd2", "CHEMICAL", 184, 188], ["CAd2", "CHEMICAL", 184, 188], ["CDVspecific", "GENE_OR_GENE_PRODUCT", 70, 81], ["puppies", "ORGANISM", 107, 114], ["puppies", "ORGANISM", 162, 169], ["CAd2", "GENE_OR_GENE_PRODUCT", 184, 188], ["Intranasal vaccination", "TREATMENT", 0, 22], ["this vector", "TREATMENT", 28, 39], ["CDVspecific immunity", "PROBLEM", 70, 90], ["seronegative puppies", "PROBLEM", 94, 114], ["a poor immune response", "PROBLEM", 119, 141]]], ["The inability of the CAd2 vector vaccine to elicit a CDVspecific serological response following intranasal inoculation was attributed to anti-CAd2 mucosal immunity in preexposed animals.Canine Ad vectorsLike most other Ad, CAd are also prevalent in their natural hosts.", [["mucosal", "ANATOMY", 147, 154], ["CAd2", "GENE_OR_GENE_PRODUCT", 21, 25], ["mucosal", "MULTI-TISSUE_STRUCTURE", 147, 154], ["Canine", "ORGANISM", 186, 192], ["Ad", "ORGANISM", 193, 195], ["Ad", "ORGANISM", 219, 221], ["CAd", "GENE_OR_GENE_PRODUCT", 223, 226], ["Canine", "SPECIES", 186, 192], ["Canine", "SPECIES", 186, 192], ["the CAd2 vector vaccine", "TREATMENT", 17, 40], ["a CDVspecific serological response", "PROBLEM", 51, 85], ["intranasal inoculation", "TREATMENT", 96, 118], ["Canine Ad vectorsLike", "TREATMENT", 186, 207], ["CAd", "PROBLEM", 223, 226], ["CAd", "OBSERVATION", 223, 226]]], ["Importantly, however, neutralizing antibodies against CAd2 are not prevalent in humans [52] .", [["CAd2", "GENE_OR_GENE_PRODUCT", 54, 58], ["humans", "ORGANISM", 80, 86], ["neutralizing antibodies", "PROTEIN", 22, 45], ["CAd2", "PROTEIN", 54, 58], ["humans", "SPECIES", 80, 86], ["humans", "SPECIES", 80, 86], ["neutralizing antibodies", "TEST", 22, 45], ["CAd2", "PROBLEM", 54, 58]]], ["CAd2 vectors can efficiently transduce a variety of human cells [54, 78] but do not grow in these cells.", [["cells", "ANATOMY", 58, 63], ["cells", "ANATOMY", 98, 103], ["CAd2", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 52, 57], ["cells", "CELL", 58, 63], ["cells", "CELL", 98, 103], ["CAd2 vectors", "DNA", 0, 12], ["human cells", "CELL_TYPE", 52, 63], ["human", "SPECIES", 52, 57], ["human", "SPECIES", 52, 57]]], ["Although CAd2 was found to interact with CAR [80] , its tropism is distinct from HAd5 as indicated by preferential transduction of nervous tissue [78, 81] , and novel tropism of a chimeric HAd5 vector carrying the CAd2 fiber [47] .", [["nervous tissue", "ANATOMY", 131, 145], ["CAd2", "CHEMICAL", 9, 13], ["CAd2", "GENE_OR_GENE_PRODUCT", 9, 13], ["CAR [80", "GENE_OR_GENE_PRODUCT", 41, 48], ["HAd5", "GENE_OR_GENE_PRODUCT", 81, 85], ["nervous tissue", "TISSUE", 131, 145], ["HAd5", "GENE_OR_GENE_PRODUCT", 189, 193], ["CAd2", "PROTEIN", 9, 13], ["CAR", "PROTEIN", 41, 44], ["HAd5", "PROTEIN", 81, 85], ["chimeric HAd5 vector", "DNA", 180, 200], ["a chimeric HAd5 vector", "TREATMENT", 178, 200], ["nervous tissue", "ANATOMY", 131, 145]]], ["This feature of CAd2 should be helpful in designing alternate vectors for the targeted gene delivery.Chimpanzee Ad vectorsNine serotypes of chimpanzee Ad are currently known, which are classified as simian Ad (SAd) under Mastadenovirus genus [50] .", [["CAd2", "GENE_OR_GENE_PRODUCT", 16, 20], ["Ad", "ORGANISM", 112, 114], ["chimpanzee", "ORGANISM", 140, 150], ["Ad", "ORGANISM", 151, 153], ["simian Ad", "ORGANISM", 199, 208], ["CAd2", "PROTEIN", 16, 20], ["chimpanzee", "SPECIES", 140, 150], ["simian", "SPECIES", 199, 205], ["CAd2", "TREATMENT", 16, 20], ["alternate vectors", "TREATMENT", 52, 69], ["the targeted gene delivery", "TREATMENT", 74, 100], ["Chimpanzee Ad vectors", "TREATMENT", 101, 122]]], ["The complete nucleotide sequences of SAd25 (also referred as AdC68 or Pan 6), as well as SAd22, SAd23 and SAd24 are now available [46, 82, 83] .", [["nucleotide", "CHEMICAL", 13, 23], ["nucleotide", "CHEMICAL", 13, 23], ["SAd24", "CHEMICAL", 106, 111], ["SAd25", "GENE_OR_GENE_PRODUCT", 37, 42], ["Pan 6", "GENE_OR_GENE_PRODUCT", 70, 75], ["SAd22", "GENE_OR_GENE_PRODUCT", 89, 94], ["SAd23", "GENE_OR_GENE_PRODUCT", 96, 101], ["SAd24", "GENE_OR_GENE_PRODUCT", 106, 111], ["SAd25", "PROTEIN", 37, 42], ["AdC68", "DNA", 61, 66], ["Pan 6", "PROTEIN", 70, 75], ["SAd22", "DNA", 89, 94], ["SAd23", "DNA", 96, 101], ["SAd24", "DNA", 106, 111], ["SAd25", "TEST", 37, 42], ["AdC68", "TEST", 61, 66], ["SAd22", "TEST", 89, 94], ["SAd23", "TEST", 96, 101], ["SAd24", "TEST", 106, 111]]], ["SAd25 is grouped under HAd subgroup E based on its sequence homology and genome organization.", [["SAd25", "GENE_OR_GENE_PRODUCT", 0, 5], ["SAd25", "DNA", 0, 5], ["HAd subgroup E", "DNA", 23, 37], ["SAd25", "TEST", 0, 5], ["subgroup E", "TREATMENT", 27, 37]]], ["These viruses do not cause any apparent clinical symptoms in chimpanzees.", [["chimpanzees", "ORGANISM", 61, 72], ["These viruses", "PROBLEM", 0, 13], ["clinical symptoms in chimpanzees", "PROBLEM", 40, 72]]], ["Unlike other nonhuman Ad, which were initially developed as vaccine vectors for their natural hosts, interest towards developing gene delivery vectors based on SAd has gained impetus primarily because of their ability to circumvent preexisting immunity to HAd vectors [13, 46, 84] .Chimpanzee Ad vectorsBecause of their close homology with HAd, transcomplementation of El function of SAd viruses by HAd5 El was anticipated.", [["SAd", "CHEMICAL", 160, 163], ["nonhuman", "ORGANISM", 13, 21], ["Ad", "ORGANISM", 22, 24], ["Ad", "ORGANISM", 293, 295], ["HAd", "GENE_OR_GENE_PRODUCT", 340, 343], ["SAd viruses", "ORGANISM", 384, 395], ["HAd5", "GENE_OR_GENE_PRODUCT", 399, 403], ["HAd5 El", "DNA", 399, 406], ["vaccine vectors", "TREATMENT", 60, 75], ["gene delivery vectors", "TREATMENT", 129, 150], ["SAd viruses", "PROBLEM", 384, 395]]], ["The first El-deleted replication-defective SAd25 recombinant carrying the enhanced green fluorescent protein (EGFP) as a reporter gene was rescued by homologous recombination in the human El-complementing 293 cell line [46] (Fig. 3) .", [["293 cell line", "ANATOMY", 205, 218], ["SAd25", "GENE_OR_GENE_PRODUCT", 43, 48], ["green fluorescent protein", "GENE_OR_GENE_PRODUCT", 83, 108], ["EGFP", "GENE_OR_GENE_PRODUCT", 110, 114], ["human", "ORGANISM", 182, 187], ["293 cell line [46", "CELL", 205, 222], ["Fig. 3", "CELL", 225, 231], ["SAd25 recombinant", "PROTEIN", 43, 60], ["enhanced green fluorescent protein", "PROTEIN", 74, 108], ["EGFP", "PROTEIN", 110, 114], ["reporter gene", "DNA", 121, 134], ["human El-complementing 293 cell line", "CELL_LINE", 182, 218], ["human", "SPECIES", 182, 187], ["human", "SPECIES", 182, 187], ["The first El-deleted replication", "TREATMENT", 0, 32], ["defective SAd25", "PROBLEM", 33, 48], ["a reporter gene", "TREATMENT", 119, 134]]], ["Rescue of recombinant SAd vectors in cell lines that complement HAd5 El is not associated with any potential risk of generating replication-competent Ad vectors [46, 84] .Chimpanzee Ad vectorsWith continued efforts towards developing an efficacious vaccine against HIV, interest grew for an HAd vector vaccine against HIV-1 that has shown great promise in animal models [23, 24, 85] .", [["cell lines", "ANATOMY", 37, 47], ["HIV", "DISEASE", 265, 268], ["SAd", "GENE_OR_GENE_PRODUCT", 22, 25], ["cell lines", "CELL", 37, 47], ["HAd5", "GENE_OR_GENE_PRODUCT", 64, 68], ["Ad", "ORGANISM", 150, 152], ["Ad", "ORGANISM", 182, 184], ["HIV", "ORGANISM", 265, 268], ["HIV-1", "ORGANISM", 318, 323], ["recombinant SAd vectors", "DNA", 10, 33], ["cell lines", "CELL_LINE", 37, 47], ["HAd5 El", "DNA", 64, 71], ["HIV", "SPECIES", 265, 268], ["HIV-1", "SPECIES", 318, 323], ["HIV", "SPECIES", 265, 268], ["HIV-1", "SPECIES", 318, 323], ["Rescue of recombinant SAd vectors", "TREATMENT", 0, 33], ["Chimpanzee Ad vectorsWith", "TREATMENT", 171, 196], ["an efficacious vaccine", "TREATMENT", 234, 256], ["HIV", "PROBLEM", 265, 268], ["vector vaccine", "TREATMENT", 295, 309], ["HIV", "PROBLEM", 318, 321], ["cell lines", "OBSERVATION", 37, 47], ["great", "OBSERVATION_MODIFIER", 339, 344]]], ["Here again, the preexisting immunity against HAd5 in the human population may dampen the initial preclinical promise as these vaccines enter clinical trials.", [["HAd5", "CHEMICAL", 45, 49], ["HAd5", "GENE_OR_GENE_PRODUCT", 45, 49], ["human", "ORGANISM", 57, 62], ["HAd5", "PROTEIN", 45, 49], ["human", "SPECIES", 57, 62], ["human", "SPECIES", 57, 62], ["these vaccines", "TREATMENT", 120, 134]]], ["SAd25-based HIV-1 vaccines are, therefore, being investigated for their efficacy, safety and potential as an alternative to HAd5 vector vaccines [13, 14, 86 ].", [["SAd25", "CHEMICAL", 0, 5], ["SAd25", "SIMPLE_CHEMICAL", 0, 5], ["HIV-1", "ORGANISM", 12, 17], ["HAd5", "ORGANISM", 124, 128], ["HIV-1", "SPECIES", 12, 17], ["HIV-1", "SPECIES", 12, 17], ["HAd5", "SPECIES", 124, 128], ["SAd25", "TEST", 0, 5], ["HIV-1 vaccines", "TREATMENT", 12, 26], ["an alternative to HAd5 vector vaccines", "TREATMENT", 106, 144]]], ["An El-deleted SAd25 vector expressing the truncated-form of the HIV-1 gag antigen induced a gag-specific CD8+ T cell response following oral administration in a mouse model [14] .", [["CD8+ T cell", "ANATOMY", 105, 116], ["oral", "ANATOMY", 136, 140], ["SAd25", "GENE_OR_GENE_PRODUCT", 14, 19], ["HIV-1", "ORGANISM", 64, 69], ["gag", "ORGANISM", 70, 73], ["gag", "GENE_OR_GENE_PRODUCT", 92, 95], ["CD8", "GENE_OR_GENE_PRODUCT", 105, 108], ["oral", "ORGANISM_SUBDIVISION", 136, 140], ["mouse", "ORGANISM", 161, 166], ["El-deleted SAd25 vector", "DNA", 3, 26], ["HIV-1 gag antigen", "PROTEIN", 64, 81], ["CD8", "PROTEIN", 105, 108], ["HIV-1", "SPECIES", 64, 69], ["mouse", "SPECIES", 161, 166], ["HIV-1", "SPECIES", 64, 69], ["mouse", "SPECIES", 161, 166], ["An El", "TEST", 0, 5], ["the HIV", "TEST", 60, 67], ["gag antigen", "TEST", 70, 81], ["a gag", "TEST", 90, 95], ["oral administration", "TREATMENT", 136, 155]]], ["The T cell response could be augmented with a systemic-booster immunization.", [["T cell", "ANATOMY", 4, 10], ["T cell", "CELL", 4, 10], ["a systemic-booster immunization", "TREATMENT", 44, 75]]], ["Immunization using HAd5 and SAd25 vectors expressing the HIV-1 gag antigen induced strong, antigen-specific cellular as well as humoral responses in mice as well as monkeys [86] .Chimpanzee Ad vectorsRecently, molecular clones of three SAd serotypes, SAd-22, -23 and -24 (also referred to as Pan-5, -6 and -7, respectively) were developed by deleting their El sequences [83] .", [["cellular", "ANATOMY", 108, 116], ["HAd5", "GENE_OR_GENE_PRODUCT", 19, 23], ["SAd25", "GENE_OR_GENE_PRODUCT", 28, 33], ["HIV-1", "ORGANISM", 57, 62], ["gag antigen", "GENE_OR_GENE_PRODUCT", 63, 74], ["cellular", "CELL", 108, 116], ["mice", "ORGANISM", 149, 153], ["monkeys", "ORGANISM", 165, 172], ["Ad", "ORGANISM", 190, 192], ["SAd", "GENE_OR_GENE_PRODUCT", 236, 239], ["SAd-22", "ORGANISM", 251, 257], ["HAd5 and SAd25 vectors", "DNA", 19, 41], ["HIV-1 gag antigen", "PROTEIN", 57, 74], ["SAd-22, -23 and -24", "DNA", 251, 270], ["Pan-5, -6 and -7", "DNA", 292, 308], ["El sequences", "DNA", 357, 369], ["HIV-1", "SPECIES", 57, 62], ["mice", "SPECIES", 149, 153], ["HIV-1", "SPECIES", 57, 62], ["mice", "SPECIES", 149, 153], ["Immunization", "TREATMENT", 0, 12], ["HAd5", "TREATMENT", 19, 23], ["SAd25 vectors", "TREATMENT", 28, 41], ["the HIV", "TEST", 53, 60], ["gag antigen", "TEST", 63, 74], ["Chimpanzee Ad vectorsRecently", "TREATMENT", 179, 208], ["three SAd serotypes", "PROBLEM", 230, 249], ["SAd", "TEST", 251, 254]]], ["Similar to SAd25, El-functions of these SAd serotypes were also complemented by HAd5 El, and replication-defective vectors could propagate in human 293 cells.Chimpanzee Ad vectorsVarious chimpanzee Ad, including SAd25, are not naturally prevalent in the human population [46, 83] .", [["293 cells", "ANATOMY", 148, 157], ["SAd25", "GENE_OR_GENE_PRODUCT", 11, 16], ["SAd", "GENE_OR_GENE_PRODUCT", 40, 43], ["HAd5", "GENE_OR_GENE_PRODUCT", 80, 84], ["human", "ORGANISM", 142, 147], ["293 cells", "CELL", 148, 157], ["Chimpanzee", "ORGANISM", 158, 168], ["Ad vectorsVarious chimpanzee", "ORGANISM", 169, 197], ["Ad", "ORGANISM", 198, 200], ["SAd25", "GENE_OR_GENE_PRODUCT", 212, 217], ["human", "ORGANISM", 254, 259], ["SAd25", "PROTEIN", 11, 16], ["replication-defective vectors", "DNA", 93, 122], ["human 293 cells", "CELL_LINE", 142, 157], ["human", "SPECIES", 142, 147], ["chimpanzee", "SPECIES", 187, 197], ["human", "SPECIES", 254, 259], ["human", "SPECIES", 142, 147], ["Chimpanzee Ad vectorsVarious chimpanzee", "SPECIES", 158, 197], ["human", "SPECIES", 254, 259], ["SAd25", "TEST", 11, 16], ["these SAd serotypes", "PROBLEM", 34, 53], ["replication-defective vectors", "TREATMENT", 93, 122], ["Chimpanzee Ad vectorsVarious chimpanzee Ad", "TREATMENT", 158, 200]]], ["In a panel of human, chimpanzee, or rhesus monkey serum samples, 80% of samples from the chimpanzee had neutralizing antibodies against SAd25 while only 2% of human or rhesus monkey samples had SAd25-neutralizing antibodies.", [["serum samples", "ANATOMY", 50, 63], ["samples", "ANATOMY", 72, 79], ["samples", "ANATOMY", 182, 189], ["human", "ORGANISM", 14, 19], ["chimpanzee", "ORGANISM", 21, 31], ["rhesus", "ORGANISM", 36, 42], ["monkey", "ORGANISM", 43, 49], ["serum samples", "ORGANISM_SUBSTANCE", 50, 63], ["samples", "CANCER", 72, 79], ["chimpanzee", "ORGANISM", 89, 99], ["SAd25", "GENE_OR_GENE_PRODUCT", 136, 141], ["human", "ORGANISM", 159, 164], ["rhesus", "ORGANISM", 168, 174], ["monkey", "ORGANISM", 175, 181], ["SAd25", "GENE_OR_GENE_PRODUCT", 194, 199], ["neutralizing antibodies", "PROTEIN", 104, 127], ["SAd25", "PROTEIN", 136, 141], ["SAd25", "PROTEIN", 194, 199], ["neutralizing antibodies", "PROTEIN", 200, 223], ["human", "SPECIES", 14, 19], ["chimpanzee", "SPECIES", 21, 31], ["rhesus monkey", "SPECIES", 36, 49], ["chimpanzee", "SPECIES", 89, 99], ["human", "SPECIES", 159, 164], ["rhesus monkey", "SPECIES", 168, 181], ["human", "SPECIES", 14, 19], ["chimpanzee", "SPECIES", 21, 31], ["rhesus monkey", "SPECIES", 36, 49], ["chimpanzee", "SPECIES", 89, 99], ["human", "SPECIES", 159, 164], ["rhesus monkey", "SPECIES", 168, 181], ["human", "TEST", 14, 19], ["chimpanzee", "TEST", 21, 31], ["serum samples", "TEST", 50, 63], ["samples", "TEST", 72, 79], ["the chimpanzee", "TEST", 85, 99], ["neutralizing antibodies", "TEST", 104, 127], ["SAd25", "TEST", 136, 141], ["SAd25", "TEST", 194, 199], ["neutralizing antibodies", "PROBLEM", 200, 223]]], ["Preexisting immunity against several common serotypes of HAd including HAd5, did not reduce the antibody response to the transgene expressed by an SAd25 vector in a mouse model [84] .", [["HAd5", "CHEMICAL", 71, 75], ["HAd", "GENE_OR_GENE_PRODUCT", 57, 60], ["HAd5", "GENE_OR_GENE_PRODUCT", 71, 75], ["SAd25", "GENE_OR_GENE_PRODUCT", 147, 152], ["mouse", "ORGANISM", 165, 170], ["SAd25 vector", "DNA", 147, 159], ["mouse", "SPECIES", 165, 170], ["mouse", "SPECIES", 165, 170], ["the antibody response", "PROBLEM", 92, 113], ["an SAd25 vector", "TREATMENT", 144, 159]]], ["Preexposure of mice to replication-defective or replicationcompetent HAd5 blunted the antibody response following inoculation with a HAd5 vector but did not affect after immunization with a SAd25 vector [84, 87] .", [["HAd5", "CHEMICAL", 69, 73], ["mice", "ORGANISM", 15, 19], ["HAd5", "SIMPLE_CHEMICAL", 69, 73], ["HAd5", "GENE_OR_GENE_PRODUCT", 133, 137], ["replicationcompetent HAd5", "PROTEIN", 48, 73], ["HAd5 vector", "DNA", 133, 144], ["SAd25 vector", "DNA", 190, 202], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19], ["defective or replicationcompetent HAd5", "PROBLEM", 35, 73], ["the antibody response", "PROBLEM", 82, 103], ["a HAd5 vector", "TREATMENT", 131, 144], ["immunization", "TREATMENT", 170, 182]]], ["Similar observations were made for other SAd serotypes (SAd22, SAd23 and SAd24) [83] .", [["SAd", "GENE_OR_GENE_PRODUCT", 41, 44], ["other SAd serotypes", "PROBLEM", 35, 54], ["SAd22", "TEST", 56, 61], ["SAd23", "TEST", 63, 68]]], ["Interestingly, antibodies against SAd22, SAd24, or SAd25 cross-neutralized each other but did not neutralize SAd23.", [["SAd22", "GENE_OR_GENE_PRODUCT", 34, 39], ["SAd24", "GENE_OR_GENE_PRODUCT", 41, 46], ["SAd25", "GENE_OR_GENE_PRODUCT", 51, 56], ["SAd23", "GENE_OR_GENE_PRODUCT", 109, 114], ["antibodies", "PROTEIN", 15, 25], ["SAd22", "PROTEIN", 34, 39], ["SAd24", "PROTEIN", 41, 46], ["SAd25", "PROTEIN", 51, 56], ["SAd23", "PROTEIN", 109, 114], ["antibodies", "TEST", 15, 25], ["SAd22", "TEST", 34, 39], ["SAd24", "TEST", 41, 46]]], ["SAd25 as well as SAd22, SAd23 and SAd24 efficiently transduced human HeLa and A549 cells [83] .", [["HeLa", "ANATOMY", 69, 73], ["A549 cells", "ANATOMY", 78, 88], ["SAd25", "GENE_OR_GENE_PRODUCT", 0, 5], ["SAd22", "GENE_OR_GENE_PRODUCT", 17, 22], ["SAd23", "GENE_OR_GENE_PRODUCT", 24, 29], ["SAd24", "GENE_OR_GENE_PRODUCT", 34, 39], ["human", "ORGANISM", 63, 68], ["HeLa", "CELL", 69, 73], ["A549 cells", "CELL", 78, 88], ["SAd25", "PROTEIN", 0, 5], ["SAd22", "PROTEIN", 17, 22], ["SAd23", "PROTEIN", 24, 29], ["SAd24", "PROTEIN", 34, 39], ["transduced human HeLa", "CELL_LINE", 52, 73], ["A549 cells", "CELL_LINE", 78, 88], ["human", "SPECIES", 63, 68], ["human", "SPECIES", 63, 68], ["SAd25", "TEST", 0, 5], ["SAd22", "TEST", 17, 22], ["SAd23", "TEST", 24, 29], ["SAd24", "TEST", 34, 39], ["A549 cells", "TEST", 78, 88]]], ["Since various SAd serotypes do not cross-neutralize each other, these can be used for readministration of the immunogen.Chimpanzee Ad vectorsChimpanzee Ad vectors efficiently transduced various human cells in culture [46, 83] .", [["cells", "ANATOMY", 200, 205], ["Chimpanzee", "ORGANISM", 120, 130], ["Ad vectorsChimpanzee Ad", "ORGANISM", 131, 154], ["human", "ORGANISM", 194, 199], ["cells", "CELL", 200, 205], ["human cells", "CELL_TYPE", 194, 205], ["human", "SPECIES", 194, 199], ["human", "SPECIES", 194, 199], ["various SAd serotypes", "PROBLEM", 6, 27], ["the immunogen", "TREATMENT", 106, 119], ["Chimpanzee Ad vectorsChimpanzee Ad vectors", "TREATMENT", 120, 162], ["culture", "TEST", 209, 216]]], ["The transduction profile of these vectors was comparable to that of HAd5.", [["HAd5", "CHEMICAL", 68, 72], ["HAd5", "GENE_OR_GENE_PRODUCT", 68, 72], ["HAd5", "PROTEIN", 68, 72]]], ["It has been shown that SAd25 is internalized via the CAR receptor [88] .", [["SAd25", "CHEMICAL", 23, 28], ["SAd25", "GENE_OR_GENE_PRODUCT", 23, 28], ["CAR receptor", "GENE_OR_GENE_PRODUCT", 53, 65], ["SAd25", "PROTEIN", 23, 28], ["CAR receptor", "PROTEIN", 53, 65]]], ["Ongoing research will provide further insight on their safety and efficacy for human vaccination.Ovine Ad vectorsThere are seven distinct serotypes of Ad isolated from sheep.", [["human", "ORGANISM", 79, 84], ["Ovine", "ORGANISM", 97, 102], ["Ad", "ORGANISM", 103, 105], ["Ad", "ORGANISM", 151, 153], ["sheep", "ORGANISM", 168, 173], ["human", "SPECIES", 79, 84], ["sheep", "SPECIES", 168, 173], ["human", "SPECIES", 79, 84], ["Ad", "SPECIES", 151, 153], ["sheep", "SPECIES", 168, 173], ["human vaccination", "TREATMENT", 79, 96], ["Ovine Ad vectors", "TREATMENT", 97, 113], ["seven", "OBSERVATION_MODIFIER", 123, 128], ["distinct", "OBSERVATION_MODIFIER", 129, 137], ["serotypes", "OBSERVATION", 138, 147], ["Ad isolated", "OBSERVATION_MODIFIER", 151, 162]]], ["These are referred to as ovine Ad serotypes 1-7 (OAd1-7).", [["ovine", "ORGANISM", 25, 30], ["Ad serotypes 1-7", "ORGANISM", 31, 47], ["OAd1-7", "GENE_OR_GENE_PRODUCT", 49, 55], ["ovine Ad serotypes", "TEST", 25, 43]]], ["Serotypes 1-6 are assigned to the genus Mastadenovirus.", [["Serotypes", "TREATMENT", 0, 9], ["genus Mastadenovirus", "ANATOMY", 34, 54]]], ["Serotype 7 (OAd7, isolate 287 or AdC68) is a nonpathogenic Ad of sheep.", [["Serotype 7", "ORGANISM", 0, 10], ["OAd7", "GENE_OR_GENE_PRODUCT", 12, 16], ["AdC68", "GENE_OR_GENE_PRODUCT", 33, 38], ["Ad", "ORGANISM", 59, 61], ["sheep", "ORGANISM", 65, 70], ["sheep", "SPECIES", 65, 70], ["sheep", "SPECIES", 65, 70], ["Serotype", "TEST", 0, 8], ["sheep", "OBSERVATION", 65, 70]]], ["It has a unique genome organization distinct from that of genus Mastadenovirus or Aviadenovirus.", [["Mastadenovirus", "GENE_OR_GENE_PRODUCT", 64, 78], ["Aviadenovirus", "GENE_OR_GENE_PRODUCT", 82, 95], ["genus Mastadenovirus", "PROBLEM", 58, 78], ["Aviadenovirus", "PROBLEM", 82, 95], ["unique", "OBSERVATION_MODIFIER", 9, 15], ["genome organization", "OBSERVATION", 16, 35], ["distinct", "OBSERVATION_MODIFIER", 36, 44], ["genus Mastadenovirus", "OBSERVATION", 58, 78]]], ["The complete nucleotide sequence of OAd7 is now available.", [["nucleotide", "CHEMICAL", 13, 23], ["OAd7", "CHEMICAL", 36, 40], ["nucleotide", "CHEMICAL", 13, 23], ["OAd7", "SIMPLE_CHEMICAL", 36, 40], ["OAd7", "DNA", 36, 40], ["The complete nucleotide sequence of OAd7", "TEST", 0, 40]]], ["The OAd7 genome is characterized by a high AT content and the lack of a clearly distinguishable El region [89] .", [["OAd7", "GENE_OR_GENE_PRODUCT", 4, 8], ["OAd7 genome", "DNA", 4, 15], ["El region", "DNA", 96, 105], ["a high AT content", "PROBLEM", 36, 53], ["genome", "OBSERVATION", 9, 15], ["high", "OBSERVATION_MODIFIER", 38, 42]]], ["Owing to these differences, OAd7 along with Ad isolates from deer, possum, duck, snake, etc. is now classified under a new genus Atadenovirus [90] .", [["OAd7", "CHEMICAL", 28, 32], ["OAd7", "SIMPLE_CHEMICAL", 28, 32], ["Ad", "ORGANISM", 44, 46], ["deer", "ORGANISM", 61, 65], ["possum", "ORGANISM_SUBDIVISION", 67, 73], ["duck", "ORGANISM", 75, 79], ["snake", "ORGANISM_SUBDIVISION", 81, 86], ["OAd7", "PROTEIN", 28, 32], ["deer", "SPECIES", 61, 65], ["duck", "SPECIES", 75, 79], ["deer", "SPECIES", 61, 65], ["Ad isolates", "TREATMENT", 44, 55]]], ["Recombinant OAd7 vectors can be constructed and rescued by homologous recombination in E. coli followed by transfection of a permissive ovine fetal lung cell line (CSL503) [91] (Fig. 3) .", [["fetal lung cell line", "ANATOMY", 142, 162], ["OAd7", "GENE_OR_GENE_PRODUCT", 12, 16], ["E. coli", "ORGANISM", 87, 94], ["ovine", "ORGANISM", 136, 141], ["fetal lung cell line", "CELL", 142, 162], ["CSL503", "CELL", 164, 170], ["Recombinant OAd7 vectors", "DNA", 0, 24], ["permissive ovine fetal lung cell line", "CELL_LINE", 125, 162], ["CSL503", "CELL_LINE", 164, 170], ["E. coli", "SPECIES", 87, 94], ["E. coli", "SPECIES", 87, 94], ["Recombinant OAd7 vectors", "TREATMENT", 0, 24], ["E. coli", "PROBLEM", 87, 94], ["a permissive ovine fetal lung cell line", "TREATMENT", 123, 162], ["lung", "ANATOMY", 148, 152], ["cell line", "OBSERVATION", 153, 162]]], ["Another, more efficient cosmidbased strategy for vector generation following vector rescue in an ovine fetal skin fibroblastic cell line has also been developed [92] .", [["fetal skin fibroblastic cell line", "ANATOMY", 103, 136], ["ovine", "ORGANISM", 97, 102], ["fetal skin fibroblastic cell line", "CELL", 103, 136], ["ovine fetal skin fibroblastic cell line", "CELL_LINE", 97, 136], ["ovine", "SPECIES", 97, 102], ["efficient cosmidbased strategy", "TREATMENT", 14, 44], ["vector generation", "TREATMENT", 49, 66], ["vector rescue", "TREATMENT", 77, 90], ["an ovine fetal skin fibroblastic cell line", "TREATMENT", 94, 136], ["skin", "ANATOMY", 109, 113], ["fibroblastic cell line", "OBSERVATION", 114, 136]]], ["Three dispensable, nonessential regions of the viral genome, where foreign genes can be inserted, have been delineated [93] .", [["viral genome", "DNA", 47, 59], ["foreign genes", "DNA", 67, 80], ["the viral genome", "PROBLEM", 43, 59], ["foreign genes", "TREATMENT", 67, 80], ["nonessential", "OBSERVATION_MODIFIER", 19, 31], ["regions", "OBSERVATION_MODIFIER", 32, 39], ["viral genome", "OBSERVATION", 47, 59], ["foreign genes", "OBSERVATION", 67, 80]]], ["These are referred as the sites I, II and III (Fig. 2) .", [["sites I, II and III", "DNA", 26, 45]]], ["The site I is located between the pVIII and fiber genes; the site II is located towards the right end of the viral genome [94] ; and the site III is located between the E4 region and right end transcription unit [95] .", [["right end", "ANATOMY", 92, 101], ["pVIII", "GENE_OR_GENE_PRODUCT", 34, 39], ["fiber", "CELLULAR_COMPONENT", 44, 49], ["E4", "GENE_OR_GENE_PRODUCT", 169, 171], ["site I", "DNA", 4, 10], ["pVIII", "DNA", 34, 39], ["fiber genes", "DNA", 44, 55], ["site II", "DNA", 61, 68], ["right end", "DNA", 92, 101], ["viral genome", "DNA", 109, 121], ["site III", "DNA", 137, 145], ["E4 region", "DNA", 169, 178], ["right end transcription unit", "DNA", 183, 211], ["pVIII", "ANATOMY", 34, 39], ["fiber genes", "OBSERVATION", 44, 55], ["right", "ANATOMY_MODIFIER", 92, 97], ["viral genome", "OBSERVATION", 109, 121], ["E4", "ANATOMY_MODIFIER", 169, 171], ["region", "ANATOMY_MODIFIER", 172, 178], ["right", "ANATOMY_MODIFIER", 183, 188]]], ["Recombinant OAd7 vectors carrying transgene inserts at the site III are most stable making it the most preferred region for foreign gene insertion.", [["OAd7", "GENE_OR_GENE_PRODUCT", 12, 16], ["Recombinant OAd7 vectors", "DNA", 0, 24], ["transgene inserts", "DNA", 34, 51], ["site III", "DNA", 59, 67], ["foreign gene insertion", "DNA", 124, 146], ["Recombinant OAd7 vectors", "TREATMENT", 0, 24], ["foreign gene insertion", "TREATMENT", 124, 146], ["transgene inserts", "OBSERVATION", 34, 51], ["stable", "OBSERVATION_MODIFIER", 77, 83], ["foreign gene insertion", "OBSERVATION", 124, 146]]], ["The biology and potential gene delivery applications of OAd7 have recently been reviewed [93] .Ovine Ad vectorsA number of recombinant OAd7 vectors expressing foreign genes encoding immunogenic proteins have been developed.", [["OAd7", "CHEMICAL", 56, 60], ["OAd7", "CHEMICAL", 56, 60], ["OAd7", "SIMPLE_CHEMICAL", 56, 60], ["Ovine", "ORGANISM", 95, 100], ["Ad", "ORGANISM", 101, 103], ["OAd7", "GENE_OR_GENE_PRODUCT", 135, 139], ["OAd7", "PROTEIN", 56, 60], ["recombinant OAd7 vectors", "DNA", 123, 147], ["foreign genes", "DNA", 159, 172], ["immunogenic proteins", "PROTEIN", 182, 202], ["potential gene delivery applications", "TREATMENT", 16, 52], ["Ovine Ad vectorsA", "TREATMENT", 95, 112], ["recombinant OAd7 vectors", "TREATMENT", 123, 147], ["foreign genes encoding immunogenic proteins", "PROBLEM", 159, 202], ["foreign genes", "OBSERVATION", 159, 172]]], ["An OAd7 recombinant expressing hepatitis C virus NS3 protein elicited a strong and sustained antigen specific T-cell response in mice [96] .", [["T-cell", "ANATOMY", 110, 116], ["OAd7", "GENE_OR_GENE_PRODUCT", 3, 7], ["hepatitis C virus", "ORGANISM", 31, 48], ["NS3", "ORGANISM", 49, 52], ["T-cell", "CELL", 110, 116], ["mice", "ORGANISM", 129, 133], ["OAd7 recombinant expressing hepatitis C virus NS3 protein", "PROTEIN", 3, 60], ["hepatitis C virus NS3", "SPECIES", 31, 52], ["mice", "SPECIES", 129, 133], ["hepatitis C virus", "SPECIES", 31, 48], ["mice", "SPECIES", 129, 133], ["An OAd7 recombinant", "TREATMENT", 0, 19], ["hepatitis C virus NS3 protein", "PROBLEM", 31, 60], ["sustained antigen", "TEST", 83, 100]]], ["High levels of transgene were expressed following vector administration by intravenous route [49] .", [["intravenous", "ANATOMY", 75, 86], ["intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 75, 86], ["vector administration", "TREATMENT", 50, 71]]], ["Vector biodistribution was similar in the spleen, heart, kidney and the liver while the lung was infected to a lower degree.", [["spleen", "ANATOMY", 42, 48], ["heart", "ANATOMY", 50, 55], ["kidney", "ANATOMY", 57, 63], ["liver", "ANATOMY", 72, 77], ["lung", "ANATOMY", 88, 92], ["spleen", "ORGAN", 42, 48], ["heart", "ORGAN", 50, 55], ["kidney", "ORGAN", 57, 63], ["liver", "ORGAN", 72, 77], ["lung", "ORGAN", 88, 92], ["Vector biodistribution", "TEST", 0, 22], ["similar", "OBSERVATION_MODIFIER", 27, 34], ["spleen", "ANATOMY", 42, 48], ["heart", "ANATOMY", 50, 55], ["kidney", "ANATOMY", 57, 63], ["liver", "ANATOMY", 72, 77], ["lung", "ANATOMY", 88, 92], ["infected", "OBSERVATION", 97, 105], ["lower degree", "OBSERVATION_MODIFIER", 111, 123]]], ["Similarly, high serum levels of the transgene product were produced following intramuscular administration of an OAd7 vectors expressing human alpha 1-antitrypsin gene in mice [97] .", [["serum", "ANATOMY", 16, 21], ["intramuscular", "ANATOMY", 78, 91], ["serum", "ORGANISM_SUBSTANCE", 16, 21], ["intramuscular", "IMMATERIAL_ANATOMICAL_ENTITY", 78, 91], ["human", "ORGANISM", 137, 142], ["alpha 1-antitrypsin", "GENE_OR_GENE_PRODUCT", 143, 162], ["mice", "ORGANISM", 171, 175], ["transgene product", "PROTEIN", 36, 53], ["human alpha 1-antitrypsin gene", "DNA", 137, 167], ["human", "SPECIES", 137, 142], ["mice", "SPECIES", 171, 175], ["human", "SPECIES", 137, 142], ["mice", "SPECIES", 171, 175], ["high serum levels", "PROBLEM", 11, 28], ["the transgene product", "TREATMENT", 32, 53], ["intramuscular administration", "TREATMENT", 78, 106], ["an OAd7 vectors", "TREATMENT", 110, 125], ["human alpha", "TEST", 137, 148], ["high", "OBSERVATION_MODIFIER", 11, 15]]], ["An OAd7 vector expressing Taenia ovis antigen 45 W antigen inserted at site I under the control of the viral major late promoter elicited effective immunity against parasite challenge when used in combination with a DNA vaccine in a prime/boost approach [98] .Ovine Ad vectorsRecombinant OAd7 vectors have also been used for gene therapy [99] .", [["OAd7", "GENE_OR_GENE_PRODUCT", 3, 7], ["Taenia ovis antigen 45 W antigen", "GENE_OR_GENE_PRODUCT", 26, 58], ["DNA", "CELLULAR_COMPONENT", 216, 219], ["Ovine", "ORGANISM", 260, 265], ["Ad", "ORGANISM", 266, 268], ["OAd7 vector", "DNA", 3, 14], ["Taenia ovis antigen 45 W antigen", "PROTEIN", 26, 58], ["site I", "DNA", 71, 77], ["viral major late promoter", "DNA", 103, 128], ["Taenia ovis", "SPECIES", 26, 37], ["Taenia ovis", "SPECIES", 26, 37], ["Ovine Ad vectorsRecombinant OAd7", "SPECIES", 260, 292], ["An OAd7 vector", "TREATMENT", 0, 14], ["Taenia ovis antigen", "TREATMENT", 26, 45], ["the viral major late promoter", "TREATMENT", 99, 128], ["parasite challenge", "TREATMENT", 165, 183], ["a DNA vaccine", "TREATMENT", 214, 227], ["a prime/boost approach", "TREATMENT", 231, 253], ["Ovine Ad vectorsRecombinant OAd7 vectors", "TREATMENT", 260, 300], ["gene therapy", "TREATMENT", 325, 337]]], ["A recombinant vector expressing human \u24231antitrypsin (hAAT) gene under the control of the Rous sarcoma virus promoter was used for investigating gene transfer potential and in vivo distribution of the vector in immunocompetent as well as immunodeficient mouse models.", [["Rous sarcoma", "DISEASE", 89, 101], ["human", "ORGANISM", 32, 37], ["\u24231antitrypsin", "GENE_OR_GENE_PRODUCT", 38, 51], ["hAAT", "GENE_OR_GENE_PRODUCT", 53, 57], ["Rous sarcoma virus", "ORGANISM", 89, 107], ["mouse", "ORGANISM", 253, 258], ["human \u24231antitrypsin (hAAT) gene", "DNA", 32, 63], ["Rous sarcoma virus promoter", "DNA", 89, 116], ["human", "SPECIES", 32, 37], ["Rous sarcoma virus", "SPECIES", 89, 107], ["mouse", "SPECIES", 253, 258], ["human", "SPECIES", 32, 37], ["Rous sarcoma virus", "SPECIES", 89, 107], ["mouse", "SPECIES", 253, 258], ["A recombinant vector", "TREATMENT", 0, 20], ["human \u24231antitrypsin (hAAT)", "TREATMENT", 32, 58], ["the Rous sarcoma virus promoter", "TREATMENT", 85, 116], ["immunodeficient mouse models", "TREATMENT", 237, 265]]], ["The level and duration of hAAT gene expression were similar to those achieved with a HAd5 counterpart.", [["hAAT", "GENE_OR_GENE_PRODUCT", 26, 30], ["HAd5", "GENE_OR_GENE_PRODUCT", 85, 89], ["hAAT gene", "DNA", 26, 35], ["HAd5 counterpart", "CELL_LINE", 85, 101]]], ["However, the tissue-tropism of the OAd7 vector differed from that of HAd as the liver was not the dominant target.", [["tissue", "ANATOMY", 13, 19], ["liver", "ANATOMY", 80, 85], ["tissue", "TISSUE", 13, 19], ["OAd7", "GENE_OR_GENE_PRODUCT", 35, 39], ["HAd", "GENE_OR_GENE_PRODUCT", 69, 72], ["liver", "ORGAN", 80, 85], ["OAd7 vector", "DNA", 35, 46], ["HAd", "PROTEIN", 69, 72], ["the OAd7 vector", "TREATMENT", 31, 46], ["tropism", "OBSERVATION_MODIFIER", 20, 27], ["liver", "ANATOMY", 80, 85], ["dominant", "OBSERVATION_MODIFIER", 98, 106], ["target", "OBSERVATION", 107, 113]]], ["Transgene expres-sion was stable in the immunodeficient mice implying the role of vector immunity in clearance of transduced cells.", [["cells", "ANATOMY", 125, 130], ["Transgene", "GENE_OR_GENE_PRODUCT", 0, 9], ["immunodeficient mice", "ORGANISM", 40, 60], ["cells", "CELL", 125, 130], ["transduced cells", "CELL_LINE", 114, 130], ["mice", "SPECIES", 56, 60], ["mice", "SPECIES", 56, 60], ["the immunodeficient mice", "TREATMENT", 36, 60], ["transduced cells", "TREATMENT", 114, 130], ["stable", "OBSERVATION_MODIFIER", 26, 32], ["transduced cells", "OBSERVATION", 114, 130]]], ["Importantly, efficient gene transfer with the OAd7 vector in mice immunized with HAd vectors and vice versa [49] , thus underscoring the potential of OAd7 vectors for circumvention of HAd5 immunity.", [["OAd7", "GENE_OR_GENE_PRODUCT", 46, 50], ["mice", "ORGANISM", 61, 65], ["HAd", "GENE_OR_GENE_PRODUCT", 81, 84], ["OAd7", "GENE_OR_GENE_PRODUCT", 150, 154], ["HAd5", "GENE_OR_GENE_PRODUCT", 184, 188], ["OAd7 vector", "DNA", 46, 57], ["HAd vectors", "DNA", 81, 92], ["mice", "SPECIES", 61, 65], ["mice", "SPECIES", 61, 65], ["the OAd7 vector", "TREATMENT", 42, 57], ["OAd7 vectors", "TREATMENT", 150, 162], ["circumvention of HAd5 immunity", "TREATMENT", 167, 197]]], ["Other studies have investigated the usefulness of OAd7 vectors in gene-directed enzymeprodrug therapy approach [99, 100] .", [["OAd7", "GENE_OR_GENE_PRODUCT", 50, 54], ["OAd7 vectors", "DNA", 50, 62], ["Other studies", "TEST", 0, 13], ["OAd7 vectors", "TREATMENT", 50, 62], ["gene-directed enzymeprodrug therapy approach", "TREATMENT", 66, 110]]], ["Systemic administration of a single dose of a recombinant OAd7 vector carrying the E. coli purine nucleoside phosphorylase (PNP) gene followed by the prodrug fludarabine phosphate resulted in significant suppression of prostate cancer progression in an immunocompetent mouse model [100] .Ovine Ad vectorsA serological survey of human serum samples indicated that OAd7 neutralizing antibodies are not prevalent in humans [49] .", [["prostate cancer", "ANATOMY", 219, 234], ["serum samples", "ANATOMY", 334, 347], ["purine nucleoside", "CHEMICAL", 91, 108], ["fludarabine phosphate", "CHEMICAL", 158, 179], ["prostate cancer", "DISEASE", 219, 234], ["purine nucleoside", "CHEMICAL", 91, 108], ["fludarabine phosphate", "CHEMICAL", 158, 179], ["OAd7", "GENE_OR_GENE_PRODUCT", 58, 62], ["E. coli", "ORGANISM", 83, 90], ["purine nucleoside phosphorylase", "GENE_OR_GENE_PRODUCT", 91, 122], ["PNP", "GENE_OR_GENE_PRODUCT", 124, 127], ["fludarabine", "SIMPLE_CHEMICAL", 158, 169], ["prostate cancer", "CANCER", 219, 234], ["mouse", "ORGANISM", 269, 274], ["Ovine", "ORGANISM", 288, 293], ["Ad", "ORGANISM", 294, 296], ["human", "ORGANISM", 328, 333], ["serum samples", "ORGANISM_SUBSTANCE", 334, 347], ["OAd7", "GENE_OR_GENE_PRODUCT", 363, 367], ["humans", "ORGANISM", 413, 419], ["recombinant OAd7 vector", "DNA", 46, 69], ["E. coli purine nucleoside phosphorylase (PNP) gene", "DNA", 83, 133], ["OAd7 neutralizing antibodies", "PROTEIN", 363, 391], ["E. coli", "SPECIES", 83, 90], ["mouse", "SPECIES", 269, 274], ["human", "SPECIES", 328, 333], ["humans", "SPECIES", 413, 419], ["E. coli", "SPECIES", 83, 90], ["mouse", "SPECIES", 269, 274], ["human", "SPECIES", 328, 333], ["OAd7", "SPECIES", 363, 367], ["humans", "SPECIES", 413, 419], ["a recombinant OAd7 vector", "TREATMENT", 44, 69], ["the E. coli purine nucleoside phosphorylase (PNP) gene", "TREATMENT", 79, 133], ["the prodrug fludarabine phosphate", "TREATMENT", 146, 179], ["prostate cancer progression", "PROBLEM", 219, 246], ["an immunocompetent mouse model", "TREATMENT", 250, 280], ["Ovine Ad vectorsA", "TEST", 288, 305], ["human serum samples", "TEST", 328, 347], ["neutralizing antibodies", "TEST", 368, 391], ["significant", "OBSERVATION_MODIFIER", 192, 203], ["suppression", "OBSERVATION_MODIFIER", 204, 215], ["prostate", "ANATOMY", 219, 227], ["cancer", "OBSERVATION", 228, 234]]], ["Furthermore, HAd5 neutralizing antibodies do not cross neutralize OAd7 [49] .", [["HAd5", "GENE_OR_GENE_PRODUCT", 13, 17], ["HAd5 neutralizing antibodies", "PROTEIN", 13, 41], ["HAd5 neutralizing antibodies", "TEST", 13, 41]]], ["Anti-HAd5 antibodies present in experimental animals impeded gene transfer with HAd5 vectors but did not prevent gene transfer with OAd7 vectors, indicating the potential of these vectors for evading HAd5 immunity [49] .", [["Anti-HAd5 antibodies", "GENE_OR_GENE_PRODUCT", 0, 20], ["HAd5", "GENE_OR_GENE_PRODUCT", 80, 84], ["OAd7", "GENE_OR_GENE_PRODUCT", 132, 136], ["HAd5", "GENE_OR_GENE_PRODUCT", 200, 204], ["Anti-HAd5 antibodies", "PROTEIN", 0, 20], ["HAd5 vectors", "DNA", 80, 92], ["OAd7 vectors", "DNA", 132, 144], ["Anti-HAd5 antibodies", "TREATMENT", 0, 20], ["HAd5 vectors", "TREATMENT", 80, 92], ["OAd7 vectors", "TREATMENT", 132, 144], ["these vectors", "TREATMENT", 174, 187]]], ["OAd7 vectors efficiently transduced a variety of human cells in culture.", [["cells", "ANATOMY", 55, 60], ["OAd7", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 49, 54], ["cells", "CELL", 55, 60], ["OAd7 vectors", "DNA", 0, 12], ["human cells", "CELL_TYPE", 49, 60], ["human", "SPECIES", 49, 54], ["OAd7", "SPECIES", 0, 4], ["human", "SPECIES", 49, 54], ["OAd7 vectors", "TREATMENT", 0, 12], ["human cells", "PROBLEM", 49, 60], ["culture", "TEST", 64, 71], ["human cells", "OBSERVATION", 49, 60]]], ["Importantly, OAd7 infection of several nonovine cells tested was abortive as progeny virus could not be detected despite some replication of viral DNA [101] .", [["nonovine cells", "ANATOMY", 39, 53], ["OAd7", "CHEMICAL", 13, 17], ["infection", "DISEASE", 18, 27], ["OAd7", "GENE_OR_GENE_PRODUCT", 13, 17], ["nonovine cells", "CELL", 39, 53], ["DNA", "CELLULAR_COMPONENT", 147, 150], ["nonovine cells", "CELL_LINE", 39, 53], ["OAd7 infection", "PROBLEM", 13, 27], ["several nonovine cells", "PROBLEM", 31, 53], ["progeny virus", "PROBLEM", 77, 90], ["viral DNA", "PROBLEM", 141, 150]]], ["These observations have significant impact with respect to suitability and safety of the OAd7 vector system for future use in humans.", [["humans", "ORGANISM", 126, 132], ["humans", "SPECIES", 126, 132], ["humans", "SPECIES", 126, 132], ["the OAd7 vector system", "TREATMENT", 85, 107]]], ["Although receptors involved in OAd7 internalization are not known, OAd7 appears to use receptors distinct from those of HAd5.", [["OAd7", "CHEMICAL", 67, 71], ["OAd7", "GENE_OR_GENE_PRODUCT", 31, 35], ["OAd7", "SIMPLE_CHEMICAL", 67, 71], ["HAd5", "GENE_OR_GENE_PRODUCT", 120, 124], ["OAd7", "PROTEIN", 31, 35], ["OAd7", "PROTEIN", 67, 71], ["HAd5", "PROTEIN", 120, 124]]], ["This is supported by distinct in vivo tropism and differential transduction profile of OAd7 and HAd5 [49, 93] , as well as altered tropism of a chimeric OAd7 vector carrying the fiber knob domain of HAd5 [102] .Porcine Ad vectorsFive serotypes of porcine Ad (PAd1-5) are currently known to infect pigs [51] .", [["PAd1-5", "CHEMICAL", 259, 265], ["OAd7", "GENE_OR_GENE_PRODUCT", 87, 91], ["OAd7", "GENE_OR_GENE_PRODUCT", 153, 157], ["Porcine", "ORGANISM", 211, 218], ["Ad", "ORGANISM", 219, 221], ["porcine Ad", "ORGANISM", 247, 257], ["PAd1-5", "ORGANISM", 259, 265], ["pigs", "ORGANISM", 297, 301], ["OAd7", "PROTEIN", 87, 91], ["chimeric OAd7 vector", "DNA", 144, 164], ["fiber knob domain", "PROTEIN", 178, 195], ["Porcine", "SPECIES", 211, 218], ["porcine", "SPECIES", 247, 254], ["pigs", "SPECIES", 297, 301], ["differential transduction profile", "TEST", 50, 83], ["HAd5", "TEST", 96, 100], ["altered tropism", "PROBLEM", 123, 138], ["a chimeric OAd7 vector", "TREATMENT", 142, 164], ["Porcine Ad vectors", "TREATMENT", 211, 229], ["porcine Ad (PAd1", "TREATMENT", 247, 263], ["distinct", "OBSERVATION_MODIFIER", 21, 29], ["vivo tropism", "OBSERVATION", 33, 45]]], ["PAd3 is the most prevalent serotype, and was isolated from a healthy piglet.", [["piglet", "ANATOMY", 69, 75], ["PAd3", "GENE_OR_GENE_PRODUCT", 0, 4], ["piglet", "ORGANISM", 69, 75], ["PAd3", "PROTEIN", 0, 4], ["piglet", "SPECIES", 69, 75], ["most prevalent", "OBSERVATION_MODIFIER", 12, 26], ["healthy piglet", "OBSERVATION", 61, 75]]], ["It is not associated with any clinical disease in pigs.", [["pigs", "ORGANISM", 50, 54], ["pigs", "SPECIES", 50, 54], ["pigs", "SPECIES", 50, 54], ["any clinical disease in pigs", "PROBLEM", 26, 54], ["not associated with", "UNCERTAINTY", 6, 25], ["disease", "OBSERVATION", 39, 46]]], ["PAd3 is not known to naturally infect species other than porcine.", [["PAd3", "CHEMICAL", 0, 4], ["PAd3", "GENE_OR_GENE_PRODUCT", 0, 4], ["porcine", "ORGANISM", 57, 64], ["PAd3", "PROTEIN", 0, 4], ["porcine", "SPECIES", 57, 64], ["porcine", "SPECIES", 57, 64], ["naturally infect species", "PROBLEM", 21, 45], ["porcine", "TREATMENT", 57, 64], ["not known to", "UNCERTAINTY", 8, 20]]], ["Being a Mastadenovirus, PAd3 shares structural and genomic organization with HAd5 [103] .", [["PAd3", "CHEMICAL", 24, 28], ["PAd3", "GENE_OR_GENE_PRODUCT", 24, 28], ["PAd3", "DNA", 24, 28], ["genomic organization", "OBSERVATION", 51, 71]]], ["The PAd3 genome consists of distinct E1A, E1B, E2, E3 and E4 transcription regions.", [["PAd3", "GENE_OR_GENE_PRODUCT", 4, 8], ["E1A", "GENE_OR_GENE_PRODUCT", 37, 40], ["E1B", "GENE_OR_GENE_PRODUCT", 42, 45], ["E2", "GENE_OR_GENE_PRODUCT", 47, 49], ["E3", "GENE_OR_GENE_PRODUCT", 51, 53], ["E4", "GENE_OR_GENE_PRODUCT", 58, 60], ["PAd3 genome", "DNA", 4, 15], ["E1A, E1B, E2, E3 and E4 transcription regions", "DNA", 37, 82], ["distinct", "OBSERVATION_MODIFIER", 28, 36], ["E1A", "OBSERVATION", 37, 40]]], ["Replicationcompetent as well as replication-defective PAd3 vectors have been developed as gene delivery vehicles [48, 55, 104] .", [["PAd3", "GENE_OR_GENE_PRODUCT", 54, 58], ["PAd3 vectors", "DNA", 54, 66], ["Replicationcompetent", "TREATMENT", 0, 20], ["replication-defective PAd3 vectors", "TREATMENT", 32, 66]]], ["The E3 region is dispensable for virus growth and has been used for inserting foreign genes [104] .Porcine Ad vectorsThe potential utility of PAd3 for vaccine purpose was demonstrated before the vector construction was attempted.", [["PAd3", "CHEMICAL", 142, 146], ["E3", "GENE_OR_GENE_PRODUCT", 4, 6], ["Porcine", "ORGANISM", 99, 106], ["Ad", "ORGANISM", 107, 109], ["PAd3", "SIMPLE_CHEMICAL", 142, 146], ["E3 region", "DNA", 4, 13], ["foreign genes", "DNA", 78, 91], ["PAd3", "PROTEIN", 142, 146], ["Porcine", "SPECIES", 99, 106], ["virus growth", "PROBLEM", 33, 45], ["Porcine Ad vectors", "TREATMENT", 99, 117], ["PAd3", "TREATMENT", 142, 146], ["vaccine purpose", "TREATMENT", 151, 166], ["the vector construction", "TREATMENT", 191, 214], ["dispensable for", "UNCERTAINTY", 17, 32], ["virus growth", "OBSERVATION", 33, 45]]], ["Oral vaccination of pigs with PAd3 stimulated both systemic and mucosal virus neutralizing antibodies [105] .", [["Oral", "ANATOMY", 0, 4], ["PAd3", "CHEMICAL", 30, 34], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["pigs", "ORGANISM", 20, 24], ["PAd3", "GENE_OR_GENE_PRODUCT", 30, 34], ["mucosal virus", "ORGANISM", 64, 77], ["PAd3", "PROTEIN", 30, 34], ["pigs", "SPECIES", 20, 24], ["pigs", "SPECIES", 20, 24], ["Oral vaccination of pigs", "TREATMENT", 0, 24], ["PAd3", "TREATMENT", 30, 34], ["mucosal virus neutralizing antibodies", "TEST", 64, 101], ["mucosal virus", "ANATOMY", 64, 77]]], ["First use of a recombinant PAd3 in pigs was carried out with a vector having no deletions and carrying the classical swine fever virus (CSFV) gp55 (E2) gene cassette in the right hand end of the viral genome [106] .", [["right hand", "ANATOMY", 173, 183], ["PAd3", "CHEMICAL", 27, 31], ["swine fever", "DISEASE", 117, 128], ["E2", "CHEMICAL", 148, 150], ["PAd3", "GENE_OR_GENE_PRODUCT", 27, 31], ["pigs", "ORGANISM", 35, 39], ["classical swine fever virus", "ORGANISM", 107, 134], ["CSFV", "ORGANISM", 136, 140], ["gp55 (E2)", "GENE_OR_GENE_PRODUCT", 142, 151], ["recombinant PAd3", "PROTEIN", 15, 31], ["classical swine fever virus (CSFV) gp55 (E2) gene cassette", "DNA", 107, 165], ["right hand end", "DNA", 173, 187], ["viral genome", "DNA", 195, 207], ["pigs", "SPECIES", 35, 39], ["swine fever virus", "SPECIES", 117, 134], ["pigs", "SPECIES", 35, 39], ["swine fever virus", "SPECIES", 117, 134], ["CSFV", "SPECIES", 136, 140], ["a recombinant PAd3 in pigs", "TREATMENT", 13, 39], ["a vector", "TREATMENT", 61, 69], ["deletions", "PROBLEM", 80, 89], ["the classical swine fever virus", "PROBLEM", 103, 134], ["CSFV) gp55 (E2) gene cassette", "TREATMENT", 136, 165], ["right", "ANATOMY_MODIFIER", 173, 178], ["viral genome", "OBSERVATION", 195, 207]]], ["This vector induced high levels of anti-gp55 antibodies following a single subcutaneous inoculation in outbred pigs leading to complete protection from CSFV challenge.", [["subcutaneous", "ANATOMY", 75, 87], ["CSFV", "DISEASE", 152, 156], ["anti-gp55 antibodies", "GENE_OR_GENE_PRODUCT", 35, 55], ["pigs", "ORGANISM", 111, 115], ["CSFV", "ORGANISM", 152, 156], ["anti-gp55 antibodies", "PROTEIN", 35, 55], ["pigs", "SPECIES", 111, 115], ["pigs", "SPECIES", 111, 115], ["CSFV", "SPECIES", 152, 156], ["anti-gp55 antibodies", "TREATMENT", 35, 55], ["a single subcutaneous inoculation", "TREATMENT", 66, 99], ["outbred pigs", "TREATMENT", 103, 115], ["CSFV challenge", "TREATMENT", 152, 166], ["CSFV", "OBSERVATION", 152, 156]]], ["Subsequently, a prime-boost vaccination strategy involving vaccination of weaned and neonatal pigs first with a DNA plasmid carrying the CSFV gp55 and then with a recombinant PAd3 expressing CSFV gp55 [107] , conferred complete protection against experimental CSFV challenge in weaned pigs.", [["pigs", "ORGANISM", 94, 98], ["DNA", "CELLULAR_COMPONENT", 112, 115], ["CSFV", "ORGANISM", 137, 141], ["gp55", "GENE_OR_GENE_PRODUCT", 142, 146], ["PAd3", "GENE_OR_GENE_PRODUCT", 175, 179], ["CSFV", "ORGANISM", 191, 195], ["CSFV", "ORGANISM", 260, 264], ["pigs", "ORGANISM", 285, 289], ["DNA plasmid", "DNA", 112, 123], ["CSFV gp55", "DNA", 137, 146], ["PAd3", "PROTEIN", 175, 179], ["pigs", "SPECIES", 94, 98], ["pigs", "SPECIES", 285, 289], ["pigs", "SPECIES", 94, 98], ["CSFV", "SPECIES", 137, 141], ["CSFV", "SPECIES", 191, 195], ["CSFV", "SPECIES", 260, 264], ["pigs", "SPECIES", 285, 289], ["a prime-boost vaccination strategy", "TREATMENT", 14, 48], ["vaccination", "TREATMENT", 59, 70], ["neonatal pigs", "TREATMENT", 85, 98], ["a DNA plasmid", "TREATMENT", 110, 123], ["the CSFV gp55", "TREATMENT", 133, 146], ["a recombinant PAd3", "TREATMENT", 161, 179], ["CSFV gp55", "TREATMENT", 191, 200], ["experimental CSFV challenge", "TREATMENT", 247, 274], ["CSFV", "OBSERVATION", 260, 264]]], ["A PAd3 vector carrying the pseudorabies (Aujeszky's disease) virus (PRV) gD gene [104] in the E3 region yielded high levels of PRV-specific antibodies in vaccinated pigs [107] .", [["Aujeszky's disease", "DISEASE", 41, 59], ["PAd3", "GENE_OR_GENE_PRODUCT", 2, 6], ["pseudorabies (", "ORGANISM", 27, 41], ["Aujeszky's disease) virus", "ORGANISM", 41, 66], ["PRV", "ORGANISM", 68, 71], ["gD", "GENE_OR_GENE_PRODUCT", 73, 75], ["E3", "GENE_OR_GENE_PRODUCT", 94, 96], ["pigs", "ORGANISM", 165, 169], ["PAd3 vector", "DNA", 2, 13], ["pseudorabies (Aujeszky's disease) virus (PRV) gD gene", "DNA", 27, 80], ["E3 region", "DNA", 94, 103], ["PRV-specific antibodies", "PROTEIN", 127, 150], ["pseudorabies", "SPECIES", 27, 39], ["Aujeszky", "SPECIES", 41, 49], ["pigs", "SPECIES", 165, 169], ["pseudorabies", "SPECIES", 27, 39], ["Aujeszky's disease) virus", "SPECIES", 41, 66], ["PRV", "SPECIES", 68, 71], ["PRV", "SPECIES", 127, 130], ["pigs", "SPECIES", 165, 169], ["A PAd3 vector", "TREATMENT", 0, 13], ["the pseudorabies (Aujeszky's disease) virus", "PROBLEM", 23, 66], ["high levels of PRV", "PROBLEM", 112, 130], ["specific antibodies", "TEST", 131, 150]]], ["Animals that received two doses of the vector showed improved antibody titers and increased protection in comparison to those given a single dose.Porcine Ad vectorsAlthough replication-competent PAd vectors may be very useful for vaccine purposes in swine, their use in heterologous species including humans may not be favorable due to safety concerns.", [["Animals", "ORGANISM", 0, 7], ["Porcine", "ORGANISM", 146, 153], ["Ad", "ORGANISM", 154, 156], ["PAd", "ORGANISM", 195, 198], ["swine", "ORGANISM", 250, 255], ["humans", "ORGANISM", 301, 307], ["PAd vectors", "DNA", 195, 206], ["Porcine", "SPECIES", 146, 153], ["swine", "SPECIES", 250, 255], ["humans", "SPECIES", 301, 307], ["swine", "SPECIES", 250, 255], ["humans", "SPECIES", 301, 307], ["the vector", "TREATMENT", 35, 45], ["improved antibody titers", "PROBLEM", 53, 77], ["Porcine Ad vectorsAlthough replication", "TREATMENT", 146, 184], ["competent PAd vectors", "TREATMENT", 185, 206], ["vaccine purposes", "TREATMENT", 230, 246]]], ["Therefore, an important requirement for potential application of PAd3 vectors in species other than swine was to render them replication-defective.", [["PAd3", "GENE_OR_GENE_PRODUCT", 65, 69], ["swine", "ORGANISM", 100, 105], ["PAd3 vectors", "DNA", 65, 77], ["swine", "SPECIES", 100, 105], ["swine", "SPECIES", 100, 105], ["potential application of PAd3 vectors", "TREATMENT", 40, 77]]], ["The E1 region of PAd3 is homologous to the E1 region of HAd5.", [["E1", "GENE_OR_GENE_PRODUCT", 4, 6], ["PAd3", "GENE_OR_GENE_PRODUCT", 17, 21], ["HAd5", "GENE_OR_GENE_PRODUCT", 56, 60], ["E1 region", "DNA", 4, 13], ["PAd3", "PROTEIN", 17, 21], ["E1 region", "DNA", 43, 52], ["HAd5", "DNA", 56, 60]]], ["Like BAd3 E1, PAd3 E1 can also complement the E1 functions of HAd5.", [["BAd3 E1", "GENE_OR_GENE_PRODUCT", 5, 12], ["PAd3 E1", "GENE_OR_GENE_PRODUCT", 14, 21], ["E1", "GENE_OR_GENE_PRODUCT", 46, 48], ["HAd5", "GENE_OR_GENE_PRODUCT", 62, 66], ["BAd3 E1", "PROTEIN", 5, 12], ["PAd3 E1", "PROTEIN", 14, 21], ["HAd5", "PROTEIN", 62, 66]]], ["Reciprocally, HAd5 E1 can complement E1A functions of PAd3 [48, 108] .", [["HAd5 E1", "GENE_OR_GENE_PRODUCT", 14, 21], ["E1A", "GENE_OR_GENE_PRODUCT", 37, 40], ["PAd3", "GENE_OR_GENE_PRODUCT", 54, 58], ["HAd5 E1", "PROTEIN", 14, 21], ["E1A", "PROTEIN", 37, 40], ["PAd3", "TEST", 54, 58]]], ["A number of E1-complementing cell lines were made by transforming porcine retinal cells with HAd5 E1 [48, 55, 104] .", [["cell lines", "ANATOMY", 29, 39], ["retinal cells", "ANATOMY", 74, 87], ["E1", "GENE_OR_GENE_PRODUCT", 12, 14], ["cell lines", "CELL", 29, 39], ["porcine", "ORGANISM", 66, 73], ["retinal cells", "CELL", 74, 87], ["HAd5 E1", "GENE_OR_GENE_PRODUCT", 93, 100], ["E1-complementing cell lines", "CELL_LINE", 12, 39], ["porcine retinal cells", "CELL_TYPE", 66, 87], ["E1-complementing cell lines", "TREATMENT", 12, 39], ["cell lines", "OBSERVATION", 29, 39], ["retinal cells", "OBSERVATION", 74, 87]]], ["This trans-complementation facilitated generation of E1A-deleted PAd3 vectors in porcine cell lines that express HAd5 E1 (Fig. 3) .Porcine Ad vectorsAs mentioned earlier, Ad are widely prevalent in their natural hosts.", [["cell lines", "ANATOMY", 89, 99], ["E1A", "GENE_OR_GENE_PRODUCT", 53, 56], ["PAd3", "GENE_OR_GENE_PRODUCT", 65, 69], ["porcine", "ORGANISM", 81, 88], ["cell lines", "CELL", 89, 99], ["HAd5 E1", "GENE_OR_GENE_PRODUCT", 113, 120], ["Porcine", "ORGANISM", 131, 138], ["Ad", "ORGANISM", 139, 141], ["Ad", "ORGANISM", 171, 173], ["E1A", "PROTEIN", 53, 56], ["PAd3 vectors", "DNA", 65, 77], ["porcine cell lines", "CELL_LINE", 81, 99], ["HAd5 E1", "PROTEIN", 113, 120], ["Porcine", "SPECIES", 131, 138], ["E1A-deleted PAd3 vectors", "TREATMENT", 53, 77], ["porcine cell lines", "TREATMENT", 81, 99], ["Porcine Ad vectors", "TREATMENT", 131, 149], ["porcine cell lines", "OBSERVATION", 81, 99], ["widely", "OBSERVATION_MODIFIER", 178, 184], ["prevalent", "OBSERVATION_MODIFIER", 185, 194]]], ["PAd3 is the most prevalent serotype in pigs [109] .", [["PAd3", "CHEMICAL", 0, 4], ["PAd3", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 39, 43], ["PAd3", "PROTEIN", 0, 4], ["pigs", "SPECIES", 39, 43], ["most prevalent", "OBSERVATION_MODIFIER", 12, 26]]], ["In a survey to determine the extent of preexisting PAd3 immunity in Australia, 90% of pigs tested had significant titers of virus neutralizing antibodies.", [["PAd3", "GENE_OR_GENE_PRODUCT", 51, 55], ["pigs", "ORGANISM", 86, 90], ["virus neutralizing antibodies", "PROTEIN", 124, 153], ["pigs", "SPECIES", 86, 90], ["pigs", "SPECIES", 86, 90], ["significant titers of virus neutralizing antibodies", "PROBLEM", 102, 153]]], ["Consequently, concerns were expressed regarding the suitability of PAd3 vectors for use in swine herds [110] .", [["PAd3", "GENE_OR_GENE_PRODUCT", 67, 71], ["PAd3 vectors", "DNA", 67, 79], ["swine", "SPECIES", 91, 96], ["swine", "SPECIES", 91, 96], ["PAd3 vectors", "TREATMENT", 67, 79]]], ["However, a study where pigs were preexposed to wild-type PAd3 prior to vaccination with a recombinant PAd3 vector expressing CSFV gp55, revealed that efficacy of the vector vaccine was not inhibited by the presence of PAd3 specific neutralizing antibodies [111] .", [["PAd3", "CHEMICAL", 218, 222], ["pigs", "ORGANISM", 23, 27], ["PAd3", "GENE_OR_GENE_PRODUCT", 57, 61], ["PAd3", "GENE_OR_GENE_PRODUCT", 102, 106], ["CSFV", "ORGANISM", 125, 129], ["gp55", "GENE_OR_GENE_PRODUCT", 130, 134], ["PAd3", "GENE_OR_GENE_PRODUCT", 218, 222], ["recombinant PAd3 vector", "DNA", 90, 113], ["CSFV gp55", "PROTEIN", 125, 134], ["PAd3", "PROTEIN", 218, 222], ["pigs", "SPECIES", 23, 27], ["pigs", "SPECIES", 23, 27], ["CSFV", "SPECIES", 125, 129], ["a study", "TEST", 9, 16], ["vaccination", "TREATMENT", 71, 82], ["a recombinant PAd3 vector", "TREATMENT", 88, 113], ["CSFV gp55", "TREATMENT", 125, 134], ["the vector vaccine", "TREATMENT", 162, 180], ["PAd3 specific neutralizing antibodies", "TEST", 218, 255]]], ["Thus, the PAd3 vector still holds great potential for use in swine.Porcine Ad vectorsImportantly, we recently reported that PAd3 is not prevalent in the human population as indicated by the lack of neutralizing antibodies in human serum samples [48] .", [["serum samples", "ANATOMY", 231, 244], ["PAd3", "GENE_OR_GENE_PRODUCT", 10, 14], ["swine", "ORGANISM", 61, 66], ["Porcine", "ORGANISM", 67, 74], ["Ad", "ORGANISM", 75, 77], ["PAd3", "GENE_OR_GENE_PRODUCT", 124, 128], ["human", "ORGANISM", 153, 158], ["human", "ORGANISM", 225, 230], ["serum", "ORGANISM_SUBSTANCE", 231, 236], ["PAd3 vector", "DNA", 10, 21], ["PAd3", "PROTEIN", 124, 128], ["neutralizing antibodies", "PROTEIN", 198, 221], ["swine", "SPECIES", 61, 66], ["Porcine", "SPECIES", 67, 74], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 225, 230], ["swine", "SPECIES", 61, 66], ["human", "SPECIES", 153, 158], ["human", "SPECIES", 225, 230], ["the PAd3 vector", "TREATMENT", 6, 21], ["neutralizing antibodies", "TEST", 198, 221], ["human serum samples", "TEST", 225, 244]]], ["HAd5 neutralizing antibodies in human serum did not cross neutralize PAd3.", [["serum", "ANATOMY", 38, 43], ["HAd5", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 32, 37], ["serum", "ORGANISM_SUBSTANCE", 38, 43], ["PAd3", "GENE_OR_GENE_PRODUCT", 69, 73], ["HAd5 neutralizing antibodies", "PROTEIN", 0, 28], ["PAd3", "PROTEIN", 69, 73], ["human", "SPECIES", 32, 37], ["HAd5", "SPECIES", 0, 4], ["human", "SPECIES", 32, 37], ["neutralizing antibodies", "TEST", 5, 28], ["human serum", "TEST", 32, 43]]], ["It has been demonstrated that PAd3 can efficiently overcome anti-HAd5 immunity in a mouse model [36] .", [["PAd3", "CHEMICAL", 30, 34], ["PAd3", "GENE_OR_GENE_PRODUCT", 30, 34], ["anti-HAd5", "GENE_OR_GENE_PRODUCT", 60, 69], ["mouse", "ORGANISM", 84, 89], ["PAd3", "PROTEIN", 30, 34], ["mouse", "SPECIES", 84, 89], ["mouse", "SPECIES", 84, 89]]], ["PAd3 efficiently transduced cells of human, murine, porcine or bovine origin, indicating its usefulness as a gene delivery vector [56] .", [["cells", "ANATOMY", 28, 33], ["PAd3", "GENE_OR_GENE_PRODUCT", 0, 4], ["cells", "CELL", 28, 33], ["human", "ORGANISM", 37, 42], ["murine", "ORGANISM", 44, 50], ["porcine", "ORGANISM", 52, 59], ["bovine", "ORGANISM", 63, 69], ["PAd3", "PROTEIN", 0, 4], ["transduced cells", "CELL_LINE", 17, 33], ["human", "SPECIES", 37, 42], ["murine", "SPECIES", 44, 50], ["porcine", "SPECIES", 52, 59], ["bovine", "SPECIES", 63, 69], ["human", "SPECIES", 37, 42], ["porcine or bovine origin", "TREATMENT", 52, 76], ["a gene delivery vector", "TREATMENT", 107, 129], ["transduced cells", "OBSERVATION", 17, 33], ["bovine origin", "OBSERVATION", 63, 76]]], ["Being highly species-specific, PAd3 infects but does not replicate in the cells of canine, ovine, bovine and human origin [104] .", [["cells", "ANATOMY", 74, 79], ["PAd3", "GENE_OR_GENE_PRODUCT", 31, 35], ["cells", "CELL", 74, 79], ["canine", "ORGANISM", 83, 89], ["ovine", "ORGANISM", 91, 96], ["bovine", "ORGANISM", 98, 104], ["human", "ORGANISM", 109, 114], ["PAd3", "PROTEIN", 31, 35], ["canine", "SPECIES", 83, 89], ["ovine", "SPECIES", 91, 96], ["bovine", "SPECIES", 98, 104], ["human", "SPECIES", 109, 114], ["canine", "SPECIES", 83, 89], ["ovine", "SPECIES", 91, 96], ["human", "SPECIES", 109, 114], ["PAd3 infects", "PROBLEM", 31, 43], ["species", "OBSERVATION", 13, 20]]], ["Unlike HAd5, transduction by PAd3 appears to be CAR-and integrin-independent [112] , indicating its distinct tropism and potential application in designing novel targeted vectors.Porcine Ad vectorsPAd5 is also being investigated as a potential gene expression vector.", [["HAd5", "GENE_OR_GENE_PRODUCT", 7, 11], ["PAd3", "GENE_OR_GENE_PRODUCT", 29, 33], ["CAR", "GENE_OR_GENE_PRODUCT", 48, 51], ["Porcine", "ORGANISM", 179, 186], ["Ad", "ORGANISM", 187, 189], ["vectorsPAd5", "GENE_OR_GENE_PRODUCT", 190, 201], ["HAd5", "PROTEIN", 7, 11], ["PAd3", "PROTEIN", 29, 33], ["CAR", "PROTEIN", 48, 51], ["Porcine Ad vectorsPAd5", "DNA", 179, 201], ["potential gene expression vector", "DNA", 234, 266], ["Porcine", "SPECIES", 179, 186], ["Ad", "SPECIES", 187, 189], ["its distinct tropism", "PROBLEM", 96, 116], ["novel targeted vectors", "TREATMENT", 156, 178], ["Porcine Ad vectorsPAd5", "TREATMENT", 179, 201], ["distinct", "OBSERVATION_MODIFIER", 100, 108], ["tropism", "OBSERVATION", 109, 116], ["expression vector", "OBSERVATION", 249, 266]]], ["PAd5 was originally isolated in Japan [113] and it does not cause any serious disease in pigs.", [["PAd5", "CHEMICAL", 0, 4], ["PAd5", "GENE_OR_GENE_PRODUCT", 0, 4], ["pigs", "ORGANISM", 89, 93], ["PAd5", "PROTEIN", 0, 4], ["pigs", "SPECIES", 89, 93], ["pigs", "SPECIES", 89, 93], ["any serious disease in pigs", "PROBLEM", 66, 93], ["does not cause", "UNCERTAINTY", 51, 65], ["serious", "OBSERVATION_MODIFIER", 70, 77], ["disease", "OBSERVATION", 78, 85]]], ["Its complete genomic sequence is now available [114] .", [["Its complete genomic sequence", "TEST", 0, 29]]], ["Since the majority of the E3 region is not essential for virus replication, PAd5 vectors carrying the 2.2 kb S gene fragment of swine transmissible gastroenteritis virus (TGEV) in the E3 region were constructed [115, 116] .", [["transmissible gastroenteritis", "DISEASE", 134, 163], ["E3", "GENE_OR_GENE_PRODUCT", 26, 28], ["PAd5", "GENE_OR_GENE_PRODUCT", 76, 80], ["swine transmissible gastroenteritis virus", "ORGANISM", 128, 169], ["TGEV", "ORGANISM", 171, 175], ["E3", "GENE_OR_GENE_PRODUCT", 184, 186], ["E3 region", "DNA", 26, 35], ["PAd5 vectors", "DNA", 76, 88], ["2.2 kb S gene fragment", "DNA", 102, 124], ["E3 region", "DNA", 184, 193], ["swine transmissible gastroenteritis virus", "SPECIES", 128, 169], ["swine transmissible gastroenteritis virus", "SPECIES", 128, 169], ["TGEV", "SPECIES", 171, 175], ["virus replication", "TREATMENT", 57, 74], ["PAd5 vectors", "TREATMENT", 76, 88], ["the 2.2 kb S gene fragment", "PROBLEM", 98, 124], ["swine transmissible gastroenteritis virus", "PROBLEM", 128, 169], ["not essential for", "UNCERTAINTY", 39, 56], ["virus replication", "OBSERVATION", 57, 74], ["fragment", "OBSERVATION_MODIFIER", 116, 124], ["transmissible", "OBSERVATION_MODIFIER", 134, 147], ["gastroenteritis virus", "OBSERVATION", 148, 169]]], ["These vectors induced TGEV-specific systemic as well as mucosal immune responses following oral administration of pigs [115] .Fowl Ad vectorsSeveral Ad have been isolated from birds [117] .", [["mucosal", "ANATOMY", 56, 63], ["oral", "ANATOMY", 91, 95], ["TGEV", "ORGANISM", 22, 26], ["mucosal", "PATHOLOGICAL_FORMATION", 56, 63], ["oral", "ORGANISM_SUBDIVISION", 91, 95], ["pigs", "ORGANISM", 114, 118], ["Ad", "ORGANISM", 149, 151], ["pigs", "SPECIES", 114, 118], ["TGEV", "SPECIES", 22, 26], ["These vectors", "TREATMENT", 0, 13], ["TGEV", "PROBLEM", 22, 26], ["oral administration of pigs", "TREATMENT", 91, 118], ["Fowl Ad vectorsSeveral Ad", "PROBLEM", 126, 151]]], ["Some other avian Ad (such as Egg Drop Syndrome 76 virus) are included in the new genus Atadenovirus [51] , based on their distinct structural and genomic features.", [["avian", "ORGANISM", 11, 16], ["Ad", "ORGANISM", 17, 19], ["Egg Drop Syndrome 76 virus", "ORGANISM", 29, 55], ["Egg Drop Syndrome 76 virus", "SPECIES", 29, 55], ["Some other avian Ad", "PROBLEM", 0, 19], ["Egg Drop Syndrome", "PROBLEM", 29, 46], ["virus", "PROBLEM", 50, 55], ["genomic features", "OBSERVATION", 146, 162]]], ["Group I Aviadenovirus includes fowl Ad (FAd) 1-12, and are mostly nonpathogenic or cause only mild infections.", [["infections", "DISEASE", 99, 109], ["fowl Ad (FAd) 1-12", "GENE_OR_GENE_PRODUCT", 31, 49], ["Group I Aviadenovirus", "TEST", 0, 21], ["fowl Ad (FAd)", "TEST", 31, 44], ["mild infections", "PROBLEM", 94, 109], ["nonpathogenic", "OBSERVATION", 66, 79], ["mild", "OBSERVATION_MODIFIER", 94, 98], ["infections", "OBSERVATION", 99, 109]]], ["FAd1 (Chicken embryo lethal orphan, CELO) was isolated from chickens [118] , and is not associated with any disease.", [["embryo", "ANATOMY", 14, 20], ["FAd1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Chicken embryo lethal orphan", "GENE_OR_GENE_PRODUCT", 6, 34], ["CELO", "GENE_OR_GENE_PRODUCT", 36, 40], ["chickens", "ORGANISM", 60, 68], ["FAd1", "PROTEIN", 0, 4], ["Chicken embryo lethal orphan", "PROTEIN", 6, 34], ["Chicken", "SPECIES", 6, 13], ["chickens", "SPECIES", 60, 68], ["chickens", "SPECIES", 60, 68], ["FAd1 (Chicken embryo lethal orphan", "TREATMENT", 0, 34], ["any disease", "PROBLEM", 104, 115], ["not associated with", "UNCERTAINTY", 84, 103], ["disease", "OBSERVATION", 108, 115]]], ["Inoculation of 1-day-old specific pathogen-free (SPF) chickens with FAd1 via various routes induced anti-FAd1 antibodies 3-4 weeks post inoculation, and did not cause any adverse clinical or pathological effects.", [["FAd1", "CHEMICAL", 68, 72], ["chickens", "ORGANISM", 54, 62], ["FAd1", "SIMPLE_CHEMICAL", 68, 72], ["anti-FAd1 antibodies", "PROTEIN", 100, 120], ["chickens", "SPECIES", 54, 62], ["SPF", "SPECIES", 49, 52], ["chickens", "SPECIES", 54, 62], ["old specific pathogen", "PROBLEM", 21, 42], ["FAd1", "TREATMENT", 68, 72], ["anti-FAd1 antibodies", "PROBLEM", 100, 120], ["inoculation", "PROBLEM", 136, 147], ["any adverse clinical or pathological effects", "PROBLEM", 167, 211], ["1-day", "OBSERVATION_MODIFIER", 15, 20]]], ["FAd1 is distinct from mammalian Ad as it possesses a larger genome (43804 bp) and two fibers rather than a single fiber at each vertex of the viral capsid.", [["fibers", "ANATOMY", 86, 92], ["FAd1", "GENE_OR_GENE_PRODUCT", 0, 4], ["Ad", "ORGANISM", 32, 34], ["fibers", "CELLULAR_COMPONENT", 86, 92], ["single fiber", "CELLULAR_COMPONENT", 107, 119], ["FAd1", "PROTEIN", 0, 4], ["43804 bp", "DNA", 68, 76], ["bp", "TEST", 74, 76], ["the viral capsid", "PROBLEM", 138, 154], ["distinct", "OBSERVATION_MODIFIER", 8, 16], ["larger", "OBSERVATION_MODIFIER", 53, 59], ["genome", "OBSERVATION", 60, 66], ["viral capsid", "OBSERVATION", 142, 154]]], ["The complete nucleotide sequence of FAd1 is known and contains no recognizable regions corresponding to HAd5 E1A, E1B, E3 or E4 [119] .", [["nucleotide", "CHEMICAL", 13, 23], ["nucleotide", "CHEMICAL", 13, 23], ["FAd1", "GENE_OR_GENE_PRODUCT", 36, 40], ["HAd5 E1A", "GENE_OR_GENE_PRODUCT", 104, 112], ["E1B", "GENE_OR_GENE_PRODUCT", 114, 117], ["E3", "GENE_OR_GENE_PRODUCT", 119, 121], ["E4", "GENE_OR_GENE_PRODUCT", 125, 127], ["FAd1", "DNA", 36, 40], ["HAd5 E1A", "DNA", 104, 112], ["E1B", "DNA", 114, 117], ["E3", "PROTEIN", 119, 121], ["E4", "DNA", 125, 127], ["The complete nucleotide sequence of FAd1", "TEST", 0, 40], ["recognizable regions", "PROBLEM", 66, 86], ["no", "UNCERTAINTY", 63, 65]]], ["FAd1 E1 functions can not be complemented by HAd5 E1 [120] .", [["FAd1 E1", "GENE_OR_GENE_PRODUCT", 0, 7], ["FAd1 E1", "PROTEIN", 0, 7]]], ["However, FAd1 can transform mammalian cells [121] , and induce tumors in hamsters [122] .", [["cells", "ANATOMY", 38, 43], ["tumors", "ANATOMY", 63, 69], ["tumors", "DISEASE", 63, 69], ["FAd1", "GENE_OR_GENE_PRODUCT", 9, 13], ["mammalian cells", "CELL", 28, 43], ["tumors", "CANCER", 63, 69], ["hamsters", "ORGANISM", 73, 81], ["FAd1", "PROTEIN", 9, 13], ["mammalian cells", "CELL_TYPE", 28, 43], ["tumors", "OBSERVATION", 63, 69]]], ["The transforming genes of FAd1 are partially characterized.", [["FAd1", "GENE_OR_GENE_PRODUCT", 26, 30], ["transforming genes", "DNA", 4, 22], ["FAd1", "DNA", 26, 30], ["partially characterized", "OBSERVATION_MODIFIER", 35, 58]]], ["The unique FAd1 open reading frame 8 encodes an anti-apoptotic protein, GAM-1 (Gallus anti morte protein 1), which is an E1B 19K protein homologue [123] , and interacts with retinoblastoma protein leading to E2F pathway of transcription activation [124] .", [["FAd1", "GENE_OR_GENE_PRODUCT", 11, 15], ["GAM-1", "GENE_OR_GENE_PRODUCT", 72, 77], ["Gallus anti morte protein 1", "GENE_OR_GENE_PRODUCT", 79, 106], ["E1B 19K", "GENE_OR_GENE_PRODUCT", 121, 128], ["retinoblastoma protein", "GENE_OR_GENE_PRODUCT", 174, 196], ["E2F", "GENE_OR_GENE_PRODUCT", 208, 211], ["FAd1 open reading frame 8", "DNA", 11, 36], ["anti-apoptotic protein", "PROTEIN", 48, 70], ["GAM-1", "PROTEIN", 72, 77], ["Gallus anti morte protein 1", "PROTEIN", 79, 106], ["E1B 19K protein", "PROTEIN", 121, 136], ["retinoblastoma protein", "PROTEIN", 174, 196], ["E2F", "PROTEIN", 208, 211], ["Gallus", "SPECIES", 79, 85], ["an anti-apoptotic protein", "TEST", 45, 70], ["GAM", "TEST", 72, 75], ["Gallus anti morte protein", "TEST", 79, 104], ["an E1B", "TEST", 118, 124], ["K protein homologue", "TEST", 127, 146], ["retinoblastoma protein", "PROBLEM", 174, 196], ["retinoblastoma", "OBSERVATION", 174, 188]]], ["Deletion of the GAM-1 gene renders the virus replication-defective, and the defect could be partially recovered by inducing a heat shock in the producer cell line [125] .Fowl Ad vectorsInitially, FAd1-based vectors were constructed by using the classical approach of homologous recombination in bacteria to generate the recombinant Ad genome, followed by transfection of the permissive Leghorn male hepatoma (LMH) cells to rescue replication-competent vectors [126] (Fig. 3) .", [["cell line", "ANATOMY", 153, 162], ["Leghorn male hepatoma (LMH) cells", "ANATOMY", 386, 419], ["shock", "DISEASE", 131, 136], ["GAM-1", "GENE_OR_GENE_PRODUCT", 16, 21], ["cell line [125]", "CELL", 153, 168], ["FAd1", "GENE_OR_GENE_PRODUCT", 196, 200], ["Ad", "ORGANISM", 332, 334], ["Leghorn male hepatoma (LMH) cells", "CELL", 386, 419], ["GAM-1 gene", "DNA", 16, 26], ["producer cell line", "CELL_LINE", 144, 162], ["FAd1", "DNA", 196, 200], ["Ad genome", "DNA", 332, 341], ["permissive Leghorn male hepatoma (LMH) cells", "CELL_LINE", 375, 419], ["Leghorn male hepatoma", "SPECIES", 386, 407], ["Deletion of the GAM", "PROBLEM", 0, 19], ["the virus replication", "PROBLEM", 35, 56], ["the defect", "PROBLEM", 72, 82], ["a heat shock", "PROBLEM", 124, 136], ["Fowl Ad vectorsInitially", "TREATMENT", 170, 194], ["FAd1-based vectors", "TREATMENT", 196, 214], ["homologous recombination", "TREATMENT", 267, 291], ["bacteria", "PROBLEM", 295, 303], ["the permissive Leghorn male hepatoma (LMH) cells", "TREATMENT", 371, 419], ["rescue replication", "TREATMENT", 423, 441], ["defect", "OBSERVATION", 76, 82], ["cell line", "OBSERVATION", 153, 162], ["hepatoma", "ANATOMY", 399, 407]]], ["A cosmid-based strategy has also been adopted for generating FAd1 recombinants [127] .", [["FAd1", "GENE_OR_GENE_PRODUCT", 61, 65], ["FAd1 recombinants", "DNA", 61, 78], ["A cosmid-based strategy", "TREATMENT", 0, 23]]], ["Deletions up to 3.6 kb could be introduced between map units 91 and 99 in FAd1 genome that allow for foreign gene insertion up to 4 kb (Fig. 2) .", [["FAd1", "GENE_OR_GENE_PRODUCT", 74, 78], ["FAd1 genome", "DNA", 74, 85], ["Deletions", "PROBLEM", 0, 9], ["map units", "TEST", 51, 60], ["foreign gene insertion", "TREATMENT", 101, 123]]], ["Immunization of chickens with a recombinant FAd1 vector expressing infectious bursal disease virus (IBDV) VP2 protein provided complete protection against virulent IBDV challenge [128] .", [["infectious bursal disease", "DISEASE", 67, 92], ["IBDV", "DISEASE", 164, 168], ["chickens", "ORGANISM", 16, 24], ["FAd1", "GENE_OR_GENE_PRODUCT", 44, 48], ["infectious bursal disease virus", "ORGANISM", 67, 98], ["IBDV", "ORGANISM", 100, 104], ["VP2", "ORGANISM", 106, 109], ["IBDV", "ORGANISM", 164, 168], ["recombinant FAd1 vector", "DNA", 32, 55], ["infectious bursal disease virus (IBDV) VP2 protein", "PROTEIN", 67, 117], ["chickens", "SPECIES", 16, 24], ["infectious bursal disease virus", "SPECIES", 67, 98], ["chickens", "SPECIES", 16, 24], ["infectious bursal disease virus", "SPECIES", 67, 98], ["IBDV", "SPECIES", 100, 104], ["IBDV", "SPECIES", 164, 168], ["Immunization", "TREATMENT", 0, 12], ["chickens", "TREATMENT", 16, 24], ["a recombinant FAd1 vector", "TREATMENT", 30, 55], ["infectious bursal disease virus", "PROBLEM", 67, 98], ["VP2 protein", "TREATMENT", 106, 117], ["virulent IBDV challenge", "TREATMENT", 155, 178]]], ["The immunity induced by this vector was similar to that induced by the fowlpox virus vector, Marek's disease virus vector, or turkey herpesvirus vector, thus establishing utility of FAd1 as a vaccine vector.", [["Marek's disease", "DISEASE", 93, 108], ["FAd1", "CHEMICAL", 182, 186], ["fowlpox virus", "ORGANISM", 71, 84], ["Marek's disease virus", "ORGANISM", 93, 114], ["turkey herpesvirus", "ORGANISM", 126, 144], ["FAd1", "GENE_OR_GENE_PRODUCT", 182, 186], ["FAd1", "DNA", 182, 186], ["turkey herpesvirus", "SPECIES", 126, 144], ["fowlpox virus", "SPECIES", 71, 84], ["Marek's disease virus", "SPECIES", 93, 114], ["turkey herpesvirus", "SPECIES", 126, 144], ["the fowlpox virus vector", "TREATMENT", 67, 91], ["Marek's disease virus vector", "PROBLEM", 93, 121], ["a vaccine vector", "TREATMENT", 190, 206]]], ["Recently, an FAd1 vector has also been examined for cancer therapy in a mouse model of subcutaneous melanoma [129] .", [["cancer", "ANATOMY", 52, 58], ["subcutaneous melanoma", "ANATOMY", 87, 108], ["cancer", "DISEASE", 52, 58], ["subcutaneous melanoma", "DISEASE", 87, 108], ["FAd1", "GENE_OR_GENE_PRODUCT", 13, 17], ["cancer", "CANCER", 52, 58], ["mouse", "ORGANISM", 72, 77], ["subcutaneous melanoma", "CANCER", 87, 108], ["FAd1 vector", "DNA", 13, 24], ["mouse", "SPECIES", 72, 77], ["mouse", "SPECIES", 72, 77], ["an FAd1 vector", "TREATMENT", 10, 24], ["cancer therapy", "TREATMENT", 52, 66], ["subcutaneous melanoma", "PROBLEM", 87, 108], ["cancer", "OBSERVATION", 52, 58], ["subcutaneous", "ANATOMY", 87, 99], ["melanoma", "OBSERVATION", 100, 108]]], ["FAd1 efficiently transduced primary human dermal fibroblast, HepG2 and A549 cells with efficiency comparable to HAd5 vectors.", [["dermal fibroblast", "ANATOMY", 42, 59], ["HepG2", "ANATOMY", 61, 66], ["A549 cells", "ANATOMY", 71, 81], ["FAd1", "GENE_OR_GENE_PRODUCT", 0, 4], ["human", "ORGANISM", 36, 41], ["dermal fibroblast", "CELL", 42, 59], ["HepG2", "CELL", 61, 66], ["A549 cells", "CELL", 71, 81], ["HAd5", "GENE_OR_GENE_PRODUCT", 112, 116], ["FAd1", "PROTEIN", 0, 4], ["primary human dermal fibroblast", "CELL_LINE", 28, 59], ["HepG2", "CELL_LINE", 61, 66], ["A549 cells", "CELL_LINE", 71, 81], ["HAd5 vectors", "DNA", 112, 124], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["HepG2 and A549 cells", "TREATMENT", 61, 81], ["HAd5 vectors", "TREATMENT", 112, 124], ["dermal fibroblast", "OBSERVATION", 42, 59], ["A549 cells", "OBSERVATION", 71, 81]]], ["Since FAd1 infects but does not replicate in a variety of human, porcine, equine and simian cell lines [126, 127] , FAd1-derived vectors may also be of potential application for vaccination of these non-avian species.Fowl Ad vectorsIn addition to FAd1, FAd8, FAd9 and FAd10 have also been explored for developing expression vectors.", [["cell lines", "ANATOMY", 92, 102], ["FAd1", "GENE_OR_GENE_PRODUCT", 6, 10], ["human", "ORGANISM", 58, 63], ["porcine", "ORGANISM", 65, 72], ["equine", "ORGANISM", 74, 80], ["simian", "ORGANISM", 85, 91], ["cell lines", "CELL", 92, 102], ["FAd1", "GENE_OR_GENE_PRODUCT", 116, 120], ["FAd1", "GENE_OR_GENE_PRODUCT", 247, 251], ["FAd8", "GENE_OR_GENE_PRODUCT", 253, 257], ["FAd9", "GENE_OR_GENE_PRODUCT", 259, 263], ["FAd10", "GENE_OR_GENE_PRODUCT", 268, 273], ["FAd1", "PROTEIN", 6, 10], ["human, porcine, equine and simian cell lines", "CELL_LINE", 58, 102], ["FAd1", "DNA", 247, 251], ["FAd8", "DNA", 253, 257], ["FAd9", "DNA", 259, 263], ["FAd10", "DNA", 268, 273], ["human", "SPECIES", 58, 63], ["porcine", "SPECIES", 65, 72], ["equine", "SPECIES", 74, 80], ["human", "SPECIES", 58, 63], ["FAd1 infects", "PROBLEM", 6, 18], ["porcine, equine and simian cell lines", "TREATMENT", 65, 102], ["FAd1-derived vectors", "TREATMENT", 116, 136], ["vaccination", "TREATMENT", 178, 189], ["these non-avian species", "PROBLEM", 193, 216], ["infects", "OBSERVATION", 11, 18], ["simian cell lines", "OBSERVATION", 85, 102]]], ["Oral vaccination of 1-day-old broiler chickens with recombinant FAd8 expressing the S1 gene of infectious bronchitis virus (IBV) inserted at a 2.4 kb or 50 bp deletion site of the FAd8 genome elicited an IBV S1-specific antibody response [130] .", [["Oral", "ANATOMY", 0, 4], ["infectious bronchitis", "DISEASE", 95, 116], ["Oral", "ORGANISM_SUBDIVISION", 0, 4], ["chickens", "ORGANISM", 38, 46], ["FAd8", "GENE_OR_GENE_PRODUCT", 64, 68], ["S1", "GENE_OR_GENE_PRODUCT", 84, 86], ["infectious bronchitis virus", "ORGANISM", 95, 122], ["IBV", "ORGANISM", 124, 127], ["FAd8", "GENE_OR_GENE_PRODUCT", 180, 184], ["recombinant FAd8", "PROTEIN", 52, 68], ["S1 gene", "DNA", 84, 91], ["50 bp deletion site", "DNA", 153, 172], ["FAd8 genome", "DNA", 180, 191], ["chickens", "SPECIES", 38, 46], ["infectious bronchitis virus", "SPECIES", 95, 122], ["chickens", "SPECIES", 38, 46], ["infectious bronchitis virus", "SPECIES", 95, 122], ["IBV", "SPECIES", 124, 127], ["IBV", "SPECIES", 204, 207], ["Oral vaccination", "TREATMENT", 0, 16], ["old broiler chickens", "TREATMENT", 26, 46], ["recombinant FAd8", "TREATMENT", 52, 68], ["infectious bronchitis virus", "PROBLEM", 95, 122], ["an IBV S1", "TEST", 201, 210], ["specific antibody response", "TEST", 211, 237], ["infectious", "OBSERVATION_MODIFIER", 95, 105], ["bronchitis", "OBSERVATION", 106, 116]]], ["A single vaccination was found to impart protective immunity against challenge with a homologous IBV.", [["IBV", "ORGANISM", 97, 100], ["IBV", "SPECIES", 97, 100], ["A single vaccination", "TREATMENT", 0, 20], ["a homologous IBV", "TREATMENT", 84, 100]]], ["Another recombinant FAd8 vector expressing chicken interferon gamma was used for in vivo delivery of cytokine and tested for its ability to boost immunity to a coccidial parasite in chickens [131] .", [["FAd8", "GENE_OR_GENE_PRODUCT", 20, 24], ["chicken", "ORGANISM", 43, 50], ["interferon gamma", "GENE_OR_GENE_PRODUCT", 51, 67], ["chickens", "ORGANISM", 182, 190], ["recombinant FAd8 vector", "DNA", 8, 31], ["chicken interferon gamma", "PROTEIN", 43, 67], ["cytokine", "PROTEIN", 101, 109], ["chicken", "SPECIES", 43, 50], ["chickens", "SPECIES", 182, 190], ["chicken", "SPECIES", 43, 50], ["chickens", "SPECIES", 182, 190], ["Another recombinant FAd8 vector", "TREATMENT", 0, 31], ["chicken interferon gamma", "TREATMENT", 43, 67], ["cytokine", "TREATMENT", 101, 109]]], ["For FAd9, deletions in the long tandem repeat region 2 (TR-2) towards the right end of the viral genome were not lethal, and the insertion of a reporter gene was well tolerated [132] .", [["right end", "ANATOMY", 74, 83], ["FAd9", "GENE_OR_GENE_PRODUCT", 4, 8], ["long tandem repeat region 2", "GENE_OR_GENE_PRODUCT", 27, 54], ["TR-2", "GENE_OR_GENE_PRODUCT", 56, 60], ["FAd9", "DNA", 4, 8], ["long tandem repeat region 2", "DNA", 27, 54], ["TR-2", "DNA", 56, 60], ["right end", "DNA", 74, 83], ["viral genome", "DNA", 91, 103], ["reporter gene", "DNA", 144, 157], ["deletions in the long tandem repeat region", "PROBLEM", 10, 52], ["TR", "TEST", 56, 58], ["right", "ANATOMY_MODIFIER", 74, 79], ["viral genome", "OBSERVATION", 91, 103]]], ["A recombinant FAd10 vector expressing IBDV VP2 was constructed by inserting the expression cassette in the right end of the genome between map units 90.8 and 100, upstream of the inverted terminal repeat [134] .", [["right end", "ANATOMY", 107, 116], ["FAd10", "ORGANISM", 14, 19], ["IBDV", "ORGANISM", 38, 42], ["VP2", "ORGANISM", 43, 46], ["recombinant FAd10 vector", "DNA", 2, 26], ["IBDV VP2", "DNA", 38, 46], ["expression cassette", "DNA", 80, 99], ["inverted terminal repeat", "DNA", 179, 203], ["IBDV", "SPECIES", 38, 42], ["IBDV", "SPECIES", 38, 42], ["A recombinant FAd10 vector", "TREATMENT", 0, 26], ["IBDV VP2", "TREATMENT", 38, 46], ["the expression cassette", "TREATMENT", 76, 99], ["map units", "TEST", 139, 148], ["right", "ANATOMY_MODIFIER", 107, 112]]], ["Intravenous inoculation of this recombinant vector in 3-week-old birds resulted in protective immunity against IBDV.", [["IBDV", "DISEASE", 111, 115], ["Intravenous", "IMMATERIAL_ANATOMICAL_ENTITY", 0, 11], ["birds", "ORGANISM", 65, 70], ["IBDV", "ORGANISM", 111, 115], ["IBDV", "SPECIES", 111, 115], ["IBDV", "SPECIES", 111, 115], ["Intravenous inoculation", "TREATMENT", 0, 23], ["this recombinant vector", "TREATMENT", 27, 50], ["protective immunity", "TREATMENT", 83, 102]]], ["However, the vector instillation into the conjunctival sac (mucosal route) failed to elicit significant immunity against IBDV VP2, highlighting the importance of the route of administration in successful vaccination using FAd vectors.Conclusions and future directionsClinical use of HAd vectors is hampered by vector immunity that is prevalent in the majority of the human population, and also develops rapidly after first use of the vector.", [["conjunctival sac", "ANATOMY", 42, 58], ["mucosal", "ANATOMY", 60, 67], ["conjunctival sac", "MULTI-TISSUE_STRUCTURE", 42, 58], ["mucosal route", "MULTI-TISSUE_STRUCTURE", 60, 73], ["IBDV", "ORGANISM", 121, 125], ["VP2", "ORGANISM", 126, 129], ["HAd", "GENE_OR_GENE_PRODUCT", 283, 286], ["human", "ORGANISM", 367, 372], ["IBDV VP2", "PROTEIN", 121, 129], ["IBDV", "SPECIES", 121, 125], ["human", "SPECIES", 367, 372], ["IBDV", "SPECIES", 121, 125], ["human", "SPECIES", 367, 372], ["the vector instillation", "TREATMENT", 9, 32], ["IBDV VP2", "TREATMENT", 121, 129], ["successful vaccination using FAd vectors", "TREATMENT", 193, 233], ["HAd vectors", "TREATMENT", 283, 294], ["the vector", "TREATMENT", 430, 440], ["conjunctival sac", "ANATOMY", 42, 58]]], ["Nonhuman Ad are not prevalent in humans, and are not cross-neutralized by HAd neutralizing antibodies.", [["Ad", "ORGANISM", 9, 11], ["humans", "ORGANISM", 33, 39], ["HAd", "GENE_OR_GENE_PRODUCT", 74, 77], ["HAd neutralizing antibodies", "PROTEIN", 74, 101], ["humans", "SPECIES", 33, 39], ["humans", "SPECIES", 33, 39], ["neutralizing antibodies", "PROBLEM", 78, 101], ["not", "UNCERTAINTY", 16, 19], ["prevalent", "OBSERVATION_MODIFIER", 20, 29]]], ["These vectors efficiently transduce human cells in culture and circumvent preexisting HAd immunity.", [["cells", "ANATOMY", 42, 47], ["human", "ORGANISM", 36, 41], ["cells", "CELL", 42, 47], ["HAd", "GENE_OR_GENE_PRODUCT", 86, 89], ["human cells", "CELL_TYPE", 36, 47], ["human", "SPECIES", 36, 41], ["human", "SPECIES", 36, 41], ["These vectors", "TREATMENT", 0, 13], ["human cells", "PROBLEM", 36, 47], ["culture", "TEST", 51, 58], ["human cells", "OBSERVATION", 36, 47]]], ["An ever increasing number of preclinical and clinical studies demonstrating the utility of HAd vectors for therapeutic or prophylactic gene delivery have provided further momentum to the research efforts in the area of developing nonhuman Ad vectors.", [["HAd", "GENE_OR_GENE_PRODUCT", 91, 94], ["nonhuman", "ORGANISM", 230, 238], ["Ad", "ORGANISM", 239, 241], ["clinical studies", "TEST", 45, 61], ["prophylactic gene delivery", "TREATMENT", 122, 148], ["increasing", "OBSERVATION_MODIFIER", 8, 18], ["number", "OBSERVATION_MODIFIER", 19, 25]]], ["In addition, these nonhuman Ad vectors also present a platform for designing improved vaccines for veterinary use.Conclusions and future directionsWhile, all nonhuman Ad vectors presented in this review have shown initial promise for gene transfer to human cells and evasion of HAd5 immunity, further investigation is needed before their use in humans could become a reality.Conclusions and future directionsAn important concern with nonhuman Ad vectors would be their safety for humans.", [["cells", "ANATOMY", 257, 262], ["nonhuman", "ORGANISM", 19, 27], ["Ad", "ORGANISM", 28, 30], ["nonhuman", "ORGANISM", 158, 166], ["Ad", "ORGANISM", 167, 169], ["human", "ORGANISM", 251, 256], ["cells", "CELL", 257, 262], ["HAd5", "GENE_OR_GENE_PRODUCT", 278, 282], ["humans", "ORGANISM", 345, 351], ["nonhuman", "ORGANISM", 434, 442], ["Ad", "ORGANISM", 443, 445], ["humans", "ORGANISM", 480, 486], ["human cells", "CELL_TYPE", 251, 262], ["human", "SPECIES", 251, 256], ["humans", "SPECIES", 345, 351], ["humans", "SPECIES", 480, 486], ["human", "SPECIES", 251, 256], ["humans", "SPECIES", 345, 351], ["Ad", "SPECIES", 443, 445], ["humans", "SPECIES", 480, 486], ["Ad vectors", "TREATMENT", 28, 38], ["designing improved vaccines", "TREATMENT", 67, 94], ["gene transfer to human cells", "TREATMENT", 234, 262], ["HAd5 immunity", "TREATMENT", 278, 291], ["further investigation", "TEST", 293, 314], ["Ad vectors", "TREATMENT", 443, 453]]], ["Despite the fact that most nonhuman Ad vectors are replication-defective in human cells, and deletion of essential genes leads to blunting of viral replication, thorough examination of viral gene expression and viral genome persistence in a variety of human cells and in a nonhuman primate model will be necessary to ascertain safety of these vectors.", [["cells", "ANATOMY", 82, 87], ["cells", "ANATOMY", 258, 263], ["nonhuman", "ORGANISM", 27, 35], ["Ad", "ORGANISM", 36, 38], ["human", "ORGANISM", 76, 81], ["cells", "CELL", 82, 87], ["human", "ORGANISM", 252, 257], ["cells", "CELL", 258, 263], ["human cells", "CELL_TYPE", 76, 87], ["essential genes", "DNA", 105, 120], ["human cells", "CELL_TYPE", 252, 263], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 252, 257], ["Ad", "SPECIES", 36, 38], ["human", "SPECIES", 76, 81], ["human", "SPECIES", 252, 257], ["Ad vectors", "TREATMENT", 36, 46], ["defective in human cells", "PROBLEM", 63, 87], ["deletion of essential genes", "PROBLEM", 93, 120], ["blunting of viral replication", "PROBLEM", 130, 159], ["thorough examination", "TEST", 161, 181], ["viral gene expression", "PROBLEM", 185, 206], ["viral genome persistence", "PROBLEM", 211, 235], ["human cells", "TREATMENT", 252, 263], ["a nonhuman primate model", "TREATMENT", 271, 295], ["defective", "OBSERVATION", 63, 72], ["human cells", "OBSERVATION", 76, 87], ["blunting", "OBSERVATION_MODIFIER", 130, 138], ["viral replication", "OBSERVATION", 142, 159], ["viral genome", "OBSERVATION", 211, 223]]], ["Similarly, information regarding packaging sequences, receptor utilization and other determinants of tissue tropism, and in vivo persistence and state of the vector genome will determine the relative usefulness of these vectors.", [["tissue", "ANATOMY", 101, 107], ["tissue", "TISSUE", 101, 107], ["packaging sequences", "DNA", 33, 52], ["vector genome", "DNA", 158, 171], ["packaging sequences", "TREATMENT", 33, 52], ["receptor utilization", "TREATMENT", 54, 74], ["tissue tropism", "PROBLEM", 101, 115], ["tissue tropism", "OBSERVATION", 101, 115]]], ["Although preliminary studies have shown the feasibility of sequential administration of various nonhuman Ad vectors, this aspect needs to be investigated further in suitable animal models.", [["nonhuman", "ORGANISM", 96, 104], ["Ad", "ORGANISM", 105, 107], ["preliminary studies", "TEST", 9, 28], ["Ad vectors", "TREATMENT", 105, 115]]], ["It will be important to investigate whether the humoral immune response against nonhuman Ad vectors cross-neutralizes other nonhuman Ad vectors.", [["nonhuman", "ORGANISM", 80, 88], ["Ad", "ORGANISM", 89, 91], ["nonhuman", "ORGANISM", 124, 132], ["Ad", "ORGANISM", 133, 135]]], ["Such information will be useful for devising strategies for booster vaccination.", [["booster vaccination", "TREATMENT", 60, 79]]], ["Feasibility of construction of a 'minimal genome' Ad vector (such as gutless or gutted) by deleting the majority of viral genes in order to increase both the duration and expression of the target genes and the packaging capacity of all these nonhuman Ad vectors needs to be explored.", [["Ad", "ORGANISM", 50, 52], ["nonhuman", "ORGANISM", 242, 250], ["Ad", "ORGANISM", 251, 253], ["viral genes", "DNA", 116, 127], ["target genes", "DNA", 189, 201], ["a 'minimal genome'", "TREATMENT", 31, 49], ["Ad vector", "TREATMENT", 50, 59], ["viral genes", "PROBLEM", 116, 127], ["Ad vectors", "TREATMENT", 251, 261], ["viral genes", "OBSERVATION", 116, 127]]], ["Such vectors will be useful in developing vectors carrying multiple genes encoding antigens and/or immunomodulatory proteins.", [["antigens", "PROTEIN", 83, 91], ["immunomodulatory proteins", "PROTEIN", 99, 124], ["Such vectors", "TREATMENT", 0, 12], ["multiple genes encoding antigens", "PROBLEM", 59, 91], ["immunomodulatory proteins", "PROBLEM", 99, 124]]], ["Careful assessment of optimal dose of these vectors, and any associated vector toxicity would also be required.", [["toxicity", "DISEASE", 79, 87], ["Careful assessment", "TEST", 0, 18], ["these vectors", "TREATMENT", 38, 51], ["any associated vector toxicity", "PROBLEM", 57, 87]]]], "471f86c0aa831b75726b025e0b54d623fc1b8479": [["IntroductionThe standard method for rapidly detecting known human viruses in clinical samples is the polymerase chain reaction (PCR), in which short oligonucleotides are used to amplify and probe specific regions of viral genomes.", [["samples", "ANATOMY", 86, 93], ["human", "ORGANISM", 60, 65], ["viral genomes", "DNA", 216, 229], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["known human viruses", "PROBLEM", 54, 73], ["the polymerase chain reaction", "PROBLEM", 97, 126], ["PCR", "TEST", 128, 131], ["short oligonucleotides", "TREATMENT", 143, 165], ["viral genomes", "PROBLEM", 216, 229], ["human viruses", "OBSERVATION", 60, 73], ["viral genomes", "OBSERVATION", 216, 229]]], ["The limitations of this technique include the targeting of a relatively small number of viruses per assay and a dependence on sequence conservation among viral strains.", [["this technique", "TREATMENT", 19, 33], ["a dependence", "PROBLEM", 110, 122], ["sequence conservation", "TREATMENT", 126, 147], ["viral strains", "PROBLEM", 154, 167], ["small", "OBSERVATION_MODIFIER", 72, 77], ["viruses", "OBSERVATION", 88, 95], ["viral strains", "OBSERVATION", 154, 167]]], ["Thus, metagenomic analysis of HTS data can provide extensive viral genotyping information, as well as the characterization of complex multiple infections (Thorburn et al. 2015) .", [["infections", "DISEASE", 143, 153], ["metagenomic analysis", "TEST", 6, 26], ["HTS data", "TEST", 30, 38], ["complex multiple infections", "PROBLEM", 126, 153], ["complex", "OBSERVATION_MODIFIER", 126, 133], ["multiple", "OBSERVATION_MODIFIER", 134, 142], ["infections", "OBSERVATION", 143, 153]]], ["Several metagenomic pipelines using de novo assembly and homology matching have been developed for virus detection (Wang, Jia, and Zhao 2013; Scheuch, H\u00f6 per, and Beer 2015; Li et al. 2016; Ren et al. 2017; Zheng et al. 2017; Maarala et al. 2018) .", [["Several metagenomic pipelines", "TREATMENT", 0, 29], ["metagenomic pipelines", "OBSERVATION", 8, 29]]], ["However, analyzing HTS data using such approaches brings heavy computing and bioinformatic demands that are difficult to meet and standardize in diagnostic laboratories (Flygare et al. 2016) .", [["analyzing HTS data", "TEST", 9, 27], ["such approaches", "TREATMENT", 34, 49]]], ["As a consequence, we have developed DisCVR, which is a fast, accurate and easy-to-use tool for detecting known human viruses in clinical samples.IntroductionDisCVR employs an abundance-based method, which is a metagenomic approach for rapidly profiling the organisms present in a sample.", [["samples", "ANATOMY", 137, 144], ["human", "ORGANISM", 111, 116], ["samples", "CANCER", 137, 144], ["human", "SPECIES", 111, 116], ["human", "SPECIES", 111, 116], ["DisCVR", "PROBLEM", 36, 42], ["known human viruses in clinical samples", "PROBLEM", 105, 144], ["IntroductionDisCVR", "TREATMENT", 145, 163], ["a metagenomic approach", "TREATMENT", 208, 230], ["rapidly profiling the organisms", "PROBLEM", 235, 266], ["viruses", "OBSERVATION", 117, 124]]], ["It works by creating a database of short nucleotide sequences (k-mers) from a large set of viral reference sequences, tagging the k-mers taxonomically according to the viruses from which they came, screening each read in the HTS dataset for the presence of virus k-mers, and organizing a summary of the viruses present in the sample via the tags.", [["nucleotide", "CHEMICAL", 41, 51], ["short nucleotide sequences", "DNA", 35, 61], ["viral reference sequences", "DNA", 91, 116], ["short nucleotide sequences", "PROBLEM", 35, 61], ["screening", "TEST", 198, 207], ["the HTS dataset", "TEST", 221, 236], ["virus k-mers", "PROBLEM", 257, 269], ["the viruses", "PROBLEM", 299, 310], ["virus", "OBSERVATION", 257, 262], ["viruses", "OBSERVATION", 303, 310]]], ["This approach makes data analysis very efficient, thereby minimizing the computing effort required (Orton et al. 2016) .IntroductionSeveral existing tools utilize the abundance-based method to classify the reads in an HTS dataset.", [["data analysis", "TEST", 20, 33]]], ["This classifier is trained by using a set of unique profiles of fifteen nucleotide k-mers from microbial genomes, and then allows users to upload the dataset to a web site and obtain a summary of results listing the best taxonomic match for each read.", [["nucleotide", "CHEMICAL", 72, 82], ["nucleotide", "CHEMICAL", 72, 82], ["microbial genomes", "DNA", 95, 112], ["web site", "DNA", 163, 171], ["fifteen nucleotide k-mers", "TREATMENT", 64, 89]]], ["CoMeta (Kawulok and Deorowicz 2015) creates a database of all k-mers for each rank in the taxonomic tree, and then uses these databases to classify the reads at each rank.", [["all k-mers", "TREATMENT", 58, 68]]], ["CLARK (Ounit et al. 2015) collects targetspecific k-mer sets from reference genomes belonging to a certain taxonomic rank (e.g. genus), and then classifies reads at that rank.", [["targetspecific k-mer sets", "DNA", 35, 60]]], ["This approach reduces the database size but requires a different database to be built for each rank.", [["size", "OBSERVATION_MODIFIER", 35, 39]]], ["To improve the accuracy of the classification, CSSSCL (Borozan and Ferretti 2016) creates a BLAST database, a k-mer database and a compression database from a collection of reference genomes.", [["a BLAST database", "TEST", 90, 106], ["a k-mer database", "TEST", 108, 124], ["a compression database", "TEST", 129, 151]]], ["Sequences in the sample are classified according to a combined sequence similarity score (CSSS) (Borozan, Watt, and Ferretti 2015) calculated from information in the pre-computed databases.", [["sample", "ANATOMY", 17, 23]]], ["In contrast to Kraken, CLARK, and CoMeta, all of which assign individual reads, MetaPalette (Koslicki and Falush 2016) profiles the entire dataset and returns the relative proportions of organisms present by using k-mer sizes of 30 and 50, based on the rationale that using two different k-mer sizes allows strain-level variation to be captured more accurately.", [["Kraken", "PROTEIN", 15, 21], ["CLARK", "PROTEIN", 23, 28], ["CoMeta", "PROTEIN", 34, 40], ["organisms", "PROBLEM", 187, 196], ["k-mer sizes", "TEST", 214, 225], ["two different k-mer sizes", "TREATMENT", 274, 299], ["sizes", "OBSERVATION_MODIFIER", 294, 299]]], ["This weight, which is a function of the kmer count in the reference and the database, provides a database-specific measure of how likely it is that a k-mer originated from a particular reference sequence.IntroductionDespite the growing number and popularity of k-mer-based classification tools, these tools have limitations.", [["This weight", "TEST", 0, 11], ["the kmer count", "TEST", 36, 50], ["a database", "TEST", 95, 105], ["k-mer-based classification tools", "PROBLEM", 261, 293], ["growing", "OBSERVATION_MODIFIER", 228, 235], ["number", "OBSERVATION_MODIFIER", 236, 242]]], ["The databases are built using a limited set of reference sequences and therefore are of restricted utility for classifying organisms with sequences that diverge from the reference.", [["reference sequences", "TEST", 47, 66]]], ["This limitation can be a particular problem when significant variation exists in an organism at strain level.", [["significant variation", "PROBLEM", 49, 70], ["an organism at strain level", "PROBLEM", 81, 108]]], ["This is designed to screen for a limited set of user-specified viruses, comes preloaded with probe-sets for grapevine viruses, and cannot easily be updated for large sets of viruses from other hosts.IntroductionHere, we present DisCVR, a k-mer-based classification tool for detecting known human viruses from HTS data derived from clinical samples.", [["samples", "ANATOMY", 340, 347], ["human", "ORGANISM", 290, 295], ["samples", "CANCER", 340, 347], ["human", "SPECIES", 290, 295], ["grapevine viruses", "SPECIES", 108, 125], ["human", "SPECIES", 290, 295], ["grapevine viruses", "PROBLEM", 108, 125], ["large sets of viruses", "PROBLEM", 160, 181], ["known human viruses", "PROBLEM", 284, 303], ["HTS data", "TEST", 309, 317], ["clinical samples", "TEST", 331, 347], ["viruses", "OBSERVATION", 63, 70], ["viruses", "OBSERVATION", 174, 181]]], ["DisCVR can be installed on a desktop computer to allow diagnostic laboratories to analyze large, confidential datasets by using a simple, straightforward graphical user interface (GUI) without specialized bioinformatics expertise.", [["diagnostic laboratories", "TEST", 55, 78]]], ["It is optimized to run on Windows, Linux and Mac OS, using minimal RAM and processing power without compromising speed and accuracy.", [["minimal RAM", "TREATMENT", 59, 70], ["accuracy", "TEST", 123, 131]]], ["The tool currently integrates curated viral databases at the taxonomic levels of species and strain, but may be used to build a customized database at any taxonomic level, thereby overcoming the limitations of using a restricted set of reference sequences.", [["viral databases", "TEST", 38, 53], ["strain", "PROBLEM", 93, 99]]], ["DisCVR utilizes k-mer counts derived from an entire HTS dataset to detect the viruses present in a sample, and validates the results by showing the coverage and depth of reads mapping to a reference sequence.The k-mer databasesA k-mer is a short sequence of k nucleotides.", [["nucleotides", "CHEMICAL", 260, 271], ["DisCVR", "PROTEIN", 0, 6], ["k-mer databasesA k-mer", "DNA", 212, 234], ["k-mer counts", "TEST", 16, 28], ["an entire HTS dataset", "TEST", 42, 63], ["the viruses", "PROBLEM", 74, 85], ["a reference sequence", "TEST", 187, 207], ["The k-mer databasesA", "TEST", 208, 228], ["a short sequence of k nucleotides", "PROBLEM", 238, 271], ["viruses", "OBSERVATION", 78, 85]]], ["A k-mer dataset is generated iteratively by sliding a window of size k along a sequence one nucleotide at a time.", [["nucleotide", "CHEMICAL", 92, 102], ["nucleotide", "CHEMICAL", 92, 102], ["k-mer dataset", "DNA", 2, 15], ["A k-mer dataset", "TREATMENT", 0, 15]]], ["Extracting k-mers and counting their frequencies in a set of sequences can be computationally intensive, especially when k is large and the sequences are numerous.", [["Extracting k-mers", "PROBLEM", 0, 17], ["large", "OBSERVATION_MODIFIER", 126, 131]]], ["KAnalyze (Audano and Vannberg 2014) was chosen for integration into DisCVR because the k-mers it generates are sorted lexicographically, thus making the search for matches very efficient.", [["DisCVR", "DNA", 68, 74], ["KAnalyze (Audano and Vannberg", "TREATMENT", 0, 29]]], ["KAnalyze also uses the canonical representation of a kmer, which is lexicographically the smaller of a k-mer and its reverse complement.", [["kmer", "GENE_OR_GENE_PRODUCT", 53, 57], ["kmer", "PROTEIN", 53, 57], ["smaller", "OBSERVATION_MODIFIER", 90, 97]]], ["These features allow the program to work with 3 Gb RAM.The k-mer databasesFor the purpose of this study, we define a virus k-mer as a kmer that uniquely represents a virus or set of related viruses, to the exclusion of the host.", [["The k-mer databases", "TEST", 55, 74], ["this study", "TEST", 93, 103], ["a virus k-mer", "PROBLEM", 115, 128], ["a virus", "PROBLEM", 164, 171], ["related viruses", "PROBLEM", 182, 197], ["virus", "OBSERVATION", 166, 171]]], ["A shared k-mer is defined as a k-mer that is common to a virus and the host.", [["k-mer", "OBSERVATION", 9, 14], ["virus", "OBSERVATION", 57, 62]]], ["By excluding shared kmers, it is not necessary for the user to remove host reads before using DisCVR, thus speeding up the overall processing time.", [["DisCVR", "TREATMENT", 94, 100]]], ["If k is small, many copies of shared k-mers are generated, and if k is large, many copies of virus k-mers are found.", [["k-mers", "DNA", 37, 43], ["virus k-mers", "PROBLEM", 93, 105], ["small", "OBSERVATION_MODIFIER", 8, 13], ["large", "OBSERVATION_MODIFIER", 71, 76], ["virus k-mers", "OBSERVATION", 93, 105]]], ["Choosing the optimal k-mer size depends on balancing the advantages of speed (small k) with those of specificity and sensitivity (large k).", [["sensitivity", "TEST", 117, 128], ["size", "OBSERVATION_MODIFIER", 27, 31]]], ["Furthermore, it is necessary to reduce the number of low-complexity k-mers in the virus k-mer database, as these may be repetitive in sequence and present in otherwise unrelated viruses.", [["otherwise unrelated viruses", "PROBLEM", 158, 185], ["may be", "UNCERTAINTY", 113, 119], ["viruses", "OBSERVATION", 178, 185]]], ["The filtering of low-complexity k-mers and the selection of the size of k is explained in Supplementary Section S1 (Shannon 1948; Sims et al. 2009; Wu et al. 2009 ).The k-mer databasesFor constructing the virus k-mer databases, three comprehensive datasets of complete or partial viral sequences were extracted from the NCBI taxonomy database.", [["virus k-mer databases", "DNA", 205, 226], ["viral sequences", "DNA", 280, 295], ["The filtering of low-complexity k-mers", "TREATMENT", 0, 38], ["The k-mer databases", "TEST", 165, 184], ["the virus k-mer databases", "TEST", 201, 226], ["partial viral sequences", "PROBLEM", 272, 295], ["low-complexity", "OBSERVATION_MODIFIER", 17, 31], ["size", "OBSERVATION_MODIFIER", 64, 68]]], ["The first, the human hemorrhagic virus dataset (shortened below to 'hemorrhagic dataset'), contained 33,367 sequences of the hemorrhagic fever viruses listed by the Centers for Disease Control and Prevention (Centers for Disease Control and Prevention, n.d.).The k-mer databasesThe second, the human respiratory virus dataset ('respiratory dataset'), contained 442,282 sequences of viruses associated with respiratory disease.", [["respiratory", "ANATOMY", 406, 417], ["hemorrhagic", "DISEASE", 21, 32], ["hemorrhagic", "DISEASE", 68, 79], ["hemorrhagic fever", "DISEASE", 125, 142], ["respiratory disease", "DISEASE", 406, 425], ["human", "ORGANISM", 15, 20], ["human", "ORGANISM", 294, 299], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 294, 299], ["human hemorrhagic virus", "SPECIES", 15, 38], ["human respiratory virus", "SPECIES", 294, 317], ["the human hemorrhagic virus dataset", "PROBLEM", 11, 46], ["the hemorrhagic fever viruses", "PROBLEM", 121, 150], ["Disease Control", "TREATMENT", 177, 192], ["Disease Control", "TREATMENT", 221, 236], ["The k-mer databases", "TEST", 259, 278], ["the human respiratory virus dataset", "PROBLEM", 290, 325], ["viruses", "PROBLEM", 382, 389], ["respiratory disease", "PROBLEM", 406, 425], ["hemorrhagic", "OBSERVATION_MODIFIER", 21, 32], ["virus", "OBSERVATION", 33, 38], ["hemorrhagic", "OBSERVATION_MODIFIER", 125, 136], ["fever", "OBSERVATION", 137, 142], ["respiratory disease", "OBSERVATION", 406, 425]]], ["The third, the human pathogenic virus dataset ('pathogenic dataset'), consisted of 1,762,968 sequences of viruses identified in the UK Health and Safety Executive list of biological agents (Health and Safety Executive: The Approved List of Biological Agents 2013).Database buildDisCVR operates via three modules concerned with database build, sample classification and validation (Fig. 1) .Database buildCurrently, the database build module includes three virus k-mer databases, derived from the hemorrhagic, respiratory, and pathogenic datasets, for use in the sample classification module.", [["respiratory", "ANATOMY", 509, 520], ["hemorrhagic", "DISEASE", 496, 507], ["human", "ORGANISM", 15, 20], ["buildDisCVR", "DNA", 273, 284], ["human", "SPECIES", 15, 20], ["human", "SPECIES", 15, 20], ["viruses", "PROBLEM", 106, 113], ["sample classification", "TEST", 343, 364], ["three virus k-mer databases", "PROBLEM", 450, 477], ["the hemorrhagic, respiratory, and pathogenic datasets", "PROBLEM", 492, 545], ["viruses", "OBSERVATION", 106, 113], ["hemorrhagic", "OBSERVATION_MODIFIER", 496, 507], ["respiratory", "ANATOMY", 509, 520], ["pathogenic datasets", "OBSERVATION", 526, 545]]], ["In addition, some of the sequences in these datasets, defined largely by their presence in the NCBI RefSeq database, are used as a set of reference genome sequences in the validation module.", [["NCBI RefSeq database", "DNA", 95, 115], ["reference genome sequences", "DNA", 138, 164], ["the sequences", "TEST", 21, 34]]], ["DisCVR also allows the user to create customized databases and sets of reference sequences using the commandline utility scripts provided with the DisCVR distribution.", [["reference sequences", "TEST", 71, 90]]], ["The database build module involves selecting the relevant viral dataset, collecting the k-mers, and removing those that are shared with the host or are of low complexity.", [["low complexity", "OBSERVATION_MODIFIER", 155, 169]]], ["Each remaining k-mer is then identified with a taxonomic tag and an indication of the number of times it occurs in the sequences.", [["a taxonomic tag", "PROBLEM", 45, 60], ["k-mer", "OBSERVATION", 15, 20]]], ["The k-mers are further subdivided into those that exist in a single virus (i.e. specific k-mers) and those that exist in multiple viruses (i.e. nonspecific k-mers).", [["a single virus", "PROBLEM", 59, 73], ["multiple viruses", "PROBLEM", 121, 137], ["multiple", "OBSERVATION_MODIFIER", 121, 129], ["viruses", "OBSERVATION", 130, 137]]], ["These assignments are made at the level of species and strain and are used in the output to illustrate the degree of specificity of the k-mers matching a virus (Fig. 2 ).Sample classificationTo analyze an HTS dataset, the file is loaded into DisCVR via the GUI.", [["strain", "PROBLEM", 55, 61], ["the output", "TEST", 78, 88], ["an HTS dataset", "TEST", 202, 216], ["GUI", "ANATOMY", 257, 260]]], ["As the number of k-mers in the sample can be enormous, various data structures were considered to optimize the classification on machines with limited RAM.", [["enormous", "OBSERVATION_MODIFIER", 45, 53]]], ["Although searching the trie is fast O(n), where n is the size of the k-mer, it requires O(n 2 ) overall time to build, and the space needed is quadratic.", [["size", "OBSERVATION_MODIFIER", 57, 61]]], ["Instead, DisCVR uses a fast searching algorithm that groups similar k-mers together.", [["DisCVR", "PROTEIN", 9, 15]]], ["Briefly, the k-mers in the virus database are divided among smaller sub-files according to the first five nucleotides.", [["nucleotides", "CHEMICAL", 106, 117], ["the k-mers in the virus database", "PROBLEM", 9, 41], ["smaller", "OBSERVATION_MODIFIER", 60, 67]]], ["The same procedure is used to divide the k-mers derived from the entire HTS dataset.", [["The same procedure", "TREATMENT", 0, 18]]], ["Searching commences by loading the corresponding sub-files from the virus k-mer database and the sample k-mers into memory, and performing a binary search for the presence of each sample k-mer among the database k-mers.", [["sub-files", "DNA", 49, 58], ["virus k-mer database", "DNA", 68, 88]]], ["Only matched k-mers are retrieved.", [["k-mers", "OBSERVATION", 13, 19]]], ["Finally, DisCVR displays a straightforward list of all the virus hits detected, along with summary statistics and taxonomic information on the sample k-mers (Fig. 2) .ValidationDisCVR helps the user to assess the significance of the findings by facilitating an examination of k-mer distribution (allowing up to three mismatches) across a reference sequence representing the target genome.", [["DisCVR", "PROTEIN", 9, 15], ["target genome", "DNA", 374, 387], ["all the virus hits", "PROBLEM", 51, 69], ["an examination", "TEST", 258, 272], ["a reference sequence", "TEST", 336, 356], ["target genome", "OBSERVATION", 374, 387]]], ["As an alternative, it also incorporates an examination of sequence read distribution carried out by using Tanoti (Sreenu, n.d.) , which is a BLAST-guided, reference-based short read aligner that is particularly tolerant of mismatches.", [["an examination of sequence", "TEST", 40, 66]]], ["In each case, the output is a graph showing the depth and coverage of k-mers or sequence reads across the reference genome and a summary of statistics for the mapping results (Fig. 3) .AccuracyThe respiratory database was used to analyze published RNA-seq data from nasopharyngeal swab samples (n \u00bc 89) that had been collected from adults with upper respiratory tract infections (Thorburn et al. 2015) (Supplementary Table S2 ; the average number of reads per sample was 660,640, range 30,872-1,278,122).", [["nasopharyngeal swab samples", "ANATOMY", 266, 293], ["respiratory tract infections", "DISEASE", 350, 378], ["nasopharyngeal swab samples", "CANCER", 266, 293], ["tract", "ORGANISM_SUBDIVISION", 362, 367], ["reference genome", "DNA", 106, 122], ["the output", "TEST", 14, 24], ["a graph", "TEST", 28, 35], ["coverage of k-mers", "TREATMENT", 58, 76], ["the mapping", "TEST", 155, 166], ["The respiratory database", "TEST", 193, 217], ["published RNA", "TEST", 238, 251], ["nasopharyngeal swab samples", "TEST", 266, 293], ["upper respiratory tract infections", "PROBLEM", 344, 378], ["nasopharyngeal", "ANATOMY", 266, 280], ["upper", "ANATOMY_MODIFIER", 344, 349], ["respiratory tract", "ANATOMY", 350, 367]]], ["The samples had been tested using a standard real-time PCR (RT-PCR) assay for human rhinovirus (HRV), influenza viruses A and B (IFA/ IFB), respiratory syncytial virus (RSV), adenovirus (ADV), human metapneumovirus (hMPV), parainfluenza viruses (PIV) 1-4, and human coronaviruses (HCoV) HKU1, NL63, OC43 and 229E (Thorburn et al. 2015) .", [["samples", "ANATOMY", 4, 11], ["influenza viruses", "DISEASE", 102, 119], ["respiratory syncytial virus (RSV), adenovirus (ADV), human metapneumovirus (hMPV), parainfluenza viruses", "DISEASE", 140, 244], ["human", "ORGANISM", 78, 83], ["rhinovirus", "ORGANISM", 84, 94], ["influenza viruses A", "ORGANISM", 102, 121], ["B", "GENE_OR_GENE_PRODUCT", 126, 127], ["IFA/ IFB", "ORGANISM", 129, 137], ["respiratory syncytial virus", "ORGANISM", 140, 167], ["RSV", "ORGANISM", 169, 172], ["adenovirus", "ORGANISM", 175, 185], ["ADV", "ORGANISM", 187, 190], ["human metapneumovirus", "ORGANISM", 193, 214], ["hMPV", "ORGANISM", 216, 220], ["parainfluenza viruses", "ORGANISM", 223, 244], ["PIV) 1-4", "ORGANISM", 246, 254], ["human", "ORGANISM", 260, 265], ["coronaviruses", "ORGANISM", 266, 279], ["HCoV", "ORGANISM", 281, 285], ["HKU1", "GENE_OR_GENE_PRODUCT", 287, 291], ["human", "SPECIES", 78, 83], ["influenza viruses", "SPECIES", 102, 119], ["respiratory syncytial virus (RSV", "SPECIES", 140, 172], ["human", "SPECIES", 193, 198], ["metapneumovirus", "SPECIES", 199, 214], ["hMPV", "SPECIES", 216, 220], ["parainfluenza viruses", "SPECIES", 223, 244], ["human", "SPECIES", 260, 265], ["human rhinovirus", "SPECIES", 78, 94], ["HRV", "SPECIES", 96, 99], ["respiratory syncytial virus", "SPECIES", 140, 167], ["RSV", "SPECIES", 169, 172], ["adenovirus", "SPECIES", 175, 185], ["ADV", "SPECIES", 187, 190], ["human metapneumovirus", "SPECIES", 193, 214], ["hMPV", "SPECIES", 216, 220], ["PIV", "SPECIES", 246, 249], ["human coronaviruses", "SPECIES", 260, 279], ["HCoV", "SPECIES", 281, 285], ["The samples", "TEST", 0, 11], ["a standard real-time PCR", "TEST", 34, 58], ["RT-PCR", "TEST", 60, 66], ["human rhinovirus", "PROBLEM", 78, 94], ["HRV", "TEST", 96, 99], ["influenza viruses", "PROBLEM", 102, 119], ["B (IFA/ IFB)", "TEST", 126, 138], ["respiratory syncytial virus (RSV)", "PROBLEM", 140, 173], ["adenovirus", "PROBLEM", 175, 185], ["human metapneumovirus (hMPV", "PROBLEM", 193, 220], ["parainfluenza viruses", "PROBLEM", 223, 244], ["PIV", "TEST", 246, 249], ["HKU1", "TEST", 287, 291], ["OC43", "TEST", 299, 303], ["respiratory syncytial", "ANATOMY", 140, 161], ["parainfluenza viruses", "OBSERVATION", 223, 244]]], ["The top hit for each sample (i.e. the virus having the greatest number of distinct k-mers) using DisCVR was compared with the virus detected previously by RT-PCR.", [["sample", "ANATOMY", 21, 27], ["DisCVR", "DNA", 97, 103], ["each sample", "TEST", 16, 27], ["the virus", "PROBLEM", 34, 43], ["DisCVR", "TREATMENT", 97, 103], ["the virus", "PROBLEM", 122, 131]]], ["The samples were also classified using three independent k-mer-based programs that require command-line usage on a Linux operating system: Kraken (Wood and Salzberg 2014), KrakenHLL (Breitwieser and Salzberg 2018) , and CLARK (Ounit et al. 2015) .", [["samples", "ANATOMY", 4, 11]]], ["As the pre-built database for Kraken only contains the RefSeq viral genomes (11,489 sequences), a more comprehensive k-mer database was built for each program from the same 442,282 sequences in the respiratory dataset in order to standardize the results.", [["pre-built database", "DNA", 7, 25], ["Kraken", "DNA", 30, 36], ["RefSeq viral genomes", "DNA", 55, 75], ["11,489 sequences", "DNA", 77, 93], ["442,282 sequences", "DNA", 173, 190], ["the RefSeq viral genomes", "PROBLEM", 51, 75], ["viral genomes", "OBSERVATION", 62, 75]]], ["This successfully accommodated within species sequence diversity, which is not normally taken into account using the pre-built database.AccuracyThe initial objective was to determine the number of distinct k-mers that would maximize both sensitivity (effectiveness in identifying samples containing viruses) and specificity (effectiveness in identifying samples lacking viruses) for DisCVR.", [["samples", "ANATOMY", 354, 361], ["DisCVR", "PROTEIN", 383, 389], ["the pre-built database", "TEST", 113, 135], ["viruses", "PROBLEM", 299, 306], ["lacking viruses", "PROBLEM", 362, 377], ["DisCVR", "PROBLEM", 383, 389]]], ["The output of DisCVR was categorized on the basis of the number of distinct k-mers for the top hit, and that of the other programs was assessed on the basis of the number of reads assigned to the top hit.", [["DisCVR", "DNA", 14, 20], ["output", "OBSERVATION_MODIFIER", 4, 10]]], ["For each tool, sensitivity and specificity were defined as TP/(TP \u00fe FN) and TN/(TN \u00fe FP), respectively, where TP, FN, TN, and FP are the number of true positive, false negative, true negative, and false positive samples relative to the RT-PCR results.", [["samples", "ANATOMY", 212, 219], ["TP", "GENE_OR_GENE_PRODUCT", 59, 61], ["TP \u00fe FN", "GENE_OR_GENE_PRODUCT", 63, 70], ["TP", "GENE_OR_GENE_PRODUCT", 110, 112], ["FN", "GENE_OR_GENE_PRODUCT", 114, 116], ["TP", "PROTEIN", 59, 61], ["TP", "PROTEIN", 63, 65], ["FN", "PROTEIN", 68, 70], ["TN", "PROTEIN", 76, 78], ["TN", "PROTEIN", 80, 82], ["FN", "PROTEIN", 114, 116], ["TN", "PROTEIN", 118, 120], ["each tool", "TEST", 4, 13], ["sensitivity", "TEST", 15, 26], ["specificity", "TEST", 31, 42], ["TP/(TP \u00fe FN", "TEST", 59, 70], ["TN", "TEST", 76, 78], ["TP", "TEST", 110, 112], ["FN", "TEST", 114, 116], ["TN", "TEST", 118, 120], ["FP", "TEST", 126, 128], ["false positive samples", "PROBLEM", 197, 219], ["the RT-PCR", "TEST", 232, 242]]], ["We define samples as (1) negative when neither RT-PCR nor DisCVR detected a virus, (3) false negative when a virus was detected by RT-PCR but not by DisCVR, and (4) false positive when a virus was detected by DisCVR but not by RT-PCR.", [["samples", "ANATOMY", 10, 17], ["samples", "TEST", 10, 17], ["neither RT-PCR", "TEST", 39, 53], ["DisCVR", "TEST", 58, 64], ["a virus", "PROBLEM", 74, 81], ["a virus", "PROBLEM", 107, 114], ["PCR", "TEST", 134, 137], ["false positive", "PROBLEM", 165, 179], ["a virus", "PROBLEM", 185, 192], ["RT", "TEST", 227, 229], ["PCR", "TEST", 230, 233]]], ["Receiver Operating Characteristics (ROC) curves were generated for DisCVR, Kraken, KrakenHLL and CLARK using the pROC package in R and Youden's statistic (Youden 1950 ).ApplicationDisCVR was used to analyze 177 HTS RNA-seq libraries derived from serum specimens collected in Nigeria from healthy individuals (n \u00bc 120) and patients with unexplained acute febrile illness (n \u00bc 57) and analyzed in a previous study (Stremlau et al. 2015) .", [["serum specimens", "ANATOMY", 246, 261], ["acute febrile illness", "DISEASE", 348, 369], ["serum specimens", "ORGANISM_SUBSTANCE", 246, 261], ["patients", "ORGANISM", 322, 330], ["patients", "SPECIES", 322, 330], ["ROC) curves", "TEST", 36, 47], ["DisCVR", "PROBLEM", 67, 73], ["the pROC package", "TREATMENT", 109, 125], ["ApplicationDisCVR", "TREATMENT", 169, 186], ["HTS RNA", "TEST", 211, 218], ["seq libraries", "TEST", 219, 232], ["serum specimens", "TEST", 246, 261], ["unexplained acute febrile illness", "PROBLEM", 336, 369], ["a previous study", "TEST", 395, 411], ["acute", "OBSERVATION_MODIFIER", 348, 353], ["febrile", "OBSERVATION", 354, 361]]], ["The top hit using DisCVR was compared with the viral reads identified using BLASTn and BLASTx in the original study (https://doi.org/10.1371/journal.pntd.0003631.s017).ResultsThe ROC curve (Fig. 4) derived from the datasets from respiratory tract infections (Thorburn et al. 2015) compares the sensitivity and specificity for different k-mer thresholds.", [["respiratory tract", "ANATOMY", 229, 246], ["respiratory tract infections", "DISEASE", 229, 257], ["DisCVR", "DNA", 18, 24], ["viral reads", "DNA", 47, 58], ["the viral reads", "TEST", 43, 58], ["the original study", "TEST", 97, 115], ["The ROC curve", "TEST", 175, 188], ["respiratory tract infections", "PROBLEM", 229, 257], ["the sensitivity", "TEST", 290, 305], ["different k-mer thresholds", "TEST", 326, 352], ["respiratory tract", "ANATOMY", 229, 246]]], ["It suggests that a value of 850 k-mers is the optimal threshold on the basis of the point on the curve furthest from the identity (diagonal) line (Supplementary Table S2 ).", [["a value", "TEST", 17, 24]]], ["The ROC curves of DisCVR and the other programs (Fig. 4) did not differ significantly from each other, and had overlapping confidence intervals.", [["The ROC curves", "TEST", 0, 14]]], ["Kraken and CLARK rated as slightly more sensitive but less specific than DisCVR as a result of HCoV NL63 being the top hit in sample 1D3 and the second hit in DisCVR (Table 1; Supplementary Table S2 ).", [["HCoV NL63", "DNA", 95, 104], ["HCoV", "SPECIES", 95, 99]]], ["The top hit in DisCVR was HRV-A, which was the second hit in Kraken and CLARK but was not detected using RT-PCR.", [["DisCVR", "CANCER", 15, 21], ["DisCVR", "DNA", 15, 21], ["CLARK", "DNA", 72, 77], ["HRV", "TEST", 26, 29], ["RT-PCR", "TEST", 105, 111], ["top", "OBSERVATION_MODIFIER", 4, 7], ["hit", "OBSERVATION", 8, 11]]], ["It was not informative to compare average execution time and memory usage for the programs, as it is not possible to run CLARK, Kraken, and KrakenHLL natively on Windows operating systems.", [["not possible", "UNCERTAINTY", 101, 113]]], ["Also, on a Linux operating systems CLARK and Kraken required more than 30 Gb of RAM to run samples against the respiratory dataset, whereas DisCVR ran with only 8 Gb.ResultsA total of 48/89 (54%) of the samples had been shown to contain viruses by RT-PCR, and the remaining 41/89 lacked all viruses tested.", [["samples", "ANATOMY", 91, 98], ["samples", "ANATOMY", 203, 210], ["samples", "CANCER", 203, 210], ["DisCVR", "PROTEIN", 140, 146], ["the respiratory dataset", "PROBLEM", 107, 130], ["ResultsA total", "TEST", 166, 180], ["the samples", "TEST", 199, 210], ["PCR", "TEST", 251, 254], ["respiratory", "ANATOMY", 111, 122], ["viruses", "OBSERVATION", 237, 244], ["all", "OBSERVATION_MODIFIER", 287, 290], ["viruses", "OBSERVATION", 291, 298]]], ["Considering only the samples in the set of eightynine for which DisCVR identified 850 k-mers for the top hit, the following findings were made.", [["samples", "ANATOMY", 21, 28], ["eightynine", "CHEMICAL", 43, 53], ["eightynine", "SIMPLE_CHEMICAL", 43, 53], ["850 k-mers", "DNA", 82, 92]]], ["DisCVR identified the viruses that were detected by RT-PCR in 32/48 (67%) of samples (true positives).", [["samples", "ANATOMY", 77, 84], ["samples", "CANCER", 77, 84], ["the viruses", "PROBLEM", 18, 29], ["RT-PCR", "TEST", 52, 58], ["samples", "TEST", 77, 84], ["viruses", "OBSERVATION", 22, 29]]], ["It did not detect viruses in samples in which no viruses had been found by RT-PCR in 22/41 (54%) of samples (true negatives).", [["samples", "ANATOMY", 29, 36], ["samples", "ANATOMY", 100, 107], ["samples", "CANCER", 29, 36], ["samples", "CANCER", 100, 107], ["viruses in samples", "PROBLEM", 18, 36], ["viruses", "PROBLEM", 49, 56], ["PCR", "TEST", 78, 81], ["samples", "TEST", 100, 107], ["viruses", "OBSERVATION", 18, 25], ["no", "UNCERTAINTY", 46, 48], ["viruses", "OBSERVATION", 49, 56]]], ["It detected viruses in samples in which no viruses had been detected by RT-PCR in 19/41 (46%) of samples (false positives), and either detected viruses that did not correspond with those detected by RT-PCR or did not find any virus with 850 k-mers in 16/48 (33%) of samples (false negatives).ResultsThe RT-PCR assay was limited by the range of viruses that it could detect, by its dependence on sequence conservation, and consequently also by its potential to identify infections by multiple viruses.", [["samples", "ANATOMY", 23, 30], ["samples", "ANATOMY", 97, 104], ["samples", "ANATOMY", 266, 273], ["infections", "DISEASE", 469, 479], ["samples", "CANCER", 23, 30], ["samples", "CANCER", 97, 104], ["samples", "CANCER", 266, 273], ["viruses", "PROBLEM", 12, 19], ["viruses", "PROBLEM", 43, 50], ["RT", "TEST", 72, 74], ["PCR", "TEST", 75, 78], ["samples (false positives", "PROBLEM", 97, 121], ["viruses", "PROBLEM", 144, 151], ["RT-PCR", "TEST", 199, 205], ["any virus", "PROBLEM", 222, 231], ["k-mers", "TEST", 241, 247], ["samples", "TEST", 266, 273], ["The RT-PCR assay", "TEST", 299, 315], ["infections", "PROBLEM", 469, 479], ["multiple viruses", "PROBLEM", 483, 499], ["viruses", "OBSERVATION", 12, 19], ["no", "UNCERTAINTY", 40, 42], ["viruses", "OBSERVATION", 43, 50], ["viruses", "OBSERVATION", 144, 151], ["infections", "OBSERVATION", 469, 479], ["multiple", "OBSERVATION_MODIFIER", 483, 491], ["viruses", "OBSERVATION", 492, 499]]], ["Consequently, the false positive results were assessed using the validation module (Table 2) , and the false negative results were investigated by examining the second hits recorded by DisCVR (Table 1 ).", [["the validation module", "TEST", 61, 82]]], ["In most false positive cases, the validation module showed that there were multiple reads mapping (mean \u00bc 98 6 73 reads) to several regions of the reference genome (mean \u00bc 6 6 1% coverage of sites), thus confirming the presence of the viruses identified by DisCVR even though they had not been detected by RT-PCR.", [["reference genome", "DNA", 147, 163], ["the validation module", "TEST", 30, 51], ["multiple reads mapping", "TEST", 75, 97], ["mean", "TEST", 99, 103], ["the viruses", "PROBLEM", 231, 242], ["PCR", "TEST", 309, 312], ["positive cases", "OBSERVATION", 14, 28], ["viruses", "OBSERVATION", 235, 242]]], ["Some samples had low coverage because a single RefSeq sequence in the validation represented the entire species but diverged in sequence from the virus present in the sample.", [["samples", "ANATOMY", 5, 12], ["RefSeq sequence", "DNA", 47, 62], ["Some samples", "TEST", 0, 12], ["low coverage", "TREATMENT", 17, 29], ["a single RefSeq sequence", "TEST", 38, 62], ["the entire species", "PROBLEM", 93, 111], ["the virus", "PROBLEM", 142, 151], ["virus", "OBSERVATION", 146, 151]]], ["For example, sample 1B3 yielded HRV-A89 (the reference for species Rhinovirus A) as the top hit, with only 7.6 per cent genome coverage and four mapped reads.", [["A89", "DNA", 36, 39], ["HRV-A89", "SPECIES", 32, 39], ["sample", "TEST", 13, 19], ["HRV", "TEST", 32, 35], ["the top hit", "TEST", 84, 95]]], ["Using the capability of DisCVR to build a customized database drawn from the 100 prototypic strains of Rhinovirus A, HRV-A49 was revealed as the top hit, with 81.71 per cent genome coverage and 263 mapped reads.", [["Rhinovirus A", "CANCER", 103, 115], ["HRV-A49", "ORGANISM", 117, 124], ["DisCVR", "PROTEIN", 24, 30], ["A49", "DNA", 121, 124], ["Rhinovirus A", "SPECIES", 103, 115], ["HRV-A49", "SPECIES", 117, 124], ["Rhinovirus", "PROBLEM", 103, 113], ["HRV", "TEST", 117, 120]]], ["This dramatic improvement illustrates the potential to strengthen the validation module by adding user-specific curated sets of sequences or by the proposed expansion of RefSeq entries capturing a greater degree of diversity (Brister et al. 2015) .", [["RefSeq entries", "DNA", 170, 184], ["RefSeq entries", "TEST", 170, 184], ["dramatic", "OBSERVATION_MODIFIER", 5, 13], ["improvement", "OBSERVATION", 14, 25], ["greater degree", "OBSERVATION_MODIFIER", 197, 211]]], ["In the sixteen false negative cases, DisCVR detected the virus identified by RT-PCR as the top hit in three samples (1G2, 1I5, and 2B6), but the number of distinct k-mers was <850 (Table 1; Supplementary Table S2 ).", [["samples", "ANATOMY", 108, 115], ["DisCVR", "DNA", 37, 43], ["DisCVR", "TEST", 37, 43], ["the virus", "PROBLEM", 53, 62], ["RT-PCR", "TEST", 77, 83], ["negative cases", "OBSERVATION", 21, 35]]], ["In addition, the virus identified by RT-PCR was detected as the second hit in 10 samples (1B5, 1D3, 1E5, 1G1, 1F7, 1F8, 2A2, 2B9, 2C4, and 2D3) , and, in one case (1C2), the RT-PCR assay did not have the potential of identifying the top hit (enterovirus D).", [["samples", "ANATOMY", 81, 88], ["2C4", "GENE_OR_GENE_PRODUCT", 130, 133], ["2D3", "GENE_OR_GENE_PRODUCT", 139, 142], ["the virus", "PROBLEM", 13, 22], ["RT-PCR", "TEST", 37, 43], ["the RT-PCR assay", "TEST", 170, 186], ["virus", "OBSERVATION", 17, 22]]], ["An important finding was made in two of these samples (1B5 and 1D3), in which the viruses detected by RT-PCR were not the top hits but still had 850 distinct k-mers in the sample (Table 1 ).", [["samples", "ANATOMY", 46, 53], ["these samples", "TEST", 40, 53], ["the viruses", "PROBLEM", 78, 89], ["RT-PCR", "TEST", 102, 108], ["viruses", "OBSERVATION", 82, 89]]], ["This suggests that these patients were infected by multiple viruses.", [["patients", "ORGANISM", 25, 33], ["patients", "SPECIES", 25, 33], ["multiple viruses", "PROBLEM", 51, 67], ["multiple", "OBSERVATION_MODIFIER", 51, 59], ["viruses", "OBSERVATION", 60, 67]]], ["Finally, DisCVR did not detect any k-mers for the virus detected by RT-PCR in two samples (1C9 and 2D4), but identified HRV-A in 1C9, which was validated by reference assembly.", [["samples", "ANATOMY", 82, 89], ["1C9", "DNA", 129, 132], ["the virus", "PROBLEM", 46, 55], ["RT-PCR", "TEST", 68, 74], ["HRV", "TEST", 120, 123]]], ["The validation module thus yielded strong evidence for the presence of the viruses detected by DisCVR, at least where the number of k-mers was 850.", [["The validation module", "TEST", 0, 21], ["the viruses", "PROBLEM", 71, 82], ["viruses", "OBSERVATION", 75, 82]]], ["These findings were taken into account in reassessing the sensitivity and specificity of DisCVR at 79 and 100 per cent, respectively (Fig. 4) .", [["the sensitivity", "TEST", 54, 69], ["DisCVR", "TEST", 89, 95]]], ["The optimal threshold for CLARK and Kraken based on the ROC curves suggests 150 reads as the threshold.", [["CLARK", "PROTEIN", 26, 31], ["the ROC curves", "TEST", 52, 66]]], ["Recalculating the sensitivity and specificity based on this threshold gave values of 70.7 and 91.7 per cent for CLARK and 68.7 and 76 per cent for Kraken.ResultsThe threshold of 850 k-mers was also used in the analysis of the Nigerian datasets (Stremlau et al. 2015) .", [["this threshold", "TEST", 55, 69], ["values", "TEST", 75, 81], ["CLARK", "TEST", 112, 117]]], ["The top hit from DisCVR was the same as that from the BLAST results in the original study for 101/177 (57%) cases, and viruses were detected in both healthy (n \u00bc 68) and febrile (n \u00bc 33) patients (Supplementary Table S5 ).", [["febrile", "DISEASE", 170, 177], ["patients", "ORGANISM", 187, 195], ["patients", "SPECIES", 187, 195], ["the original study", "TEST", 71, 89], ["viruses", "PROBLEM", 119, 126], ["febrile", "PROBLEM", 170, 177], ["top", "OBSERVATION_MODIFIER", 4, 7], ["hit", "OBSERVATION", 8, 11]]], ["In nine cases, the top hit from DisCVR differed from the top BLAST hit, but the second hit matched.", [["DisCVR", "DNA", 32, 38], ["top BLAST hit", "DNA", 57, 70], ["BLAST hit", "OBSERVATION", 61, 70]]], ["In fifty-five cases, the number of k-mers was below the threshold in DisCVR, and the number of reads with BLAST matches was also low (an average of twenty-four reads per dataset).", [["BLAST matches", "TEST", 106, 119]]], ["In the remaining twelve discordant samples, DisCVR detected human immunodeficiency virus 1 (n \u00bc 9), XMRVrelated virus (n \u00bc 1), and human T-lymphotropic virus 1 (n \u00bc 1) as the top hit, whereas the BLAST results supported the presence of human ADV or Heterosigma akashiwo RNA virus (an algal virus).", [["samples", "ANATOMY", 35, 42], ["human immunodeficiency virus", "DISEASE", 60, 88], ["ADV", "CHEMICAL", 242, 245], ["human immunodeficiency virus 1", "ORGANISM", 60, 90], ["n \u00bc 9", "ORGANISM", 92, 97], ["XMRVrelated virus", "ORGANISM", 100, 117], ["human T-lymphotropic virus 1", "ORGANISM", 131, 159], ["human", "ORGANISM", 236, 241], ["ADV", "ORGANISM", 242, 245], ["Heterosigma akashiwo RNA virus", "ORGANISM", 249, 279], ["algal virus", "ORGANISM", 284, 295], ["human immunodeficiency virus 1", "SPECIES", 60, 90], ["human", "SPECIES", 131, 136], ["T-lymphotropic virus 1", "SPECIES", 137, 159], ["human", "SPECIES", 236, 241], ["human immunodeficiency virus 1", "SPECIES", 60, 90], ["XMRVrelated virus", "SPECIES", 100, 117], ["human T-lymphotropic virus 1", "SPECIES", 131, 159], ["human ADV", "SPECIES", 236, 245], ["Heterosigma akashiwo RNA virus", "SPECIES", 249, 279], ["DisCVR", "TEST", 44, 50], ["human immunodeficiency virus", "PROBLEM", 60, 88], ["XMRVrelated virus", "TEST", 100, 117], ["human T-lymphotropic virus", "TEST", 131, 157], ["the BLAST", "TEST", 192, 201], ["human ADV", "PROBLEM", 236, 245], ["Heterosigma akashiwo RNA virus", "PROBLEM", 249, 279], ["an algal virus", "PROBLEM", 281, 295]]], ["Mapping of reads to reference genomes suggested that the DisCVR and BLAST hits are false positives.DiscussionUsing HTS in diagnostic settings offers many advantages, including the ability to sequence pathogen genomes both individually and as communities.", [["DisCVR and BLAST hits", "DNA", 57, 78], ["the DisCVR", "TEST", 53, 63], ["BLAST hits", "TEST", 68, 78], ["false positives", "PROBLEM", 83, 98], ["false positives", "OBSERVATION", 83, 98]]], ["However, the uptake of HTS in such settings has been slow, due partly to the cost, turnover time and bioinformatic demands of this technology.", [["the uptake of HTS", "PROBLEM", 9, 26], ["this technology", "TREATMENT", 126, 141], ["uptake", "OBSERVATION_MODIFIER", 13, 19]]], ["We developed DisCVR to help address these challenges.", [["DisCVR", "TREATMENT", 13, 19]]], ["DisCVR is a fast, accurate program for detecting viruses from HTS data using the increasingly exploited approach of k-mer classification. the advantage of a non-targeted approach and also enables typing below the species level (e.g. subtype, serotype, genotype, or strain).", [["viruses", "PROBLEM", 49, 56], ["HTS data", "TEST", 62, 70], ["a non-targeted approach", "TREATMENT", 155, 178], ["serotype", "PROBLEM", 242, 250]]], ["Unlike other tools for detecting viruses from HTS data, DisCVR is easy to use in diagnostic settings through the GUI, requires no bioinformatic expertise, and can be used on the Windows operating systems that are commonly used in diagnostic laboratories.", [["HTS data", "TEST", 46, 54]]], ["The basic output is easy to interpret, and the advanced output provides more detailed statistics and a validation capability.", [["The basic output", "TEST", 0, 16], ["the advanced output", "TEST", 43, 62], ["a validation capability", "TEST", 101, 124], ["output", "OBSERVATION_MODIFIER", 10, 16]]], ["DisCVR was designed for detecting known viruses and cannot be used to discover novel viruses.", [["known viruses", "PROBLEM", 34, 47], ["novel viruses", "PROBLEM", 79, 92], ["viruses", "OBSERVATION", 40, 47]]], ["Indeed, the paper on the Nigerian patients (Stremlau et al. 2015) reported novel rhabdoviruses in healthy patients using a metagenomic approach, and these were not detected by DisCVR.", [["patients", "ORGANISM", 34, 42], ["rhabdoviruses", "CANCER", 81, 94], ["patients", "ORGANISM", 106, 114], ["patients", "SPECIES", 34, 42], ["patients", "SPECIES", 106, 114], ["a metagenomic approach", "TREATMENT", 121, 143]]], ["However, metagenomics requires bioinformatic infrastructure and expertise at levels that are not commonly available in diagnostic laboratories.", [["bioinformatic infrastructure", "TEST", 31, 59], ["expertise at levels", "TEST", 64, 83], ["diagnostic laboratories", "TEST", 119, 142]]], ["Nonetheless, DisCVR enables the detection of 148 pathogenic human viruses using one of the three implemented datasets (the pathogenic dataset), and more using the others.", [["human", "ORGANISM", 60, 65], ["DisCVR", "PROTEIN", 13, 19], ["human", "SPECIES", 60, 65], ["human", "SPECIES", 60, 65], ["the detection", "TEST", 28, 41], ["pathogenic human viruses", "PROBLEM", 49, 73]]], ["This represents a greater than ten-fold increase in target species over multiplex RT-PCR.", [["a greater than ten-fold increase", "PROBLEM", 16, 48], ["target species", "PROBLEM", 52, 66], ["multiplex RT-PCR", "TEST", 72, 88], ["greater", "OBSERVATION_MODIFIER", 18, 25], ["increase", "OBSERVATION_MODIFIER", 40, 48], ["target species", "OBSERVATION", 52, 66]]], ["Moreover, the number of viruses incorporated into the DisCVR databases is flexible and can also be expanded by building custom databases.DiscussionIn the datasets from respiratory tract infections, DisCVR had high sensitivity and specificity levels but did not identify all the viruses detected by RT-PCR when the threshold of 850 k-mers was used.", [["respiratory tract", "ANATOMY", 168, 185], ["respiratory tract infections", "DISEASE", 168, 196], ["respiratory tract", "ORGANISM_SUBDIVISION", 168, 185], ["DisCVR databases", "DNA", 54, 70], ["viruses", "PROBLEM", 24, 31], ["respiratory tract infections", "PROBLEM", 168, 196], ["high sensitivity", "PROBLEM", 209, 225], ["specificity levels", "TEST", 230, 248], ["PCR", "TEST", 301, 304], ["the threshold", "TEST", 310, 323], ["viruses", "OBSERVATION", 24, 31], ["respiratory tract", "ANATOMY", 168, 185], ["viruses", "OBSERVATION", 278, 285]]], ["This threshold may be set by the user and was calculated for the respiratory dataset for which we had paired RT-PCR and HTS data.", [["the respiratory dataset", "TEST", 61, 84], ["paired RT-PCR", "TEST", 102, 115], ["HTS data", "TEST", 120, 128]]], ["As more datasets with paired information become available, it will be possible to tune the threshold more accurately to specific sample types and sizes.", [["sample", "ANATOMY", 129, 135], ["sizes", "OBSERVATION_MODIFIER", 146, 151]]], ["For example, the coverage depth of sequencing data is likely to play an important role in the threshold of detection.", [["sequencing data", "TEST", 35, 50], ["likely to play", "UNCERTAINTY", 54, 68]]], ["Further efforts could also be made to calibrate DisCVR from artificially constructed communities of viruses in various proportions.DiscussionFinally, DisCVR is configured as a human viral diagnostic tool, but could be readily expanded to include non-viral human pathogens and pathogens with non-human hosts by using the custom-build scripts in the DisCVR distribution.", [["human", "ORGANISM", 176, 181], ["human", "ORGANISM", 256, 261], ["DisCVR", "PROTEIN", 48, 54], ["DisCVR", "PROTEIN", 150, 156], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 256, 261], ["human", "SPECIES", 176, 181], ["human", "SPECIES", 256, 261], ["non-viral human pathogens", "PROBLEM", 246, 271], ["non-human hosts", "TREATMENT", 291, 306], ["viruses", "OBSERVATION", 100, 107]]]], "PMC7173036": [["IntroductionEnveloped viruses enter cells by fusing their lipid bilayer membrane with a cellular membrane.", [["cells", "ANATOMY", 36, 41], ["lipid bilayer membrane", "ANATOMY", 58, 80], ["cellular membrane", "ANATOMY", 88, 105], ["cells", "CELL", 36, 41], ["lipid bilayer membrane", "CELLULAR_COMPONENT", 58, 80], ["cellular membrane", "CELLULAR_COMPONENT", 88, 105], ["IntroductionEnveloped viruses enter cells", "TREATMENT", 0, 41], ["viruses", "OBSERVATION", 22, 29], ["cellular membrane", "OBSERVATION", 88, 105]]], ["They bear on their surface oligomers of a fusion protein, often part of a polypeptide that performs other functions, such as receptor binding.", [["surface", "ANATOMY", 19, 26], ["fusion protein", "PROTEIN", 42, 56], ["a fusion protein", "TREATMENT", 40, 56], ["a polypeptide", "TREATMENT", 72, 85]]], ["Most viral fusion proteins require priming by proteolytic processing, either of the fusion protein itself or of an accompanying protein.", [["viral fusion proteins", "PROTEIN", 5, 26], ["fusion protein", "PROTEIN", 84, 98], ["Most viral fusion proteins", "PROBLEM", 0, 26], ["proteolytic processing", "TREATMENT", 46, 68], ["the fusion protein", "TREATMENT", 80, 98], ["an accompanying protein", "PROBLEM", 112, 135], ["fusion", "OBSERVATION", 11, 17]]], ["The priming step, which often occurs during transport of the fusion protein to the cell surface but may also occur extracellularly, then prepares the fusion protein for triggering by events that accompany attachment and uptake.", [["cell surface", "ANATOMY", 83, 95], ["cell surface", "CELLULAR_COMPONENT", 83, 95], ["fusion protein", "PROTEIN", 61, 75], ["fusion protein", "PROTEIN", 150, 164], ["the fusion protein", "TREATMENT", 57, 75], ["the fusion protein", "TREATMENT", 146, 164]]], ["For example, proton binding is frequently such a trigger, which provides the virus with a mechanism for detecting that it has arrived in the low\u2010pH milieu of an endosome.IntroductionTwo classes of viral fusion proteins have been identified so far by structural studies.", [["endosome", "ANATOMY", 161, 169], ["proton", "SIMPLE_CHEMICAL", 13, 19], ["endosome", "CELLULAR_COMPONENT", 161, 169], ["viral fusion proteins", "PROTEIN", 197, 218], ["proton binding", "PROBLEM", 13, 27], ["viral fusion proteins", "TREATMENT", 197, 218], ["structural studies", "TEST", 250, 268], ["viral fusion", "OBSERVATION", 197, 209]]], ["The fusion of two bilayers that these proteins catalyze is likely to proceed by the same pathway in both cases.", [["The fusion", "TREATMENT", 0, 10], ["fusion", "OBSERVATION", 4, 10]]], ["That is, these proteins are like enzymes that have different structures but that still catalyze the same chemical reaction.IntroductionThe bilayer fusion reaction common to all the enveloped viral entry pathways is shown schematically in Fig. 1(for a review, see Cohen et al., 2002).", [["bilayer", "ANATOMY", 139, 146], ["enzymes", "PROTEIN", 33, 40], ["the same chemical reaction", "PROBLEM", 96, 122], ["The bilayer fusion reaction", "TREATMENT", 135, 162], ["chemical reaction", "OBSERVATION", 105, 122], ["bilayer fusion", "OBSERVATION", 139, 153]]], ["It is believed to pass through an intermediate known as a \u201chemifusion stalk\u201d (Fig. 1B) (Markin 1984, Siegel 1993).", [["a \u201chemifusion stalk", "TREATMENT", 56, 75]]], ["In this intermediate, the two apposed leaflets have fused, but not the distal ones.", [["leaflets", "ANATOMY", 38, 46], ["leaflets", "MULTI-TISSUE_STRUCTURE", 38, 46], ["intermediate", "OBSERVATION_MODIFIER", 8, 20], ["apposed leaflets", "OBSERVATION", 30, 46], ["fused", "OBSERVATION", 52, 57], ["distal", "OBSERVATION_MODIFIER", 71, 77]]], ["Hemifused bilayers can proceed to form a \u201cfusion pore\u201d (Fig. 1D) or form a structure in which the two distal leaflets create a single bilayer.", [["pore", "ANATOMY", 49, 53], ["distal leaflets", "ANATOMY", 102, 117], ["a \u201cfusion pore\u201d (Fig. 1D)", "TREATMENT", 39, 64], ["distal", "ANATOMY_MODIFIER", 102, 108], ["leaflets", "OBSERVATION", 109, 117]]], ["This state, which can spread laterally, is called a \u201chemifusion diaphragm\u201d (Fig. 1E).", [["diaphragm", "ANATOMY", 64, 73], ["diaphragm", "ANATOMY", 64, 73]]], ["Bilayers do not fuse spontaneously (e.g., concentrated liposomes are quite stable), because the reaction in Fig. 1 has a high activation barrier, both at the step between the precursor bilayers and the hemifusion stalk and at the step between the hemifusion stalk and the fusion pore.", [["pore", "ANATOMY", 279, 283], ["liposomes", "SIMPLE_CHEMICAL", 55, 64], ["hemifusion stalk", "CELLULAR_COMPONENT", 202, 218], ["fusion pore", "CELLULAR_COMPONENT", 272, 283], ["the reaction in Fig", "PROBLEM", 92, 111], ["a high activation barrier", "PROBLEM", 119, 144], ["the fusion pore", "TREATMENT", 268, 283], ["stable", "OBSERVATION_MODIFIER", 75, 81], ["bilayers", "ANATOMY_MODIFIER", 185, 193], ["fusion pore", "OBSERVATION", 272, 283]]], ["A newly opened pore appears to revert frequently to a hemifusion structure (\u201cflickering\u201d), and the largest kinetic barrier may be for the step in which the pore dilates rather than reverts.", [["pore", "ANATOMY", 15, 19], ["pore", "ANATOMY", 156, 160], ["hemifusion", "DISEASE", 54, 64], ["A newly opened pore", "PROBLEM", 0, 19], ["the largest kinetic barrier", "TREATMENT", 95, 122], ["largest", "OBSERVATION_MODIFIER", 99, 106], ["kinetic barrier", "OBSERVATION", 107, 122], ["pore", "OBSERVATION_MODIFIER", 156, 160], ["dilates", "OBSERVATION", 161, 168]]], ["Once the fusion pore has dilated, the fused stucture is stable with respect to the initial, unfused structure.Influenza A Hemagglutinin ::: Class I Viral Fusion ProteinsThe precursor trimer, HA0, and the primed HA1\u2013HA2 are similar in structure (Fig. 2A,B).", [["pore", "ANATOMY", 16, 20], ["HA0", "GENE_OR_GENE_PRODUCT", 191, 194], ["HA1\u2013HA2", "GENE_OR_GENE_PRODUCT", 211, 218], ["Class I Viral Fusion Proteins", "PROTEIN", 140, 169], ["HA0", "PROTEIN", 191, 194], ["HA1", "PROTEIN", 211, 214], ["HA2", "PROTEIN", 215, 218], ["B", "PROTEIN", 253, 254], ["Influenza", "SPECIES", 110, 119], ["the fusion pore", "TREATMENT", 5, 20], ["dilated", "PROBLEM", 25, 32], ["the fused stucture", "PROBLEM", 34, 52], ["Influenza", "PROBLEM", 110, 119], ["The precursor trimer, HA0", "TEST", 169, 194], ["the primed HA1\u2013HA2", "PROBLEM", 200, 218], ["fusion", "OBSERVATION", 9, 15], ["dilated", "OBSERVATION", 25, 32], ["fused stucture", "OBSERVATION", 38, 52], ["stable", "OBSERVATION_MODIFIER", 56, 62], ["unfused structure", "OBSERVATION", 92, 109], ["Viral Fusion", "OBSERVATION", 148, 160], ["precursor trimer", "OBSERVATION", 173, 189], ["similar", "OBSERVATION_MODIFIER", 223, 230]]], ["The receptor\u2010binding domain, the core of HA1, is borne on a stalk formed not only by HA2 but also by the N\u2010 and C\u2010terminal segments of HA1.", [["N\u2010", "CHEMICAL", 105, 107], ["HA1", "GENE_OR_GENE_PRODUCT", 41, 44], ["N\u2010", "SIMPLE_CHEMICAL", 105, 107], ["receptor\u2010binding domain", "PROTEIN", 4, 27], ["HA1", "PROTEIN", 41, 44], ["HA2", "PROTEIN", 85, 88], ["N\u2010 and C\u2010terminal segments", "PROTEIN", 105, 131], ["HA1", "PROTEIN", 135, 138]]], ["The loop of HA0 destined to be cleaved by furin is exposed and partly disordered.", [["HA0", "CHEMICAL", 12, 15], ["HA0", "GENE_OR_GENE_PRODUCT", 12, 15], ["furin", "GENE_OR_GENE_PRODUCT", 42, 47], ["HA0", "PROTEIN", 12, 15], ["furin", "PROTEIN", 42, 47], ["The loop of HA0", "TREATMENT", 0, 15], ["loop", "OBSERVATION_MODIFIER", 4, 8]]], ["After cleavage, the N terminus of HA2 (the fusion peptide) tucks between the long helices that cluster around the threefold axis (for many references on influenza virus HA before 2000, see Skehel and Wiley, 2000).Influenza A Hemagglutinin ::: Class I Viral Fusion ProteinsSialic acid, linked to complex glycans on either glycoproteins or glycolipids, is the receptor for influenza virus.", [["ProteinsSialic acid", "CHEMICAL", 264, 283], ["influenza virus", "DISEASE", 371, 386], ["N", "CHEMICAL", 20, 21], ["ProteinsSialic acid", "CHEMICAL", 264, 283], ["HA2", "GENE_OR_GENE_PRODUCT", 34, 37], ["influenza virus", "ORGANISM", 371, 386], ["N terminus", "PROTEIN", 20, 30], ["HA2", "PROTEIN", 34, 37], ["complex glycans", "PROTEIN", 295, 310], ["influenza virus", "SPECIES", 153, 168], ["Influenza", "SPECIES", 213, 222], ["cleavage", "TREATMENT", 6, 14], ["the N terminus of HA2", "TREATMENT", 16, 37], ["the fusion peptide)", "TREATMENT", 39, 58], ["influenza virus HA", "PROBLEM", 153, 171], ["Influenza", "PROBLEM", 213, 222], ["Viral Fusion ProteinsSialic acid", "TEST", 251, 283], ["glycolipids", "TREATMENT", 338, 349], ["influenza virus", "PROBLEM", 371, 386], ["Viral Fusion", "OBSERVATION", 251, 263]]], ["Receptor binding does not induce any significant conformational changes in HA.", [["Receptor binding", "PROBLEM", 0, 16], ["any significant conformational changes in HA", "PROBLEM", 33, 77], ["significant", "OBSERVATION_MODIFIER", 37, 48], ["conformational", "OBSERVATION", 49, 63]]], ["It merely attaches the virus to the cell surface and allows capture by endocytic vesicles.", [["cell surface", "ANATOMY", 36, 48], ["endocytic vesicles", "ANATOMY", 71, 89], ["cell surface", "CELLULAR_COMPONENT", 36, 48], ["endocytic vesicles", "CELLULAR_COMPONENT", 71, 89], ["virus", "OBSERVATION", 23, 28], ["cell", "OBSERVATION_MODIFIER", 36, 40], ["surface", "OBSERVATION_MODIFIER", 41, 48], ["endocytic vesicles", "OBSERVATION", 71, 89]]], ["The trigger for a fusion\u2010inducing conformational change is the binding of one or more protons, as the pH of the endosome becomes progressively lower.", [["endosome", "ANATOMY", 112, 120], ["protons", "SIMPLE_CHEMICAL", 86, 93], ["endosome", "CELLULAR_COMPONENT", 112, 120], ["a fusion\u2010inducing conformational change", "PROBLEM", 16, 55], ["progressively", "OBSERVATION_MODIFIER", 129, 142], ["lower", "OBSERVATION_MODIFIER", 143, 148]]], ["Most strains of influenza A have a critical pH of about 5\u20135.5, corresponding to the pH of a relatively late endosomal compartment.", [["endosomal compartment", "ANATOMY", 108, 129], ["influenza", "DISEASE", 16, 25], ["influenza A", "ORGANISM", 16, 27], ["endosomal compartment", "CELLULAR_COMPONENT", 108, 129], ["influenza", "PROBLEM", 16, 25], ["the pH", "TEST", 80, 86], ["influenza", "OBSERVATION", 16, 25], ["relatively", "OBSERVATION_MODIFIER", 92, 102], ["late", "OBSERVATION_MODIFIER", 103, 107], ["endosomal compartment", "OBSERVATION", 108, 129]]], ["No particular titrating residue accounts for the transition; rather, when the charge on the protein destabilizes it sufficiently, a cooperative conformational rearrangement ensues (Daniels et al., 1985).Influenza A Hemagglutinin ::: Class I Viral Fusion ProteinsThe conformational change triggered by proton binding (Fig 2, Fig 3) has the following characteristics (Skehel and Wiley, 2000).", [["Class I Viral Fusion Proteins", "PROTEIN", 233, 262], ["Influenza", "SPECIES", 203, 212], ["particular titrating residue", "PROBLEM", 3, 31], ["Influenza", "PROBLEM", 203, 212], ["The conformational change", "PROBLEM", 262, 287], ["proton binding (Fig", "TREATMENT", 301, 320], ["titrating residue", "OBSERVATION", 14, 31], ["Viral Fusion", "OBSERVATION", 241, 253]]], ["(1) The HA1 receptor\u2010binding domains separate from each other.", [["HA1 receptor\u2010binding domains", "PROTEIN", 8, 36], ["The HA1 receptor\u2010binding domains", "TREATMENT", 4, 36]]], ["Because HA1 is linked to HA2 by a disulfide bond, it cannot dissociate completely, but the final conformation of HA2 requires that HA1 move away from the threefold axis to allow HA2 to form new threefold contacts.", [["disulfide", "CHEMICAL", 34, 43], ["HA1", "GENE_OR_GENE_PRODUCT", 8, 11], ["HA1", "PROTEIN", 8, 11], ["HA2", "PROTEIN", 25, 28], ["HA2", "PROTEIN", 113, 116], ["HA1", "PROTEIN", 131, 134], ["HA2", "PROTEIN", 178, 181], ["HA1", "PROBLEM", 8, 11], ["HA2", "PROBLEM", 113, 116]]], ["(2) HA2 straightens by a loop\u2010to\u2010helix transition of a segment previously tucked beneath HA1 (Bullough 1994, Carr 1993).", [["HA2", "PROBLEM", 4, 7]]], ["This rearrangement thrusts the N\u2010terminal fusion peptide up (using the coordinates of Fig. 2 as a reference for \u201cup\u201d and \u201cdown\u201d), where it can encounter the membrane of the target cell.", [["membrane", "ANATOMY", 157, 165], ["cell", "ANATOMY", 180, 184], ["membrane", "CELLULAR_COMPONENT", 157, 165], ["cell", "CELL", 180, 184], ["target cell", "CELL_TYPE", 173, 184], ["the N\u2010terminal fusion peptide", "TREATMENT", 27, 56], ["target cell", "OBSERVATION", 173, 184]]], ["The extended intermediate, with fusion peptides inserted into the target cell membrane, may have a lifetime of seconds to minutes.", [["cell membrane", "ANATOMY", 73, 86], ["cell membrane", "CELLULAR_COMPONENT", 73, 86], ["fusion peptides", "TREATMENT", 32, 47], ["intermediate", "OBSERVATION_MODIFIER", 13, 25], ["fusion peptides", "OBSERVATION", 32, 47], ["target cell membrane", "OBSERVATION", 66, 86]]], ["(3) The long helix of HA2 breaks and reverses direction, and the distal part of the HA2 chain zips up along the stem formed by long central helix, which now runs from the fusion peptide to the breakpoint.", [["stem", "ANATOMY", 112, 116], ["long central helix", "CELLULAR_COMPONENT", 127, 145], ["HA2", "PROTEIN", 22, 25], ["HA2 chain", "PROTEIN", 84, 93], ["The long helix of HA2 breaks", "PROBLEM", 4, 32], ["long central helix", "PROBLEM", 127, 145], ["the fusion peptide", "TREATMENT", 167, 185], ["long helix", "OBSERVATION_MODIFIER", 8, 18], ["HA2 breaks", "OBSERVATION", 22, 32], ["reverses", "OBSERVATION_MODIFIER", 37, 45], ["direction", "OBSERVATION_MODIFIER", 46, 55], ["distal", "ANATOMY_MODIFIER", 65, 71], ["HA2", "ANATOMY_MODIFIER", 84, 87], ["chain zips", "OBSERVATION", 88, 98], ["stem", "ANATOMY_MODIFIER", 112, 116], ["long", "OBSERVATION_MODIFIER", 127, 131], ["central helix", "OBSERVATION", 132, 145], ["fusion", "OBSERVATION", 171, 177]]], ["In its final conformation, the HA2 ectodomain has its N terminus, which bears the fusion peptide, adjacent to its C terminus, which leads to the transmembrane anchor (Chen et al., 1999).", [["transmembrane", "ANATOMY", 145, 158], ["N", "CHEMICAL", 54, 55], ["transmembrane", "CELLULAR_COMPONENT", 145, 158], ["HA2 ectodomain", "PROTEIN", 31, 45], ["N terminus", "PROTEIN", 54, 64], ["C terminus", "PROTEIN", 114, 124], ["the HA2 ectodomain", "PROBLEM", 27, 45], ["the fusion peptide", "TREATMENT", 78, 96], ["final conformation", "OBSERVATION", 7, 25], ["terminus", "OBSERVATION_MODIFIER", 56, 64], ["fusion peptide", "OBSERVATION", 82, 96], ["terminus", "OBSERVATION_MODIFIER", 116, 124]]], ["In other words, the two membrane\u2010interacting segments on each chain are next to each other.", [["membrane\u2010interacting segments", "PROTEIN", 24, 53]]], ["Thus, assuming that all three fusion peptides insert into the target membrane and that the C\u2010terminal transmembrane segments remain anchored in the viral membrane, the zipping up of the distal part of HA2 will drag the two membranes together (Fig. 3).Influenza A Hemagglutinin ::: Class I Viral Fusion ProteinsOnly the inital (Fig. 2B) and final (Fig. 2C) conformations of HA2 can be studied easily by structural methods.", [["membrane", "ANATOMY", 69, 77], ["C\u2010terminal transmembrane segments", "ANATOMY", 91, 124], ["membrane", "ANATOMY", 154, 162], ["membranes", "ANATOMY", 223, 232], ["membrane", "CELLULAR_COMPONENT", 69, 77], ["viral membrane", "CELLULAR_COMPONENT", 148, 162], ["membranes", "CELLULAR_COMPONENT", 223, 232], ["C\u2010terminal transmembrane segments", "PROTEIN", 91, 124], ["HA2", "PROTEIN", 201, 204], ["inital", "PROTEIN", 319, 325], ["HA2", "PROTEIN", 373, 376], ["Influenza", "SPECIES", 251, 260], ["all three fusion peptides", "TREATMENT", 20, 45], ["the C\u2010terminal transmembrane segments", "TREATMENT", 87, 124], ["Influenza", "PROBLEM", 251, 260], ["the inital (Fig. 2B", "TREATMENT", 315, 334], ["final (Fig", "TREATMENT", 340, 350], ["HA2", "PROBLEM", 373, 376], ["viral membrane", "OBSERVATION", 148, 162], ["distal", "OBSERVATION_MODIFIER", 186, 192], ["two membranes", "OBSERVATION", 219, 232], ["Viral Fusion", "OBSERVATION", 289, 301]]], ["Evidence for the pathway described previously and shown diagrammatically in Fig. 3 comes from biophysical studies of HA\u2010mediated fusion and from the effects of various mutations on the fusion process (reviewed extensively elsewhere and outlined only in summary here).1The low\u2010pH trigger.", [["HA\u2010", "GENE_OR_GENE_PRODUCT", 117, 120], ["biophysical studies", "TEST", 94, 113], ["HA\u2010mediated fusion", "TREATMENT", 117, 135], ["various mutations", "PROBLEM", 160, 177], ["the fusion process", "TREATMENT", 181, 199], ["The low\u2010pH trigger", "PROBLEM", 268, 286], ["fusion", "OBSERVATION", 129, 135]]], ["The threshold pH for fusion can be affected by a variety of amino acid substitutions, and some that increase the threshold pH can be selected by isolating virus resistant to amantadine (which raises the pH of endosomes).", [["endosomes", "ANATOMY", 209, 218], ["amino acid", "CHEMICAL", 60, 70], ["amantadine", "CHEMICAL", 174, 184], ["amino acid", "CHEMICAL", 60, 70], ["amantadine", "CHEMICAL", 174, 184], ["amino acid", "AMINO_ACID", 60, 70], ["amantadine", "SIMPLE_CHEMICAL", 174, 184], ["endosomes", "CELLULAR_COMPONENT", 209, 218], ["The threshold pH", "TEST", 0, 16], ["fusion", "PROBLEM", 21, 27], ["amino acid substitutions", "PROBLEM", 60, 84], ["the threshold pH", "PROBLEM", 109, 125], ["isolating virus", "PROBLEM", 145, 160], ["amantadine", "TREATMENT", 174, 184], ["acid substitutions", "OBSERVATION", 66, 84]]], ["These mutations map in a variety of locations, which have in common that they appear to contribute to interactions that hold together the HA trimer (Daniels et al., 1985).", [["HA trimer", "PROTEIN", 138, 147], ["These mutations map", "PROBLEM", 0, 19]]], ["Thus, there appears not to be a single, localized trigger, but rather a cumulative effect of various groups that bind protons at pH 5 and above.2Fusion peptide emergence and insertion.", [["2Fusion peptide", "CHEMICAL", 144, 159], ["protons", "SIMPLE_CHEMICAL", 118, 125], ["a single, localized trigger", "PROBLEM", 30, 57], ["2Fusion peptide emergence", "TREATMENT", 144, 169], ["insertion", "TREATMENT", 174, 183], ["appears not to be", "UNCERTAINTY", 12, 29]]], ["The amino acid sequence of the loop in HA2 has a particularly strong helical coiled\u2010coil signature, and peptides with this sequence form stable coiled coils in solution (Carr and Kim, 1993).", [["amino acid", "CHEMICAL", 4, 14], ["amino acid", "CHEMICAL", 4, 14], ["amino acid", "AMINO_ACID", 4, 14], ["amino acid sequence", "PROTEIN", 4, 23], ["HA2", "PROTEIN", 39, 42], ["The amino acid sequence", "TEST", 0, 23], ["the loop in HA2", "PROBLEM", 27, 42], ["loop", "OBSERVATION_MODIFIER", 31, 35], ["stable", "OBSERVATION_MODIFIER", 137, 143]]], ["Release of the constraints imposed on the conformation of this peptide by HA1 is therefore likely to lead to coiled\u2010coil formation and translocation of the fusion peptide away from the base of the trimer.", [["HA1", "GENE_OR_GENE_PRODUCT", 74, 77], ["coiled\u2010coil", "SIMPLE_CHEMICAL", 109, 120], ["HA1", "PROTEIN", 74, 77], ["coiled\u2010coil formation", "PROBLEM", 109, 130], ["the fusion peptide", "TREATMENT", 152, 170], ["fusion", "OBSERVATION", 156, 162], ["base", "ANATOMY_MODIFIER", 185, 189], ["trimer", "ANATOMY_MODIFIER", 197, 203]]], ["Experiments with target membranes containing photoactivatable cross\u2010linking reagents demonstrate insertion of the fusion peptide into the target cell membrane, probably before fusion (Tsurudome et al., 1992).", [["membranes", "ANATOMY", 24, 33], ["cell membrane", "ANATOMY", 145, 158], ["membranes", "CELLULAR_COMPONENT", 24, 33], ["cell membrane", "CELLULAR_COMPONENT", 145, 158], ["target membranes", "TREATMENT", 17, 33], ["photoactivatable cross\u2010linking reagents", "TREATMENT", 45, 84], ["insertion of the fusion peptide", "TREATMENT", 97, 128], ["fusion", "OBSERVATION", 114, 120], ["target cell membrane", "OBSERVATION", 138, 158]]], ["A peptide having the amino acid sequence of the first 20 residues of HA2 forms a gently kinked, amphipathic helix in the presence of detergent micelles (Han et al., 2001).", [["amino acid", "CHEMICAL", 21, 31], ["amino acid", "CHEMICAL", 21, 31], ["amino acid", "AMINO_ACID", 21, 31], ["amino acid sequence", "PROTEIN", 21, 40], ["HA2", "PROTEIN", 69, 72], ["amphipathic helix", "PROTEIN", 96, 113], ["the amino acid sequence", "TREATMENT", 17, 40], ["a gently kinked, amphipathic helix", "PROBLEM", 79, 113], ["gently kinked", "OBSERVATION_MODIFIER", 81, 94], ["amphipathic helix", "OBSERVATION", 96, 113]]], ["On a membrane, this structure would lie partially embedded in the outer monolayer, with the two ends dipping somewhat more deeply into the bilayer outer leaflet than the apex of the kink.", [["membrane", "ANATOMY", 5, 13], ["outer monolayer", "ANATOMY", 66, 81], ["outer leaflet", "ANATOMY", 147, 160], ["membrane", "CELLULAR_COMPONENT", 5, 13], ["outer monolayer", "CELLULAR_COMPONENT", 66, 81], ["outer leaflet", "CELLULAR_COMPONENT", 147, 160], ["a membrane", "TREATMENT", 3, 13], ["outer", "OBSERVATION_MODIFIER", 66, 71], ["monolayer", "OBSERVATION_MODIFIER", 72, 81], ["bilayer", "ANATOMY_MODIFIER", 139, 146], ["outer", "ANATOMY_MODIFIER", 147, 152], ["leaflet", "ANATOMY_MODIFIER", 153, 160], ["apex", "ANATOMY_MODIFIER", 170, 174], ["kink", "OBSERVATION", 182, 186]]], ["That is, the fusion peptide probably inserts only into the proximal leaflet of a membrane lipid bilayer.", [["proximal leaflet", "ANATOMY", 59, 75], ["membrane lipid bilayer", "ANATOMY", 81, 103], ["membrane", "CELLULAR_COMPONENT", 81, 89], ["lipid bilayer", "CELLULAR_COMPONENT", 90, 103], ["the fusion peptide", "TREATMENT", 9, 27], ["fusion", "OBSERVATION", 13, 19], ["proximal", "ANATOMY_MODIFIER", 59, 67], ["leaflet", "ANATOMY_MODIFIER", 68, 75], ["membrane lipid bilayer", "OBSERVATION", 81, 103]]], ["The effects of mutations in the fusion peptide vary with position (Qiao 1999, Steinhauer 1995).", [["mutations", "PROBLEM", 15, 24], ["the fusion peptide", "TREATMENT", 28, 46]]], ["They do not correlate in any simple way with the structure just described, but it may be difficult to deconvolute the requirements for its conformation in the mature HA1\u2013HA2 trimer from those for productive membrane insertion.3Fold\u2010back.", [["membrane", "ANATOMY", 207, 215], ["membrane", "CELLULAR_COMPONENT", 207, 215], ["HA1", "PROTEIN", 166, 169], ["HA2 trimer", "PROTEIN", 170, 180], ["productive membrane insertion", "TREATMENT", 196, 225], ["membrane insertion", "OBSERVATION", 207, 225]]], ["The best evidence for an extended \u201cprefusion intermediate,\u201d with the fusion peptides inserted into the target cell membrane but with the C\u2010terminal parts of the fusion protein still at the opposite end of the molecule, comes from work on HIV\u20101 gp41 (Furuta 1998, Rimsky 1998) (see later).", [["cell membrane", "ANATOMY", 110, 123], ["cell membrane", "CELLULAR_COMPONENT", 110, 123], ["C\u2010terminal parts", "PROTEIN", 137, 153], ["fusion protein", "PROTEIN", 161, 175], ["HIV\u20101 gp41", "PROTEIN", 238, 248], ["HIV", "SPECIES", 238, 241], ["HIV", "SPECIES", 238, 241], ["an extended \u201cprefusion intermediate", "PROBLEM", 22, 57], ["the fusion peptides", "TREATMENT", 65, 84], ["the fusion protein", "TEST", 157, 175], ["prefusion intermediate", "OBSERVATION", 35, 57], ["fusion", "OBSERVATION", 69, 75], ["target cell membrane", "OBSERVATION", 103, 123], ["fusion protein", "OBSERVATION", 161, 175], ["molecule", "OBSERVATION_MODIFIER", 209, 217]]], ["In the mature HA trimer at neutral pH, the long axial helices diverge from each other at about the position at which the folding back occurs (Fig. 2B,C), and it is plausible that in the extended intermediate, the \u201clower\u201d part of the molecule is unstable and locally unfolded.", [["long axial helices", "PROTEIN", 43, 61], ["the long axial helices diverge", "PROBLEM", 39, 69], ["locally unfolded", "PROBLEM", 258, 274], ["mature", "OBSERVATION_MODIFIER", 7, 13], ["HA trimer", "OBSERVATION_MODIFIER", 14, 23], ["lower", "ANATOMY_MODIFIER", 214, 219], ["molecule", "OBSERVATION", 233, 241], ["unstable", "OBSERVATION_MODIFIER", 245, 253], ["locally", "OBSERVATION_MODIFIER", 258, 265], ["unfolded", "OBSERVATION", 266, 274]]], ["There has been some confusion in the literature about the folding back process.", [["confusion", "DISEASE", 20, 29], ["some confusion", "PROBLEM", 15, 29], ["some", "OBSERVATION_MODIFIER", 15, 19], ["confusion", "OBSERVATION", 20, 29]]], ["Although the expressions \u201cfold back\u201d and \u201cjack\u2010knifing\u201d have been used to describe the conformational change, the only way it can plausibly occur in practice is by melting at least some of the C\u2010terminal segments of the HA2 ectodomain and zipping up these segments along the central core (Fig. 3).", [["C\u2010terminal segments", "PROTEIN", 193, 212], ["HA2 ectodomain", "PROTEIN", 220, 234], ["the HA2 ectodomain", "PROBLEM", 216, 234], ["segments", "ANATOMY_MODIFIER", 204, 212], ["HA2 ectodomain", "OBSERVATION", 220, 234], ["segments", "ANATOMY_MODIFIER", 256, 264], ["central", "ANATOMY_MODIFIER", 275, 282], ["core", "ANATOMY_MODIFIER", 283, 287]]], ["If the links between the fusion peptides and the central core are flexible, then the zipping process will necessarily displace the position of the chain reversal (the fold\u2010back point) laterally, away from the constriction.", [["the fusion peptides", "TREATMENT", 21, 40], ["the zipping process", "TREATMENT", 81, 100], ["fusion", "OBSERVATION", 25, 31], ["position", "OBSERVATION_MODIFIER", 131, 139], ["chain reversal", "OBSERVATION", 147, 161], ["constriction", "OBSERVATION", 209, 221]]], ["During the transition from the extended intermediate to the folded\u2010back conformation, threefold symmetry is broken; it is restored only in the final, postfusion structure.The free energy required to deform the two membranes, squeeze them together, and initiate fusion is probably more than can be obtained from refolding of a single trimer, and it is likely that several HA trimers cooperate to form a fusion pore.", [["membranes", "ANATOMY", 214, 223], ["membranes", "CELLULAR_COMPONENT", 214, 223], ["HA trimers", "GENE_OR_GENE_PRODUCT", 371, 381], ["HA trimers", "PROTEIN", 371, 381], ["fusion", "TREATMENT", 261, 267], ["several HA trimers", "PROBLEM", 363, 381], ["a fusion pore", "TREATMENT", 400, 413], ["threefold symmetry", "OBSERVATION", 86, 104], ["broken", "OBSERVATION", 108, 114], ["restored", "OBSERVATION_MODIFIER", 122, 130], ["final", "OBSERVATION_MODIFIER", 143, 148], ["free energy", "OBSERVATION", 175, 186], ["two membranes", "OBSERVATION_MODIFIER", 210, 223]]], ["Evidence for this statement includes the observation that the lag time between acidification and fusion of cells expressing HA on their plasma membranes depends on the HA surface density (Danieli et al., 1996).", [["cells", "ANATOMY", 107, 112], ["plasma membranes", "ANATOMY", 136, 152], ["surface", "ANATOMY", 171, 178], ["cells", "CELL", 107, 112], ["HA", "GENE_OR_GENE_PRODUCT", 124, 126], ["plasma membranes", "CELLULAR_COMPONENT", 136, 152], ["acidification and fusion of cells", "TREATMENT", 79, 112], ["HA", "PROBLEM", 124, 126]]], ["One picture for the process would invoke formation of a structurally defined ring of extended intermediates, surrounding the position at which fusion will occur.", [["a structurally defined ring of extended intermediates", "PROBLEM", 54, 107], ["position", "OBSERVATION_MODIFIER", 125, 133]]], ["An alternative, more stochastic model, is also possible, as described in more detail later, in Section IV.A.4Hemifusion.", [["A.4Hemifusion", "CHEMICAL", 106, 119], ["A.4Hemifusion", "TREATMENT", 106, 119], ["more", "OBSERVATION_MODIFIER", 16, 20], ["stochastic model", "OBSERVATION", 21, 37]]], ["The fold\u2010back step brings the two membranes close together.", [["membranes", "ANATOMY", 34, 43], ["membranes", "CELLULAR_COMPONENT", 34, 43]]], ["Are there further structural features that accelerate hemifusion?", [["accelerate hemifusion", "PROBLEM", 43, 64]]], ["Distortion of one or both membranes by introduction of positive curvature would be one way to do so; stabilization of a hemifusion stalk once formed, thereby preventing reversal, would be another.", [["membranes", "ANATOMY", 26, 35], ["membranes", "CELLULAR_COMPONENT", 26, 35], ["Distortion of one or both membranes", "PROBLEM", 0, 35], ["positive curvature", "PROBLEM", 55, 73], ["a hemifusion stalk", "TREATMENT", 118, 136], ["one", "OBSERVATION_MODIFIER", 14, 17], ["both", "OBSERVATION_MODIFIER", 21, 25], ["membranes", "OBSERVATION", 26, 35], ["positive curvature", "OBSERVATION", 55, 73]]], ["We need to know more about the conformation and properties of an inserted fusion peptide before we can assess these possibilities.", [["an inserted fusion peptide", "TREATMENT", 62, 88]]], ["The discovery, that class II fusion peptides insert only into the outer part of the target membrane, suggests a possible mechanism for hemifusion stalk stabilization (see later).5Fusion pore formation.", [["outer part", "ANATOMY", 66, 76], ["membrane", "ANATOMY", 91, 99], ["stalk", "ANATOMY", 146, 151], ["5Fusion pore", "ANATOMY", 178, 190], ["class II fusion peptides", "GENE_OR_GENE_PRODUCT", 20, 44], ["membrane", "CELLULAR_COMPONENT", 91, 99], ["class II fusion peptides", "TREATMENT", 20, 44], ["hemifusion stalk stabilization", "TREATMENT", 135, 165], ["5Fusion pore formation", "TREATMENT", 178, 200], ["fusion peptides", "OBSERVATION", 29, 44], ["outer", "ANATOMY_MODIFIER", 66, 71], ["target membrane", "OBSERVATION", 84, 99], ["suggests a possible", "UNCERTAINTY", 101, 120]]], ["A noteworthy feature of the rearranged structure of HA2 ectodomain is a tight \u201ccap,\u201d formed by the way the C\u2010terminal part of the polypeptide chain associates with the N\u2010terminal end of the central, three\u2010helix bundle (Fig. 2C) (Chen et al., 1999).", [["HA2 ectodomain", "GENE_OR_GENE_PRODUCT", 52, 66], ["HA2 ectodomain", "PROTEIN", 52, 66], ["tight \u201ccap", "PROTEIN", 72, 82], ["C\u2010terminal part", "PROTEIN", 107, 122], ["polypeptide chain", "PROTEIN", 130, 147], ["N\u2010terminal end", "PROTEIN", 168, 182], ["three\u2010helix bundle", "PROTEIN", 199, 217], ["HA2 ectodomain", "PROBLEM", 52, 66], ["a tight \u201ccap", "PROBLEM", 70, 82], ["HA2 ectodomain", "OBSERVATION", 52, 66], ["tight", "OBSERVATION_MODIFIER", 72, 77], ["\u201ccap", "OBSERVATION_MODIFIER", 78, 82], ["polypeptide chain", "OBSERVATION", 130, 147], ["central", "ANATOMY_MODIFIER", 190, 197], ["three\u2010helix bundle", "ANATOMY", 199, 217]]], ["This cap is likely to snap the folded\u2010back conformation into place.", [["likely to", "UNCERTAINTY", 12, 21], ["folded", "OBSERVATION", 31, 37], ["\u2010back conformation", "OBSERVATION", 37, 55]]], ["In the model for the fusion reaction diagrammed in Fig. 3, the final step involves stabilization of the fusion pore by interposition of the transmembrane anchors of HA2.", [["pore", "ANATOMY", 111, 115], ["transmembrane", "ANATOMY", 140, 153], ["transmembrane anchors", "PROTEIN", 140, 161], ["HA2", "PROTEIN", 165, 168], ["the fusion reaction", "PROBLEM", 17, 36], ["the fusion pore", "TREATMENT", 100, 115], ["the transmembrane anchors of HA2", "TREATMENT", 136, 168], ["fusion", "OBSERVATION", 21, 27], ["fusion", "OBSERVATION", 104, 110]]], ["Formation of the HA2 cap may be a critical feature of this step.", [["HA2 cap", "PROTEIN", 17, 24], ["the HA2 cap", "PROBLEM", 13, 24]]], ["When HA is linked to a glycophosphatidylinositol (GPI) anchor or to a truncated transmembrane anchor that does not cross the bilayer, it catalyzes hemifusion quite readily, but it promotes fusion poorly, if at all (Kemble 1994, Melikyan 1995).", [["transmembrane", "ANATOMY", 80, 93], ["glycophosphatidylinositol", "CHEMICAL", 23, 48], ["glycophosphatidylinositol", "CHEMICAL", 23, 48], ["glycophosphatidylinositol", "SIMPLE_CHEMICAL", 23, 48], ["transmembrane", "CELLULAR_COMPONENT", 80, 93], ["glycophosphatidylinositol (GPI) anchor", "PROTEIN", 23, 61], ["truncated transmembrane anchor", "PROTEIN", 70, 100], ["HA", "PROBLEM", 5, 7], ["a glycophosphatidylinositol (GPI) anchor", "TREATMENT", 21, 61], ["a truncated transmembrane anchor", "TREATMENT", 68, 100]]], ["Catalyzing fusion does not require a specific structure or amino acid sequence on the inside of the membrane; the transmembrane anchor must simply traverse the bilayer completely (Armstrong et al., 2000).", [["membrane", "ANATOMY", 100, 108], ["transmembrane", "ANATOMY", 114, 127], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "CHEMICAL", 59, 69], ["amino acid", "AMINO_ACID", 59, 69], ["membrane", "CELLULAR_COMPONENT", 100, 108], ["transmembrane", "CELLULAR_COMPONENT", 114, 127], ["amino acid sequence", "PROTEIN", 59, 78], ["transmembrane anchor", "PROTEIN", 114, 134], ["Catalyzing fusion", "TREATMENT", 0, 17], ["amino acid sequence", "TEST", 59, 78], ["the transmembrane anchor", "TREATMENT", 110, 134], ["fusion", "OBSERVATION", 11, 17]]], ["Truncation of the SV5 fusion protein produces a similar result (Dutch and Lamb, 2001).", [["SV5", "GENE_OR_GENE_PRODUCT", 18, 21], ["SV5 fusion protein", "PROTEIN", 18, 36], ["the SV5 fusion protein", "TEST", 14, 36], ["SV5 fusion", "OBSERVATION", 18, 28]]], ["Snapping the HA2 cap into place and dragging the cytosolic end of the transmembrane anchor into a newly opened pore will prevent the pore from resealing (which it will otherwise tend to do) and force the fusion reaction to proceed to completion.", [["cytosolic", "ANATOMY", 49, 58], ["transmembrane", "ANATOMY", 70, 83], ["pore", "ANATOMY", 111, 115], ["pore", "ANATOMY", 133, 137], ["transmembrane", "CELLULAR_COMPONENT", 70, 83], ["HA2 cap", "PROTEIN", 13, 20], ["cytosolic end", "PROTEIN", 49, 62], ["transmembrane anchor", "PROTEIN", 70, 90], ["Snapping the HA2 cap", "TREATMENT", 0, 20], ["the fusion reaction", "PROBLEM", 200, 219]]]], "be9bdbb4987a83ad38fb0b65018528055e13eab7": [["IntroductionType 2 diabetes is a complex disease that presents beta cell failure in the setting of insulin resistance.", [["beta cell", "ANATOMY", 63, 72], ["Type 2 diabetes", "DISEASE", 12, 27], ["beta cell failure", "DISEASE", 63, 80], ["beta cell", "CELL", 63, 72], ["insulin", "GENE_OR_GENE_PRODUCT", 99, 106], ["Type 2 diabetes", "PROBLEM", 12, 27], ["a complex disease", "PROBLEM", 31, 48], ["beta cell failure", "PROBLEM", 63, 80], ["insulin resistance", "PROBLEM", 99, 117], ["diabetes", "OBSERVATION", 19, 27], ["complex", "OBSERVATION_MODIFIER", 33, 40], ["disease", "OBSERVATION", 41, 48], ["beta cell failure", "OBSERVATION", 63, 80], ["insulin resistance", "OBSERVATION", 99, 117]]], ["At the beginning of the disease, pancreatic beta cells adapt to insulin resistance by increasing their mass and secretory function.", [["pancreatic beta cells", "ANATOMY", 33, 54], ["pancreatic beta cells", "CELL", 33, 54], ["insulin", "GENE_OR_GENE_PRODUCT", 64, 71], ["pancreatic beta cells", "CELL_TYPE", 33, 54], ["the disease", "PROBLEM", 20, 31], ["pancreatic beta cells", "TREATMENT", 33, 54], ["insulin resistance", "TREATMENT", 64, 82], ["increasing their mass", "PROBLEM", 86, 107], ["disease", "OBSERVATION", 24, 31], ["pancreatic", "ANATOMY", 33, 43], ["beta cells", "OBSERVATION", 44, 54], ["insulin resistance", "OBSERVATION", 64, 82], ["mass", "OBSERVATION", 103, 107], ["secretory function", "OBSERVATION", 112, 130]]], ["Nevertheless, the sustained hyperglycaemia and hyperlipidaemia eventually exert a negative impact on beta cell function and lead to impaired insulin secretion and decreased insulin gene expression, ultimately causing beta cell apoptosis [1, 2] .", [["beta cell", "ANATOMY", 101, 110], ["beta cell", "ANATOMY", 217, 226], ["hyperglycaemia", "DISEASE", 28, 42], ["hyperlipidaemia", "DISEASE", 47, 62], ["beta cell", "CELL", 101, 110], ["insulin", "GENE_OR_GENE_PRODUCT", 141, 148], ["insulin", "GENE_OR_GENE_PRODUCT", 173, 180], ["beta cell", "CELL", 217, 226], ["the sustained hyperglycaemia", "PROBLEM", 14, 42], ["hyperlipidaemia", "PROBLEM", 47, 62], ["beta cell function", "TEST", 101, 119], ["impaired insulin secretion", "PROBLEM", 132, 158], ["decreased insulin gene expression", "PROBLEM", 163, 196], ["beta cell apoptosis", "PROBLEM", 217, 236], ["hyperglycaemia", "OBSERVATION", 28, 42], ["beta cell", "OBSERVATION_MODIFIER", 101, 110], ["insulin secretion", "OBSERVATION", 141, 158], ["beta cell apoptosis", "OBSERVATION", 217, 236]]], ["Moreover, the follow-up of beta cell mass in diabetic patients and in people strongly at risk for diabetes and their response to pharmacological treatment may be crucial for early diagnosis and treatment selection, making the search for beta cell mass markers a high priority for investigation [3] .IntroductionTransmembrane protein 27 (TMEM27) was first described in the kidney as an angiotensin-converting enzyme 2 (ACE2) homologue involved in amino acid transport [4, 5] .", [["beta cell", "ANATOMY", 27, 36], ["beta cell", "ANATOMY", 237, 246], ["kidney", "ANATOMY", 372, 378], ["diabetic", "DISEASE", 45, 53], ["diabetes", "DISEASE", 98, 106], ["angiotensin", "CHEMICAL", 385, 396], ["amino acid", "CHEMICAL", 446, 456], ["amino acid", "CHEMICAL", 446, 456], ["beta cell", "CELL", 27, 36], ["patients", "ORGANISM", 54, 62], ["people", "ORGANISM", 70, 76], ["beta cell", "CELL", 237, 246], ["Transmembrane protein 27", "GENE_OR_GENE_PRODUCT", 311, 335], ["TMEM27", "GENE_OR_GENE_PRODUCT", 337, 343], ["kidney", "ORGAN", 372, 378], ["angiotensin-converting enzyme 2", "GENE_OR_GENE_PRODUCT", 385, 416], ["ACE2", "GENE_OR_GENE_PRODUCT", 418, 422], ["amino acid", "AMINO_ACID", 446, 456], ["Transmembrane protein 27", "PROTEIN", 311, 335], ["TMEM27", "PROTEIN", 337, 343], ["angiotensin-converting enzyme 2 (ACE2) homologue", "PROTEIN", 385, 433], ["patients", "SPECIES", 54, 62], ["people", "SPECIES", 70, 76], ["beta cell mass", "PROBLEM", 27, 41], ["diabetic patients", "PROBLEM", 45, 62], ["diabetes", "PROBLEM", 98, 106], ["pharmacological treatment", "TREATMENT", 129, 154], ["treatment selection", "TREATMENT", 194, 213], ["beta cell mass markers", "TEST", 237, 259], ["Transmembrane protein", "TEST", 311, 332], ["an angiotensin-converting enzyme 2 (ACE2) homologue", "TREATMENT", 382, 433], ["amino acid transport", "TREATMENT", 446, 466], ["beta cell", "OBSERVATION_MODIFIER", 27, 36], ["mass", "OBSERVATION", 37, 41], ["kidney", "ANATOMY", 372, 378]]], ["In the pancreas, TMEM27 is produced in beta cells [6, 7] .", [["pancreas", "ANATOMY", 7, 15], ["beta cells", "ANATOMY", 39, 49], ["pancreas", "ORGAN", 7, 15], ["TMEM27", "GENE_OR_GENE_PRODUCT", 17, 23], ["beta cells", "CELL", 39, 49], ["TMEM27", "PROTEIN", 17, 23], ["beta cells", "CELL_TYPE", 39, 49], ["pancreas", "ANATOMY", 7, 15], ["beta cells", "OBSERVATION", 39, 49]]], ["However, its biological role in this cell type remains uncertain.", [["cell", "ANATOMY", 37, 41], ["cell", "CELL", 37, 41]]], ["While one study established a potential positive role of TMEM27 in glucose-stimulated insulin exocytosis [7] , another study linked TMEM27 production to beta cell proliferation [6] .", [["beta cell", "ANATOMY", 153, 162], ["glucose", "CHEMICAL", 67, 74], ["glucose", "CHEMICAL", 67, 74], ["TMEM27", "GENE_OR_GENE_PRODUCT", 57, 63], ["glucose", "SIMPLE_CHEMICAL", 67, 74], ["insulin", "GENE_OR_GENE_PRODUCT", 86, 93], ["TMEM27", "GENE_OR_GENE_PRODUCT", 132, 138], ["beta cell", "CELL", 153, 162], ["TMEM27", "PROTEIN", 57, 63], ["TMEM27", "PROTEIN", 132, 138], ["one study", "TEST", 6, 15], ["TMEM27", "TEST", 57, 63], ["glucose", "TEST", 67, 74], ["another study", "TEST", 111, 124], ["beta cell proliferation", "TEST", 153, 176], ["beta cell proliferation", "OBSERVATION", 153, 176]]], ["The latter study also hypothesised that TMEM27, which is cleaved and shed into the extracellular space, might be used as a beta cell mass biomarker.", [["extracellular space", "ANATOMY", 83, 102], ["beta cell", "ANATOMY", 123, 132], ["TMEM27", "GENE_OR_GENE_PRODUCT", 40, 46], ["extracellular space", "CELLULAR_COMPONENT", 83, 102], ["beta cell", "CELL", 123, 132], ["TMEM27", "PROTEIN", 40, 46], ["The latter study", "TEST", 0, 16], ["a beta cell mass biomarker", "TEST", 121, 147]]], ["Furthermore, adding to the controversy concerning the physiological role of TMEM27 in beta cell homeostasis, Tmem27-knockout mice exhibited both normal insulin secretion and beta cell mass and replication [8] .IntroductionIn spite of the lack of consensus on the function of TMEM27 in beta cells, its suggested roles in cellular proliferation and insulin secretion, together with its potential use as a beta cell mass biomarker, make it an interesting candidate factor in type 2 diabetes that deserves further characterisation.", [["beta cell", "ANATOMY", 86, 95], ["beta cell", "ANATOMY", 174, 183], ["beta cells", "ANATOMY", 285, 295], ["cellular", "ANATOMY", 320, 328], ["beta cell", "ANATOMY", 403, 412], ["type 2 diabetes", "DISEASE", 472, 487], ["TMEM27", "GENE_OR_GENE_PRODUCT", 76, 82], ["beta cell", "CELL", 86, 95], ["Tmem27", "GENE_OR_GENE_PRODUCT", 109, 115], ["insulin", "GENE_OR_GENE_PRODUCT", 152, 159], ["beta cell", "CELL", 174, 183], ["TMEM27", "GENE_OR_GENE_PRODUCT", 275, 281], ["beta cells", "CELL", 285, 295], ["cellular", "CELL", 320, 328], ["insulin", "GENE_OR_GENE_PRODUCT", 347, 354], ["beta cell", "CELL", 403, 412], ["TMEM27", "PROTEIN", 76, 82], ["Tmem27", "PROTEIN", 109, 115], ["TMEM27", "PROTEIN", 275, 281], ["beta cells", "CELL_TYPE", 285, 295], ["mice", "SPECIES", 125, 129], ["mice", "SPECIES", 125, 129], ["beta cell homeostasis", "TEST", 86, 107], ["Tmem27", "TEST", 109, 115], ["beta cell mass", "PROBLEM", 174, 188], ["cellular proliferation", "PROBLEM", 320, 342], ["insulin secretion", "PROBLEM", 347, 364], ["a beta cell mass biomarker", "TEST", 401, 427], ["type 2 diabetes", "PROBLEM", 472, 487], ["insulin secretion", "OBSERVATION", 152, 169], ["beta cell", "OBSERVATION_MODIFIER", 174, 183], ["cellular proliferation", "OBSERVATION", 320, 342], ["insulin secretion", "OBSERVATION", 347, 364]]], ["In this study, we characterised TMEM27 production in human pancreatic islets, confirming that it is mainly produced in beta cells.", [["pancreatic islets", "ANATOMY", 59, 76], ["beta cells", "ANATOMY", 119, 129], ["TMEM27", "GENE_OR_GENE_PRODUCT", 32, 38], ["human", "ORGANISM", 53, 58], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 59, 76], ["beta cells", "CELL", 119, 129], ["TMEM27", "PROTEIN", 32, 38], ["human pancreatic islets", "CELL_TYPE", 53, 76], ["beta cells", "CELL_TYPE", 119, 129], ["human", "SPECIES", 53, 58], ["human", "SPECIES", 53, 58], ["this study", "TEST", 3, 13], ["pancreatic", "ANATOMY", 59, 69], ["beta cells", "OBSERVATION", 119, 129]]], ["Importantly, we report that TMEM27 expression is decreased in type 2 diabetic islets.", [["islets", "ANATOMY", 78, 84], ["diabetic", "DISEASE", 69, 77], ["TMEM27", "GENE_OR_GENE_PRODUCT", 28, 34], ["islets", "MULTI-TISSUE_STRUCTURE", 78, 84], ["TMEM27", "PROTEIN", 28, 34], ["type 2 diabetic islets", "PROBLEM", 62, 84], ["decreased", "OBSERVATION_MODIFIER", 49, 58]]], ["In addition, using gene expression analysis in human and rat islets along with gain-of-function experiments in a pancreatic beta cell line and isolated islets, we provide evidence that TMEM27 is involved in the regulation of insulin secretion with little if any control of proliferation.", [["islets", "ANATOMY", 61, 67], ["pancreatic beta cell line", "ANATOMY", 113, 138], ["islets", "ANATOMY", 152, 158], ["human", "ORGANISM", 47, 52], ["rat", "ORGANISM", 57, 60], ["islets", "MULTI-TISSUE_STRUCTURE", 61, 67], ["pancreatic beta cell line", "CELL", 113, 138], ["islets", "MULTI-TISSUE_STRUCTURE", 152, 158], ["TMEM27", "GENE_OR_GENE_PRODUCT", 185, 191], ["insulin", "GENE_OR_GENE_PRODUCT", 225, 232], ["human and rat islets", "CELL_TYPE", 47, 67], ["pancreatic beta cell line", "CELL_LINE", 113, 138], ["isolated islets", "CELL_TYPE", 143, 158], ["TMEM27", "PROTEIN", 185, 191], ["human", "SPECIES", 47, 52], ["rat", "SPECIES", 57, 60], ["human", "SPECIES", 47, 52], ["rat", "SPECIES", 57, 60], ["gene expression analysis", "TEST", 19, 43], ["human and rat islets", "TREATMENT", 47, 67], ["a pancreatic beta cell line", "TREATMENT", 111, 138], ["insulin secretion", "TREATMENT", 225, 242], ["proliferation", "PROBLEM", 273, 286], ["pancreatic", "ANATOMY", 113, 123], ["beta cell line", "OBSERVATION", 124, 138], ["proliferation", "OBSERVATION", 273, 286]]], ["Finally, we show that TMEM27 is cleaved not only by beta cells but also by kidney tubular cells, a finding that rules it out as a beta cell mass biomarker.MethodsHuman pancreas Pancreases were obtained from 11 human cadaver organ donors (eight non-diabetic donors and three donors with type 2 diabetes) from the Transplant Services Foundation at the Hospital Cl\u00ednic (Barcelona, Spain) and kept by Biobanc Hospital Cl\u00ednic-Institut d'Investigacions Biom\u00e8diques August Pi i Sunyer (IDIBAPS; Barcelona, Spain), after informed consent from donors' families and approval by the hospital's ethics committee.", [["beta cells", "ANATOMY", 52, 62], ["kidney tubular cells", "ANATOMY", 75, 95], ["beta cell", "ANATOMY", 130, 139], ["pancreas", "ANATOMY", 168, 176], ["organ", "ANATOMY", 224, 229], ["type 2 diabetes", "DISEASE", 286, 301], ["TMEM27", "GENE_OR_GENE_PRODUCT", 22, 28], ["beta cells", "CELL", 52, 62], ["kidney tubular cells", "CELL", 75, 95], ["beta cell", "CELL", 130, 139], ["pancreas", "ORGAN", 168, 176], ["human", "ORGANISM", 210, 215], ["cadaver organ", "TISSUE", 216, 229], ["donors", "ORGANISM", 230, 236], ["donors", "ORGANISM", 257, 263], ["donors", "ORGANISM", 535, 541], ["TMEM27", "PROTEIN", 22, 28], ["beta cells", "CELL_TYPE", 52, 62], ["kidney tubular cells", "CELL_TYPE", 75, 95], ["human", "SPECIES", 210, 215], ["human", "SPECIES", 210, 215], ["kidney tubular cells", "PROBLEM", 75, 95], ["a beta cell mass biomarker", "TEST", 128, 154], ["MethodsHuman pancreas Pancreases", "TREATMENT", 155, 187], ["human cadaver organ donors", "TREATMENT", 210, 236], ["eight non-diabetic donors", "TREATMENT", 238, 263], ["type 2 diabetes", "PROBLEM", 286, 301], ["kidney", "ANATOMY", 75, 81], ["tubular cells", "OBSERVATION", 82, 95], ["pancreas", "ANATOMY", 168, 176]]], ["Islets were isolated as previously described [9] .", [["Islets", "ANATOMY", 0, 6], ["Islets", "CELL", 0, 6], ["Islets", "PROBLEM", 0, 6]]], ["Fragmented pancreases were fixed overnight in formaldehyde 4% (vol./vol.; Sigma, St Louis, MO, USA) at 4\u00b0C, dehydrated and embedded in paraffin prior to sectioning.MethodsAnimals The principles of laboratory animal care were followed (European and local government guidelines) and protocols were approved by the Animal Research Committee of the University of Barcelona.", [["pancreases", "ANATOMY", 11, 21], ["formaldehyde", "CHEMICAL", 46, 58], ["formaldehyde", "CHEMICAL", 46, 58], ["paraffin", "CHEMICAL", 135, 143], ["pancreases", "ORGAN", 11, 21], ["Fragmented pancreases", "PROBLEM", 0, 21], ["sectioning", "TREATMENT", 153, 163], ["protocols", "TREATMENT", 281, 290], ["pancreases", "ANATOMY", 11, 21]]], ["Tungstate treatment has been described previously [10] .", [["Tungstate", "CHEMICAL", 0, 9], ["Tungstate", "CHEMICAL", 0, 9], ["Tungstate", "SIMPLE_CHEMICAL", 0, 9], ["Tungstate treatment", "TREATMENT", 0, 19]]], ["Briefly, adult male Wistar rats (Charles River, Wilmington, MA, USA) received ad libitum a solution of 2 mg/ml sodium tungstate (Carlo Erba, Rodano, Italy) in deionised water for 6 weeks, whereas untreated rats received deionised water alone.", [["sodium tungstate", "CHEMICAL", 111, 127], ["sodium tungstate", "CHEMICAL", 111, 127], ["Wistar rats", "ORGANISM", 20, 31], ["Charles River", "ORGANISM", 33, 46], ["sodium tungstate", "SIMPLE_CHEMICAL", 111, 127], ["rats", "ORGANISM", 206, 210], ["rats", "SPECIES", 27, 31], ["rats", "SPECIES", 206, 210], ["ad libitum a solution", "TREATMENT", 78, 99], ["sodium tungstate", "TREATMENT", 111, 127]]], ["At the end of the treatment, a glucose tolerance or insulin sensitivity test was performed, with the injection intraperitoneally of either 2 g glucose/kg weight or 1 U insulin/kg weight, respectively.", [["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 143, 150], ["glucose", "CHEMICAL", 31, 38], ["glucose", "CHEMICAL", 143, 150], ["glucose", "SIMPLE_CHEMICAL", 31, 38], ["insulin", "GENE_OR_GENE_PRODUCT", 52, 59], ["glucose", "SIMPLE_CHEMICAL", 143, 150], ["insulin", "GENE_OR_GENE_PRODUCT", 168, 175], ["the treatment", "TREATMENT", 14, 27], ["a glucose tolerance", "TEST", 29, 48], ["insulin sensitivity test", "TEST", 52, 76]]], ["C57B/6 mice were obtained from Charles River and FVB mice from Taconic Farms (Germantown, NY, USA).", [["C57B/6 mice", "ORGANISM", 0, 11], ["Charles River", "ORGANISM", 31, 44], ["FVB mice", "ORGANISM", 49, 57], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 53, 57], ["mice", "SPECIES", 7, 11], ["mice", "SPECIES", 53, 57]]], ["Pancreases were fixed in 10% (vol./vol.) formalin solution (Sigma) overnight at 4\u00b0C, dehydrated and embedded in paraffin prior to sectioning.MethodsImmunofluorescence studies Pancreatic sections were deparaffinated and rehydrated.", [["Pancreases", "ANATOMY", 0, 10], ["Pancreatic sections", "ANATOMY", 175, 194], ["formalin", "CHEMICAL", 41, 49], ["formalin", "CHEMICAL", 41, 49], ["paraffin", "CHEMICAL", 112, 120], ["Pancreatic sections", "CANCER", 175, 194], ["Pancreases", "TEST", 0, 10], ["formalin solution", "TREATMENT", 41, 58], ["sectioning", "TREATMENT", 130, 140], ["MethodsImmunofluorescence", "TEST", 141, 166], ["Pancreatic sections", "TEST", 175, 194], ["Pancreatic", "ANATOMY", 175, 185]]], ["Antigen retrieval of pancreatic sections was performed with citrate buffer using a microwave oven.", [["pancreatic sections", "ANATOMY", 21, 40], ["citrate", "CHEMICAL", 60, 67], ["citrate", "CHEMICAL", 60, 67], ["pancreatic sections", "MULTI-TISSUE_STRUCTURE", 21, 40], ["citrate", "SIMPLE_CHEMICAL", 60, 67], ["Antigen retrieval of pancreatic sections", "TREATMENT", 0, 40], ["citrate buffer", "TREATMENT", 60, 74], ["a microwave oven", "TREATMENT", 81, 97], ["pancreatic", "ANATOMY", 21, 31]]], ["Primary antibodies were against insulin (Dako, Glostrup, Denmark), TMEM27 (Alexis, Lausen, Switzerland), glucagon (Dako), glucagon (Millipore, Billerica, MA, USA), pancreatic polypeptide (MP Biomedicals, Illkirch, France), somatostatin (Dako), proliferating cell nuclear antigen (PCNA; Sigma) and kidney proximal tubular cells marker fructose-1,6-bisphosphatase 2 [11] (Santa Cruz Biotechnology, Santa Cruz, CA, USA).", [["kidney proximal tubular cells", "ANATOMY", 297, 326], ["fructose-1,6-bisphosphatase", "CHEMICAL", 334, 361], ["fructose", "CHEMICAL", 334, 342], ["insulin", "GENE_OR_GENE_PRODUCT", 32, 39], ["Dako", "GENE_OR_GENE_PRODUCT", 41, 45], ["Glostrup", "GENE_OR_GENE_PRODUCT", 47, 55], ["glucagon", "GENE_OR_GENE_PRODUCT", 105, 113], ["Dako", "GENE_OR_GENE_PRODUCT", 115, 119], ["glucagon", "GENE_OR_GENE_PRODUCT", 122, 130], ["USA", "GENE_OR_GENE_PRODUCT", 158, 161], ["pancreatic polypeptide", "GENE_OR_GENE_PRODUCT", 164, 186], ["somatostatin", "GENE_OR_GENE_PRODUCT", 223, 235], ["Dako", "GENE_OR_GENE_PRODUCT", 237, 241], ["proliferating cell nuclear antigen", "GENE_OR_GENE_PRODUCT", 244, 278], ["PCNA", "GENE_OR_GENE_PRODUCT", 280, 284], ["Sigma", "GENE_OR_GENE_PRODUCT", 286, 291], ["kidney", "ORGAN", 297, 303], ["tubular cells", "CELL", 313, 326], ["fructose-1,6-bisphosphatase 2", "GENE_OR_GENE_PRODUCT", 334, 363], ["insulin", "PROTEIN", 32, 39], ["somatostatin", "PROTEIN", 223, 235], ["Dako", "PROTEIN", 237, 241], ["proliferating cell nuclear antigen", "PROTEIN", 244, 278], ["PCNA", "PROTEIN", 280, 284], ["Sigma", "PROTEIN", 286, 291], ["kidney proximal tubular cells", "CELL_TYPE", 297, 326], ["Primary antibodies", "TREATMENT", 0, 18], ["insulin", "TREATMENT", 32, 39], ["TMEM27", "TREATMENT", 67, 73], ["Alexis", "TREATMENT", 75, 81], ["Lausen", "TREATMENT", 83, 89], ["glucagon", "TREATMENT", 105, 113], ["glucagon (Millipore", "TREATMENT", 122, 141], ["Billerica", "TREATMENT", 143, 152], ["pancreatic polypeptide (MP Biomedicals", "TREATMENT", 164, 202], ["somatostatin (Dako", "TREATMENT", 223, 241], ["proliferating cell nuclear antigen", "TEST", 244, 278], ["kidney proximal tubular cells", "TEST", 297, 326], ["fructose", "TEST", 334, 342], ["pancreatic", "ANATOMY", 164, 174], ["kidney", "ANATOMY", 297, 303], ["proximal", "ANATOMY_MODIFIER", 304, 312], ["tubular cells", "OBSERVATION", 313, 326]]], ["Hoechst 33258 was used as nuclear marker (Sigma).", [["nuclear", "ANATOMY", 26, 33], ["Hoechst 33258", "CHEMICAL", 0, 13], ["Hoechst 33258", "CHEMICAL", 0, 13], ["Hoechst 33258", "SIMPLE_CHEMICAL", 0, 13], ["nuclear", "CELLULAR_COMPONENT", 26, 33]]], ["The use of PCNA for measuring islet proliferation has been validated in previous studies [10, [12] [13] [14] .", [["islet", "ANATOMY", 30, 35], ["PCNA", "GENE_OR_GENE_PRODUCT", 11, 15], ["islet", "MULTI-TISSUE_STRUCTURE", 30, 35], ["[12] [13] [14]", "SIMPLE_CHEMICAL", 94, 108], ["PCNA", "PROTEIN", 11, 15], ["PCNA", "TREATMENT", 11, 15], ["measuring islet proliferation", "PROBLEM", 20, 49], ["previous studies", "TEST", 72, 88]]], ["Images were taken using a Leica DMR HC epifluorescence microscope and a Leica TCS-SL confocal microscope.MethodsRNA isolation and real-time PCR Islet total RNA was isolated using the RNeasy Mini Kit (Qiagen, Venlo, the Netherlands).", [["Images", "TEST", 0, 6], ["a Leica TCS", "TEST", 70, 81], ["MethodsRNA isolation", "TREATMENT", 105, 125], ["the RNeasy Mini Kit", "TREATMENT", 179, 198]]], ["RNA integrity was analysed using a lab-on-achip (Agilent Technologies, Santa Clara, CA, USA).", [["RNA integrity", "TEST", 0, 13], ["a lab", "TEST", 33, 38]]], ["RNA was reverse-transcribed using SuperscriptIII (Invitrogen).", [["RNA", "RNA", 0, 3], ["SuperscriptIII", "DNA", 34, 48], ["SuperscriptIII (Invitrogen)", "TREATMENT", 34, 61]]], ["Real-time PCR was carried in a 7900HT Real Time System (Applied Biosystems, Foster City, CA, USA) using SYBR Green fluorophore.", [["SYBR Green fluorophore", "GENE_OR_GENE_PRODUCT", 104, 126]]], ["A standard curve for each primer set was generated from serial dilutions of complementary DNA (cDNA).", [["DNA", "CELLULAR_COMPONENT", 90, 93], ["complementary DNA", "DNA", 76, 93], ["cDNA", "DNA", 95, 99], ["A standard curve", "TREATMENT", 0, 16], ["each primer set", "TREATMENT", 21, 36]]], ["PCR products were verified by dissociation-curve analysis using SDS software (Applied Biosystems).", [["PCR products", "TEST", 0, 12], ["curve analysis", "TEST", 43, 57]]], ["Expression levels were normalised to TATA box binding protein (TBP) and represented in arbitrary units.", [["TATA box binding protein", "GENE_OR_GENE_PRODUCT", 37, 61], ["TBP", "GENE_OR_GENE_PRODUCT", 63, 66], ["TATA box binding protein", "PROTEIN", 37, 61], ["TBP", "PROTEIN", 63, 66], ["Expression levels", "TEST", 0, 17], ["TATA box binding protein", "TEST", 37, 61], ["TBP", "TEST", 63, 66]]], ["Levels of amylase, alpha 2a were determined to ensure islet purity.", [["islet", "ANATOMY", 54, 59], ["amylase", "GENE_OR_GENE_PRODUCT", 10, 17], ["alpha 2a", "GENE_OR_GENE_PRODUCT", 19, 27], ["islet", "MULTI-TISSUE_STRUCTURE", 54, 59], ["amylase", "PROTEIN", 10, 17], ["alpha 2a", "PROTEIN", 19, 27], ["Levels", "TEST", 0, 6], ["amylase", "TEST", 10, 17], ["alpha 2a", "TEST", 19, 27], ["amylase", "ANATOMY", 10, 17]]], ["Human and rat primer sequences are provided in Electronic supplementary material (ESM) Tables 1 and 2, respectively.MethodsConstruction of recombinant adenoviruses cDNA for TMEM27/Tmem27 was amplified from human, mouse and rat islet total RNA. cDNA preparations were myc-tagged at the 3\u2032 end and cloned into the pGEMT-easy vector (Promega, Madison, WI, USA).", [["islet", "ANATOMY", 227, 232], ["Human", "ORGANISM", 0, 5], ["rat", "ORGANISM", 10, 13], ["adenoviruses", "ORGANISM", 151, 163], ["TMEM27", "GENE_OR_GENE_PRODUCT", 173, 179], ["Tmem27", "GENE_OR_GENE_PRODUCT", 180, 186], ["human", "ORGANISM", 206, 211], ["mouse", "ORGANISM", 213, 218], ["rat", "ORGANISM", 223, 226], ["islet", "MULTI-TISSUE_STRUCTURE", 227, 232], ["pGEMT", "GENE_OR_GENE_PRODUCT", 312, 317], ["Human and rat primer sequences", "DNA", 0, 30], ["recombinant adenoviruses cDNA", "DNA", 139, 168], ["TMEM27", "DNA", 173, 179], ["Tmem27", "DNA", 180, 186], ["human, mouse and rat islet total RNA", "RNA", 206, 242], ["3\u2032 end", "DNA", 285, 291], ["pGEMT", "DNA", 312, 317], ["Human", "SPECIES", 0, 5], ["rat", "SPECIES", 10, 13], ["human", "SPECIES", 206, 211], ["mouse", "SPECIES", 213, 218], ["rat", "SPECIES", 223, 226], ["Human", "SPECIES", 0, 5], ["human", "SPECIES", 206, 211], ["mouse", "SPECIES", 213, 218], ["rat", "SPECIES", 223, 226], ["Human and rat primer sequences", "TREATMENT", 0, 30], ["recombinant adenoviruses cDNA", "TREATMENT", 139, 168], ["TMEM27/Tmem27", "TREATMENT", 173, 186], ["cDNA preparations", "TREATMENT", 244, 261]]], ["Primer sequences used for amplification are provided in ESM Table 3 .", [["Primer sequences", "DNA", 0, 16], ["Primer sequences", "TEST", 0, 16]]], ["The different cDNA preparations were subcloned into pACCMV-pLpA plasmid and cotransfected with pJM17 vector in HEK 293 cells to generate recombinant adenoviruses as described previously [15] .", [["plasmid", "ANATOMY", 64, 71], ["HEK 293 cells", "ANATOMY", 111, 124], ["pACCMV", "GENE_OR_GENE_PRODUCT", 52, 58], ["pLpA", "GENE_OR_GENE_PRODUCT", 59, 63], ["pJM17", "GENE_OR_GENE_PRODUCT", 95, 100], ["HEK 293 cells", "CELL", 111, 124], ["adenoviruses", "ORGANISM", 149, 161], ["pACCMV-pLpA plasmid", "DNA", 52, 71], ["pJM17 vector", "DNA", 95, 107], ["HEK 293 cells", "CELL_LINE", 111, 124], ["HEK 293", "SPECIES", 111, 118], ["The different cDNA preparations", "TREATMENT", 0, 31], ["pACCMV", "TEST", 52, 58], ["pLpA plasmid", "TREATMENT", 59, 71], ["recombinant adenoviruses", "PROBLEM", 137, 161]]], ["Adenoviruses were titrated by limiting dilution plaque assay.", [["plaque", "ANATOMY", 48, 54], ["Adenoviruses", "TREATMENT", 0, 12]]], ["As a control, an adenovirus expressing \u03b2-galactosidase was used [15] .", [["adenovirus", "ORGANISM", 17, 27], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 39, 54], ["\u03b2-galactosidase", "PROTEIN", 39, 54], ["adenovirus", "SPECIES", 17, 27], ["an adenovirus expressing \u03b2-galactosidase", "TREATMENT", 14, 54]]], ["Transduction efficiency was monitored by \u03b2-galactosidase staining, as described previously [16] (ESM Fig. 1 ).MethodsIslet isolation, culture and infection Islets were obtained from Wistar rats, isolated through collagenase perfusion and Histopaque gradient (Sigma) and cultured as previously described [16] .", [["Islets", "ANATOMY", 156, 162], ["infection", "DISEASE", 146, 155], ["\u03b2-galactosidase", "SIMPLE_CHEMICAL", 41, 56], ["Islets", "CELL", 156, 162], ["Wistar rats", "ORGANISM", 182, 193], ["collagenase", "GENE_OR_GENE_PRODUCT", 212, 223], ["\u03b2-galactosidase", "PROTEIN", 41, 56], ["collagenase", "PROTEIN", 212, 223], ["rats", "SPECIES", 189, 193], ["Transduction efficiency", "PROBLEM", 0, 23], ["MethodsIslet isolation", "TREATMENT", 110, 132], ["culture", "TEST", 134, 141], ["infection Islets", "PROBLEM", 146, 162], ["collagenase perfusion", "TEST", 212, 233], ["Histopaque gradient", "TEST", 238, 257]]], ["Infection was performed 12 h after isolation.MethodsBriefly, 50-100 islets were resuspended in 200 \u00b5l of recombinant adenovirus stock (1\u00d710 9 plaque-forming units/ml) for 4 h at 37\u00b0C. After infection, islets were resuspended in 2 ml of culture medium at 5.5 or 11 mmol/l glucose for insulin secretion and proliferation studies, respectively, and cultured for an additional 48 h period.MethodsRenal proximal tubule cell isolation and infection Renal proximal tubular cells were prepared from 12 FVB mice kidneys as described previously [17] .", [["islets", "ANATOMY", 68, 74], ["plaque", "ANATOMY", 142, 148], ["islets", "ANATOMY", 201, 207], ["Renal proximal tubule cell", "ANATOMY", 392, 418], ["Renal proximal tubular cells", "ANATOMY", 443, 471], ["kidneys", "ANATOMY", 503, 510], ["infection", "DISEASE", 190, 199], ["glucose", "CHEMICAL", 271, 278], ["infection", "DISEASE", 433, 442], ["glucose", "CHEMICAL", 271, 278], ["islets", "MULTI-TISSUE_STRUCTURE", 68, 74], ["adenovirus", "ORGANISM", 117, 127], ["islets", "MULTI-TISSUE_STRUCTURE", 201, 207], ["glucose", "SIMPLE_CHEMICAL", 271, 278], ["insulin", "GENE_OR_GENE_PRODUCT", 283, 290], ["Renal proximal tubule cell", "CELL", 392, 418], ["Renal proximal tubular cells", "CELL", 443, 471], ["mice", "ORGANISM", 498, 502], ["kidneys", "ORGAN", 503, 510], ["insulin", "PROTEIN", 283, 290], ["Renal proximal tubular cells", "CELL_TYPE", 443, 471], ["mice", "SPECIES", 498, 502], ["mice", "SPECIES", 498, 502], ["Infection", "PROBLEM", 0, 9], ["recombinant adenovirus stock", "TREATMENT", 105, 133], ["infection", "PROBLEM", 190, 199], ["islets", "TREATMENT", 201, 207], ["culture medium", "TEST", 236, 250], ["insulin secretion", "TEST", 283, 300], ["proliferation studies", "TEST", 305, 326], ["MethodsRenal proximal tubule cell isolation", "TREATMENT", 385, 428], ["infection Renal proximal tubular cells", "PROBLEM", 433, 471], ["infection", "OBSERVATION", 190, 199], ["Renal", "ANATOMY", 392, 397], ["proximal", "ANATOMY_MODIFIER", 398, 406], ["tubule cell isolation", "OBSERVATION", 407, 428], ["infection", "OBSERVATION", 433, 442], ["proximal", "ANATOMY_MODIFIER", 449, 457], ["tubular cells", "OBSERVATION", 458, 471], ["kidneys", "ANATOMY", 503, 510]]], ["Kidney cortex was digested with collagenase (Invitrogen) and tubule fragments were obtained by a Percoll gradient (Amersham-Biosciences, Uppsala, Sweden).", [["Kidney cortex", "ANATOMY", 0, 13], ["tubule fragments", "ANATOMY", 61, 77], ["Kidney cortex", "CANCER", 0, 13], ["collagenase", "GENE_OR_GENE_PRODUCT", 32, 43], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 45, 55], ["collagenase", "PROTEIN", 32, 43], ["collagenase (Invitrogen)", "TREATMENT", 32, 56], ["tubule fragments", "PROBLEM", 61, 77], ["a Percoll gradient", "TEST", 95, 113], ["cortex", "ANATOMY", 7, 13], ["tubule fragments", "OBSERVATION", 61, 77]]], ["The F4 band of the Percoll gradient, composed of proximal tubules, was carefully removed, washed and centrifuged.", [["Percoll", "ANATOMY", 19, 26], ["proximal tubules", "ANATOMY", 49, 65], ["tubules", "TISSUE", 58, 65], ["the Percoll gradient", "TEST", 15, 35], ["proximal tubules", "PROBLEM", 49, 65], ["Percoll gradient", "OBSERVATION", 19, 35], ["proximal tubules", "OBSERVATION", 49, 65]]], ["The final pellet was resuspended in serum-free, hormonally defined culture media [18] and seeded at a density of 1.5 mg pellet/cm 2 in six-well plates coated with rat tail collagen I and human fibronectin (Sigma).", [["pellet", "ANATOMY", 10, 16], ["serum", "ANATOMY", 36, 41], ["serum", "ORGANISM_SUBSTANCE", 36, 41], ["rat", "ORGANISM", 163, 166], ["tail collagen I", "GENE_OR_GENE_PRODUCT", 167, 182], ["human", "ORGANISM", 187, 192], ["fibronectin", "GENE_OR_GENE_PRODUCT", 193, 204], ["Sigma", "GENE_OR_GENE_PRODUCT", 206, 211], ["rat tail collagen I", "PROTEIN", 163, 182], ["human fibronectin", "PROTEIN", 187, 204], ["Sigma", "PROTEIN", 206, 211], ["rat", "SPECIES", 163, 166], ["human", "SPECIES", 187, 192], ["human", "SPECIES", 187, 192], ["The final pellet", "TREATMENT", 0, 16], ["serum", "TEST", 36, 41], ["rat tail collagen I and human fibronectin (Sigma)", "TREATMENT", 163, 212]]], ["The culture medium was changed every 48 h.", [["The culture medium", "TEST", 0, 18]]], ["Infection was performed when cells reached confluence, covering the wells with 1 ml of recombinant adenovirus stock for 1.5 h at 37\u00b0C. After infection, virus-containing medium was replaced and cells were cultured for an additional day.MethodsINS cell culture and infection INS-1 832/13 cells (kindly provided by C. B. Newgard, Duke University, Durham, NC, USA) were maintained as described elsewhere [19] , except that they were cultured at 5.5 mmol/l glucose.", [["cells", "ANATOMY", 29, 34], ["cells", "ANATOMY", 193, 198], ["cell", "ANATOMY", 246, 250], ["INS-1 832/13 cells", "ANATOMY", 273, 291], ["infection", "DISEASE", 141, 150], ["infection", "DISEASE", 263, 272], ["glucose", "CHEMICAL", 452, 459], ["glucose", "CHEMICAL", 452, 459], ["cells", "CELL", 29, 34], ["adenovirus", "ORGANISM", 99, 109], ["cells", "CELL", 193, 198], ["cell", "CELL", 246, 250], ["INS-1 832/13 cells", "CELL", 273, 291], ["glucose", "SIMPLE_CHEMICAL", 452, 459], ["MethodsINS cell culture", "CELL_LINE", 235, 258], ["infection INS-1 832/13 cells", "CELL_LINE", 263, 291], ["C. B. Newgard", "SPECIES", 312, 325], ["Infection", "PROBLEM", 0, 9], ["recombinant adenovirus stock", "TREATMENT", 87, 115], ["infection", "PROBLEM", 141, 150], ["virus-containing medium", "TREATMENT", 152, 175], ["MethodsINS cell culture", "TEST", 235, 258], ["infection INS", "TEST", 263, 276], ["glucose", "TEST", 452, 459], ["infection", "OBSERVATION", 141, 150]]], ["When required, cells were trypsinised and automatically counted with a Countess Cell Counter (Invitrogen).", [["cells", "ANATOMY", 15, 20], ["Cell", "ANATOMY", 80, 84], ["cells", "CELL", 15, 20], ["a Countess Cell Counter (Invitrogen)", "TREATMENT", 69, 105]]], ["For viral infection, cells were seeded the day before treatment in poly-L-lysine (Sigma) treated plates.", [["cells", "ANATOMY", 21, 26], ["viral infection", "DISEASE", 4, 19], ["poly-L-lysine", "CHEMICAL", 67, 80], ["poly-L-lysine", "CHEMICAL", 67, 80], ["cells", "CELL", 21, 26], ["poly-L-lysine", "SIMPLE_CHEMICAL", 67, 80], ["Sigma", "SIMPLE_CHEMICAL", 82, 87], ["viral infection", "PROBLEM", 4, 19], ["cells", "PROBLEM", 21, 26], ["treatment in poly-L-lysine (Sigma) treated plates", "TREATMENT", 54, 103], ["viral", "OBSERVATION_MODIFIER", 4, 9], ["infection", "OBSERVATION", 10, 19]]], ["Infection was performed at a multiplicity of infection of 50 for 2 h.", [["infection", "DISEASE", 45, 54], ["Infection", "PROBLEM", 0, 9], ["infection", "PROBLEM", 45, 54]]], ["Virus-containing medium was then replaced and cells were cultured for an additional day or for the time indicated.MethodsProliferation assays Studies were performed 2 days after infection.", [["cells", "ANATOMY", 46, 51], ["infection", "DISEASE", 178, 187], ["Virus", "ORGANISM", 0, 5], ["cells", "CELL", 46, 51], ["Virus-containing medium", "TREATMENT", 0, 23], ["MethodsProliferation assays Studies", "TEST", 114, 149], ["infection", "PROBLEM", 178, 187], ["medium", "OBSERVATION_MODIFIER", 17, 23]]], ["Islet proliferation was measured as described previously [20] .", [["Islet", "ANATOMY", 0, 5], ["Islet", "CELL", 0, 5], ["Islet proliferation", "PROBLEM", 0, 19]]], ["Islets were cultured in groups of 50 and their medium was replaced with a medium containing 12.5 mmol/l hydroxyurea for 24 h.", [["Islets", "ANATOMY", 0, 6], ["hydroxyurea", "CHEMICAL", 104, 115], ["hydroxyurea", "CHEMICAL", 104, 115], ["Islets", "CELL", 0, 6], ["hydroxyurea", "SIMPLE_CHEMICAL", 104, 115], ["Islets", "TEST", 0, 6], ["a medium containing 12.5 mmol/l hydroxyurea", "TREATMENT", 72, 115]]], ["Thereafter, islets were washed four times with Hanks' balanced salt solution (HBSS, Sigma), and cultured in a medium supplemented with 3.7\u00d710 5 Bq of [methyl-3 H]thymidine (initial specific activity 74 GBq/mmol; GE Healthcare, Fairfield, CT, USA) for 4 h.", [["islets", "ANATOMY", 12, 18], ["[methyl-3 H", "CHEMICAL", 150, 161], ["thymidine", "CHEMICAL", 162, 171], ["[methyl-3 H]thymidine", "CHEMICAL", 150, 171], ["islets", "MULTI-TISSUE_STRUCTURE", 12, 18], ["[methyl-3 H]thymidine", "SIMPLE_CHEMICAL", 150, 171], ["islets", "TREATMENT", 12, 18], ["Hanks' balanced salt solution", "TREATMENT", 47, 76], ["thymidine", "TREATMENT", 162, 171], ["CT", "TEST", 238, 240]]], ["Then, islets were counted, hand-picked, washed with HBSS three times, resuspended and sonicated.", [["islets", "ANATOMY", 6, 12], ["hand", "ANATOMY", 27, 31], ["islets", "MULTI-TISSUE_STRUCTURE", 6, 12], ["islets", "TREATMENT", 6, 12], ["HBSS", "TREATMENT", 52, 56]]], ["To quantify proliferation, islet radiation was measured in a Tricarb 2300TR liquid scintillation analyser (Perkin Elmer Packard, Waltham, MA, USA).", [["islet", "ANATOMY", 27, 32], ["islet", "MULTI-TISSUE_STRUCTURE", 27, 32], ["islet radiation", "TREATMENT", 27, 42], ["proliferation", "OBSERVATION_MODIFIER", 12, 25]]], ["The use of [methyl-3 H] thymidine for measuring islet proliferation has been validated in previous studies [20] [21] [22] [23] .", [["islet", "ANATOMY", 48, 53], ["[methyl-3 H", "CHEMICAL", 11, 22], ["thymidine", "CHEMICAL", 24, 33], ["[methyl-3 H] thymidine", "CHEMICAL", 11, 33], ["[methyl-3 H] thymidine", "SIMPLE_CHEMICAL", 11, 33], ["islet", "MULTI-TISSUE_STRUCTURE", 48, 53], ["[20] [21] [22] [23]", "SIMPLE_CHEMICAL", 107, 126], ["[methyl-3 H] thymidine", "TREATMENT", 11, 33], ["measuring islet proliferation", "PROBLEM", 38, 67], ["previous studies", "TEST", 90, 106]]], ["For INS-1 832/13 proliferation analysis, the medium was substituted by a medium containing 5-bromo-2\u2032-deoxyuridine (Sigma) at 10 \u03bcmol/l for 2 h.", [["5-bromo-2\u2032-deoxyuridine", "CHEMICAL", 91, 114], ["5-bromo-2\u2032-deoxyuridine", "CHEMICAL", 91, 114], ["INS-1 832/13", "CELL", 4, 16], ["5-bromo-2\u2032-deoxyuridine", "SIMPLE_CHEMICAL", 91, 114], ["Sigma", "SIMPLE_CHEMICAL", 116, 121], ["INS", "TEST", 4, 7], ["proliferation analysis", "TEST", 17, 39], ["a medium containing 5-bromo", "TREATMENT", 71, 98], ["deoxyuridine (Sigma)", "TREATMENT", 102, 122]]], ["Cells were then marked according to the FITC BrdU Flow Kit (Becton Dickinson, Franklin Lakes, NJ, USA) and proliferation was measured with a FACS Canto II (Becton Dickinson).MethodsInsulin secretion Medium was removed 2 days after infection and cells/islets were washed twice with Dulbecco's PBS or HBSS (Sigma), respectively.", [["Cells", "ANATOMY", 0, 5], ["cells", "ANATOMY", 245, 250], ["islets", "ANATOMY", 251, 257], ["infection", "DISEASE", 231, 240], ["FITC", "CHEMICAL", 40, 44], ["Cells", "CELL", 0, 5], ["MethodsInsulin", "SIMPLE_CHEMICAL", 174, 188], ["cells", "CELL", 245, 250], ["islets", "MULTI-TISSUE_STRUCTURE", 251, 257], ["FACS Canto II", "PROTEIN", 141, 154], ["MethodsInsulin secretion Medium", "TREATMENT", 174, 205], ["infection", "PROBLEM", 231, 240], ["cells/islets", "TREATMENT", 245, 257], ["Dulbecco's PBS", "TREATMENT", 281, 295]]], ["Thereafter, cells/ islets were incubated in HEPES-buffered Krebs-Ringer medium without glucose for 2 h.", [["cells", "ANATOMY", 12, 17], ["islets", "ANATOMY", 19, 25], ["glucose", "CHEMICAL", 87, 94], ["HEPES", "CHEMICAL", 44, 49], ["glucose", "CHEMICAL", 87, 94], ["cells", "CELL", 12, 17], ["islets", "MULTI-TISSUE_STRUCTURE", 19, 25], ["glucose", "SIMPLE_CHEMICAL", 87, 94], ["islets", "CELL_TYPE", 19, 25], ["cells/ islets", "TREATMENT", 12, 25], ["HEPES", "TEST", 44, 49]]], ["Then, this medium was substituted by the same medium but supplemented with glucose at 2.2 or 16.7 mmol/l for 1.5 h.", [["glucose", "CHEMICAL", 75, 82], ["glucose", "CHEMICAL", 75, 82], ["glucose", "SIMPLE_CHEMICAL", 75, 82], ["glucose", "TEST", 75, 82]]], ["At the end of the experiment, the supernatant fraction was recovered, centrifuged to prevent cell contamination and insulin was measured by ELISA (Mercodia, Uppsala, Sweden).", [["supernatant", "ANATOMY", 34, 45], ["cell", "ANATOMY", 93, 97], ["cell", "CELL", 93, 97], ["insulin", "GENE_OR_GENE_PRODUCT", 116, 123], ["insulin", "PROTEIN", 116, 123], ["the supernatant fraction", "TEST", 30, 54], ["cell contamination", "PROBLEM", 93, 111], ["insulin", "TREATMENT", 116, 123], ["cell contamination", "OBSERVATION", 93, 111]]], ["Cells were trypsinised, centrifuged and resuspended in a solution containing Tris-HCl (10 mmol/l), EDTA (1 mmol/l) and NaCl (200 mmol/l).", [["Cells", "ANATOMY", 0, 5], ["Tris-HCl", "CHEMICAL", 77, 85], ["EDTA", "CHEMICAL", 99, 103], ["NaCl", "CHEMICAL", 119, 123], ["Tris-HCl", "CHEMICAL", 77, 85], ["EDTA", "CHEMICAL", 99, 103], ["NaCl", "CHEMICAL", 119, 123], ["Cells", "CELL", 0, 5], ["Tris-HCl", "SIMPLE_CHEMICAL", 77, 85], ["EDTA", "SIMPLE_CHEMICAL", 99, 103], ["NaCl", "SIMPLE_CHEMICAL", 119, 123], ["Tris", "TREATMENT", 77, 81], ["HCl", "TREATMENT", 82, 85], ["EDTA", "TREATMENT", 99, 103], ["NaCl", "TREATMENT", 119, 123]]], ["These cells were sonicated and DNA was quantified by a fluorometer using Hoechst (Sigma) and a serial dilution of calf thymus DNA (Sigma).", [["cells", "ANATOMY", 6, 11], ["thymus", "ANATOMY", 119, 125], ["Hoechst", "CHEMICAL", 73, 80], ["cells", "CELL", 6, 11], ["DNA", "CELLULAR_COMPONENT", 31, 34], ["Hoechst", "SIMPLE_CHEMICAL", 73, 80], ["calf", "ORGANISM", 114, 118], ["thymus DNA", "ORGANISM_SUBSTANCE", 119, 129], ["calf", "SPECIES", 114, 118], ["a serial dilution of calf thymus DNA", "TREATMENT", 93, 129], ["calf thymus", "ANATOMY", 114, 125]]], ["Each experiment was performed in triplicate and the results presented are the mean of six to nine experiments.MethodsPost-transcriptional modification analysis and western blot Protein extracts were treated with N-glycosidase F (Roche, Penzberg, Germany), calf intestinal alkaline phosphatase (Invitrogen) or heparinase I (Sigma) according to the manufacturer's instructions.", [["extracts", "ANATOMY", 185, 193], ["extracts", "ORGANISM_SUBSTANCE", 185, 193], ["Roche", "ORGANISM_SUBSTANCE", 229, 234], ["calf", "ORGANISM", 256, 260], ["intestinal", "ORGAN", 261, 271], ["alkaline phosphatase", "GENE_OR_GENE_PRODUCT", 272, 292], ["Invitrogen", "GENE_OR_GENE_PRODUCT", 294, 304], ["heparinase I", "GENE_OR_GENE_PRODUCT", 309, 321], ["calf intestinal alkaline phosphatase", "PROTEIN", 256, 292], ["Invitrogen", "PROTEIN", 294, 304], ["heparinase I", "PROTEIN", 309, 321], ["calf", "SPECIES", 256, 260], ["transcriptional modification analysis", "TEST", 122, 159], ["western blot Protein extracts", "TEST", 164, 193], ["calf intestinal alkaline phosphatase", "TEST", 256, 292], ["calf intestinal", "ANATOMY", 256, 271]]], ["Protein lysates were immunoblotted with antibodies against c-myc (Sigma), TMEM27 (Alexis), actin (Sigma), phospho-Ser-Akt (Cell Signaling, Danvers, MA, USA) or Akt (Santa Cruz Biotechnology).MethodsStatistical analysis Quantitative data are expressed as mean \u00b1 SEM.", [["lysates", "ANATOMY", 8, 15], ["Cell", "ANATOMY", 123, 127], ["phospho", "CHEMICAL", 106, 113], ["Ser", "CHEMICAL", 114, 117], ["lysates", "ORGANISM_SUBSTANCE", 8, 15], ["c-myc", "GENE_OR_GENE_PRODUCT", 59, 64], ["Sigma", "GENE_OR_GENE_PRODUCT", 66, 71], ["TMEM27", "GENE_OR_GENE_PRODUCT", 74, 80], ["Alexis", "GENE_OR_GENE_PRODUCT", 82, 88], ["actin", "GENE_OR_GENE_PRODUCT", 91, 96], ["Sigma", "GENE_OR_GENE_PRODUCT", 98, 103], ["phospho-Ser-Akt", "GENE_OR_GENE_PRODUCT", 106, 121], ["Cell", "CELL", 123, 127], ["Akt", "GENE_OR_GENE_PRODUCT", 160, 163], ["antibodies", "PROTEIN", 40, 50], ["c", "PROTEIN", 59, 60], ["myc", "PROTEIN", 61, 64], ["Sigma", "PROTEIN", 66, 71], ["TMEM27", "PROTEIN", 74, 80], ["Alexis", "PROTEIN", 82, 88], ["actin", "PROTEIN", 91, 96], ["Sigma", "PROTEIN", 98, 103], ["phospho", "PROTEIN", 106, 113], ["Ser", "PROTEIN", 114, 117], ["Akt", "PROTEIN", 118, 121], ["Akt", "PROTEIN", 160, 163], ["Santa Cruz Biotechnology", "PROTEIN", 165, 189], ["Protein lysates", "TEST", 0, 15], ["antibodies", "TEST", 40, 50], ["c", "TEST", 59, 60], ["TMEM27", "TEST", 74, 80], ["Alexis", "TEST", 82, 88], ["actin (Sigma", "TEST", 91, 103], ["phospho", "TEST", 106, 113], ["MethodsStatistical analysis", "TEST", 191, 218]]], ["The statistical significance was determined by Student's t test and ANOVA, with a Tukey's post-hoc test.", [["Student's t test", "TEST", 47, 63], ["a Tukey's post-hoc test", "TEST", 80, 103]]], ["Longitudinal data (ESM Fig. 2a-c) were analysed as set out in the ESM.", [["Longitudinal data", "TEST", 0, 17]]], ["For correlation analysis, Spearman's rank correlation coefficient (\u03c1) and the associated p value were calculated using R language [24] .ResultsTMEM27 is diminished in type 2 diabetes and is mainly expressed by beta cells in the pancreas TMEM27 immunolocalisation studies performed in human pancreas found that TMEM27 production is restricted to islets, mainly in beta cells (Fig. 1a, ESM Fig. 3 and ESM Fig. 4) .", [["beta cells", "ANATOMY", 210, 220], ["pancreas", "ANATOMY", 228, 236], ["pancreas", "ANATOMY", 290, 298], ["islets", "ANATOMY", 345, 351], ["beta cells", "ANATOMY", 363, 373], ["ResultsTMEM27", "CHEMICAL", 136, 149], ["type 2 diabetes", "DISEASE", 167, 182], ["ResultsTMEM27", "GENE_OR_GENE_PRODUCT", 136, 149], ["beta cells", "CELL", 210, 220], ["pancreas", "ORGAN", 228, 236], ["TMEM27", "GENE_OR_GENE_PRODUCT", 237, 243], ["human", "ORGANISM", 284, 289], ["pancreas", "ORGAN", 290, 298], ["TMEM27", "GENE_OR_GENE_PRODUCT", 310, 316], ["islets", "MULTI-TISSUE_STRUCTURE", 345, 351], ["beta cells", "CELL", 363, 373], ["ResultsTMEM27", "PROTEIN", 136, 149], ["beta cells", "CELL_TYPE", 210, 220], ["TMEM27", "PROTEIN", 310, 316], ["islets", "CELL_TYPE", 345, 351], ["beta cells", "CELL_TYPE", 363, 373], ["human", "SPECIES", 284, 289], ["human", "SPECIES", 284, 289], ["correlation analysis", "TEST", 4, 24], ["Spearman's rank correlation", "TEST", 26, 53], ["type 2 diabetes", "PROBLEM", 167, 182], ["immunolocalisation studies", "TEST", 244, 270], ["TMEM27 production", "PROBLEM", 310, 327], ["ESM Fig.", "TEST", 384, 392], ["ESM Fig", "TEST", 399, 406], ["diminished", "OBSERVATION_MODIFIER", 153, 163], ["type 2", "OBSERVATION_MODIFIER", 167, 173], ["diabetes", "OBSERVATION", 174, 182], ["beta cells", "OBSERVATION", 210, 220], ["pancreas", "ANATOMY", 228, 236], ["pancreas", "ANATOMY", 290, 298]]], ["Because of the roles reported for TMEM27 in insulin secretion and beta cell replication [6, 7] , we wondered whether TMEM27 expression and immunolocalisation were affected in diabetic patients.", [["beta cell", "ANATOMY", 66, 75], ["diabetic", "DISEASE", 175, 183], ["TMEM27", "GENE_OR_GENE_PRODUCT", 34, 40], ["insulin", "GENE_OR_GENE_PRODUCT", 44, 51], ["beta cell", "CELL", 66, 75], ["TMEM27", "GENE_OR_GENE_PRODUCT", 117, 123], ["patients", "ORGANISM", 184, 192], ["TMEM27", "PROTEIN", 34, 40], ["TMEM27", "PROTEIN", 117, 123], ["patients", "SPECIES", 184, 192], ["TMEM27 in insulin secretion", "TREATMENT", 34, 61], ["beta cell replication", "TREATMENT", 66, 87]]], ["We determined TMEM27 gene expression by realtime PCR in isolated human islets from non-diabetic and type 2 diabetic donors, and found that TMEM27 mRNA levels were significantly diminished in type 2 diabetic islets compared with controls (healthy islets 1.00\u00b10.26, diabetic islets 0.35\u00b10.15 arbitrary units, n=8-3 respectively, p<0.05).", [["islets", "ANATOMY", 71, 77], ["islets", "ANATOMY", 207, 213], ["islets", "ANATOMY", 246, 252], ["islets", "ANATOMY", 273, 279], ["diabetic", "DISEASE", 107, 115], ["diabetic", "DISEASE", 198, 206], ["diabetic", "DISEASE", 264, 272], ["TMEM27", "GENE_OR_GENE_PRODUCT", 14, 20], ["human", "ORGANISM", 65, 70], ["islets", "MULTI-TISSUE_STRUCTURE", 71, 77], ["donors", "ORGANISM", 116, 122], ["TMEM27", "GENE_OR_GENE_PRODUCT", 139, 145], ["islets", "MULTI-TISSUE_STRUCTURE", 207, 213], ["islets", "MULTI-TISSUE_STRUCTURE", 246, 252], ["islets", "MULTI-TISSUE_STRUCTURE", 273, 279], ["TMEM27 gene", "DNA", 14, 25], ["human islets", "CELL_TYPE", 65, 77], ["TMEM27 mRNA", "RNA", 139, 150], ["human", "SPECIES", 65, 70], ["human", "SPECIES", 65, 70], ["realtime PCR", "TEST", 40, 52], ["mRNA levels", "TEST", 146, 157], ["significantly diminished", "PROBLEM", 163, 187], ["type 2 diabetic islets", "PROBLEM", 191, 213], ["islets", "TEST", 246, 252], ["diabetic islets", "TREATMENT", 264, 279], ["diminished", "OBSERVATION_MODIFIER", 177, 187]]], ["On the other hand, no differences in the pancreatic localisation of TMEM27 were observed in diabetic donors: TMEM27 was produced in insulin-positive cells as described for healthy donors (Fig. 1) .ResultsTMEM27 expression correlates with insulin and SNAPIN expression and not with cell cycle genes In order to define the possible role of TMEM27 in human islets, we aimed to establish the correlation between TMEM27 expression and the expression of several genes implicated in insulin Representative immunofluorescence images of human healthy (a-d) and diabetic (e-h) pancreases using antibodies against TMEM27 (a, e), insulin (b, f) and glucagon (c, g).", [["pancreatic", "ANATOMY", 41, 51], ["insulin-positive cells", "ANATOMY", 132, 154], ["cell", "ANATOMY", 281, 285], ["islets", "ANATOMY", 354, 360], ["pancreases", "ANATOMY", 567, 577], ["diabetic", "DISEASE", 92, 100], ["diabetic", "DISEASE", 552, 560], ["pancreatic", "ORGAN", 41, 51], ["TMEM27", "GENE_OR_GENE_PRODUCT", 68, 74], ["donors", "ORGANISM", 101, 107], ["TMEM27", "GENE_OR_GENE_PRODUCT", 109, 115], ["insulin", "GENE_OR_GENE_PRODUCT", 132, 139], ["donors", "ORGANISM", 180, 186], ["ResultsTMEM27", "GENE_OR_GENE_PRODUCT", 197, 210], ["insulin", "GENE_OR_GENE_PRODUCT", 238, 245], ["SNAPIN", "GENE_OR_GENE_PRODUCT", 250, 256], ["cell", "CELL", 281, 285], ["TMEM27", "GENE_OR_GENE_PRODUCT", 338, 344], ["human", "ORGANISM", 348, 353], ["islets", "MULTI-TISSUE_STRUCTURE", 354, 360], ["TMEM27", "GENE_OR_GENE_PRODUCT", 408, 414], ["insulin", "GENE_OR_GENE_PRODUCT", 476, 483], ["human", "ORGANISM", 528, 533], ["pancreases", "ORGAN", 567, 577], ["TMEM27", "GENE_OR_GENE_PRODUCT", 603, 609], ["insulin", "GENE_OR_GENE_PRODUCT", 618, 625], ["b, f)", "GENE_OR_GENE_PRODUCT", 627, 632], ["glucagon", "SIMPLE_CHEMICAL", 637, 645], ["TMEM27", "PROTEIN", 68, 74], ["TMEM27", "PROTEIN", 109, 115], ["insulin-positive cells", "CELL_LINE", 132, 154], ["ResultsTMEM27", "PROTEIN", 197, 210], ["SNAPIN", "PROTEIN", 250, 256], ["cell cycle genes", "DNA", 281, 297], ["TMEM27", "PROTEIN", 338, 344], ["human islets", "CELL_TYPE", 348, 360], ["TMEM27", "PROTEIN", 408, 414], ["antibodies", "PROTEIN", 584, 594], ["TMEM27", "PROTEIN", 603, 609], ["insulin", "PROTEIN", 618, 625], ["human", "SPECIES", 348, 353], ["human", "SPECIES", 528, 533], ["human", "SPECIES", 348, 353], ["human", "SPECIES", 528, 533], ["insulin-positive cells", "TREATMENT", 132, 154], ["insulin", "TREATMENT", 238, 245], ["SNAPIN expression", "TREATMENT", 250, 267], ["cell cycle genes", "TREATMENT", 281, 297], ["insulin", "TREATMENT", 476, 483], ["diabetic (e-h) pancreases", "TREATMENT", 552, 577], ["antibodies", "TEST", 584, 594], ["insulin (b, f)", "TREATMENT", 618, 632], ["glucagon", "TREATMENT", 637, 645], ["pancreatic", "ANATOMY", 41, 51], ["positive cells", "OBSERVATION", 140, 154]]], ["Merged images are shown in d and h.", [["Merged images", "TEST", 0, 13]]], ["All images are at \u00d740 amplification.", [["All images", "TEST", 0, 10]]], ["No staining was visible in exocrine tissue in either control or diabetic pancreases secretion and proliferation.", [["exocrine tissue", "ANATOMY", 27, 42], ["pancreases", "ANATOMY", 73, 83], ["diabetic", "DISEASE", 64, 72], ["exocrine tissue", "TISSUE", 27, 42], ["pancreases", "ORGAN", 73, 83], ["staining", "PROBLEM", 3, 11], ["exocrine tissue", "PROBLEM", 27, 42], ["diabetic pancreases secretion", "PROBLEM", 64, 93], ["proliferation", "PROBLEM", 98, 111], ["staining", "OBSERVATION", 3, 11], ["visible", "OBSERVATION_MODIFIER", 16, 23], ["exocrine tissue", "OBSERVATION", 27, 42], ["diabetic", "OBSERVATION_MODIFIER", 64, 72], ["pancreases", "ANATOMY", 73, 83], ["secretion", "OBSERVATION", 84, 93], ["proliferation", "OBSERVATION_MODIFIER", 98, 111]]], ["We observed a significant positive correlation between TMEM27 and insulin (Fig. 2a) .", [["TMEM27", "GENE_OR_GENE_PRODUCT", 55, 61], ["insulin", "GENE_OR_GENE_PRODUCT", 66, 73], ["TMEM27", "PROTEIN", 55, 61], ["insulin", "PROTEIN", 66, 73], ["TMEM27", "TREATMENT", 55, 61], ["insulin", "TREATMENT", 66, 73], ["significant", "OBSERVATION_MODIFIER", 14, 25], ["positive", "OBSERVATION", 26, 34]]], ["In addition, TMEM27 positively correlated with SNAPIN (Fig. 2b) , which encodes a protein related to the soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex with which TMEM27 has been shown to interact [7] .", [["N-ethylmaleimide", "CHEMICAL", 113, 129], ["TMEM27", "CHEMICAL", 202, 208], ["N-ethylmaleimide", "CHEMICAL", 113, 129], ["TMEM27", "GENE_OR_GENE_PRODUCT", 13, 19], ["SNAPIN", "GENE_OR_GENE_PRODUCT", 47, 53], ["Fig. 2b", "GENE_OR_GENE_PRODUCT", 55, 62], ["N-ethylmaleimide-sensitive factor attachment protein receptor", "GENE_OR_GENE_PRODUCT", 113, 174], ["SNARE", "GENE_OR_GENE_PRODUCT", 176, 181], ["TMEM27", "GENE_OR_GENE_PRODUCT", 202, 208], ["TMEM27", "PROTEIN", 13, 19], ["SNAPIN", "PROTEIN", 47, 53], ["soluble N-ethylmaleimide-sensitive factor attachment protein receptor (SNARE) complex", "PROTEIN", 105, 190], ["TMEM27", "PROTEIN", 202, 208], ["SNAPIN", "TREATMENT", 47, 53], ["a protein", "PROBLEM", 80, 89], ["the soluble N-ethylmaleimide", "TREATMENT", 101, 129], ["sensitive factor attachment protein receptor (SNARE", "TREATMENT", 130, 181]]], ["As expected, insulin correlated with SNAPIN ( ESM Fig. 5 ).", [["insulin", "GENE_OR_GENE_PRODUCT", 13, 20], ["insulin", "PROTEIN", 13, 20], ["SNAPIN", "PROTEIN", 37, 43], ["insulin", "TREATMENT", 13, 20], ["SNAPIN ( ESM Fig.", "TREATMENT", 37, 54]]], ["In contrast, we found no significant correlation between TMEM27 and any of the cell cycle genes studied, namely cyclin E1, CDK2, cyclin D1 and CDK6 (Fig. 2c-f ).ResultsTMEM27 is diminished in rats with increased proliferation and decreased insulin secretion To further investigate the relative contribution of TMEM27 to insulin secretion regulation as opposed to cell proliferation control, we studied Tmem27 expression in islets of Wistar rats treated with sodium tungstate [10, 25] .", [["cell", "ANATOMY", 79, 83], ["cell", "ANATOMY", 363, 367], ["islets", "ANATOMY", 423, 429], ["ResultsTMEM27", "CHEMICAL", 161, 174], ["sodium tungstate", "CHEMICAL", 458, 474], ["sodium tungstate", "CHEMICAL", 458, 474], ["TMEM27", "GENE_OR_GENE_PRODUCT", 57, 63], ["cell", "CELL", 79, 83], ["cyclin E1", "GENE_OR_GENE_PRODUCT", 112, 121], ["CDK2", "GENE_OR_GENE_PRODUCT", 123, 127], ["cyclin D1", "GENE_OR_GENE_PRODUCT", 129, 138], ["CDK6", "GENE_OR_GENE_PRODUCT", 143, 147], ["Fig. 2c-f", "GENE_OR_GENE_PRODUCT", 149, 158], ["ResultsTMEM27", "GENE_OR_GENE_PRODUCT", 161, 174], ["rats", "ORGANISM", 192, 196], ["insulin", "GENE_OR_GENE_PRODUCT", 240, 247], ["TMEM27", "GENE_OR_GENE_PRODUCT", 310, 316], ["insulin", "GENE_OR_GENE_PRODUCT", 320, 327], ["cell", "CELL", 363, 367], ["Tmem27", "GENE_OR_GENE_PRODUCT", 402, 408], ["islets", "MULTI-TISSUE_STRUCTURE", 423, 429], ["Wistar rats", "ORGANISM", 433, 444], ["sodium tungstate", "SIMPLE_CHEMICAL", 458, 474], ["TMEM27", "PROTEIN", 57, 63], ["cell cycle genes", "DNA", 79, 95], ["cyclin E1", "PROTEIN", 112, 121], ["CDK2", "PROTEIN", 123, 127], ["cyclin D1", "PROTEIN", 129, 138], ["CDK6", "PROTEIN", 143, 147], ["TMEM27", "PROTEIN", 310, 316], ["insulin", "PROTEIN", 320, 327], ["Tmem27", "PROTEIN", 402, 408], ["rats", "SPECIES", 192, 196], ["rats", "SPECIES", 440, 444], ["significant correlation between TMEM27", "PROBLEM", 25, 63], ["the cell cycle genes", "TEST", 75, 95], ["CDK2", "TEST", 123, 127], ["CDK6", "TEST", 143, 147], ["diminished in rats", "PROBLEM", 178, 196], ["increased proliferation", "PROBLEM", 202, 225], ["decreased insulin secretion", "PROBLEM", 230, 257], ["insulin secretion regulation", "TREATMENT", 320, 348], ["cell proliferation control", "TREATMENT", 363, 389], ["sodium tungstate", "TREATMENT", 458, 474], ["diminished", "OBSERVATION_MODIFIER", 178, 188], ["increased", "OBSERVATION_MODIFIER", 202, 211], ["proliferation", "OBSERVATION_MODIFIER", 212, 225], ["decreased", "OBSERVATION_MODIFIER", 230, 239], ["insulin secretion", "OBSERVATION", 240, 257]]], ["This treatment improves insulin sensitivity and glucose tolerance (ESM Fig. 2a-c) , lowers basal insulinaemia (Fig. 3a) and decreases glucosestimulated insulin secretion (Fig. 3b) .", [["glucose", "CHEMICAL", 48, 55], ["glucose", "CHEMICAL", 48, 55], ["insulin", "GENE_OR_GENE_PRODUCT", 24, 31], ["glucose", "SIMPLE_CHEMICAL", 48, 55], ["2a-c", "GENE_OR_GENE_PRODUCT", 76, 80], ["insulin", "GENE_OR_GENE_PRODUCT", 152, 159], ["This treatment", "TREATMENT", 0, 14], ["insulin sensitivity", "TEST", 24, 43], ["glucose tolerance", "TEST", 48, 65], ["ESM Fig.", "TEST", 67, 75], ["lowers basal insulinaemia", "PROBLEM", 84, 109], ["decreases glucosestimulated insulin secretion", "TREATMENT", 124, 169], ["basal", "ANATOMY_MODIFIER", 91, 96], ["insulinaemia", "OBSERVATION", 97, 109]]], ["Pancreatic islets from tungstate-treated rats present a higher ratio of PCNApositive cells (Fig. 3c) , which is indicative of enhanced proliferation.", [["Pancreatic islets", "ANATOMY", 0, 17], ["PCNApositive cells", "ANATOMY", 72, 90], ["tungstate", "CHEMICAL", 23, 32], ["tungstate", "CHEMICAL", 23, 32], ["Pancreatic islets", "MULTI-TISSUE_STRUCTURE", 0, 17], ["tungstate", "SIMPLE_CHEMICAL", 23, 32], ["rats", "ORGANISM", 41, 45], ["PCNApositive cells", "CELL", 72, 90], ["Pancreatic islets", "CELL_TYPE", 0, 17], ["PCNApositive cells", "CELL_TYPE", 72, 90], ["rats", "SPECIES", 41, 45], ["Pancreatic islets from tungstate", "PROBLEM", 0, 32], ["PCNApositive cells", "PROBLEM", 72, 90], ["enhanced proliferation", "PROBLEM", 126, 148], ["islets", "OBSERVATION", 11, 17], ["higher", "OBSERVATION_MODIFIER", 56, 62], ["PCNApositive cells", "OBSERVATION", 72, 90], ["indicative of", "UNCERTAINTY", 112, 125], ["enhanced", "OBSERVATION_MODIFIER", 126, 134], ["proliferation", "OBSERVATION", 135, 148]]], ["Therefore, tungstate treatment elicits decreased glucose-stimulated insulin secretion and increases islet proliferation, making these animals an interesting model for the analysis of the potential implication of TMEM27 in these two cellular functions.", [["islet", "ANATOMY", 100, 105], ["cellular", "ANATOMY", 232, 240], ["tungstate", "CHEMICAL", 11, 20], ["glucose", "CHEMICAL", 49, 56], ["tungstate", "CHEMICAL", 11, 20], ["glucose", "CHEMICAL", 49, 56], ["tungstate", "SIMPLE_CHEMICAL", 11, 20], ["glucose", "SIMPLE_CHEMICAL", 49, 56], ["insulin", "GENE_OR_GENE_PRODUCT", 68, 75], ["islet", "MULTI-TISSUE_STRUCTURE", 100, 105], ["TMEM27", "GENE_OR_GENE_PRODUCT", 212, 218], ["cellular", "CELL", 232, 240], ["TMEM27", "PROTEIN", 212, 218], ["tungstate treatment", "TREATMENT", 11, 30], ["decreased glucose", "PROBLEM", 39, 56], ["stimulated insulin secretion", "PROBLEM", 57, 85], ["increases islet proliferation", "PROBLEM", 90, 119], ["islet proliferation", "OBSERVATION", 100, 119]]], ["In islets from tungstate-treated rats, we found that, despite the increase observed in beta cell proliferation, Tmem27 mRNA levels were decreased in parallel to those of insulin, with a significant correlation between Tmem27 and insulin gene expression (Fig. 3d-f ), as we observed previously in human islets.ResultsTMEM27 overproduction shows that it is mainly involved in insulin secretion TMEM27 protein is highly homologous among rats, mice and humans (Fig. 4a) .", [["islets", "ANATOMY", 3, 9], ["beta cell", "ANATOMY", 87, 96], ["islets", "ANATOMY", 302, 308], ["tungstate", "CHEMICAL", 15, 24], ["tungstate", "CHEMICAL", 15, 24], ["islets", "MULTI-TISSUE_STRUCTURE", 3, 9], ["tungstate", "SIMPLE_CHEMICAL", 15, 24], ["rats", "ORGANISM", 33, 37], ["beta cell", "CELL", 87, 96], ["Tmem27", "GENE_OR_GENE_PRODUCT", 112, 118], ["insulin", "GENE_OR_GENE_PRODUCT", 170, 177], ["Tmem27", "GENE_OR_GENE_PRODUCT", 218, 224], ["insulin", "GENE_OR_GENE_PRODUCT", 229, 236], ["d-f", "GENE_OR_GENE_PRODUCT", 260, 263], ["human", "ORGANISM", 296, 301], ["islets", "MULTI-TISSUE_STRUCTURE", 302, 308], ["ResultsTMEM27", "GENE_OR_GENE_PRODUCT", 309, 322], ["insulin", "GENE_OR_GENE_PRODUCT", 374, 381], ["TMEM27", "GENE_OR_GENE_PRODUCT", 392, 398], ["rats", "ORGANISM", 434, 438], ["mice", "ORGANISM", 440, 444], ["humans", "ORGANISM", 449, 455], ["Tmem27 mRNA", "RNA", 112, 123], ["insulin", "PROTEIN", 170, 177], ["Tmem27", "PROTEIN", 218, 224], ["human islets", "CELL_TYPE", 296, 308], ["ResultsTMEM27", "PROTEIN", 309, 322], ["insulin secretion TMEM27 protein", "PROTEIN", 374, 406], ["rats", "SPECIES", 33, 37], ["human", "SPECIES", 296, 301], ["rats", "SPECIES", 434, 438], ["mice", "SPECIES", 440, 444], ["humans", "SPECIES", 449, 455], ["human", "SPECIES", 296, 301], ["mice", "SPECIES", 440, 444], ["humans", "SPECIES", 449, 455], ["beta cell proliferation", "TREATMENT", 87, 110], ["mRNA levels", "TEST", 119, 130], ["insulin", "TREATMENT", 170, 177], ["insulin gene expression", "TREATMENT", 229, 252], ["insulin secretion", "TEST", 374, 391], ["increase", "OBSERVATION_MODIFIER", 66, 74], ["beta cell proliferation", "OBSERVATION", 87, 110]]], ["Interestingly, Fig. 3 Tmem27 expression is diminished in islets from rats treated with sodium tungstate. a Insulinaemia at the end of 6 weeks' treatment of untreated controls (UT, white bars) and tungstate-treated rats (T, black bars): n=13-14, p<0.01 treated vs untreated at 16.7 mmol/l glucose. c Number of PCNA-and insulin-positive cells per mm 2 of islet at the end of treatment: n=6-8, p<0.001. f Correlation between TMEM27 and insulin \u03c1=0.724, p<0.0001, n=32 when performing immunoblots using islet protein extracts from these species, we noticed different band patterns (ESM Fig. 6a ), which might indicate the existence of interspecific differences in the processing and/or posttranslational modifications of the TMEM27 protein.", [["islets", "ANATOMY", 57, 63], ["insulin-positive cells", "ANATOMY", 318, 340], ["islet", "ANATOMY", 353, 358], ["islet protein extracts", "ANATOMY", 499, 521], ["sodium tungstate", "CHEMICAL", 87, 103], ["Insulinaemia", "DISEASE", 107, 119], ["tungstate", "CHEMICAL", 196, 205], ["glucose", "CHEMICAL", 288, 295], ["sodium tungstate", "CHEMICAL", 87, 103], ["tungstate", "CHEMICAL", 196, 205], ["glucose", "CHEMICAL", 288, 295], ["Fig. 3", "GENE_OR_GENE_PRODUCT", 15, 21], ["Tmem27", "GENE_OR_GENE_PRODUCT", 22, 28], ["islets", "MULTI-TISSUE_STRUCTURE", 57, 63], ["rats", "ORGANISM", 69, 73], ["sodium tungstate", "SIMPLE_CHEMICAL", 87, 103], ["tungstate", "SIMPLE_CHEMICAL", 196, 205], ["rats", "ORGANISM", 214, 218], ["T", "CELL", 220, 221], ["glucose", "SIMPLE_CHEMICAL", 288, 295], ["PCNA", "GENE_OR_GENE_PRODUCT", 309, 313], ["insulin", "GENE_OR_GENE_PRODUCT", 318, 325], ["islet", "MULTI-TISSUE_STRUCTURE", 353, 358], ["TMEM27", "GENE_OR_GENE_PRODUCT", 422, 428], ["insulin", "GENE_OR_GENE_PRODUCT", 433, 440], ["islet", "MULTI-TISSUE_STRUCTURE", 499, 504], ["extracts", "ORGANISM_SUBSTANCE", 513, 521], ["TMEM27", "GENE_OR_GENE_PRODUCT", 721, 727], ["Tmem27", "PROTEIN", 22, 28], ["islets", "CELL_TYPE", 57, 63], ["PCNA", "PROTEIN", 309, 313], ["insulin", "PROTEIN", 318, 325], ["TMEM27", "PROTEIN", 422, 428], ["TMEM27 protein", "PROTEIN", 721, 735], ["rats", "SPECIES", 69, 73], ["rats", "SPECIES", 214, 218], ["diminished in islets", "PROBLEM", 43, 63], ["sodium tungstate", "TREATMENT", 87, 103], ["a Insulinaemia", "PROBLEM", 105, 119], ["untreated controls (UT, white bars)", "PROBLEM", 156, 191], ["glucose", "TEST", 288, 295], ["PCNA", "TEST", 309, 313], ["insulin", "TEST", 318, 325], ["islet", "TEST", 353, 358], ["TMEM27", "TEST", 422, 428], ["insulin", "TEST", 433, 440], ["immunoblots", "TEST", 481, 492], ["islet protein extracts", "TEST", 499, 521], ["these species", "PROBLEM", 527, 540], ["different band patterns", "PROBLEM", 553, 576], ["interspecific differences", "PROBLEM", 631, 656], ["diminished", "OBSERVATION_MODIFIER", 43, 53]]], ["One possible explanation for this observation was that TMEM27 was produced in different endocrine subtypes within the islets.", [["endocrine", "ANATOMY", 88, 97], ["islets", "ANATOMY", 118, 124], ["TMEM27", "GENE_OR_GENE_PRODUCT", 55, 61], ["islets", "MULTI-TISSUE_STRUCTURE", 118, 124], ["TMEM27", "PROTEIN", 55, 61], ["possible explanation for", "UNCERTAINTY", 4, 28]]], ["However, immunofluorescence analysis revealed that TMEM27 production was mainly localised to beta cells in all three species (ESM Fig. 7) .", [["beta cells", "ANATOMY", 93, 103], ["TMEM27", "CHEMICAL", 51, 57], ["TMEM27", "GENE_OR_GENE_PRODUCT", 51, 57], ["beta cells", "CELL", 93, 103], ["TMEM27", "PROTEIN", 51, 57], ["beta cells", "CELL_TYPE", 93, 103], ["immunofluorescence analysis", "TEST", 9, 36], ["TMEM27 production", "PROBLEM", 51, 68], ["beta cells", "PROBLEM", 93, 103]]], ["Next, to establish the importance of the primary sequence of TMEM27, we adenovirally expressed rat, mouse and human Tmem27/ TMEM27 cDNA in rat INS-1 cells (ESM Fig. 6b ).", [["INS-1 cells", "ANATOMY", 143, 154], ["TMEM27", "GENE_OR_GENE_PRODUCT", 61, 67], ["rat", "ORGANISM", 95, 98], ["mouse", "ORGANISM", 100, 105], ["human", "ORGANISM", 110, 115], ["Tmem27", "GENE_OR_GENE_PRODUCT", 116, 122], ["TMEM27", "GENE_OR_GENE_PRODUCT", 124, 130], ["rat", "ORGANISM", 139, 142], ["INS-1 cells", "CELL", 143, 154], ["TMEM27", "DNA", 61, 67], ["adenovirally expressed rat, mouse and human Tmem27/ TMEM27 cDNA", "DNA", 72, 135], ["rat INS-1 cells", "CELL_LINE", 139, 154], ["rat", "SPECIES", 95, 98], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 110, 115], ["rat", "SPECIES", 139, 142], ["rat", "SPECIES", 95, 98], ["mouse", "SPECIES", 100, 105], ["human", "SPECIES", 110, 115], ["rat", "SPECIES", 139, 142], ["ESM Fig.", "TEST", 156, 164]]], ["Here again, we found characteristic band patterns for each isoform, suggesting that the differences observed were more probably due to the amino acid sequence of TMEM27 than to the presence of specific modifying or processing enzymes.ResultsWe wondered if these discrepancies had an impact on the biological function of the different TMEM27 isoforms.", [["amino acid", "CHEMICAL", 139, 149], ["amino acid", "CHEMICAL", 139, 149], ["amino acid", "AMINO_ACID", 139, 149], ["TMEM27", "GENE_OR_GENE_PRODUCT", 162, 168], ["TMEM27", "GENE_OR_GENE_PRODUCT", 334, 340], ["amino acid sequence", "PROTEIN", 139, 158], ["TMEM27", "PROTEIN", 162, 168], ["specific modifying or processing enzymes", "PROTEIN", 193, 233], ["TMEM27 isoforms", "PROTEIN", 334, 349], ["characteristic band patterns", "PROBLEM", 21, 49], ["the amino acid sequence", "TEST", 135, 158], ["processing enzymes", "TEST", 215, 233], ["these discrepancies", "PROBLEM", 256, 275], ["band patterns", "OBSERVATION", 36, 49]]], ["We therefore studied the effects of overexpressing rat, mouse and human Tmem27/TMEM27 on insulin secretion and proliferation in INS-1 cells.", [["INS-1 cells", "ANATOMY", 128, 139], ["rat", "ORGANISM", 51, 54], ["mouse", "ORGANISM", 56, 61], ["human", "ORGANISM", 66, 71], ["Tmem27", "GENE_OR_GENE_PRODUCT", 72, 78], ["TMEM27", "GENE_OR_GENE_PRODUCT", 79, 85], ["insulin", "GENE_OR_GENE_PRODUCT", 89, 96], ["INS-1 cells", "CELL", 128, 139], ["overexpressing rat, mouse and human Tmem27", "PROTEIN", 36, 78], ["TMEM27", "PROTEIN", 79, 85], ["INS-1 cells", "CELL_LINE", 128, 139], ["rat", "SPECIES", 51, 54], ["mouse", "SPECIES", 56, 61], ["human", "SPECIES", 66, 71], ["rat", "SPECIES", 51, 54], ["mouse", "SPECIES", 56, 61], ["human", "SPECIES", 66, 71], ["insulin secretion", "TREATMENT", 89, 106], ["proliferation in INS-1 cells", "PROBLEM", 111, 139]]], ["All three proteins elicited an increase in glucose-stimulated insulin secretion and a slight increase in proliferation (Fig. 4b, c) , which was not accompanied by an increase in cell number (Fig. 4d) .", [["cell", "ANATOMY", 178, 182], ["glucose", "CHEMICAL", 43, 50], ["increase in cell number", "DISEASE", 166, 189], ["glucose", "CHEMICAL", 43, 50], ["glucose", "SIMPLE_CHEMICAL", 43, 50], ["insulin", "GENE_OR_GENE_PRODUCT", 62, 69], ["cell", "CELL", 178, 182], ["an increase in glucose", "PROBLEM", 28, 50], ["stimulated insulin secretion", "PROBLEM", 51, 79], ["a slight increase in proliferation", "PROBLEM", 84, 118], ["an increase in cell number", "PROBLEM", 163, 189], ["increase", "OBSERVATION_MODIFIER", 31, 39], ["slight", "OBSERVATION_MODIFIER", 86, 92], ["increase", "OBSERVATION_MODIFIER", 93, 101], ["proliferation", "OBSERVATION_MODIFIER", 105, 118], ["increase", "OBSERVATION_MODIFIER", 166, 174], ["cell number", "OBSERVATION", 178, 189]]], ["So the different orthologues appeared to exert similar effects when overexpressed in the same cellular context.", [["cellular", "ANATOMY", 94, 102], ["cellular", "CELL", 94, 102]]], ["Finally, in order to rule out a possible artefact from the beta cell line, we tested the effect of overexpressed rat Tmem27 in isolated rat pancreatic islets and demonstrated, as in INS-1 cells, a significant enhancement in glucose-stimulated insulin secretion with no changes in proliferation levels (Fig. 5) .", [["beta cell line", "ANATOMY", 59, 73], ["pancreatic islets", "ANATOMY", 140, 157], ["INS-1 cells", "ANATOMY", 182, 193], ["Tmem27", "CHEMICAL", 117, 123], ["glucose", "CHEMICAL", 224, 231], ["glucose", "CHEMICAL", 224, 231], ["beta cell line", "CELL", 59, 73], ["rat", "ORGANISM", 113, 116], ["Tmem27", "GENE_OR_GENE_PRODUCT", 117, 123], ["rat", "ORGANISM", 136, 139], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 140, 157], ["INS-1 cells", "CELL", 182, 193], ["glucose", "SIMPLE_CHEMICAL", 224, 231], ["insulin", "GENE_OR_GENE_PRODUCT", 243, 250], ["beta cell line", "CELL_LINE", 59, 73], ["rat Tmem27", "PROTEIN", 113, 123], ["isolated rat pancreatic islets", "CELL_TYPE", 127, 157], ["INS-1 cells", "CELL_LINE", 182, 193], ["rat", "SPECIES", 113, 116], ["rat", "SPECIES", 136, 139], ["rat", "SPECIES", 113, 116], ["rat", "SPECIES", 136, 139], ["artefact", "PROBLEM", 41, 49], ["the beta cell line", "TREATMENT", 55, 73], ["isolated rat pancreatic islets", "PROBLEM", 127, 157], ["a significant enhancement in glucose-stimulated insulin secretion", "PROBLEM", 195, 260], ["changes in proliferation levels", "PROBLEM", 269, 300], ["possible", "UNCERTAINTY", 32, 40], ["artefact", "OBSERVATION", 41, 49], ["beta cell line", "OBSERVATION", 59, 73], ["pancreatic islets", "ANATOMY", 140, 157], ["significant", "OBSERVATION_MODIFIER", 197, 208], ["enhancement", "OBSERVATION_MODIFIER", 209, 220]]], ["Altogether, our data indicate that TMEM27, irrespective of the species of origin, is mainly involved in insulin secretion.ResultsTMEM27 cleavage is not beta cell specific In view of the finding that TMEM27 is exclusively cleaved and shed into the extracellular space in beta cells, the extracellular fraction of TMEM27 was proposed as a possible beta cell mass biomarker [6] .", [["beta cell", "ANATOMY", 152, 161], ["extracellular space", "ANATOMY", 247, 266], ["beta cells", "ANATOMY", 270, 280], ["extracellular", "ANATOMY", 286, 299], ["beta cell", "ANATOMY", 346, 355], ["TMEM27", "CHEMICAL", 35, 41], ["TMEM27", "GENE_OR_GENE_PRODUCT", 35, 41], ["insulin", "GENE_OR_GENE_PRODUCT", 104, 111], ["ResultsTMEM27", "GENE_OR_GENE_PRODUCT", 122, 135], ["beta cell", "CELL", 152, 161], ["TMEM27", "GENE_OR_GENE_PRODUCT", 199, 205], ["extracellular space", "CELLULAR_COMPONENT", 247, 266], ["beta cells", "CELL", 270, 280], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 286, 299], ["TMEM27", "GENE_OR_GENE_PRODUCT", 312, 318], ["beta cell", "CELL", 346, 355], ["TMEM27", "PROTEIN", 35, 41], ["ResultsTMEM27", "PROTEIN", 122, 135], ["TMEM27", "PROTEIN", 199, 205], ["beta cells", "CELL_TYPE", 270, 280], ["TMEM27", "PROTEIN", 312, 318], ["our data", "TEST", 12, 20], ["insulin secretion", "PROBLEM", 104, 121], ["the extracellular fraction", "TEST", 282, 308], ["beta cell mass biomarker", "PROBLEM", 346, 370], ["insulin secretion", "OBSERVATION", 104, 121], ["not", "UNCERTAINTY", 148, 151], ["beta cell", "OBSERVATION_MODIFIER", 152, 161], ["beta cells", "OBSERVATION", 270, 280]]], ["Here we investigated the cleavage pattern of TMEM27 in beta cells and kidney tubular cells, with or without overproduction of rat TMEM27 (which harbours a C-terminal myc tag).", [["beta cells", "ANATOMY", 55, 65], ["kidney tubular cells", "ANATOMY", 70, 90], ["C", "CHEMICAL", 155, 156], ["TMEM27", "GENE_OR_GENE_PRODUCT", 45, 51], ["beta cells", "CELL", 55, 65], ["kidney tubular cells", "CELL", 70, 90], ["rat", "ORGANISM", 126, 129], ["TMEM27", "GENE_OR_GENE_PRODUCT", 130, 136], ["TMEM27", "PROTEIN", 45, 51], ["beta cells", "CELL_TYPE", 55, 65], ["kidney tubular cells", "CELL_TYPE", 70, 90], ["rat TMEM27", "PROTEIN", 126, 136], ["C-terminal myc tag", "DNA", 155, 173], ["rat", "SPECIES", 126, 129], ["rat", "SPECIES", 126, 129], ["the cleavage pattern", "PROBLEM", 21, 41], ["kidney tubular cells", "PROBLEM", 70, 90], ["overproduction of rat TMEM27", "PROBLEM", 108, 136], ["kidney", "ANATOMY", 70, 76], ["tubular cells", "OBSERVATION", 77, 90]]], ["For this purpose we used two different antibodies: (1) a myc tag antibody which recognises the complete protein and the C-terminal fragment that remains anchored to the membrane after cleavage; and (2) an antibody against the N-terminal of the protein [6] which recognises both the complete protein and the fragment that is released into the extracellular space after cleavage (Fig. 6a) .", [["membrane", "ANATOMY", 169, 177], ["extracellular space", "ANATOMY", 342, 361], ["C", "CHEMICAL", 120, 121], ["N", "CHEMICAL", 226, 227], ["myc", "GENE_OR_GENE_PRODUCT", 57, 60], ["membrane", "CELLULAR_COMPONENT", 169, 177], ["extracellular space", "CELLULAR_COMPONENT", 342, 361], ["antibodies", "PROTEIN", 39, 49], ["myc tag antibody", "PROTEIN", 57, 73], ["C-terminal fragment", "PROTEIN", 120, 139], ["N-terminal", "PROTEIN", 226, 236], ["protein [6]", "PROTEIN", 244, 255], ["a myc tag antibody", "TEST", 55, 73], ["the C-terminal fragment", "PROBLEM", 116, 139], ["an antibody", "TEST", 202, 213], ["the fragment", "PROBLEM", 303, 315], ["terminal", "ANATOMY_MODIFIER", 122, 130], ["fragment", "OBSERVATION", 131, 139], ["complete", "OBSERVATION_MODIFIER", 282, 290], ["protein", "OBSERVATION", 291, 298], ["fragment", "OBSERVATION", 307, 315], ["extracellular", "ANATOMY_MODIFIER", 342, 355]]], ["As shown in Fig. 6b, 16 h after adenoviral infection of INS-1 cells, overproduced myctagged TMEM27 was detected as two different molecular mass bands with anti-myc antibodies.", [["INS-1 cells", "ANATOMY", 56, 67], ["adenoviral infection", "DISEASE", 32, 52], ["adenoviral", "ORGANISM", 32, 42], ["INS-1 cells", "CELL", 56, 67], ["TMEM27", "GENE_OR_GENE_PRODUCT", 92, 98], ["INS-1 cells", "CELL_LINE", 56, 67], ["myctagged TMEM27", "PROTEIN", 82, 98], ["anti-myc antibodies", "PROTEIN", 155, 174], ["adenoviral", "SPECIES", 32, 42], ["adenoviral infection of INS-1 cells", "PROBLEM", 32, 67], ["two different molecular mass bands", "PROBLEM", 115, 149], ["anti-myc antibodies", "PROBLEM", 155, 174], ["infection", "OBSERVATION", 43, 52], ["mass", "OBSERVATION", 139, 143]]], ["An additional lower molecular mass band (\u223c20 kDa) appeared 4 h later, probably corresponding to the previously described fragment of TMEM27 [6] which remains anchored to the Fig. 5 TMEM27 overproduction in rat islets enhances glucoseinduced insulin secretion without affecting proliferation. a Insulin secretion at 2.2 or 16.7 mmol/l glucose of rat islets overproducing rat TMEM27 or \u03b2-galactosidase (\u03b2-gal) as control: n=7-9, p<0.001. b Cell proliferation measured as incorporation of [methyl-3 H]thymidine in counts per minute in islets overproducing rat TMEM27 or \u03b2-gal as control.", [["islets", "ANATOMY", 210, 216], ["islets", "ANATOMY", 349, 355], ["Cell", "ANATOMY", 438, 442], ["islets", "ANATOMY", 532, 538], ["glucose", "CHEMICAL", 334, 341], ["\u03b2-gal", "CHEMICAL", 401, 406], ["[methyl-3 H", "CHEMICAL", 486, 497], ["thymidine", "CHEMICAL", 498, 507], ["TMEM27", "CHEMICAL", 557, 563], ["glucose", "CHEMICAL", 334, 341], ["[methyl-3 H]thymidine", "CHEMICAL", 486, 507], ["TMEM27", "GENE_OR_GENE_PRODUCT", 181, 187], ["rat", "ORGANISM", 206, 209], ["islets", "MULTI-TISSUE_STRUCTURE", 210, 216], ["insulin", "GENE_OR_GENE_PRODUCT", 241, 248], ["Insulin", "GENE_OR_GENE_PRODUCT", 294, 301], ["glucose", "SIMPLE_CHEMICAL", 334, 341], ["rat", "ORGANISM", 345, 348], ["islets", "MULTI-TISSUE_STRUCTURE", 349, 355], ["rat", "ORGANISM", 370, 373], ["TMEM27", "GENE_OR_GENE_PRODUCT", 374, 380], ["\u03b2-galactosidase", "GENE_OR_GENE_PRODUCT", 384, 399], ["\u03b2-gal", "GENE_OR_GENE_PRODUCT", 401, 406], ["Cell", "CELL", 438, 442], ["[methyl-3 H]thymidine", "SIMPLE_CHEMICAL", 486, 507], ["islets", "MULTI-TISSUE_STRUCTURE", 532, 538], ["rat", "ORGANISM", 553, 556], ["TMEM27", "GENE_OR_GENE_PRODUCT", 557, 563], ["\u03b2-gal", "GENE_OR_GENE_PRODUCT", 567, 572], ["TMEM27", "PROTEIN", 181, 187], ["rat islets", "CELL_TYPE", 206, 216], ["rat islets", "CELL_TYPE", 345, 355], ["rat TMEM27", "PROTEIN", 370, 380], ["\u03b2-galactosidase", "PROTEIN", 384, 399], ["\u03b2", "PROTEIN", 401, 402], ["islets", "CELL_TYPE", 532, 538], ["rat TMEM27", "PROTEIN", 553, 563], ["rat", "SPECIES", 206, 209], ["rat", "SPECIES", 345, 348], ["rat", "SPECIES", 370, 373], ["rat", "SPECIES", 553, 556], ["rat", "SPECIES", 206, 209], ["rat", "SPECIES", 370, 373], ["rat", "SPECIES", 553, 556], ["An additional lower molecular mass band", "PROBLEM", 0, 39], ["insulin secretion", "PROBLEM", 241, 258], ["affecting proliferation", "PROBLEM", 267, 290], ["a Insulin secretion", "TEST", 292, 311], ["glucose", "TEST", 334, 341], ["galactosidase", "TEST", 386, 399], ["Cell proliferation", "PROBLEM", 438, 456], ["incorporation of [methyl-3 H]thymidine", "TREATMENT", 469, 507], ["lower", "OBSERVATION_MODIFIER", 14, 19], ["molecular", "OBSERVATION_MODIFIER", 20, 29], ["mass", "OBSERVATION", 30, 34], ["fragment", "OBSERVATION", 121, 129]]], ["Data are expressed relative to the number of \u03b2-gal-infected islets, which was set at 100%, n=5 membrane after the cleavage, as it did not change after glycosidase treatment (ESM Fig. 8a ) and it has a lower apparent molecular mass than the expected size of the complete protein without modifications (27 kDa).", [["islets", "ANATOMY", 60, 66], ["membrane", "ANATOMY", 95, 103], ["\u03b2-gal", "GENE_OR_GENE_PRODUCT", 45, 50], ["islets", "MULTI-TISSUE_STRUCTURE", 60, 66], ["infected islets", "PROBLEM", 51, 66], ["the cleavage", "TREATMENT", 110, 122], ["glycosidase treatment", "TREATMENT", 151, 172], ["ESM Fig.", "TEST", 174, 182], ["a lower apparent molecular mass", "PROBLEM", 199, 230], ["infected islets", "OBSERVATION", 51, 66], ["lower", "OBSERVATION_MODIFIER", 201, 206], ["mass", "OBSERVATION", 226, 230], ["size", "OBSERVATION_MODIFIER", 249, 253]]], ["Phosphorylation and the presence of sulphated glycans were also tested and yielded negative results (ESM Fig. 8 ).ResultsNext, we studied TMEM27 processing in islets and primary proximal kidney tubular cells.", [["islets", "ANATOMY", 159, 165], ["kidney tubular cells", "ANATOMY", 187, 207], ["TMEM27", "GENE_OR_GENE_PRODUCT", 138, 144], ["islets", "MULTI-TISSUE_STRUCTURE", 159, 165], ["kidney tubular cells", "CELL", 187, 207], ["TMEM27", "PROTEIN", 138, 144], ["islets", "CELL_TYPE", 159, 165], ["primary proximal kidney tubular cells", "CELL_TYPE", 170, 207], ["Phosphorylation", "TREATMENT", 0, 15], ["sulphated glycans", "PROBLEM", 36, 53], ["primary proximal kidney tubular cells", "PROBLEM", 170, 207], ["proximal", "ANATOMY_MODIFIER", 178, 186], ["kidney", "ANATOMY", 187, 193], ["tubular cells", "OBSERVATION", 194, 207]]], ["Our results demonstrate that the smallest band detected with the myc antibody is present in INS-1, islets and proximal tubular cells (Fig. 6c) .", [["INS-1", "ANATOMY", 92, 97], ["islets", "ANATOMY", 99, 105], ["proximal tubular cells", "ANATOMY", 110, 132], ["myc", "GENE_OR_GENE_PRODUCT", 65, 68], ["INS-1", "CELL", 92, 97], ["islets", "MULTI-TISSUE_STRUCTURE", 99, 105], ["proximal tubular cells", "CELL", 110, 132], ["myc antibody", "PROTEIN", 65, 77], ["INS-1", "CELL_LINE", 92, 97], ["islets", "CELL_TYPE", 99, 105], ["proximal tubular cells", "CELL_TYPE", 110, 132], ["the smallest band", "PROBLEM", 29, 46], ["the myc antibody", "TEST", 61, 77], ["INS", "TEST", 92, 95], ["smallest", "OBSERVATION_MODIFIER", 33, 41], ["myc antibody", "OBSERVATION", 65, 77], ["proximal", "ANATOMY_MODIFIER", 110, 118], ["tubular cells", "ANATOMY", 119, 132]]], ["In addition, we detected the extracellular portion of TMEM27 (\u223c25 kDa), which has been cleaved and shed, in the culture media of uninfected and infected INS-1 and proximal tubular cells (Fig. 6d) .", [["extracellular", "ANATOMY", 29, 42], ["INS-1", "ANATOMY", 153, 158], ["proximal tubular cells", "ANATOMY", 163, 185], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 29, 42], ["TMEM27", "GENE_OR_GENE_PRODUCT", 54, 60], ["INS-1", "CELL", 153, 158], ["proximal tubular cells", "CELL", 163, 185], ["TMEM27", "PROTEIN", 54, 60], ["INS-1", "CELL_LINE", 153, 158], ["proximal tubular cells", "CELL_TYPE", 163, 185], ["the culture media", "TEST", 108, 125], ["infected", "OBSERVATION", 144, 152], ["proximal", "ANATOMY_MODIFIER", 163, 171], ["tubular cells", "ANATOMY", 172, 185]]], ["This fragment can be deglycosylated (ESM Fig. 9 ), thus confirming that it corresponds to the released fragment of TMEM27 as previously described [6] .", [["fragment", "CELLULAR_COMPONENT", 5, 13], ["TMEM27", "GENE_OR_GENE_PRODUCT", 115, 121], ["TMEM27", "PROTEIN", 115, 121], ["This fragment", "PROBLEM", 0, 13], ["fragment", "OBSERVATION", 103, 111]]], ["Therefore, our results show that the cleavage of TMEM27 is not beta cell specific and consequently cannot be used as a beta cell mass biomarker.DiscussionTMEM27 role In this study, we confirm that human TMEM27 pancreatic expression is restricted to islets, and is mainly localised in beta cells.", [["beta cell", "ANATOMY", 63, 72], ["beta cell", "ANATOMY", 119, 128], ["pancreatic", "ANATOMY", 210, 220], ["islets", "ANATOMY", 249, 255], ["beta cells", "ANATOMY", 284, 294], ["TMEM27", "GENE_OR_GENE_PRODUCT", 49, 55], ["beta cell", "CELL", 63, 72], ["beta cell", "CELL", 119, 128], ["human", "ORGANISM", 197, 202], ["TMEM27 pancreatic", "GENE_OR_GENE_PRODUCT", 203, 220], ["islets", "MULTI-TISSUE_STRUCTURE", 249, 255], ["beta cells", "CELL", 284, 294], ["TMEM27", "PROTEIN", 49, 55], ["TMEM27", "PROTEIN", 203, 209], ["islets", "CELL_TYPE", 249, 255], ["beta cells", "CELL_TYPE", 284, 294], ["human", "SPECIES", 197, 202], ["human", "SPECIES", 197, 202], ["the cleavage of TMEM27", "PROBLEM", 33, 55], ["a beta cell mass biomarker", "TEST", 117, 143], ["this study", "TEST", 169, 179], ["beta cell", "OBSERVATION_MODIFIER", 63, 72], ["pancreatic", "ANATOMY", 210, 220], ["beta cells", "OBSERVATION", 284, 294]]], ["Importantly, we show that TMEM27 mRNA levels are significantly reduced in islets from type 2 diabetic patients.", [["islets", "ANATOMY", 74, 80], ["diabetic", "DISEASE", 93, 101], ["TMEM27", "GENE_OR_GENE_PRODUCT", 26, 32], ["islets", "MULTI-TISSUE_STRUCTURE", 74, 80], ["patients", "ORGANISM", 102, 110], ["TMEM27 mRNA", "RNA", 26, 37], ["patients", "SPECIES", 102, 110], ["TMEM27 mRNA levels", "TEST", 26, 44], ["significantly", "OBSERVATION_MODIFIER", 49, 62], ["reduced", "OBSERVATION_MODIFIER", 63, 70]]], ["This finding is in accordance with available whole-genome profiling data that show TMEM27 as one of the 370 genes differentially expressed between diabetic and control human islets [26] .", [["islets", "ANATOMY", 174, 180], ["diabetic", "DISEASE", 147, 155], ["TMEM27", "GENE_OR_GENE_PRODUCT", 83, 89], ["human", "ORGANISM", 168, 173], ["islets", "MULTI-TISSUE_STRUCTURE", 174, 180], ["TMEM27", "DNA", 83, 89], ["human", "SPECIES", 168, 173], ["human", "SPECIES", 168, 173], ["diabetic and control human islets", "TREATMENT", 147, 180]]], ["In the same line, a recent report shows that TMEM27 expression is tenfold lower in islets from recent diagnosed type 1 diabetic pancreatic donors as compared with healthy controls [27] .", [["islets", "ANATOMY", 83, 89], ["pancreatic", "ANATOMY", 128, 138], ["diabetic", "DISEASE", 119, 127], ["TMEM27", "GENE_OR_GENE_PRODUCT", 45, 51], ["islets", "MULTI-TISSUE_STRUCTURE", 83, 89], ["pancreatic", "ORGAN", 128, 138], ["donors", "ORGANISM", 139, 145], ["TMEM27", "PROTEIN", 45, 51], ["tenfold lower in islets", "PROBLEM", 66, 89], ["recent diagnosed type 1 diabetic pancreatic donors", "PROBLEM", 95, 145], ["tenfold", "OBSERVATION_MODIFIER", 66, 73], ["lower", "OBSERVATION_MODIFIER", 74, 79], ["diabetic", "OBSERVATION_MODIFIER", 119, 127], ["pancreatic", "ANATOMY", 128, 138]]], ["Taken together, these data point to TMEM27 as a potentially important protein for consideration in beta cell physiology and diabetes in humans.DiscussionStudies in rodents have also shown alterations in the expression of Tmem27 in animals with altered glucose homeostasis and/or diabetes.", [["beta cell", "ANATOMY", 99, 108], ["diabetes", "DISEASE", 124, 132], ["glucose", "CHEMICAL", 252, 259], ["diabetes", "DISEASE", 279, 287], ["glucose", "CHEMICAL", 252, 259], ["TMEM27", "GENE_OR_GENE_PRODUCT", 36, 42], ["beta cell", "CELL", 99, 108], ["humans", "ORGANISM", 136, 142], ["Tmem27", "GENE_OR_GENE_PRODUCT", 221, 227], ["glucose", "SIMPLE_CHEMICAL", 252, 259], ["TMEM27", "PROTEIN", 36, 42], ["Tmem27", "PROTEIN", 221, 227], ["humans", "SPECIES", 136, 142], ["humans", "SPECIES", 136, 142], ["beta cell physiology", "PROBLEM", 99, 119], ["diabetes in humans", "PROBLEM", 124, 142], ["altered glucose homeostasis", "PROBLEM", 244, 271], ["diabetes", "PROBLEM", 279, 287], ["beta cell", "OBSERVATION", 99, 108], ["glucose homeostasis", "OBSERVATION", 252, 271], ["diabetes", "OBSERVATION", 279, 287]]], ["For instance, Tmem27 is downregulated in models with islet hypoplasia and hypoinsulinaemia, such as Hnf-1\u03b1-knockout and transgenic mice overexpressing a human dominant-negative form of HNF-1\u03b1 (P291fsinsC-HNF-1\u03b1) [7] , whereas it is upregulated in models with islet hypertrophia and hyperinsulinaemia such as ob/ob, db/db, aP2-Srebp-1c, KKAY or high-fat-diet Fig. 6 TMEM27 cleavage is not beta cell specific. a Scheme of the TMEM27 protein depicting hypothetical cleavage, N-glycosylation sites and parts of the protein recognised by antibodies used in immunoblot assays: an antibody against the N-terminal portion of TMEM27 [5] that recognises the complete protein and the fragment that is shed to the extracellular space after cleavage, and an anti-myc antibody that recognises the myc tag fused at the C-terminus of TMEM27 in the adenoviral construct, meaning the complete protein and the membrane-anchored TMEM27 fragment that remains after cleavage. b Time course for production of adenovirally encoded rat TMEM27 in INS-1 832/13 cells.", [["islet", "ANATOMY", 53, 58], ["islet", "ANATOMY", 259, 264], ["beta cell", "ANATOMY", 388, 397], ["extracellular space", "ANATOMY", 702, 721], ["membrane", "ANATOMY", 891, 899], ["INS-1 832/13 cells", "ANATOMY", 1021, 1039], ["Tmem27", "CHEMICAL", 14, 20], ["islet hypoplasia", "DISEASE", 53, 69], ["hypoinsulinaemia", "DISEASE", 74, 90], ["hypertrophia", "DISEASE", 265, 277], ["hyperinsulinaemia", "DISEASE", 282, 299], ["N", "CHEMICAL", 472, 473], ["N", "CHEMICAL", 595, 596], ["Tmem27", "GENE_OR_GENE_PRODUCT", 14, 20], ["islet", "MULTI-TISSUE_STRUCTURE", 53, 58], ["Hnf-1\u03b1", "GENE_OR_GENE_PRODUCT", 100, 106], ["mice", "ORGANISM", 131, 135], ["human", "ORGANISM", 153, 158], ["HNF-1\u03b1", "GENE_OR_GENE_PRODUCT", 185, 191], ["P291fsinsC-HNF-1\u03b1", "GENE_OR_GENE_PRODUCT", 193, 210], ["islet", "MULTI-TISSUE_STRUCTURE", 259, 264], ["aP2-Srebp-1c", "GENE_OR_GENE_PRODUCT", 322, 334], ["KKAY", "GENE_OR_GENE_PRODUCT", 336, 340], ["TMEM27", "GENE_OR_GENE_PRODUCT", 365, 371], ["beta cell", "CELL", 388, 397], ["TMEM27", "GENE_OR_GENE_PRODUCT", 424, 430], ["TMEM27", "GENE_OR_GENE_PRODUCT", 617, 623], ["extracellular space", "CELLULAR_COMPONENT", 702, 721], ["myc", "GENE_OR_GENE_PRODUCT", 783, 786], ["TMEM27", "GENE_OR_GENE_PRODUCT", 818, 824], ["adenoviral", "ORGANISM", 832, 842], ["membrane", "CELLULAR_COMPONENT", 891, 899], ["TMEM27", "GENE_OR_GENE_PRODUCT", 909, 915], ["rat", "ORGANISM", 1007, 1010], ["TMEM27", "CELL", 1011, 1017], ["INS-1 832/13 cells", "CELL", 1021, 1039], ["Tmem27", "PROTEIN", 14, 20], ["Hnf", "PROTEIN", 100, 103], ["1\u03b1", "PROTEIN", 104, 106], ["human dominant-negative form", "PROTEIN", 153, 181], ["HNF-1\u03b1", "PROTEIN", 185, 191], ["P291fsinsC", "PROTEIN", 193, 203], ["HNF", "PROTEIN", 204, 207], ["aP2", "PROTEIN", 322, 325], ["TMEM27", "PROTEIN", 365, 371], ["TMEM27 protein", "PROTEIN", 424, 438], ["N-glycosylation sites", "PROTEIN", 472, 493], ["antibodies", "PROTEIN", 533, 543], ["N-terminal portion", "PROTEIN", 595, 613], ["TMEM27", "PROTEIN", 617, 623], ["anti-myc antibody", "PROTEIN", 745, 762], ["myc tag", "PROTEIN", 783, 790], ["C-terminus", "PROTEIN", 804, 814], ["TMEM27", "PROTEIN", 818, 824], ["membrane-anchored TMEM27 fragment", "PROTEIN", 891, 924], ["adenovirally encoded rat TMEM27", "PROTEIN", 986, 1017], ["INS-1 832/13 cells", "CELL_LINE", 1021, 1039], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 153, 158], ["rat", "SPECIES", 1007, 1010], ["mice", "SPECIES", 131, 135], ["human", "SPECIES", 153, 158], ["islet hypoplasia", "PROBLEM", 53, 69], ["hypoinsulinaemia", "PROBLEM", 74, 90], ["Hnf", "TEST", 100, 103], ["HNF", "TEST", 185, 188], ["P291fsinsC", "TEST", 193, 203], ["islet hypertrophia", "PROBLEM", 259, 277], ["hyperinsulinaemia", "PROBLEM", 282, 299], ["ob/ob", "TEST", 308, 313], ["db/db", "TEST", 315, 320], ["aP2", "TEST", 322, 325], ["Srebp", "TEST", 326, 331], ["KKAY", "TEST", 336, 340], ["hypothetical cleavage", "PROBLEM", 449, 470], ["glycosylation sites", "TREATMENT", 474, 493], ["the protein", "TEST", 507, 518], ["immunoblot assays", "TEST", 552, 569], ["an antibody", "TEST", 571, 582], ["the fragment", "PROBLEM", 669, 681], ["an anti-myc antibody", "TEST", 742, 762], ["the myc tag", "TEST", 779, 790], ["the membrane-anchored TMEM27 fragment", "TREATMENT", 887, 924], ["islet hypoplasia", "OBSERVATION", 53, 69], ["hyperinsulinaemia", "OBSERVATION", 282, 299], ["ob", "ANATOMY", 311, 313], ["not beta cell", "OBSERVATION_MODIFIER", 384, 397], ["fragment", "OBSERVATION", 673, 681], ["adenoviral construct", "OBSERVATION", 832, 852]]], ["Time 0 refers to time of infection.", [["infection", "DISEASE", 25, 34], ["infection", "PROBLEM", 25, 34], ["infection", "OBSERVATION", 25, 34]]], ["Multiple bands corresponding to the TMEM27 protein are detected by immunoblot with the c-myc antibody (arrows).", [["TMEM27", "GENE_OR_GENE_PRODUCT", 36, 42], ["c-myc antibody", "GENE_OR_GENE_PRODUCT", 87, 101], ["TMEM27 protein", "PROTEIN", 36, 50], ["c-myc antibody", "PROTEIN", 87, 101], ["Multiple bands", "PROBLEM", 0, 14], ["the TMEM27 protein", "TEST", 32, 50], ["immunoblot", "TEST", 67, 77], ["the c-myc antibody", "TEST", 83, 101], ["bands", "OBSERVATION", 9, 14]]], ["Beta-actin serves as a loading control.", [["Beta-actin", "CHEMICAL", 0, 10], ["Beta-actin", "CHEMICAL", 0, 10], ["Beta-actin", "SIMPLE_CHEMICAL", 0, 10], ["Beta-actin", "PROTEIN", 0, 10], ["Beta-actin serves", "TREATMENT", 0, 17], ["a loading control", "TREATMENT", 21, 38]]], ["A non-specific band (arrowhead) is sometimes detected in INS-1 832/13 extracts.", [["extracts", "ANATOMY", 70, 78], ["extracts", "ORGANISM_SUBSTANCE", 70, 78], ["A non-specific band (arrowhead)", "PROBLEM", 0, 31], ["INS", "TEST", 57, 60], ["non-specific", "OBSERVATION_MODIFIER", 2, 14], ["band", "OBSERVATION_MODIFIER", 15, 19]]], ["Molecular mass markers are shown on the left. c INS-1 832/13 cells, islets and primary proximal tubular cells were infected with the adenovirus encoding myc-tagged rat TMEM27.", [["c INS-1 832/13 cells", "ANATOMY", 46, 66], ["islets", "ANATOMY", 68, 74], ["primary proximal tubular cells", "ANATOMY", 79, 109], ["c INS-1 832/13 cells", "CELL", 46, 66], ["islets", "MULTI-TISSUE_STRUCTURE", 68, 74], ["primary proximal tubular cells", "CELL", 79, 109], ["adenovirus", "ORGANISM", 133, 143], ["rat", "ORGANISM", 164, 167], ["TMEM27", "GENE_OR_GENE_PRODUCT", 168, 174], ["c INS-1 832/13 cells", "CELL_LINE", 46, 66], ["islets", "CELL_TYPE", 68, 74], ["primary proximal tubular cells", "CELL_TYPE", 79, 109], ["myc-tagged rat TMEM27", "PROTEIN", 153, 174], ["rat", "SPECIES", 164, 167], ["rat", "SPECIES", 164, 167], ["Molecular mass markers", "PROBLEM", 0, 22], ["c INS", "TEST", 46, 51], ["islets", "TEST", 68, 74], ["primary proximal tubular cells", "PROBLEM", 79, 109], ["the adenovirus", "TREATMENT", 129, 143], ["mass", "OBSERVATION", 10, 14], ["left", "ANATOMY_MODIFIER", 40, 44], ["proximal", "ANATOMY_MODIFIER", 87, 95], ["tubular cells", "OBSERVATION", 96, 109]]], ["Total protein extracts from non-infected and infected cells were immunoblotted using the anti-c-myc antibody.", [["extracts", "ANATOMY", 14, 22], ["cells", "ANATOMY", 54, 59], ["extracts", "ORGANISM_SUBSTANCE", 14, 22], ["cells", "CELL", 54, 59], ["anti-c-myc", "GENE_OR_GENE_PRODUCT", 89, 99], ["non-infected and infected cells", "CELL_TYPE", 28, 59], ["anti-c-myc antibody", "PROTEIN", 89, 108], ["Total protein extracts", "TEST", 0, 22], ["infected cells", "PROBLEM", 45, 59], ["the anti-c-myc antibody", "TEST", 85, 108], ["non-infected", "OBSERVATION_MODIFIER", 28, 40], ["infected cells", "OBSERVATION", 45, 59]]], ["Note that a lowmolecular-mass band (<25 kDa) is visible in INS-1 832/13, islets and proximal tubular cells.", [["INS-1 832/13", "ANATOMY", 59, 71], ["islets", "ANATOMY", 73, 79], ["proximal tubular cells", "ANATOMY", 84, 106], ["INS-1 832/13", "CELL", 59, 71], ["islets", "MULTI-TISSUE_STRUCTURE", 73, 79], ["proximal tubular cells", "CELL", 84, 106], ["lowmolecular-mass band", "PROTEIN", 12, 34], ["INS-1 832/13", "CELL_LINE", 59, 71], ["proximal tubular cells", "CELL_TYPE", 84, 106], ["a lowmolecular-mass band", "PROBLEM", 10, 34], ["INS", "TEST", 59, 62], ["islets and proximal tubular cells", "PROBLEM", 73, 106], ["mass", "OBSERVATION", 25, 29], ["proximal", "ANATOMY_MODIFIER", 84, 92], ["tubular cells", "OBSERVATION", 93, 106]]], ["Lanes from untreated cells (negative controls) are included to validate specificity of the bands recognised. d Immunoblot of TMEM27 (using an antibody against the N-terminal of the protein) in supernatant fractions from primary proximal tubular and INS-1 832/13 cells not infected and infected with the adenovirus encoding rat TMEM27.", [["cells", "ANATOMY", 21, 26], ["supernatant fractions", "ANATOMY", 193, 214], ["primary proximal tubular", "ANATOMY", 220, 244], ["INS-1 832/13 cells", "ANATOMY", 249, 267], ["N", "CHEMICAL", 163, 164], ["cells", "CELL", 21, 26], ["TMEM27", "GENE_OR_GENE_PRODUCT", 125, 131], ["tubular", "CELL", 237, 244], ["INS-1 832/13 cells", "CELL", 249, 267], ["adenovirus", "ORGANISM", 303, 313], ["rat", "ORGANISM", 323, 326], ["TMEM27", "GENE_OR_GENE_PRODUCT", 327, 333], ["TMEM27", "PROTEIN", 125, 131], ["N-terminal", "PROTEIN", 163, 173], ["primary proximal tubular and INS-1 832/13 cells", "CELL_LINE", 220, 267], ["adenovirus encoding rat TMEM27", "PROTEIN", 303, 333], ["rat", "SPECIES", 323, 326], ["adenovirus", "SPECIES", 303, 313], ["rat", "SPECIES", 323, 326], ["the bands", "PROBLEM", 87, 96], ["an antibody", "TEST", 139, 150], ["supernatant fractions", "TEST", 193, 214], ["primary proximal tubular and INS", "TEST", 220, 252], ["proximal", "ANATOMY_MODIFIER", 228, 236], ["tubular", "ANATOMY", 237, 244]]], ["Lanes from infected cells (positive controls) are included to validate specificity of the recognised bands obese mice [6, 7] .", [["cells", "ANATOMY", 20, 25], ["cells", "CELL", 20, 25], ["mice", "ORGANISM", 113, 117], ["infected cells", "CELL_TYPE", 11, 25], ["mice", "SPECIES", 113, 117], ["mice", "SPECIES", 113, 117], ["infected cells", "OBSERVATION", 11, 25]]], ["Though all these data might be interpreted as indicative of the existence of a link between Tmem27 expression and beta cell dysfunction, the truth is that the role of TMEM27 in the physiology of the pancreatic beta cell is still a matter of controversy.", [["beta cell", "ANATOMY", 114, 123], ["pancreatic beta cell", "ANATOMY", 199, 219], ["Tmem27", "GENE_OR_GENE_PRODUCT", 92, 98], ["beta cell", "CELL", 114, 123], ["TMEM27", "GENE_OR_GENE_PRODUCT", 167, 173], ["pancreatic beta cell", "CELL", 199, 219], ["Tmem27", "PROTEIN", 92, 98], ["TMEM27", "PROTEIN", 167, 173], ["pancreatic beta cell", "CELL_TYPE", 199, 219], ["a link between Tmem27 expression", "PROBLEM", 77, 109], ["beta cell dysfunction", "PROBLEM", 114, 135], ["beta cell dysfunction", "OBSERVATION", 114, 135], ["pancreatic", "ANATOMY", 199, 209], ["beta cell", "OBSERVATION", 210, 219]]], ["One study points towards its implication in insulin secretion as a component of the SNARE complex [7] , while another indicates that it is mainly involved in beta cell replication [6] .", [["beta cell", "ANATOMY", 158, 167], ["insulin", "GENE_OR_GENE_PRODUCT", 44, 51], ["SNARE", "GENE_OR_GENE_PRODUCT", 84, 89], ["beta cell", "CELL", 158, 167], ["SNARE complex", "PROTEIN", 84, 97], ["One study", "TEST", 0, 9], ["insulin secretion", "TREATMENT", 44, 61], ["beta cell replication", "TREATMENT", 158, 179]]], ["Furthermore, another recent study reports that Tmem27knockout mice do not display any prominent pancreatic phenotype [8] .DiscussionTo shed some light on the relative contribution of TMEM27 to the regulation of insulin secretion and proliferation in beta cells, we investigated the correlations between TMEM27 expression and genes implicated in insulin secretion and proliferation in human pancreatic islets.", [["pancreatic", "ANATOMY", 96, 106], ["beta cells", "ANATOMY", 250, 260], ["pancreatic islets", "ANATOMY", 390, 407], ["Tmem27knockout mice", "ORGANISM", 47, 66], ["pancreatic", "CANCER", 96, 106], ["TMEM27", "GENE_OR_GENE_PRODUCT", 183, 189], ["insulin", "GENE_OR_GENE_PRODUCT", 211, 218], ["beta cells", "CELL", 250, 260], ["TMEM27", "GENE_OR_GENE_PRODUCT", 303, 309], ["insulin", "GENE_OR_GENE_PRODUCT", 345, 352], ["human", "ORGANISM", 384, 389], ["pancreatic islets", "MULTI-TISSUE_STRUCTURE", 390, 407], ["TMEM27", "PROTEIN", 183, 189], ["beta cells", "CELL_TYPE", 250, 260], ["TMEM27", "PROTEIN", 303, 309], ["human pancreatic islets", "CELL_TYPE", 384, 407], ["mice", "SPECIES", 62, 66], ["human", "SPECIES", 384, 389], ["mice", "SPECIES", 62, 66], ["human", "SPECIES", 384, 389], ["another recent study", "TEST", 13, 33], ["any prominent pancreatic phenotype", "PROBLEM", 82, 116], ["insulin secretion", "PROBLEM", 211, 228], ["proliferation in beta cells", "PROBLEM", 233, 260], ["insulin secretion", "PROBLEM", 345, 362], ["proliferation in human pancreatic islets", "PROBLEM", 367, 407], ["prominent", "OBSERVATION_MODIFIER", 86, 95], ["pancreatic", "ANATOMY", 96, 106], ["insulin secretion", "OBSERVATION", 345, 362], ["pancreatic islets", "ANATOMY", 390, 407]]], ["In fact, we found a significant and positive correlation with insulin and SNAPIN but not with cyclins (E1 and D1), CDK2 or CDK6, which suggests that TMEM27 expression is more directly correlated to changes in insulin secretion than to beta cell proliferation.", [["beta cell", "ANATOMY", 235, 244], ["insulin", "GENE_OR_GENE_PRODUCT", 62, 69], ["SNAPIN", "GENE_OR_GENE_PRODUCT", 74, 80], ["cyclins", "GENE_OR_GENE_PRODUCT", 94, 101], ["E1", "GENE_OR_GENE_PRODUCT", 103, 105], ["D1", "GENE_OR_GENE_PRODUCT", 110, 112], ["CDK2", "GENE_OR_GENE_PRODUCT", 115, 119], ["CDK6", "GENE_OR_GENE_PRODUCT", 123, 127], ["TMEM27", "GENE_OR_GENE_PRODUCT", 149, 155], ["insulin", "GENE_OR_GENE_PRODUCT", 209, 216], ["beta cell", "CELL", 235, 244], ["insulin", "PROTEIN", 62, 69], ["SNAPIN", "PROTEIN", 74, 80], ["cyclins", "PROTEIN", 94, 101], ["E1", "PROTEIN", 103, 105], ["D1", "PROTEIN", 110, 112], ["CDK2", "PROTEIN", 115, 119], ["CDK6", "PROTEIN", 123, 127], ["TMEM27", "PROTEIN", 149, 155], ["insulin", "TREATMENT", 62, 69], ["SNAPIN", "TREATMENT", 74, 80], ["cyclins (E1 and D1", "TREATMENT", 94, 112], ["CDK2", "PROBLEM", 115, 119], ["CDK6", "PROBLEM", 123, 127], ["changes in insulin secretion", "PROBLEM", 198, 226], ["beta cell proliferation", "PROBLEM", 235, 258], ["significant", "OBSERVATION_MODIFIER", 20, 31], ["positive", "OBSERVATION", 36, 44], ["cell proliferation", "OBSERVATION", 240, 258]]], ["While interpretation of these data has obvious limitations, as these studies are restricted to the key regulators of the cell cycle [28] and we cannot rule out the existence of correlations at the level of protein expression, we reached a similar conclusion when we used an experimental rat model based on tungstate treatment [10, 25] .", [["cell", "ANATOMY", 121, 125], ["tungstate", "CHEMICAL", 306, 315], ["tungstate", "CHEMICAL", 306, 315], ["cell", "CELL", 121, 125], ["rat", "ORGANISM", 287, 290], ["tungstate", "SIMPLE_CHEMICAL", 306, 315], ["rat", "SPECIES", 287, 290], ["rat", "SPECIES", 287, 290], ["these data", "TEST", 24, 34], ["these studies", "TEST", 63, 76], ["the cell cycle", "TEST", 117, 131], ["an experimental rat model", "TREATMENT", 271, 296], ["tungstate treatment", "TREATMENT", 306, 325]]], ["This model offers us the possibility to assess Tmem27 expression in a scenario of increased beta cell proliferation and diminished insulin secretion, which is substantially different from the models mentioned above, in which both secretory and proliferative activities were affected in a similar manner.", [["beta cell", "ANATOMY", 92, 101], ["Tmem27", "GENE_OR_GENE_PRODUCT", 47, 53], ["beta cell", "CELL", 92, 101], ["insulin", "GENE_OR_GENE_PRODUCT", 131, 138], ["Tmem27", "PROTEIN", 47, 53], ["beta cell", "CELL_TYPE", 92, 101], ["increased beta cell proliferation", "PROBLEM", 82, 115], ["diminished insulin secretion", "PROBLEM", 120, 148], ["increased", "OBSERVATION_MODIFIER", 82, 91], ["beta cell proliferation", "OBSERVATION", 92, 115], ["diminished", "OBSERVATION_MODIFIER", 120, 130], ["insulin secretion", "OBSERVATION", 131, 148], ["substantially", "OBSERVATION_MODIFIER", 159, 172], ["different", "OBSERVATION_MODIFIER", 173, 182], ["proliferative activities", "OBSERVATION", 244, 268]]], ["In tungstatetreated rats, we found downregulation of islet Tmem27 expression.", [["islet", "ANATOMY", 53, 58], ["rats", "ORGANISM", 20, 24], ["islet", "MULTI-TISSUE_STRUCTURE", 53, 58], ["Tmem27", "GENE_OR_GENE_PRODUCT", 59, 65], ["Tmem27", "PROTEIN", 59, 65], ["rats", "SPECIES", 20, 24]]], ["Thus, altogether, our expression data in humans and rats favour a role of TMEM27 in insulin secretion rather than cell proliferation.DiscussionAs the above expression data cannot provide a clear-cut answer regarding the biological function of TMEM27 in beta cells, we undertook an in vitro gain-of-function approach and adenovirally expressed TMEM27/Tmem27 in INS-1 cells.", [["cell", "ANATOMY", 114, 118], ["beta cells", "ANATOMY", 253, 263], ["INS-1 cells", "ANATOMY", 360, 371], ["humans", "ORGANISM", 41, 47], ["rats", "ORGANISM", 52, 56], ["TMEM27", "GENE_OR_GENE_PRODUCT", 74, 80], ["insulin", "GENE_OR_GENE_PRODUCT", 84, 91], ["cell", "CELL", 114, 118], ["TMEM27", "GENE_OR_GENE_PRODUCT", 243, 249], ["beta cells", "CELL", 253, 263], ["TMEM27", "GENE_OR_GENE_PRODUCT", 343, 349], ["Tmem27", "GENE_OR_GENE_PRODUCT", 350, 356], ["INS-1 cells", "CELL", 360, 371], ["TMEM27", "PROTEIN", 74, 80], ["TMEM27", "PROTEIN", 243, 249], ["beta cells", "CELL_TYPE", 253, 263], ["TMEM27", "PROTEIN", 343, 349], ["Tmem27", "PROTEIN", 350, 356], ["INS-1 cells", "CELL_LINE", 360, 371], ["humans", "SPECIES", 41, 47], ["rats", "SPECIES", 52, 56], ["humans", "SPECIES", 41, 47], ["insulin secretion", "PROBLEM", 84, 101], ["adenovirally", "TEST", 320, 332], ["cell proliferation", "OBSERVATION", 114, 132]]], ["Because previous studies overexpressing either mouse Tmem27 [6] or human TMEM27 [7] in insulinoma cells and transgenic mice had reached different conclusions, we wondered whether different TMEM27 isoforms were responsible for the discrepancies.", [["insulinoma cells", "ANATOMY", 87, 103], ["mouse", "ORGANISM", 47, 52], ["Tmem27 [6]", "GENE_OR_GENE_PRODUCT", 53, 63], ["human", "ORGANISM", 67, 72], ["TMEM27 [7", "GENE_OR_GENE_PRODUCT", 73, 82], ["insulinoma cells", "CELL", 87, 103], ["transgenic mice", "ORGANISM", 108, 123], ["TMEM27", "GENE_OR_GENE_PRODUCT", 189, 195], ["human TMEM27", "PROTEIN", 67, 79], ["insulinoma cells", "CELL_TYPE", 87, 103], ["TMEM27 isoforms", "PROTEIN", 189, 204], ["mouse", "SPECIES", 47, 52], ["human", "SPECIES", 67, 72], ["mice", "SPECIES", 119, 123], ["mouse", "SPECIES", 47, 52], ["human", "SPECIES", 67, 72], ["mice", "SPECIES", 119, 123], ["previous studies", "TEST", 8, 24], ["human TMEM27", "TEST", 67, 79], ["insulinoma cells", "PROBLEM", 87, 103], ["the discrepancies", "PROBLEM", 226, 243]]], ["In fact, our preliminary observation that rat, mouse and human TMEM27 proteins showed different band patterns in immunoblot analysis, not only in protein extracts from isolated islets but also when overproduced in INS-1 cells, provided support for the hypothesis that inter-specific variations in the posttranslational modifications and/or processing of TMEM27 proteins might account for the reported differences in function.", [["extracts", "ANATOMY", 154, 162], ["islets", "ANATOMY", 177, 183], ["INS-1 cells", "ANATOMY", 214, 225], ["rat", "ORGANISM", 42, 45], ["mouse", "ORGANISM", 47, 52], ["human", "ORGANISM", 57, 62], ["TMEM27", "GENE_OR_GENE_PRODUCT", 63, 69], ["extracts", "ORGANISM_SUBSTANCE", 154, 162], ["islets", "MULTI-TISSUE_STRUCTURE", 177, 183], ["INS-1 cells", "CELL", 214, 225], ["TMEM27", "GENE_OR_GENE_PRODUCT", 354, 360], ["rat, mouse and human TMEM27 proteins", "PROTEIN", 42, 78], ["INS-1 cells", "CELL_LINE", 214, 225], ["TMEM27 proteins", "PROTEIN", 354, 369], ["rat", "SPECIES", 42, 45], ["mouse", "SPECIES", 47, 52], ["human", "SPECIES", 57, 62], ["rat", "SPECIES", 42, 45], ["mouse", "SPECIES", 47, 52], ["human", "SPECIES", 57, 62], ["human TMEM27 proteins", "TEST", 57, 78], ["different band patterns", "PROBLEM", 86, 109], ["immunoblot analysis", "TEST", 113, 132], ["isolated islets", "PROBLEM", 168, 183], ["support", "TREATMENT", 236, 243], ["the hypothesis", "PROBLEM", 248, 262], ["inter-specific variations in the posttranslational modifications", "PROBLEM", 268, 332], ["TMEM27 proteins", "PROBLEM", 354, 369], ["islets", "OBSERVATION", 177, 183], ["posttranslational modifications", "OBSERVATION", 301, 332]]], ["Nevertheless, our data show strikingly similar results when these three isoforms are overexpressed in INS-1 cells: a significant enhancement in glucose-induced insulin secretion with a very modest increase in proliferation, which was not reflected in measurable increases in cell number.", [["INS-1 cells", "ANATOMY", 102, 113], ["cell", "ANATOMY", 275, 279], ["glucose", "CHEMICAL", 144, 151], ["glucose", "CHEMICAL", 144, 151], ["INS-1 cells", "CELL", 102, 113], ["glucose", "SIMPLE_CHEMICAL", 144, 151], ["insulin", "GENE_OR_GENE_PRODUCT", 160, 167], ["cell", "CELL", 275, 279], ["INS-1 cells", "CELL_LINE", 102, 113], ["our data", "TEST", 14, 22], ["a significant enhancement in glucose-induced insulin secretion", "PROBLEM", 115, 177], ["significant", "OBSERVATION_MODIFIER", 117, 128], ["enhancement", "OBSERVATION", 129, 140], ["insulin secretion", "OBSERVATION", 160, 177], ["very", "OBSERVATION_MODIFIER", 185, 189], ["modest", "OBSERVATION_MODIFIER", 190, 196], ["increase", "OBSERVATION_MODIFIER", 197, 205], ["proliferation", "OBSERVATION", 209, 222], ["measurable", "OBSERVATION_MODIFIER", 251, 261], ["increases", "OBSERVATION_MODIFIER", 262, 271], ["cell number", "OBSERVATION", 275, 286]]], ["Likewise, overproduction of the rat isoform in isolated rat islets resulted in modifications in insulin secretion but not in proliferation rates.DiscussionIn summary, the expression data and our gain-offunction studies point to a role for TMEM27 in insulin secretion, but little if any contribution to beta cell proliferation.DiscussionTMEM27 as a beta cell mass biomarker Currently there are no reliable methods for measuring beta cell mass in living humans.", [["islets", "ANATOMY", 60, 66], ["beta cell", "ANATOMY", 302, 311], ["beta cell", "ANATOMY", 348, 357], ["beta cell", "ANATOMY", 427, 436], ["rat", "ORGANISM", 32, 35], ["rat", "ORGANISM", 56, 59], ["islets", "MULTI-TISSUE_STRUCTURE", 60, 66], ["insulin", "GENE_OR_GENE_PRODUCT", 96, 103], ["TMEM27", "GENE_OR_GENE_PRODUCT", 239, 245], ["insulin", "GENE_OR_GENE_PRODUCT", 249, 256], ["beta cell", "CELL", 302, 311], ["beta cell", "CELL", 348, 357], ["beta cell", "CELL", 427, 436], ["humans", "ORGANISM", 452, 458], ["rat isoform", "PROTEIN", 32, 43], ["isolated rat islets", "CELL_TYPE", 47, 66], ["TMEM27", "PROTEIN", 239, 245], ["rat", "SPECIES", 32, 35], ["rat", "SPECIES", 56, 59], ["humans", "SPECIES", 452, 458], ["rat", "SPECIES", 56, 59], ["humans", "SPECIES", 452, 458], ["isolated rat islets", "TREATMENT", 47, 66], ["modifications in insulin secretion", "PROBLEM", 79, 113], ["TMEM27 in insulin secretion", "TREATMENT", 239, 266], ["beta cell proliferation", "PROBLEM", 302, 325], ["a beta cell mass biomarker", "TEST", 346, 372], ["measuring beta cell mass", "PROBLEM", 417, 441], ["insulin secretion", "OBSERVATION", 96, 113], ["beta cell proliferation", "OBSERVATION", 302, 325], ["no", "UNCERTAINTY", 393, 395], ["beta cell", "OBSERVATION_MODIFIER", 427, 436], ["mass", "OBSERVATION", 437, 441]]], ["For this reason, most studies are performed in cadaver donors, as the risks of pancreas biopsies outweigh the benefits of research.", [["pancreas", "ANATOMY", 79, 87], ["cadaver", "ORGANISM", 47, 54], ["donors", "ORGANISM", 55, 61], ["pancreas biopsies", "MULTI-TISSUE_STRUCTURE", 79, 96], ["most studies", "TEST", 17, 29], ["pancreas biopsies", "TREATMENT", 79, 96], ["pancreas", "ANATOMY", 79, 87]]], ["However, the monitoring of beta cell mass in association with insulin secretion could be extremely useful for describing and predicting the dynamics of beta cell loss and, very importantly, may improve the early diagnosis and treatment of diabetes mellitus [29, 30] .", [["beta cell", "ANATOMY", 27, 36], ["beta cell", "ANATOMY", 152, 161], ["diabetes mellitus", "DISEASE", 239, 256], ["beta cell", "CELL", 27, 36], ["insulin", "GENE_OR_GENE_PRODUCT", 62, 69], ["beta cell", "CELL", 152, 161], ["beta cell mass", "PROBLEM", 27, 41], ["insulin secretion", "PROBLEM", 62, 79], ["beta cell loss", "PROBLEM", 152, 166], ["diabetes mellitus", "PROBLEM", 239, 256], ["beta cell mass", "OBSERVATION", 27, 41], ["beta cell loss", "OBSERVATION", 152, 166]]], ["TMEM27 was reported to be cleaved and shed (in a constitutive way) into the extracellular compartment only by pancreatic beta cells.", [["extracellular compartment", "ANATOMY", 76, 101], ["pancreatic beta cells", "ANATOMY", 110, 131], ["TMEM27", "CHEMICAL", 0, 6], ["TMEM27", "GENE_OR_GENE_PRODUCT", 0, 6], ["extracellular compartment", "CELLULAR_COMPONENT", 76, 101], ["pancreatic beta cells", "CELL", 110, 131], ["TMEM27", "PROTEIN", 0, 6], ["pancreatic beta cells", "CELL_TYPE", 110, 131], ["extracellular compartment", "ANATOMY", 76, 101], ["pancreatic", "ANATOMY", 110, 120], ["beta cells", "OBSERVATION", 121, 131]]], ["Because of this reported beta cell specificity, Akpinar et al. [6] proposed that the quantification of this protein in serum might be used as an indirect measure of beta cell mass, and thus it would have a role as a beta cell biomarker.DiscussionWhile our study confirms that TMEM27 is cleaved and secreted into the extracellular space by beta cells, it also shows that this ability is shared by primary kidney proximal tubular cells in which TMEM27 was identified and its role in amino acid transport demonstrated [5] .", [["beta cell", "ANATOMY", 25, 34], ["serum", "ANATOMY", 119, 124], ["beta cell", "ANATOMY", 165, 174], ["beta cell", "ANATOMY", 216, 225], ["extracellular space", "ANATOMY", 316, 335], ["beta cells", "ANATOMY", 339, 349], ["kidney proximal tubular cells", "ANATOMY", 404, 433], ["amino acid", "CHEMICAL", 481, 491], ["amino acid", "CHEMICAL", 481, 491], ["beta cell", "CELL", 25, 34], ["serum", "ORGANISM_SUBSTANCE", 119, 124], ["beta cell", "CELL", 165, 174], ["beta cell", "CELL", 216, 225], ["TMEM27", "GENE_OR_GENE_PRODUCT", 276, 282], ["extracellular space", "CELLULAR_COMPONENT", 316, 335], ["beta cells", "CELL", 339, 349], ["kidney proximal tubular cells", "CELL", 404, 433], ["TMEM27", "GENE_OR_GENE_PRODUCT", 443, 449], ["amino acid", "AMINO_ACID", 481, 491], ["TMEM27", "PROTEIN", 276, 282], ["beta cells", "CELL_TYPE", 339, 349], ["primary kidney proximal tubular cells", "CELL_TYPE", 396, 433], ["TMEM27", "PROTEIN", 443, 449], ["this protein in serum", "PROBLEM", 103, 124], ["beta cell mass", "PROBLEM", 165, 179], ["a beta cell biomarker", "TEST", 214, 235], ["our study", "TEST", 252, 261], ["primary kidney proximal tubular cells", "PROBLEM", 396, 433], ["amino acid transport", "TEST", 481, 501], ["beta cell mass", "OBSERVATION", 165, 179], ["beta cells", "OBSERVATION", 339, 349], ["kidney", "ANATOMY", 404, 410], ["proximal", "ANATOMY_MODIFIER", 411, 419], ["tubular cells", "OBSERVATION", 420, 433]]], ["A possible explanation for this inconsistency might be the use of primary cultures in our study, whereas Akpinar et al. [6] used immortalised cell lines.", [["primary cultures", "ANATOMY", 66, 82], ["cell lines", "ANATOMY", 142, 152], ["immortalised cell lines", "CELL", 129, 152], ["primary cultures", "CELL_LINE", 66, 82], ["immortalised cell lines", "CELL_LINE", 129, 152], ["this inconsistency", "PROBLEM", 27, 45], ["primary cultures", "TEST", 66, 82], ["our study", "TEST", 86, 95], ["immortalised cell lines", "TREATMENT", 129, 152], ["possible explanation for", "UNCERTAINTY", 2, 26], ["immortalised cell lines", "OBSERVATION", 129, 152]]], ["Our data suggest that circulating TMEM27 in serum can have at least two different origins: pancreatic beta cells and kidney proximal tubular cells.DiscussionWe therefore conclude that the extracellular fraction of TMEM27 cannot be reliably used as a beta cell mass biomarker. also thank P. L. Fern\u00e1ndez from the Department of Anatomical Pathology (IDIBAPS/Hospital Clinic/University of Barcelona, Barcelona, Spain), Banco de Tumores del Biobanco (Hospital Cl\u00ednic/ IDIBAPS, Barcelona, Spain), Xarxa de Bancs de Tumors de Catalunya (Barcelona, Spain) and M. Vives from the laboratory of Immunobiology for Research and Applications to Diagnosis (Research Institute Germans Trias I Pujol, Badalona, Spain) for supplying pancreatic samples.", [["serum", "ANATOMY", 44, 49], ["pancreatic beta cells", "ANATOMY", 91, 112], ["kidney proximal tubular cells", "ANATOMY", 117, 146], ["extracellular", "ANATOMY", 188, 201], ["beta cell", "ANATOMY", 250, 259], ["pancreatic samples", "ANATOMY", 716, 734], ["TMEM27", "GENE_OR_GENE_PRODUCT", 34, 40], ["serum", "ORGANISM_SUBSTANCE", 44, 49], ["pancreatic beta cells", "CELL", 91, 112], ["kidney proximal tubular cells", "CELL", 117, 146], ["extracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 188, 201], ["TMEM27", "GENE_OR_GENE_PRODUCT", 214, 220], ["beta cell", "CELL", 250, 259], ["pancreatic samples", "CANCER", 716, 734], ["TMEM27", "PROTEIN", 34, 40], ["pancreatic beta cells", "CELL_TYPE", 91, 112], ["kidney proximal tubular cells", "CELL_TYPE", 117, 146], ["TMEM27", "PROTEIN", 214, 220], ["Our data", "TEST", 0, 8], ["circulating TMEM27 in serum", "TEST", 22, 49], ["pancreatic beta cells and kidney proximal tubular cells", "PROBLEM", 91, 146], ["the extracellular fraction", "TEST", 184, 210], ["a beta cell mass biomarker", "TEST", 248, 274], ["pancreatic", "ANATOMY", 91, 101], ["beta cells", "OBSERVATION", 102, 112], ["kidney", "ANATOMY", 117, 123], ["proximal", "ANATOMY_MODIFIER", 124, 132], ["tubular cells", "OBSERVATION", 133, 146], ["pancreatic", "ANATOMY", 716, 726]]]], "PMC7119700": [["IntroductionThe human respiratory syncytial virus (HRSV) is a negative-sense genome single-stranded RNA virus that belongs to the Paramyxoviridae family and to the Pneumovirinae subfamily (Collins et al., 2001).", [["respiratory syncytial virus", "DISEASE", 22, 49], ["human respiratory syncytial virus", "ORGANISM", 16, 49], ["HRSV", "ORGANISM", 51, 55], ["Paramyxoviridae", "GENE_OR_GENE_PRODUCT", 130, 145], ["Pneumovirinae", "GENE_OR_GENE_PRODUCT", 164, 177], ["Paramyxoviridae family", "PROTEIN", 130, 152], ["Pneumovirinae subfamily", "PROTEIN", 164, 187], ["human", "SPECIES", 16, 21], ["respiratory syncytial virus", "SPECIES", 22, 49], ["human respiratory syncytial virus", "SPECIES", 16, 49], ["HRSV", "SPECIES", 51, 55], ["The human respiratory syncytial virus", "PROBLEM", 12, 49], ["sense genome single-stranded RNA virus", "PROBLEM", 71, 109], ["respiratory syncytial", "ANATOMY", 22, 43]]], ["HRSV is considered the major pathogen causing respiratory disease in infants and neonates worldwide, which may result in serious complications such as pneumonia and bronchiolitis (Holberg et al., 1991).", [["respiratory", "ANATOMY", 46, 57], ["respiratory disease", "DISEASE", 46, 65], ["pneumonia", "DISEASE", 151, 160], ["bronchiolitis", "DISEASE", 165, 178], ["HRSV", "ORGANISM", 0, 4], ["infants", "ORGANISM", 69, 76], ["infants", "SPECIES", 69, 76], ["HRSV", "SPECIES", 0, 4], ["HRSV", "PROBLEM", 0, 4], ["the major pathogen", "PROBLEM", 19, 37], ["respiratory disease in infants", "PROBLEM", 46, 76], ["serious complications", "PROBLEM", 121, 142], ["pneumonia", "PROBLEM", 151, 160], ["bronchiolitis", "PROBLEM", 165, 178], ["respiratory disease", "OBSERVATION", 46, 65], ["serious", "OBSERVATION_MODIFIER", 121, 128], ["pneumonia", "OBSERVATION", 151, 160], ["bronchiolitis", "OBSERVATION", 165, 178]]], ["This virus is responsible for 38% of the lower respiratory tract infections in infants up to 1 year of age.", [["lower respiratory tract", "ANATOMY", 41, 64], ["respiratory tract infections", "DISEASE", 47, 75], ["lower", "ORGANISM_SUBDIVISION", 41, 46], ["respiratory tract", "ORGANISM_SUBDIVISION", 47, 64], ["infants", "ORGANISM", 79, 86], ["infants", "SPECIES", 79, 86], ["This virus", "PROBLEM", 0, 10], ["the lower respiratory tract infections", "PROBLEM", 37, 75], ["lower", "ANATOMY_MODIFIER", 41, 46], ["respiratory tract", "ANATOMY", 47, 64], ["infections", "OBSERVATION", 65, 75]]], ["Half of these infants have re-infections after 1 year (Schmidt et al., 2004).", [["re-infections", "DISEASE", 27, 40], ["infants", "ORGANISM", 14, 21], ["infants", "SPECIES", 14, 21]]], ["HRSV is also a significant cause of respiratory disease in the elderly (Han et al., 1999), immune-compromised patients, such as bone marrow transplant patients (Hall et al., 1986), and is related to the development of asthma in childhood (Lemanske, 2004).IntroductionHRSV virion is enveloped and carries a genome of about 15,000 nucleotides that encodes 11 proteins (Collins et al., 2001).", [["respiratory", "ANATOMY", 36, 47], ["bone marrow", "ANATOMY", 128, 139], ["respiratory disease", "DISEASE", 36, 55], ["immune-compromised", "DISEASE", 91, 109], ["asthma", "DISEASE", 218, 224], ["nucleotides", "CHEMICAL", 329, 340], ["HRSV", "ORGANISM", 0, 4], ["patients", "ORGANISM", 110, 118], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 128, 139], ["patients", "ORGANISM", 151, 159], ["patients", "SPECIES", 110, 118], ["patients", "SPECIES", 151, 159], ["HRSV", "SPECIES", 0, 4], ["HRSV", "PROBLEM", 0, 4], ["respiratory disease", "PROBLEM", 36, 55], ["immune-compromised patients", "PROBLEM", 91, 118], ["bone marrow transplant", "TREATMENT", 128, 150], ["asthma", "PROBLEM", 218, 224], ["IntroductionHRSV virion", "TREATMENT", 255, 278], ["significant", "OBSERVATION_MODIFIER", 15, 26], ["respiratory disease", "OBSERVATION", 36, 55], ["bone", "ANATOMY", 128, 132], ["asthma", "OBSERVATION", 218, 224]]], ["The nucleoprotein or N protein associates with the viral RNA, forming a helical structure and guaranteeing resistance to RNases (Meric et al., 1994).", [["nucleoprotein or N protein", "PROTEIN", 4, 30], ["viral RNA", "RNA", 51, 60], ["RNases", "PROTEIN", 121, 127], ["the viral RNA", "PROBLEM", 47, 60], ["viral RNA", "OBSERVATION", 51, 60]]], ["The phosphoprotein or P protein has two known functions: it interacts with the N protein, giving specificity for viral RNA encapsidation (Curran et al., 1995, Spehner et al., 1997); and interacts with the L protein (the major unit of the virus replication complex), conferring stability and the correct placement in the ribonucleo-complex for RNA synthesis (Bowman et al., 1999, Horikami et al., 1992).", [["phosphoprotein or P protein", "PROTEIN", 4, 31], ["N protein", "PROTEIN", 79, 88], ["L protein", "PROTEIN", 205, 214], ["virus replication complex", "PROTEIN", 238, 263], ["ribonucleo-complex", "PROTEIN", 320, 338], ["The phosphoprotein or P protein", "TREATMENT", 0, 31], ["the N protein", "TREATMENT", 75, 88], ["viral RNA encapsidation", "PROBLEM", 113, 136], ["the L protein", "TREATMENT", 201, 214], ["the virus replication complex", "TREATMENT", 234, 263], ["the correct placement", "TREATMENT", 291, 312]]], ["The genome encodes also three transmembrane surface proteins (F, G, SH), a matrix protein (M), a nucleocapsid-associated protein (M2-1), an M2-2 protein (the second product of the M2 gene) and two nonstructural proteins (NS1, NS2) (Collins et al., 2001).IntroductionThe most effective treatment against HRSV is a humanized anti-F monoclonal antibody that inhibits viral attachment to the cell surface.", [["transmembrane surface", "ANATOMY", 30, 51], ["cell surface", "ANATOMY", 388, 400], ["F, G", "GENE_OR_GENE_PRODUCT", 62, 66], ["matrix", "CELLULAR_COMPONENT", 75, 81], ["M2-1", "GENE_OR_GENE_PRODUCT", 130, 134], ["M2-2", "GENE_OR_GENE_PRODUCT", 140, 144], ["M2", "GENE_OR_GENE_PRODUCT", 180, 182], ["NS1", "GENE_OR_GENE_PRODUCT", 221, 224], ["HRSV", "ORGANISM", 303, 307], ["anti-F", "GENE_OR_GENE_PRODUCT", 323, 329], ["cell surface", "CELLULAR_COMPONENT", 388, 400], ["transmembrane surface proteins", "PROTEIN", 30, 60], ["F", "PROTEIN", 62, 63], ["G", "PROTEIN", 65, 66], ["SH", "PROTEIN", 68, 70], ["matrix protein", "PROTEIN", 75, 89], ["M", "PROTEIN", 91, 92], ["nucleocapsid-associated protein", "PROTEIN", 97, 128], ["M2", "PROTEIN", 130, 132], ["1", "PROTEIN", 133, 134], ["M2-2 protein", "PROTEIN", 140, 152], ["M2 gene", "DNA", 180, 187], ["nonstructural proteins", "PROTEIN", 197, 219], ["NS1", "PROTEIN", 221, 224], ["NS2", "PROTEIN", 226, 229], ["humanized anti-F monoclonal antibody", "PROTEIN", 313, 349], ["HRSV", "SPECIES", 303, 307], ["three transmembrane surface proteins", "TEST", 24, 60], ["a matrix protein", "TEST", 73, 89], ["a nucleocapsid", "TEST", 95, 109], ["protein", "TEST", 121, 128], ["M2", "TEST", 130, 132], ["an M2", "TEST", 137, 142], ["two nonstructural proteins", "TEST", 193, 219], ["The most effective treatment", "TREATMENT", 266, 294], ["HRSV", "PROBLEM", 303, 307], ["a humanized anti-F monoclonal antibody", "TREATMENT", 311, 349], ["viral attachment", "PROBLEM", 364, 380], ["most effective", "OBSERVATION_MODIFIER", 270, 284], ["cell surface", "OBSERVATION", 388, 400]]], ["Its administration is a recommended preventative measure for high risk groups such as premature neonates, although large-scale usage is very limited due to a poor cost-effectiveness ratio (Joffe et al., 1999).", [["high risk groups", "PROBLEM", 61, 77], ["premature neonates", "PROBLEM", 86, 104]]], ["A formalin-inactivated vaccine was tested in humans, but no protection resulted and a vaccine-enhanced disease was observed (Kim et al., 1969, Fulginiti et al., 1969).IntroductionPromising results were obtained using DNA vaccines against the bovine respiratory syncytial virus (BRSV) F protein in calves (Taylor et al., 2005); and against HRSV F and N proteins in chimpanzees (Vaughan et al., 2005).", [["formalin", "CHEMICAL", 2, 10], ["respiratory syncytial virus", "DISEASE", 249, 276], ["formalin", "CHEMICAL", 2, 10], ["formalin", "SIMPLE_CHEMICAL", 2, 10], ["humans", "ORGANISM", 45, 51], ["DNA", "CELLULAR_COMPONENT", 217, 220], ["bovine", "ORGANISM", 242, 248], ["respiratory syncytial virus", "ORGANISM", 249, 276], ["BRSV", "ORGANISM", 278, 282], ["calves", "ORGANISM", 297, 303], ["HRSV F", "GENE_OR_GENE_PRODUCT", 339, 345], ["chimpanzees", "ORGANISM", 364, 375], ["bovine respiratory syncytial virus (BRSV) F protein", "PROTEIN", 242, 293], ["HRSV F and N proteins", "PROTEIN", 339, 360], ["humans", "SPECIES", 45, 51], ["bovine", "SPECIES", 242, 248], ["respiratory syncytial virus", "SPECIES", 249, 276], ["BRSV", "SPECIES", 278, 282], ["calves", "SPECIES", 297, 303], ["humans", "SPECIES", 45, 51], ["bovine respiratory syncytial virus", "SPECIES", 242, 276], ["BRSV", "SPECIES", 278, 282], ["HRSV", "SPECIES", 339, 343], ["A formalin-inactivated vaccine", "TREATMENT", 0, 30], ["a vaccine-enhanced disease", "PROBLEM", 84, 110], ["DNA vaccines", "TREATMENT", 217, 229], ["the bovine respiratory syncytial virus", "PROBLEM", 238, 276], ["respiratory syncytial", "ANATOMY", 249, 270]]], ["However, a recent study showed that the RNA polymerase II dependent expression of HRSV F protein can only be achieved at high levels with the optimization of the gene, which involves the elimination of premature polyadenylation sites (Ternette et al., 2007a).", [["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 40, 57], ["HRSV F", "GENE_OR_GENE_PRODUCT", 82, 88], ["RNA polymerase II", "PROTEIN", 40, 57], ["HRSV F protein", "PROTEIN", 82, 96], ["premature polyadenylation sites", "DNA", 202, 233], ["HRSV", "SPECIES", 82, 86], ["a recent study", "TEST", 9, 23], ["the RNA polymerase II dependent expression of HRSV F protein", "PROBLEM", 36, 96], ["premature polyadenylation sites", "PROBLEM", 202, 233], ["premature", "OBSERVATION_MODIFIER", 202, 211], ["polyadenylation sites", "OBSERVATION", 212, 233]]], ["In a further study, the same group used the optimized F gene to test a DNA vaccine in mice, showing induction of antibodies and protection against HRSV (Ternette et al., 2007b).", [["DNA", "CELLULAR_COMPONENT", 71, 74], ["mice", "ORGANISM", 86, 90], ["HRSV", "ORGANISM", 147, 151], ["F gene", "DNA", 54, 60], ["antibodies", "PROTEIN", 113, 123], ["mice", "SPECIES", 86, 90], ["mice", "SPECIES", 86, 90], ["HRSV", "SPECIES", 147, 151], ["a further study", "TEST", 3, 18], ["a DNA vaccine", "TREATMENT", 69, 82], ["induction of antibodies", "TREATMENT", 100, 123], ["protection", "TREATMENT", 128, 138], ["HRSV", "PROBLEM", 147, 151]]], ["In another recent study, DNA vaccines containing the optimized BRSV N or F genes were used to induce robust cell-mediated immunity and protection of calves against the BRSV challenge (Boxus et al., 2007).IntroductionIn the present study, HRSV (strain A2) optimized N and P genes were synthesized and cloned in a mammalian expression plasmid under the control of a cytomegalovirus immediate early (CMVie) promoter, transcribed by RNA polymerase II.", [["cell", "ANATOMY", 108, 112], ["plasmid", "ANATOMY", 333, 340], ["DNA", "CELLULAR_COMPONENT", 25, 28], ["BRSV", "ORGANISM", 63, 67], ["F", "GENE_OR_GENE_PRODUCT", 73, 74], ["cell", "CELL", 108, 112], ["calves", "ORGANISM", 149, 155], ["BRSV", "ORGANISM", 168, 172], ["HRSV", "ORGANISM", 238, 242], ["cytomegalovirus", "ORGANISM", 364, 379], ["CMVie", "GENE_OR_GENE_PRODUCT", 397, 402], ["RNA polymerase II", "GENE_OR_GENE_PRODUCT", 429, 446], ["BRSV N or F genes", "DNA", 63, 80], ["N and P genes", "DNA", 265, 278], ["mammalian expression plasmid", "DNA", 312, 340], ["cytomegalovirus immediate early (CMVie) promoter", "DNA", 364, 412], ["RNA polymerase II", "PROTEIN", 429, 446], ["calves", "SPECIES", 149, 155], ["BRSV", "SPECIES", 168, 172], ["BRSV", "SPECIES", 63, 67], ["calves", "SPECIES", 149, 155], ["BRSV", "SPECIES", 168, 172], ["HRSV", "SPECIES", 238, 242], ["another recent study", "TEST", 3, 23], ["DNA vaccines", "TREATMENT", 25, 37], ["protection of calves", "TREATMENT", 135, 155], ["the present study", "TEST", 219, 236], ["HRSV", "PROBLEM", 238, 242], ["a mammalian expression plasmid", "TREATMENT", 310, 340], ["a cytomegalovirus immediate early (CMVie) promoter", "TREATMENT", 362, 412]]], ["After transfection of human cells, protein expression was monitored by Western blot and immunofluorescence assays for optimized and non-optimized genes.", [["cells", "ANATOMY", 28, 33], ["human", "ORGANISM", 22, 27], ["cells", "CELL", 28, 33], ["human cells", "CELL_TYPE", 22, 33], ["non-optimized genes", "DNA", 132, 151], ["human", "SPECIES", 22, 27], ["human", "SPECIES", 22, 27], ["transfection of human cells", "TREATMENT", 6, 33], ["protein expression", "TEST", 35, 53], ["immunofluorescence assays", "TEST", 88, 113]]], ["In both experiments, neither the N protein nor the P protein could be detected for plasmids containing the natural sequence of the genes.", [["plasmids", "ANATOMY", 83, 91], ["N protein", "PROTEIN", 33, 42], ["P protein", "PROTEIN", 51, 60], ["plasmids", "DNA", 83, 91], ["the N protein", "TEST", 29, 42], ["the P protein", "TEST", 47, 60], ["plasmids", "PROBLEM", 83, 91]]], ["The study shows that these proteins are expressed in different intracellular localizations compared with HRSV infected cells.", [["intracellular", "ANATOMY", 63, 76], ["cells", "ANATOMY", 119, 124], ["intracellular", "IMMATERIAL_ANATOMICAL_ENTITY", 63, 76], ["cells", "CELL", 119, 124], ["HRSV infected cells", "CELL_TYPE", 105, 124], ["HRSV", "SPECIES", 105, 109], ["The study", "TEST", 0, 9], ["these proteins", "PROBLEM", 21, 35], ["different intracellular localizations", "PROBLEM", 53, 90], ["HRSV infected cells", "PROBLEM", 105, 124], ["intracellular localizations", "OBSERVATION", 63, 90], ["infected cells", "OBSERVATION", 110, 124]]], ["Immunization tests were performed and only the optimized genes were able to generate humoral immunity.", [["Immunization tests", "TEST", 0, 18]]], ["The positive effect of HRSV N and P gene optimization is described as an approach that might be considered for the development of a DNA vaccine against HRSV.Gene optimization ::: Material and methodsHRSV (strain A2) N and P gene coding sequences (respectively, AAC14896 and AAC14897) were submitted to GeneArt (Regensburg, Germany) and optimized using the GeneOtimizer software, which optimizes the codon usage and the GC content and eliminates polyadenylation sites, splicing sites, killer motifs and RNA secondary structures.", [["HRSV", "DISEASE", 152, 156], ["DNA", "CELLULAR_COMPONENT", 132, 135], ["HRSV", "ORGANISM", 152, 156], ["HRSV N and P gene", "DNA", 23, 40], ["methodsHRSV (strain A2) N and P gene coding sequences", "DNA", 192, 245], ["GeneOtimizer software", "DNA", 356, 377], ["polyadenylation sites", "DNA", 445, 466], ["splicing sites", "DNA", 468, 482], ["killer motifs", "DNA", 484, 497], ["HRSV", "SPECIES", 23, 27], ["HRSV", "SPECIES", 152, 156], ["HRSV N", "TREATMENT", 23, 29], ["P gene optimization", "TREATMENT", 34, 53], ["a DNA vaccine", "TREATMENT", 130, 143], ["HRSV", "PROBLEM", 152, 156], ["Material", "TEST", 179, 187], ["methodsHRSV", "TEST", 192, 203], ["P gene coding sequences", "TEST", 222, 245], ["the GC content", "PROBLEM", 415, 429], ["polyadenylation sites", "PROBLEM", 445, 466], ["positive", "OBSERVATION_MODIFIER", 4, 12], ["effect", "OBSERVATION_MODIFIER", 13, 19], ["HRSV", "OBSERVATION", 23, 27], ["polyadenylation sites", "OBSERVATION", 445, 466]]], ["Afterwards, the genes were synthesized, sequenced and cloned in a standard GeneArt plasmid.", [["GeneArt plasmid", "DNA", 75, 90], ["a standard GeneArt plasmid", "TREATMENT", 64, 90]]], ["Analyses of the codon adaptation index (CAI) of the genes were made using the program provided by Evolving Code Group (http://www.evolvingcode.net/codon/cai/cai.php).", [["the codon adaptation index", "TEST", 12, 38]]], ["Analyses of premature polyadenylation sites were made using the program provided by the National Research Council, Institute of Biomedical Technologies (http://zeus2.itb.cnr.it/\u223cwebgene/wwwHC_polya.html).Cloning ::: Material and methodsThe HRSV (strain A2) N and P non-optimized genes were amplified by reverse transcription and polymerase chain reaction (RT-PCR).", [["premature polyadenylation sites", "DNA", 12, 43], ["HRSV (strain A2) N and P non-optimized genes", "DNA", 240, 284], ["HRSV", "SPECIES", 240, 244], ["premature polyadenylation sites", "PROBLEM", 12, 43], ["The HRSV (strain A2) N and P non-optimized genes", "PROBLEM", 236, 284], ["polymerase chain reaction", "PROBLEM", 329, 354], ["RT-PCR", "TEST", 356, 362], ["premature", "OBSERVATION_MODIFIER", 12, 21], ["polyadenylation sites", "OBSERVATION", 22, 43]]], ["Briefly, HEp-2 cells were infected with HRSV strain A2 and total cellular RNA was extracted using Trizol (Invitrogen, Carlsbad, USA). cDNA was generated using random primers and the SuperScript First-Strand Synthesis System for RT-PCR (Invitrogen).", [["HEp-2 cells", "ANATOMY", 9, 20], ["cellular", "ANATOMY", 65, 73], ["HEp-2 cells", "CELL", 9, 20], ["HRSV", "ORGANISM", 40, 44], ["cellular", "CELL", 65, 73], ["HEp-2 cells", "CELL_LINE", 9, 20], ["cellular RNA", "RNA", 65, 77], ["cDNA", "DNA", 134, 138], ["HRSV strain A2", "SPECIES", 40, 54], ["HEp", "TEST", 9, 12], ["HRSV strain A2", "PROBLEM", 40, 54], ["total cellular RNA", "PROBLEM", 59, 77], ["Trizol", "TREATMENT", 98, 104], ["random primers", "TREATMENT", 159, 173], ["the SuperScript", "TREATMENT", 178, 193], ["Strand Synthesis System", "TREATMENT", 200, 223], ["RT-PCR (Invitrogen", "TREATMENT", 228, 246], ["HEp", "ANATOMY", 9, 12], ["total", "OBSERVATION_MODIFIER", 59, 64], ["cellular RNA", "OBSERVATION", 65, 77]]], ["Primers were designed with restriction endonuclease sites flanking the genes for subcloning into pShuttle (Clontech, Mountain View, USA).", [["restriction endonuclease sites", "DNA", 27, 57], ["pShuttle", "DNA", 97, 105], ["restriction endonuclease sites", "TREATMENT", 27, 57]]], ["The 5\u2032\u20133\u2032 primer sequences are presented below with the restriction sites underlined:Ns: TAGCTAGCGAAGATGGGGCAAATACAACC (NheI)Nas: CCCTTAAGTTAACTCAAAGCTCTACATCATTATC (AflII)Ps: TAGCTAGCCAAATAAATCATCATGGAAAAG (NheI)Pas: CCCTTAAGGTTGGATGATTGGGTTGGTTAG (AflII)", [["5\u2032\u20133\u2032 primer sequences", "DNA", 4, 26], ["restriction sites", "DNA", 56, 73], ["CCCTTAAGGTTGGATGATTGGGTTGGTTAG (AflII)", "DNA", 218, 256], ["The 5\u2032\u20133\u2032 primer sequences", "TREATMENT", 0, 26]]]], "4e41a25c5a3a39c1e14f921dc3934d7eeaac4645": [["way we manage pain.", [["pain", "DISEASE", 14, 18], ["pain", "PROBLEM", 14, 18]]], ["Many recent attempts at pain management reform have come in response to the ongoing opioid epidemic, a response that has been likened to managing a house on fire.7 The most immediate need was to extinguish the fire, which naturally led to health care policies and interventions that were largely downstream such as encouraging change in prescriber behavior, addressing and managing opioid use disorder, and reducing opioid-related overdose and mortality.", [["pain", "DISEASE", 24, 28], ["disorder", "DISEASE", 393, 401], ["overdose", "DISEASE", 431, 439], ["pain management", "TREATMENT", 24, 39], ["health care policies", "TREATMENT", 239, 259], ["interventions", "TREATMENT", 264, 277], ["managing opioid use disorder", "PROBLEM", 373, 401], ["related overdose", "PROBLEM", 423, 439]]]], "6d15d21fb55f7f43f14414e91e18745ed676a765": [["BackgroundSevere acute respiratory syndrome coronavirus 2 (SARS-Cov-2) is a pandemic RNA virus belonging to the Betacoronaviridae genera, causing coronavirus disease 2019 . in the wait for an effective vaccine, many therapeutics are being studied for potential repurposing to treat COviD-19. while candidate drugs have shown some activity against the virus, no specific treatment has yet been licenced apart from for compassionate use in severe cases [1] .", [["acute respiratory syndrome coronavirus", "DISEASE", 17, 55], ["coronavirus disease", "DISEASE", 146, 165], ["COviD-19", "CHEMICAL", 282, 290], ["COviD-19", "CHEMICAL", 282, 290], ["BackgroundSevere acute respiratory syndrome coronavirus 2", "ORGANISM", 0, 57], ["SARS-Cov-2", "ORGANISM", 59, 69], ["BackgroundSevere acute respiratory syndrome coronavirus", "SPECIES", 0, 55], ["SARS-Cov-2", "SPECIES", 59, 69], ["BackgroundSevere acute respiratory syndrome coronavirus", "PROBLEM", 0, 55], ["SARS", "TEST", 59, 63], ["Cov", "TEST", 64, 67], ["a pandemic RNA virus", "PROBLEM", 74, 94], ["coronavirus disease", "PROBLEM", 146, 165], ["an effective vaccine", "TREATMENT", 189, 209], ["COviD", "TEST", 282, 287], ["drugs", "TREATMENT", 308, 313], ["the virus", "PROBLEM", 347, 356], ["specific treatment", "TREATMENT", 361, 379], ["acute", "OBSERVATION_MODIFIER", 17, 22], ["respiratory syndrome", "OBSERVATION", 23, 43], ["coronavirus disease", "OBSERVATION", 146, 165]]], ["Candidate drugs being explored in trials and for compassionate treatment include chloroquine, hydroxychloroquine, lopinavir, darunavir, remdesivir, favipiravir, ivermectin, thiazolide antiprotozoal and nitazoxanide [2] .BackgroundNitazoxanide is a pro-drug for tizoxanide, which has broadspectrum antiviral properties, has many viral indications and shows promising pharmacodynamics against Coronaviridae [3] . it has not yet been tested in COviD-19 patients but previously showed a low in vitro effective concentration (eC 50 ) against Middle east respiratory syndrome coronavirus and severe acute respiratory syndrome coronavirus [4] .", [["chloroquine", "CHEMICAL", 81, 92], ["hydroxychloroquine", "CHEMICAL", 94, 112], ["lopinavir", "CHEMICAL", 114, 123], ["darunavir", "CHEMICAL", 125, 134], ["remdesivir", "CHEMICAL", 136, 146], ["favipiravir", "CHEMICAL", 148, 159], ["ivermectin", "CHEMICAL", 161, 171], ["thiazolide", "CHEMICAL", 173, 183], ["nitazoxanide", "CHEMICAL", 202, 214], ["Nitazoxanide", "CHEMICAL", 230, 242], ["tizoxanide", "CHEMICAL", 261, 271], ["Middle east respiratory syndrome coronavirus", "DISEASE", 537, 581], ["acute respiratory syndrome coronavirus", "DISEASE", 593, 631], ["chloroquine", "CHEMICAL", 81, 92], ["hydroxychloroquine", "CHEMICAL", 94, 112], ["lopinavir", "CHEMICAL", 114, 123], ["darunavir", "CHEMICAL", 125, 134], ["remdesivir", "CHEMICAL", 136, 146], ["favipiravir", "CHEMICAL", 148, 159], ["ivermectin", "CHEMICAL", 161, 171], ["thiazolide", "CHEMICAL", 173, 183], ["nitazoxanide", "CHEMICAL", 202, 214], ["Nitazoxanide", "CHEMICAL", 230, 242], ["tizoxanide", "CHEMICAL", 261, 271], ["chloroquine", "SIMPLE_CHEMICAL", 81, 92], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 94, 112], ["lopinavir", "SIMPLE_CHEMICAL", 114, 123], ["darunavir", "SIMPLE_CHEMICAL", 125, 134], ["remdesivir", "SIMPLE_CHEMICAL", 136, 146], ["favipiravir", "SIMPLE_CHEMICAL", 148, 159], ["ivermectin", "SIMPLE_CHEMICAL", 161, 171], ["thiazolide antiprotozoal", "SIMPLE_CHEMICAL", 173, 197], ["nitazoxanide", "SIMPLE_CHEMICAL", 202, 214], ["Nitazoxanide", "SIMPLE_CHEMICAL", 230, 242], ["tizoxanide", "SIMPLE_CHEMICAL", 261, 271], ["COviD-19", "ORGANISM", 441, 449], ["patients", "ORGANISM", 450, 458], ["Middle east respiratory syndrome coronavirus", "ORGANISM", 537, 581], ["patients", "SPECIES", 450, 458], ["Middle east respiratory syndrome coronavirus", "SPECIES", 537, 581], ["severe acute respiratory syndrome coronavirus", "SPECIES", 586, 631], ["drugs", "TREATMENT", 10, 15], ["compassionate treatment", "TREATMENT", 49, 72], ["chloroquine", "TREATMENT", 81, 92], ["hydroxychloroquine", "TREATMENT", 94, 112], ["lopinavir", "TREATMENT", 114, 123], ["darunavir", "TREATMENT", 125, 134], ["remdesivir", "TREATMENT", 136, 146], ["favipiravir", "TREATMENT", 148, 159], ["ivermectin", "TREATMENT", 161, 171], ["thiazolide antiprotozoal", "TREATMENT", 173, 197], ["nitazoxanide", "TREATMENT", 202, 214], ["BackgroundNitazoxanide", "TREATMENT", 220, 242], ["tizoxanide", "TREATMENT", 261, 271], ["broadspectrum antiviral properties", "TREATMENT", 283, 317], ["a low in vitro effective concentration", "PROBLEM", 481, 519], ["Middle east respiratory syndrome coronavirus", "PROBLEM", 537, 581], ["severe acute respiratory syndrome coronavirus", "PROBLEM", 586, 631], ["respiratory syndrome", "OBSERVATION", 549, 569], ["severe", "OBSERVATION_MODIFIER", 586, 592], ["acute", "OBSERVATION_MODIFIER", 593, 598], ["respiratory syndrome", "OBSERVATION", 599, 619]]], ["Nitazoxanide was therefore selected as a good candidate for potentially inhibiting SARS-Cov-2.", [["Nitazoxanide", "CHEMICAL", 0, 12], ["Nitazoxanide", "CHEMICAL", 0, 12], ["Nitazoxanide", "SIMPLE_CHEMICAL", 0, 12], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 83, 93], ["Nitazoxanide", "TREATMENT", 0, 12]]], ["To assess inhibition potential, researchers compared the maximum serum concentration of tizoxanide (C max ) with the in vitro eC 50 for nitazoxanide for SARS-Cov-2.", [["serum", "ANATOMY", 65, 70], ["tizoxanide", "CHEMICAL", 88, 98], ["nitazoxanide", "CHEMICAL", 136, 148], ["SARS", "DISEASE", 153, 157], ["tizoxanide", "CHEMICAL", 88, 98], ["nitazoxanide", "CHEMICAL", 136, 148], ["serum", "ORGANISM_SUBSTANCE", 65, 70], ["tizoxanide", "SIMPLE_CHEMICAL", 88, 98], ["nitazoxanide", "SIMPLE_CHEMICAL", 136, 148], ["the maximum serum concentration of tizoxanide (C max )", "TREATMENT", 53, 107], ["the in vitro eC", "TREATMENT", 113, 128], ["nitazoxanide", "TREATMENT", 136, 148], ["SARS", "PROBLEM", 153, 157]]], ["BD with food [6] .", [["BD", "GENE_OR_GENE_PRODUCT", 0, 2]]], ["Pharmacokinetics were not influenced by repeat dosing at 500 mg BD (C max 10,400 ng/mL after single dose compared with 12,200 ng/mL on day 7) but increased considerably after repeat dosing at 1000 mg BD (C max 16,800 ng/mL after single dose vs 26,400 ng/mL on day 7) [6] .", [["repeat dosing", "TREATMENT", 175, 188]]], ["All reported C max values for tizoxanide exceeded the reported in vitro eC 50 of nitazoxanide for SARS-Cov-2 [651 ng/mL (2.12 \u03bcM)] [7] .", [["tizoxanide", "CHEMICAL", 30, 40], ["nitazoxanide", "CHEMICAL", 81, 93], ["SARS-Cov-2", "CHEMICAL", 98, 108], ["tizoxanide", "CHEMICAL", 30, 40], ["nitazoxanide", "CHEMICAL", 81, 93], ["tizoxanide", "SIMPLE_CHEMICAL", 30, 40], ["nitazoxanide", "SIMPLE_CHEMICAL", 81, 93], ["SARS-Cov-2", "SIMPLE_CHEMICAL", 98, 108], ["C max values", "TEST", 13, 25], ["tizoxanide", "TREATMENT", 30, 40], ["nitazoxanide", "TREATMENT", 81, 93], ["SARS", "PROBLEM", 98, 102]]], ["Nitazoxanide concentration has also been specifically predicted to exceed its eC 50 for SARS-Cov-2 by 3.1-fold in the lung [8] . it should be noted that this eC 50 value was reported for nitazoxanide rather than its human metabolite, tizoxanide, but previous studies have shown similar activity to nitazoxanide when tested against various strains of influenza [9] .BackgroundCare needs to be taken with in vitro potency assessments and their applicability.", [["lung", "ANATOMY", 118, 122], ["Nitazoxanide", "CHEMICAL", 0, 12], ["SARS", "DISEASE", 88, 92], ["nitazoxanide", "CHEMICAL", 187, 199], ["tizoxanide", "CHEMICAL", 234, 244], ["nitazoxanide", "CHEMICAL", 298, 310], ["influenza", "DISEASE", 350, 359], ["Nitazoxanide", "CHEMICAL", 0, 12], ["nitazoxanide", "CHEMICAL", 187, 199], ["tizoxanide", "CHEMICAL", 234, 244], ["nitazoxanide", "CHEMICAL", 298, 310], ["Nitazoxanide", "SIMPLE_CHEMICAL", 0, 12], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 88, 98], ["lung", "ORGAN", 118, 122], ["nitazoxanide", "SIMPLE_CHEMICAL", 187, 199], ["human", "ORGANISM", 216, 221], ["tizoxanide", "SIMPLE_CHEMICAL", 234, 244], ["nitazoxanide", "SIMPLE_CHEMICAL", 298, 310], ["human", "SPECIES", 216, 221], ["human", "SPECIES", 216, 221], ["Nitazoxanide concentration", "TREATMENT", 0, 26], ["SARS", "TEST", 88, 92], ["Cov", "TEST", 93, 96], ["this eC 50 value", "TEST", 153, 169], ["nitazoxanide", "TREATMENT", 187, 199], ["tizoxanide", "TREATMENT", 234, 244], ["previous studies", "TEST", 250, 266], ["nitazoxanide", "TREATMENT", 298, 310], ["influenza", "PROBLEM", 350, 359], ["vitro potency assessments", "TEST", 406, 431], ["lung", "ANATOMY", 118, 122]]], ["Generally, a high C max to eC 50 ratio in vitro means a higher potential for in vivo viral inhibition.", [["vivo viral inhibition", "TREATMENT", 80, 101], ["viral inhibition", "OBSERVATION", 85, 101]]], ["However, these values are not standardised and can be affected by many variables [10] . it is important also to consider the mechanism of action of nitazoxanide and to carry out clinical trials assessing in vivo inhibition of SARS-Cov-2.BackgroundA reduced innate immune response is hypothesised to explain age-susceptibility to SARS-Cov-2 [11] .", [["nitazoxanide", "CHEMICAL", 148, 160], ["SARS", "DISEASE", 329, 333], ["nitazoxanide", "CHEMICAL", 148, 160], ["nitazoxanide", "SIMPLE_CHEMICAL", 148, 160], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 226, 236], ["nitazoxanide", "TREATMENT", 148, 160], ["clinical trials", "TEST", 178, 193], ["SARS", "PROBLEM", 226, 230], ["SARS", "PROBLEM", 329, 333], ["immune response", "OBSERVATION", 264, 279]]], ["Nitazoxanide upregulates the host interferon pathway, amplifying the innate antiviral response [12] .", [["Nitazoxanide", "CHEMICAL", 0, 12], ["Nitazoxanide", "CHEMICAL", 0, 12], ["Nitazoxanide", "SIMPLE_CHEMICAL", 0, 12], ["interferon", "PROTEIN", 34, 44], ["Nitazoxanide", "TREATMENT", 0, 12], ["the host interferon pathway", "TREATMENT", 25, 52], ["the innate antiviral response", "TREATMENT", 65, 94]]], ["Nitazoxanide could therefore be a useful adjunctive treatment used earlier in the disease course than more potent virus-targeted treatments (hydroxychloroquine eC 50 = 1.13 \u03bcM, remdesivir eC 50 = 0.77 \u03bcM) [7] .BackgroundPrevious indications of nitazoxanide vary widely. it is licenced by the US Food and Drug Administration (FDA) for giardiasis [13] .", [["Nitazoxanide", "CHEMICAL", 0, 12], ["hydroxychloroquine", "CHEMICAL", 141, 159], ["remdesivir", "CHEMICAL", 177, 187], ["nitazoxanide", "CHEMICAL", 244, 256], ["giardiasis", "DISEASE", 334, 344], ["Nitazoxanide", "CHEMICAL", 0, 12], ["hydroxychloroquine eC", "CHEMICAL", 141, 162], ["remdesivir eC", "CHEMICAL", 177, 190], ["nitazoxanide", "CHEMICAL", 244, 256], ["Nitazoxanide", "SIMPLE_CHEMICAL", 0, 12], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 141, 159], ["nitazoxanide", "SIMPLE_CHEMICAL", 244, 256], ["Nitazoxanide", "TREATMENT", 0, 12], ["a useful adjunctive treatment", "TREATMENT", 32, 61], ["targeted treatments (hydroxychloroquine eC", "TREATMENT", 120, 162], ["remdesivir eC", "TREATMENT", 177, 190], ["nitazoxanide", "TREATMENT", 244, 256], ["Drug Administration", "TREATMENT", 304, 323], ["giardiasis", "PROBLEM", 334, 344]]], ["However, it has been trialled and used for many other diseases, including cryptosporidiosis diarrhoea in Hiv patients, influenza, hepatitis viruses, rotavirus and norovirus.", [["cryptosporidiosis diarrhoea", "DISEASE", 74, 101], ["influenza, hepatitis viruses", "DISEASE", 119, 147], ["rotavirus and norovirus", "DISEASE", 149, 172], ["Hiv", "ORGANISM", 105, 108], ["patients", "ORGANISM", 109, 117], ["hepatitis viruses", "ORGANISM", 130, 147], ["rotavirus", "ORGANISM", 149, 158], ["patients", "SPECIES", 109, 117], ["hepatitis viruses", "SPECIES", 130, 147], ["many other diseases", "PROBLEM", 43, 62], ["cryptosporidiosis diarrhoea", "PROBLEM", 74, 101], ["influenza", "PROBLEM", 119, 128], ["hepatitis viruses", "PROBLEM", 130, 147], ["rotavirus", "PROBLEM", 149, 158], ["norovirus", "PROBLEM", 163, 172], ["diseases", "OBSERVATION", 54, 62], ["hepatitis viruses", "OBSERVATION", 130, 147], ["norovirus", "OBSERVATION", 163, 172]]], ["As such, the safety profile of nitazoxanide is variably reported and needs clarification before potential large-scale trial and treatment in the COviD-19 pandemic. in general, COviD-19 treatment courses are given for 7-14 days; therefore, whether nitazoxanide is safe to use needs to be proven for this duration [14] .BackgroundNovel COviD-19 treatments must not only be safe and effective but also cheap and readily available.", [["nitazoxanide", "CHEMICAL", 31, 43], ["nitazoxanide", "CHEMICAL", 247, 259], ["nitazoxanide", "CHEMICAL", 31, 43], ["COviD-19", "CHEMICAL", 176, 184], ["nitazoxanide", "CHEMICAL", 247, 259], ["COviD-19", "CHEMICAL", 334, 342], ["nitazoxanide", "SIMPLE_CHEMICAL", 31, 43], ["COviD-19", "ORGANISM", 145, 153], ["nitazoxanide", "SIMPLE_CHEMICAL", 247, 259], ["nitazoxanide", "TREATMENT", 31, 43], ["potential large-scale trial", "TREATMENT", 96, 123], ["treatment", "TREATMENT", 128, 137], ["COviD-19 treatment courses", "TREATMENT", 176, 202], ["nitazoxanide", "TREATMENT", 247, 259], ["Novel COviD-19 treatments", "TREATMENT", 328, 353]]], ["Many potential candidate drugs currently being investigated have been shown to be producible as generic medicines at very low costs per course of treatment, including some that can be manufactured for under US$1 per day [14] .", [["drugs", "TREATMENT", 25, 30], ["generic medicines", "TREATMENT", 96, 113], ["treatment", "TREATMENT", 146, 155]]], ["These estimated generic prices can be calculated based on estimated dosage and costs of active pharmaceutical ingredients (APi), accounting for a reasonable profit margin and tax.", [["tax", "PROTEIN", 175, 178], ["active pharmaceutical ingredients", "TREATMENT", 88, 121], ["generic prices", "OBSERVATION", 16, 30], ["active", "OBSERVATION_MODIFIER", 88, 94]]], ["This approach has been used previously to estimate reliably the costs of production for hepatitis C and Hiv drugs among others [15] [16] [17] .", [["hepatitis", "DISEASE", 88, 97], ["hepatitis C", "SIMPLE_CHEMICAL", 88, 99], ["Hiv drugs", "SIMPLE_CHEMICAL", 104, 113], ["hepatitis C", "PROBLEM", 88, 99], ["Hiv drugs", "TREATMENT", 104, 113]]], ["However, prices of drugs to treat coronavirus can be far higher than costs of production, impacting access [14] .Backgroundwe aimed to review the existing evidence on the safety of nitazoxanide and calculate its potential minimum costs of production to inform its potential use for the treatment of COviD-19.Safety reviewA review of nitazoxanide clinical research was conducted in accordance with the Cochrane framework for systematic reviews, following the PRiSMA statement reporting method for systematic reviews and meta-analyses [18] .", [["coronavirus", "DISEASE", 34, 45], ["nitazoxanide", "CHEMICAL", 181, 193], ["COviD-19", "CHEMICAL", 299, 307], ["nitazoxanide", "CHEMICAL", 333, 345], ["nitazoxanide", "CHEMICAL", 181, 193], ["COviD-19", "CHEMICAL", 299, 307], ["nitazoxanide", "CHEMICAL", 333, 345], ["coronavirus", "ORGANISM", 34, 45], ["nitazoxanide", "SIMPLE_CHEMICAL", 181, 193], ["nitazoxanide", "SIMPLE_CHEMICAL", 333, 345], ["drugs", "TREATMENT", 19, 24], ["coronavirus", "PROBLEM", 34, 45], ["nitazoxanide", "TREATMENT", 181, 193], ["the treatment", "TREATMENT", 282, 295], ["COviD", "TEST", 299, 304], ["nitazoxanide", "TREATMENT", 333, 345], ["systematic reviews", "TEST", 496, 514], ["meta-analyses", "TEST", 519, 532]]], ["A search was conducted using eMBASe and MeDLiNe databases via Ovid (full search terms available upon request) and supplemented by a further search of ClinicalTrials.gov for all studies listed with nitazoxanide as an intervention.", [["nitazoxanide", "CHEMICAL", 197, 209], ["nitazoxanide", "CHEMICAL", 197, 209], ["nitazoxanide", "SIMPLE_CHEMICAL", 197, 209], ["all studies", "TEST", 173, 184], ["nitazoxanide", "TREATMENT", 197, 209], ["an intervention", "TREATMENT", 213, 228]]], ["The search was concluded on 6 April 2020.Safety reviewwe searched for randomised controlled trials (RCTs) comparing nitazoxanide with placebo or an active control in participants experiencing acute infections of any kind.", [["nitazoxanide", "CHEMICAL", 116, 128], ["infections", "DISEASE", 198, 208], ["nitazoxanide", "CHEMICAL", 116, 128], ["nitazoxanide", "SIMPLE_CHEMICAL", 116, 128], ["participants", "SPECIES", 166, 178], ["randomised controlled trials (RCTs)", "TREATMENT", 70, 105], ["nitazoxanide", "TREATMENT", 116, 128], ["placebo", "TREATMENT", 134, 141], ["an active control", "TREATMENT", 145, 162], ["acute infections", "PROBLEM", 192, 208], ["acute", "OBSERVATION_MODIFIER", 192, 197], ["infections", "OBSERVATION", 198, 208]]], ["Trials were required to be phase 2 or 3 studies carried out in either adult or paediatric trial populations.", [["3 studies", "TEST", 38, 47]]], ["Participants were required to undergo at least 5 days of nitazoxanide.", [["nitazoxanide", "CHEMICAL", 57, 69], ["nitazoxanide", "CHEMICAL", 57, 69], ["nitazoxanide", "SIMPLE_CHEMICAL", 57, 69], ["Participants", "SPECIES", 0, 12], ["nitazoxanide", "TREATMENT", 57, 69]]], ["Trials with shorter courses of treatment were excluded, as briefer exposure to the drug might positively skew results and would be less comparable with potential treatment use in COviD-19.", [["COviD-19", "CHEMICAL", 179, 187], ["treatment", "TREATMENT", 31, 40]]], ["Trials assessing the use of nitazoxanide in participants with severe chronic disease were excluded, as these could present different adverse event (Ae) profiles and drug interactions.", [["nitazoxanide", "CHEMICAL", 28, 40], ["chronic disease", "DISEASE", 69, 84], ["nitazoxanide", "CHEMICAL", 28, 40], ["nitazoxanide", "SIMPLE_CHEMICAL", 28, 40], ["participants", "SPECIES", 44, 56], ["nitazoxanide", "TREATMENT", 28, 40], ["severe chronic disease", "PROBLEM", 62, 84], ["severe", "OBSERVATION_MODIFIER", 62, 68], ["chronic", "OBSERVATION_MODIFIER", 69, 76], ["disease", "OBSERVATION", 77, 84]]], ["Studies were screened against these criteria independently by two reviewers, and mutual agreement was necessary for inclusion or exclusion where conflicts arose.Safety reviewFurther analysis was undertaken of all available safety data.", [["Safety reviewFurther analysis", "TEST", 161, 190]]], ["Data extracted were Aes grade 1-4 and serious Aes.", [["Aes", "DISEASE", 46, 49], ["Aes grade", "TEST", 20, 29]]], ["Data were also extracted on gastrointestinal (Gi) Aes, as well as hepatorenal and cardiac effects, as specific Aes of interest identified from phase 1 studies and drug licencing reports [19, 20] .", [["gastrointestinal", "ANATOMY", 28, 44], ["hepatorenal", "ANATOMY", 66, 77], ["cardiac", "ANATOMY", 82, 89], ["hepatorenal and cardiac effects", "DISEASE", 66, 97], ["gastrointestinal", "ORGANISM_SUBDIVISION", 28, 44], ["cardiac", "ORGAN", 82, 89], ["hepatorenal and cardiac effects", "PROBLEM", 66, 97], ["gastrointestinal", "ANATOMY", 28, 44], ["hepatorenal", "OBSERVATION", 66, 77], ["cardiac", "ANATOMY", 82, 89]]], ["Hepatic, renal and cardiovascular endpoints were studied because of the deleterious effects of COviD-19 on these systems [21, 22] .", [["Hepatic", "ANATOMY", 0, 7], ["renal", "ANATOMY", 9, 14], ["cardiovascular", "ANATOMY", 19, 33], ["COviD-19", "CHEMICAL", 95, 103], ["COviD-19", "CHEMICAL", 95, 103], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["renal", "MULTI-TISSUE_STRUCTURE", 9, 14], ["cardiovascular", "ANATOMICAL_SYSTEM", 19, 33], ["COviD-19", "SIMPLE_CHEMICAL", 95, 103], ["COviD", "TEST", 95, 100], ["renal", "ANATOMY", 9, 14], ["cardiovascular", "ANATOMY", 19, 33]]], ["Further, dose ranging studies from the same search were isolated for investigation of safety at higher doses, as may be needed for COviD-19.Safety reviewwe searched for data in published articles, supplementary appendices and at ClinicalTrials.gov. where there were inconsistencies, data reported in the published paper were preferred.", [["COviD-19", "CHEMICAL", 131, 139], ["dose ranging studies", "TEST", 9, 29], ["COviD", "TEST", 131, 136]]], ["To standardise the extracted data, the number of participants experiencing Aes was extracted for grade 1-4 Ae.", [["participants", "ORGANISM", 49, 61], ["participants", "SPECIES", 49, 61]]], ["For Gi Ae and serious Ae, number of events was preferred as this was more consistently reported and better represented the event occurrence rates, as one person could experience multiple events and event types.", [["Gi Ae", "CHEMICAL", 4, 9], ["Gi Ae", "GENE_OR_GENE_PRODUCT", 4, 9], ["Gi Ae", "PROTEIN", 4, 9], ["person", "SPECIES", 154, 160], ["serious", "OBSERVATION", 14, 21]]], ["All reported Ae data were extracted, rather than only those deemed related to the study drug, to avoid reporting bias as much a possible. instead, comparison control arms were used to determine the effects of the study drug.", [["comparison control arms", "TEST", 147, 170], ["the study drug", "TEST", 209, 223]]], ["Statistical comparisons of event proportions were also carried out using z-tests.Costs analysiswe followed methodology used recently to estimate the minimum costs of production for other potential treatments of COviD-19 currently undergoing clinical trials by Hill et al. to calculate the potential cost of nitazoxanide treatment based on the cost of APi [14] .", [["COviD-19", "CHEMICAL", 211, 219], ["nitazoxanide", "CHEMICAL", 307, 319], ["APi", "CHEMICAL", 351, 354], ["COviD-19", "CHEMICAL", 211, 219], ["nitazoxanide", "CHEMICAL", 307, 319], ["nitazoxanide", "SIMPLE_CHEMICAL", 307, 319], ["z-tests", "TREATMENT", 73, 80], ["COviD", "TREATMENT", 211, 216], ["nitazoxanide treatment", "TREATMENT", 307, 329]]], ["APi cost data were extracted from the Panjiva database of global shipping records between 2016 and 2019, and adjusted for 5% loss during production, costs of excipients (other components within the finished medication such as stabilisers and bulking agents), formulation, a 10% profit margin and tax [23] .", [["tax", "PROTEIN", 296, 299], ["excipients", "TREATMENT", 158, 168], ["the finished medication", "TREATMENT", 194, 217], ["stabilisers", "TREATMENT", 226, 237], ["bulking agents", "TREATMENT", 242, 256], ["formulation", "TREATMENT", 259, 270]]], ["Because treatment duration varies between protocols, we assumed a conservative 14-day duration in this study.", [["this study", "TEST", 98, 108]]], ["Two dosages, at 500 mg BD and at a higher dose of 1100 mg three times daily (TDS), were considered to account for potential COviD-19 dose optimisation including the potential need for higher doses if given without food.Costs analysisOur estimated costs were compared with publicly available list prices from a selection of countries, with prices converted to US dollars based on the average 12-month exchange rate in 2019.", [["COviD-19", "CHEMICAL", 124, 132], ["COviD-19 dose optimisation", "TREATMENT", 124, 150], ["higher doses", "TREATMENT", 184, 196], ["Costs analysis", "TEST", 219, 233]]], ["One data source was used per country, and where multiple prices were listed, the cheapest was selected [24] [25] [26] [27] [28] [29] [30] .Review of safetyAfter screening against the prespecified criteria, nine RCTs of nitazoxanide for previous indications were identified for inclusion ( Figure 1 ).", [["nitazoxanide", "CHEMICAL", 219, 231], ["[24] [25] [26] [27] [28] [29]", "CHEMICAL", 103, 132], ["nitazoxanide", "CHEMICAL", 219, 231], ["[24] [25] [26] [27] [28] [29] [30]", "SIMPLE_CHEMICAL", 103, 137], ["nitazoxanide", "SIMPLE_CHEMICAL", 219, 231], ["screening", "TEST", 161, 170], ["the prespecified criteria", "TEST", 179, 204], ["nitazoxanide", "TREATMENT", 219, 231]]], ["Seventeen trials were excluded given their short (commonly 3-day) courses of nitazoxanide treatment.", [["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "SIMPLE_CHEMICAL", 77, 89], ["nitazoxanide treatment", "TREATMENT", 77, 99]]], ["Twelve trials were excluded as they assessed nitazoxanide in patients who had severe chronic illnesses such as acquired immunodeficiency syndrome, cancers, late-stage liver disease or hepatitis C virus infection.Review of safetyThe nine included trials accounted for 1514 participants for an estimated 95.3 person-years-of-follow-up [31] [32] [33] [34] [35] [36] [37] [38] [39] .", [["cancers", "ANATOMY", 147, 154], ["liver", "ANATOMY", 167, 172], ["nitazoxanide", "CHEMICAL", 45, 57], ["acquired immunodeficiency syndrome", "DISEASE", 111, 145], ["cancers", "DISEASE", 147, 154], ["late-stage liver disease", "DISEASE", 156, 180], ["hepatitis C virus infection", "DISEASE", 184, 211], ["nitazoxanide", "CHEMICAL", 45, 57], ["[31] [32] [33] [34] [35] [36] [37] [38]", "CHEMICAL", 333, 372], ["nitazoxanide", "SIMPLE_CHEMICAL", 45, 57], ["patients", "ORGANISM", 61, 69], ["cancers", "CANCER", 147, 154], ["liver", "ORGAN", 167, 172], ["hepatitis C virus", "ORGANISM", 184, 201], ["[31] [32] [33] [34] [35] [36] [37] [38] [39]", "SIMPLE_CHEMICAL", 333, 377], ["patients", "SPECIES", 61, 69], ["hepatitis C virus", "SPECIES", 184, 201], ["participants", "SPECIES", 272, 284], ["hepatitis C virus", "SPECIES", 184, 201], ["Twelve trials", "TEST", 0, 13], ["nitazoxanide", "TREATMENT", 45, 57], ["severe chronic illnesses", "PROBLEM", 78, 102], ["acquired immunodeficiency syndrome", "PROBLEM", 111, 145], ["cancers", "PROBLEM", 147, 154], ["late-stage liver disease", "PROBLEM", 156, 180], ["hepatitis C virus infection", "PROBLEM", 184, 211], ["severe", "OBSERVATION_MODIFIER", 78, 84], ["chronic", "OBSERVATION_MODIFIER", 85, 92], ["illnesses", "OBSERVATION", 93, 102], ["immunodeficiency syndrome", "OBSERVATION", 120, 145], ["late", "OBSERVATION_MODIFIER", 156, 160], ["-stage", "OBSERVATION_MODIFIER", 160, 166], ["liver", "ANATOMY", 167, 172], ["disease", "OBSERVATION", 173, 180], ["hepatitis", "OBSERVATION", 184, 193], ["virus infection", "OBSERVATION", 196, 211]]], ["Of these patients, 925 were on nitazoxanide.", [["nitazoxanide", "CHEMICAL", 31, 43], ["nitazoxanide", "CHEMICAL", 31, 43], ["patients", "ORGANISM", 9, 17], ["nitazoxanide", "SIMPLE_CHEMICAL", 31, 43], ["patients", "SPECIES", 9, 17], ["nitazoxanide", "TREATMENT", 31, 43]]], ["One trial reported results in separate paediatric and adult populations [38] . in total, only 50/1514 (3.3%) participants were paediatric.", [["participants", "ORGANISM", 109, 121], ["participants", "SPECIES", 109, 121]]], ["Studies were carried out in a wide range of countries worldwide: USA, egypt, Peru, Mexico and Haiti.", [["Studies", "TEST", 0, 7]]], ["The most common dosing of nitazoxanide was 500 mg BD, but some studies used 1000 mg BD.", [["nitazoxanide", "CHEMICAL", 26, 38], ["nitazoxanide", "CHEMICAL", 26, 38], ["nitazoxanide", "SIMPLE_CHEMICAL", 26, 38], ["nitazoxanide", "TREATMENT", 26, 38], ["some studies", "TEST", 58, 70]]], ["Paediatric doses varied and were determined by weight or age.", [["Paediatric doses", "TREATMENT", 0, 16]]], ["On pooling available study demographics, 45.6% of participants were female, and the mean age of participants was 37 years.Review of safetyFive studies used placebo comparison (n = 1077) and four used antibiotic comparators including metronidazole (n = 437), vancomycin and standard tuberculosis therapy (Table 1) .", [["metronidazole", "CHEMICAL", 233, 246], ["vancomycin", "CHEMICAL", 258, 268], ["tuberculosis", "DISEASE", 282, 294], ["metronidazole", "CHEMICAL", 233, 246], ["vancomycin", "CHEMICAL", 258, 268], ["participants", "ORGANISM", 50, 62], ["participants", "ORGANISM", 96, 108], ["metronidazole", "SIMPLE_CHEMICAL", 233, 246], ["vancomycin", "SIMPLE_CHEMICAL", 258, 268], ["participants", "SPECIES", 50, 62], ["participants", "SPECIES", 96, 108], ["antibiotic comparators", "TREATMENT", 200, 222], ["metronidazole", "TREATMENT", 233, 246], ["vancomycin", "TREATMENT", 258, 268], ["standard tuberculosis therapy", "TREATMENT", 273, 302], ["tuberculosis", "OBSERVATION", 282, 294]]], ["Study populations had a variety of pathologies, including Clostridium difficile, Helicobacter pylori, Mycobacterium tuberculosis, viral influenza and amoebiasis.", [["Clostridium difficile", "DISEASE", 58, 79], ["Helicobacter pylori", "DISEASE", 81, 100], ["Mycobacterium tuberculosis", "DISEASE", 102, 128], ["viral influenza", "DISEASE", 130, 145], ["amoebiasis", "DISEASE", 150, 160], ["Clostridium difficile", "ORGANISM", 58, 79], ["Helicobacter pylori", "ORGANISM", 81, 100], ["Mycobacterium tuberculosis", "ORGANISM", 102, 128], ["viral influenza", "ORGANISM", 130, 145], ["Clostridium difficile", "SPECIES", 58, 79], ["Helicobacter pylori", "SPECIES", 81, 100], ["Mycobacterium tuberculosis", "SPECIES", 102, 128], ["viral influenza", "SPECIES", 130, 145], ["Clostridium difficile", "SPECIES", 58, 79], ["Helicobacter pylori", "SPECIES", 81, 100], ["Mycobacterium tuberculosis", "SPECIES", 102, 128], ["Study populations", "TEST", 0, 17], ["pathologies", "PROBLEM", 35, 46], ["Clostridium difficile", "PROBLEM", 58, 79], ["Helicobacter pylori", "PROBLEM", 81, 100], ["Mycobacterium tuberculosis", "PROBLEM", 102, 128], ["viral influenza", "PROBLEM", 130, 145], ["amoebiasis", "PROBLEM", 150, 160], ["Clostridium difficile", "OBSERVATION", 58, 79], ["Helicobacter pylori", "OBSERVATION", 81, 100], ["Mycobacterium tuberculosis", "OBSERVATION", 102, 128], ["viral influenza", "OBSERVATION", 130, 145]]], ["Table 2 shows the overall event numbers and percentage proportions for each of the three Ae endpoints, as well as the comparative significance of differences between nitazoxanide and comparator arms.", [["nitazoxanide", "CHEMICAL", 166, 178], ["nitazoxanide", "CHEMICAL", 166, 178], ["nitazoxanide", "SIMPLE_CHEMICAL", 166, 178], ["nitazoxanide", "TREATMENT", 166, 178]]], ["These results are further stratified by comparator type into results from studies using a placebo control and studies using active antimicrobial control regimens.", [["studies", "TEST", 74, 81], ["a placebo control", "TREATMENT", 88, 105], ["studies", "TEST", 110, 117], ["active antimicrobial control regimens", "TREATMENT", 124, 161]]], ["The results from those trials that used placebo comparison isolate the specific effects of nitazoxanide.Review of safetyThere was no significant difference in Ae proportions for any of the endpoints assessed, across all trials or on subgroup analysis of active-controlled and placebo-controlled trials.", [["nitazoxanide", "CHEMICAL", 91, 103], ["nitazoxanide", "CHEMICAL", 91, 103], ["nitazoxanide", "SIMPLE_CHEMICAL", 91, 103], ["those trials", "TREATMENT", 17, 29], ["placebo comparison", "TREATMENT", 40, 58], ["nitazoxanide", "TREATMENT", 91, 103], ["significant difference in Ae proportions", "PROBLEM", 133, 173], ["subgroup analysis", "TEST", 233, 250], ["placebo-controlled trials", "TREATMENT", 276, 301], ["no", "UNCERTAINTY", 130, 132], ["significant", "OBSERVATION_MODIFIER", 133, 144], ["difference", "OBSERVATION", 145, 155]]], ["The largest difference in event proportions was seen in Gi Aes occurring in placebo-controlled trials, with 33/131 participants (25.2%) on nitazoxanide vs 10/65 participants (15.4%) on placebo, but this was also not statistically significant (Table 2 ).", [["Aes", "CHEMICAL", 59, 62], ["nitazoxanide", "CHEMICAL", 139, 151], ["nitazoxanide", "CHEMICAL", 139, 151], ["Gi Aes", "GENE_OR_GENE_PRODUCT", 56, 62], ["nitazoxanide", "SIMPLE_CHEMICAL", 139, 151], ["participants", "SPECIES", 115, 127], ["participants", "SPECIES", 161, 173], ["Gi Aes", "PROBLEM", 56, 62], ["placebo", "TREATMENT", 76, 83], ["nitazoxanide", "TREATMENT", 139, 151], ["placebo", "TREATMENT", 185, 192], ["largest", "OBSERVATION_MODIFIER", 4, 11], ["difference", "OBSERVATION_MODIFIER", 12, 22]]], ["Figure 2a illustrates the event proportions occurring across all trials and Figure2b, the event proportions on subgroup analysis.Hepatorenal and cardiovascular endpointsSafety data reported in all nine included studies showed specific hepatic, renal and cardiovascular Aes were either not widely assessed (via biomarkers or symptom reporting) or not widely reported.", [["Hepatorenal", "ANATOMY", 129, 140], ["cardiovascular", "ANATOMY", 145, 159], ["hepatic", "ANATOMY", 235, 242], ["renal", "ANATOMY", 244, 249], ["cardiovascular", "ANATOMY", 254, 268], ["hepatic, renal and cardiovascular", "DISEASE", 235, 268], ["hepatic", "MULTI-TISSUE_STRUCTURE", 235, 242], ["renal", "CANCER", 244, 249], ["Figure2b", "TREATMENT", 76, 84], ["subgroup analysis", "TEST", 111, 128], ["Hepatorenal and cardiovascular endpoints", "PROBLEM", 129, 169], ["Safety data", "TEST", 169, 180], ["symptom", "PROBLEM", 324, 331], ["cardiovascular", "ANATOMY", 145, 159], ["endpoints", "OBSERVATION", 160, 169], ["hepatic", "ANATOMY", 235, 242], ["renal", "ANATOMY", 244, 249], ["cardiovascular", "ANATOMY", 254, 268]]], ["Some studies had a threshold of 1%-5% incidence rate before an adverse event type would be reported, which would explain why these adverse events are not consistently reported.", [["Some studies", "TEST", 0, 12], ["these adverse events", "PROBLEM", 125, 145]]], ["As a marker of hepatic effect, two studies reported elevations in liver function tests in participants receiving nitazoxanide compared with control ( Table 3) .", [["hepatic", "ANATOMY", 15, 22], ["liver", "ANATOMY", 66, 71], ["nitazoxanide", "CHEMICAL", 113, 125], ["nitazoxanide", "CHEMICAL", 113, 125], ["hepatic", "ORGAN", 15, 22], ["liver", "ORGAN", 66, 71], ["nitazoxanide", "SIMPLE_CHEMICAL", 113, 125], ["participants", "SPECIES", 90, 102], ["two studies", "TEST", 31, 42], ["elevations in liver function tests", "PROBLEM", 52, 86], ["nitazoxanide", "TREATMENT", 113, 125], ["hepatic", "ANATOMY", 15, 22], ["elevations", "OBSERVATION_MODIFIER", 52, 62], ["liver", "ANATOMY", 66, 71]]], ["As a marker of potential renal effect, two studies reported higher rates of chromaturia (yellow urine) in participants taking nitazoxanide, but all of these cases were mild and clinically insignificant (Table 3) .", [["renal", "ANATOMY", 25, 30], ["urine", "ANATOMY", 96, 101], ["chromaturia", "DISEASE", 76, 87], ["nitazoxanide", "CHEMICAL", 126, 138], ["nitazoxanide", "CHEMICAL", 126, 138], ["renal", "ORGAN", 25, 30], ["urine", "ORGANISM_SUBSTANCE", 96, 101], ["nitazoxanide", "SIMPLE_CHEMICAL", 126, 138], ["participants", "SPECIES", 106, 118], ["potential renal effect", "PROBLEM", 15, 37], ["two studies", "TEST", 39, 50], ["chromaturia (yellow urine", "PROBLEM", 76, 101], ["nitazoxanide", "TREATMENT", 126, 138], ["renal", "ANATOMY", 25, 30], ["effect", "OBSERVATION", 31, 37], ["mild", "OBSERVATION_MODIFIER", 168, 172]]], ["No cardiovascular Aes were recorded or reported in any of the nine studies (Table 3) .Hepatorenal and cardiovascular endpointswHO vigiAccess, which contained records of 472 Aes for nitazoxanide, showed very few reported cases of hepatotoxicity (n = 3), jaundice (n = 5) and other hepatobiliary disorders (n = 10)Hepatorenal and cardiovascular endpoints[40].", [["cardiovascular", "ANATOMY", 3, 17], ["Hepatorenal", "ANATOMY", 86, 97], ["cardiovascular", "ANATOMY", 102, 116], ["hepatobiliary", "ANATOMY", 280, 293], ["Hepatorenal", "ANATOMY", 312, 323], ["cardiovascular", "ANATOMY", 328, 342], ["nitazoxanide", "CHEMICAL", 181, 193], ["hepatotoxicity", "DISEASE", 229, 243], ["jaundice", "DISEASE", 253, 261], ["hepatobiliary disorders", "DISEASE", 280, 303], ["nitazoxanide", "CHEMICAL", 181, 193], ["nitazoxanide", "SIMPLE_CHEMICAL", 181, 193], ["hepatobiliary", "ORGAN", 280, 293], ["the nine studies", "TEST", 58, 74], ["Hepatorenal and cardiovascular endpointswHO vigiAccess", "PROBLEM", 86, 140], ["nitazoxanide", "TREATMENT", 181, 193], ["hepatotoxicity", "PROBLEM", 229, 243], ["jaundice", "PROBLEM", 253, 261], ["other hepatobiliary disorders", "PROBLEM", 274, 303], ["Hepatorenal and cardiovascular endpoints", "PROBLEM", 312, 352], ["cardiovascular", "ANATOMY", 3, 17], ["cardiovascular", "ANATOMY", 102, 116], ["hepatotoxicity", "OBSERVATION", 229, 243], ["jaundice", "OBSERVATION", 253, 261], ["hepatobiliary", "ANATOMY", 280, 293], ["Hepatorenal", "ANATOMY", 312, 323], ["cardiovascular", "ANATOMY", 328, 342]]], ["More Aes were reported as renal and urinary disorders, but the vast majority were cases of chromaturia (n = 63).", [["renal", "ANATOMY", 26, 31], ["urinary", "ANATOMY", 36, 43], ["renal and urinary disorders", "DISEASE", 26, 53], ["chromaturia", "DISEASE", 91, 102], ["Aes", "CANCER", 5, 8], ["renal", "ORGAN", 26, 31], ["urinary", "ORGANISM_SUBSTANCE", 36, 43], ["renal and urinary disorders", "PROBLEM", 26, 53], ["chromaturia", "TEST", 91, 102], ["renal", "ANATOMY", 26, 31], ["urinary", "ANATOMY", 36, 43], ["disorders", "OBSERVATION", 44, 53]]], ["Of note were nine cases of dysuria and four cases of azotaemia [40] .", [["dysuria", "DISEASE", 27, 34], ["azotaemia", "DISEASE", 53, 62], ["dysuria", "PROBLEM", 27, 34], ["azotaemia", "PROBLEM", 53, 62], ["dysuria", "OBSERVATION", 27, 34]]], ["No thrombotic disorders were noted on vigiAccess, but there were nine cases of dysrhythmia and three cases of acute coronary syndrome [40].Dose-dependent adverse eventsOn review of the available literature, no concerns were raised regarding dose-dependent Aes.", [["coronary", "ANATOMY", 116, 124], ["thrombotic disorders", "DISEASE", 3, 23], ["dysrhythmia", "DISEASE", 79, 90], ["acute coronary syndrome", "DISEASE", 110, 133], ["thrombotic disorders", "PROBLEM", 3, 23], ["dysrhythmia", "PROBLEM", 79, 90], ["acute coronary syndrome", "PROBLEM", 110, 133], ["dependent adverse events", "PROBLEM", 144, 168], ["dependent Aes", "PROBLEM", 246, 259], ["thrombotic", "OBSERVATION_MODIFIER", 3, 13], ["disorders", "OBSERVATION", 14, 23], ["acute", "OBSERVATION_MODIFIER", 110, 115], ["coronary", "ANATOMY", 116, 124], ["syndrome", "OBSERVATION", 125, 133]]], ["However, in one study which used single doses at 1000 mg up to 4000 mg, mild Gi Aes escalated with dose [5] .", [["Gi Aes", "CHEMICAL", 77, 83], ["Gi Aes", "SIMPLE_CHEMICAL", 77, 83], ["mild Gi Aes", "PROBLEM", 72, 83]]], ["On investigation of QT interval, no prolongation was observed with increased dose [41] .Costs analysisRegarding minimum costs of production, our analysis show that based on a weighted-mean APi cost of $61/kg, and a daily dose of 1000 mg (500 mg BD), a 14-day course of treatment with nitazoxanide would cost $1.41 after accounting for loss, excipients, formulation, profit and tax (Figure 3a) .", [["nitazoxanide", "CHEMICAL", 284, 296], ["nitazoxanide", "CHEMICAL", 284, 296], ["nitazoxanide", "SIMPLE_CHEMICAL", 284, 296], ["tax", "PROTEIN", 377, 380], ["QT interval", "TEST", 20, 31], ["prolongation", "PROBLEM", 36, 48], ["our analysis", "TEST", 141, 153], ["treatment", "TREATMENT", 269, 278], ["nitazoxanide", "TREATMENT", 284, 296], ["loss", "PROBLEM", 335, 339]]], ["At a higher dose of 1100 mg TDS, our estimated cost increased to $4.08 per 14-day course (Figure 3b ), equivalent to $0.29 per day.DiscussionThis analysis reviews clinical data on the safety of nitazoxanide and summarises available data from nine relevant RCTs, accounting for 1514 participants and an estimated 95.3 person-yearsof-follow-up.", [["nitazoxanide", "CHEMICAL", 194, 206], ["nitazoxanide", "CHEMICAL", 194, 206], ["nitazoxanide", "SIMPLE_CHEMICAL", 194, 206], ["participants", "SPECIES", 282, 294], ["clinical data", "TEST", 163, 176], ["nitazoxanide", "TREATMENT", 194, 206]]], ["Nitazoxanide demonstrates overall favourable safety, with no significant difference in the occurrence of total Aes, serious or Gi Aes compared with other antimicrobial regimens or with placebo control.DiscussionRegarding minimum costs of production, our analysis found that based on a daily dose of 1000 mg (500 mg BD), a 14-day course of treatment with nitazoxanide would cost $1.41.", [["Nitazoxanide", "CHEMICAL", 0, 12], ["Aes", "DISEASE", 111, 114], ["Gi Aes", "CHEMICAL", 127, 133], ["nitazoxanide", "CHEMICAL", 354, 366], ["Nitazoxanide", "CHEMICAL", 0, 12], ["nitazoxanide", "CHEMICAL", 354, 366], ["Nitazoxanide", "SIMPLE_CHEMICAL", 0, 12], ["Gi Aes", "SIMPLE_CHEMICAL", 127, 133], ["nitazoxanide", "SIMPLE_CHEMICAL", 354, 366], ["Nitazoxanide", "TREATMENT", 0, 12], ["total Aes", "PROBLEM", 105, 114], ["Gi Aes", "PROBLEM", 127, 133], ["other antimicrobial regimens", "TREATMENT", 148, 176], ["placebo control", "TREATMENT", 185, 200], ["our analysis", "TEST", 250, 262], ["treatment", "TREATMENT", 339, 348], ["nitazoxanide", "TREATMENT", 354, 366], ["overall", "OBSERVATION_MODIFIER", 26, 33], ["favourable", "OBSERVATION_MODIFIER", 34, 44]]], ["Therefore, if efficacy against COviD-19 is demonstrated in clinical studies, nitazoxanide may represent safe and affordable treatment in the ongoing pandemic.LimitationsOur analysis is limited to the publicly available body of literature. in the nine studies eligible for inclusion, treatment duration ranged 5-14 days, so the findings of this review can be applied only to similarly short courses of nitazoxanide and longer-term safety cannot be commented on.", [["COviD-19", "CHEMICAL", 31, 39], ["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 401, 413], ["COviD-19", "CHEMICAL", 31, 39], ["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 401, 413], ["COviD-19", "SIMPLE_CHEMICAL", 31, 39], ["nitazoxanide", "SIMPLE_CHEMICAL", 77, 89], ["nitazoxanide", "SIMPLE_CHEMICAL", 401, 413], ["COviD", "TEST", 31, 36], ["clinical studies", "TEST", 59, 75], ["nitazoxanide", "TREATMENT", 77, 89], ["affordable treatment", "TREATMENT", 113, 133], ["Our analysis", "TEST", 169, 181], ["treatment duration", "TEST", 283, 301], ["nitazoxanide", "TREATMENT", 401, 413], ["longer-term safety", "TREATMENT", 418, 436]]], ["Although this is similar to the likely duration of COviD-19 treatment, any potential usage in prevention would require further evidence to assess cumulative toxicity effect.LimitationsAlthough in vitro findings suggest that nitazoxanide might be active against COviD-19, it is not yet clear at what doses it needs to be administered to achieve clinical effect. it is likely that higher doses are needed.", [["COviD-19", "CHEMICAL", 51, 59], ["toxicity", "DISEASE", 157, 165], ["nitazoxanide", "CHEMICAL", 224, 236], ["COviD-19", "CHEMICAL", 51, 59], ["nitazoxanide", "CHEMICAL", 224, 236], ["COviD-19", "CHEMICAL", 261, 269], ["COviD-19", "GENE_OR_GENE_PRODUCT", 51, 59], ["nitazoxanide", "SIMPLE_CHEMICAL", 224, 236], ["COviD-19 treatment", "TREATMENT", 51, 69], ["cumulative toxicity effect", "PROBLEM", 146, 172], ["nitazoxanide", "TREATMENT", 224, 236], ["COviD", "TEST", 261, 266], ["is likely", "UNCERTAINTY", 364, 373]]], ["The studies included in this reviewReviewJournal of Virus Eradication 2020; 6 : 52-60ReviewNitazoxanide safety and pricing review 57 most commonly used doses of 500 mg BD, with age and weight variability in paediatric dosing.", [["The studies", "TEST", 0, 11], ["Virus Eradication", "TREATMENT", 52, 69], ["Nitazoxanide", "TREATMENT", 91, 103], ["paediatric dosing", "TREATMENT", 207, 224]]], ["Dose ranging studies were small and of shorter duration. if doses of >1000 mg per day are required for COviD-19 treatment, the possibility of dose-dependent Ae should be considered and further review will be required.ReviewThe generalisability of these findings is limited to the settings and populations in which the included trials were carried out, with a large proportion of the participants from the included studies being young (mean age 37 years).", [["COviD-19", "CHEMICAL", 103, 111], ["COviD-19", "CHEMICAL", 103, 111], ["participants", "SPECIES", 383, 395], ["Dose ranging studies", "TEST", 0, 20], ["COviD-19 treatment", "TREATMENT", 103, 121], ["small", "OBSERVATION_MODIFIER", 26, 31]]], ["This means findings may be less applicable to older COviD-19 patients.Gastrointestinal effectsPhase 1 studies of nitazoxanide identified Gi events as the most common side effect.", [["Gastrointestinal", "ANATOMY", 70, 86], ["nitazoxanide", "CHEMICAL", 113, 125], ["nitazoxanide", "CHEMICAL", 113, 125], ["patients", "ORGANISM", 61, 69], ["nitazoxanide", "SIMPLE_CHEMICAL", 113, 125], ["Gi", "GENE_OR_GENE_PRODUCT", 137, 139], ["patients", "SPECIES", 61, 69], ["Gastrointestinal effects", "PROBLEM", 70, 94], ["nitazoxanide", "TREATMENT", 113, 125], ["Gi events", "PROBLEM", 137, 146], ["may be", "UNCERTAINTY", 20, 26]]], ["These events were mild and no other serious events were noted [6, 20] .", [["other serious events", "PROBLEM", 30, 50], ["mild", "OBSERVATION_MODIFIER", 18, 22]]], ["On literature review, many small studies for 3 days of nitazoxanide to treat diarrhoeal disease inCardiovascular effectsA growing body of evidence demonstrates the cardiovascular effect of COviD-19.", [["cardiovascular", "ANATOMY", 164, 178], ["nitazoxanide", "CHEMICAL", 55, 67], ["diarrhoeal disease", "DISEASE", 77, 95], ["COviD-19", "CHEMICAL", 189, 197], ["nitazoxanide", "CHEMICAL", 55, 67], ["COviD-19", "CHEMICAL", 189, 197], ["nitazoxanide", "SIMPLE_CHEMICAL", 55, 67], ["COviD-19", "GENE_OR_GENE_PRODUCT", 189, 197], ["nitazoxanide", "TREATMENT", 55, 67], ["diarrhoeal disease inCardiovascular effects", "PROBLEM", 77, 120], ["COviD", "TEST", 189, 194], ["cardiovascular effect", "OBSERVATION", 164, 185]]], ["Relatively common complications include myocarditis, with changes on eCG and echocardiogram. increases in troponin and B-type natriuretic peptide may be prognostic [42] [43] [44] .", [["myocarditis", "DISEASE", 40, 51], ["eCG", "SIMPLE_CHEMICAL", 69, 72], ["troponin", "GENE_OR_GENE_PRODUCT", 106, 114], ["B-type natriuretic peptide", "GENE_OR_GENE_PRODUCT", 119, 145], ["troponin", "PROTEIN", 106, 114], ["Relatively common complications", "PROBLEM", 0, 31], ["myocarditis", "PROBLEM", 40, 51], ["eCG", "TEST", 69, 72], ["echocardiogram", "TEST", 77, 91], ["troponin", "TEST", 106, 114], ["B-type natriuretic peptide", "TEST", 119, 145], ["myocarditis", "OBSERVATION", 40, 51]]], ["There is also a procoagulatory effect of moderate to severe COviD-19 [45] , with prothrombotic states leading to embolic events [46, 47] and D-dimer being shown to act as a prognostic indicator [48, 49] .Cardiovascular effectsGiven the known cardiovascular complications of COviD-19, it is important to assess the cardiovascular effects of potential treatments.", [["Cardiovascular", "ANATOMY", 204, 218], ["cardiovascular", "ANATOMY", 242, 256], ["cardiovascular", "ANATOMY", 314, 328], ["COviD-19", "CHEMICAL", 60, 68], ["COviD-19", "CHEMICAL", 274, 282], ["D-dimer", "SIMPLE_CHEMICAL", 141, 148], ["cardiovascular", "ANATOMICAL_SYSTEM", 242, 256], ["cardiovascular", "ANATOMICAL_SYSTEM", 314, 328], ["a procoagulatory effect", "PROBLEM", 14, 37], ["moderate to severe COviD", "PROBLEM", 41, 65], ["prothrombotic states", "PROBLEM", 81, 101], ["embolic events", "PROBLEM", 113, 127], ["D-dimer", "PROBLEM", 141, 148], ["Cardiovascular effects", "PROBLEM", 204, 226], ["the known cardiovascular complications", "PROBLEM", 232, 270], ["COviD", "TEST", 274, 279], ["potential treatments", "TREATMENT", 340, 360], ["moderate", "OBSERVATION_MODIFIER", 41, 49], ["severe", "OBSERVATION_MODIFIER", 53, 59], ["embolic", "OBSERVATION", 113, 120], ["cardiovascular", "ANATOMY", 242, 256], ["complications", "OBSERVATION", 257, 270]]], ["A phase 1 study of nitazoxanide showed no QT prolongation in healthy volunteers [41] .", [["nitazoxanide", "CHEMICAL", 19, 31], ["QT prolongation", "DISEASE", 42, 57], ["nitazoxanide", "CHEMICAL", 19, 31], ["nitazoxanide", "SIMPLE_CHEMICAL", 19, 31], ["A phase 1 study", "TEST", 0, 15], ["nitazoxanide", "TREATMENT", 19, 31], ["QT prolongation in healthy volunteers", "PROBLEM", 42, 79], ["no", "UNCERTAINTY", 39, 41]]], ["However, there has been no specific further study in later stage clinical trials.", [["specific further study", "TEST", 27, 49], ["no", "UNCERTAINTY", 24, 26]]], ["None of the nine studies included in this review reported any cardiovascular Aes, although it is possible that studies did not monitor for relevant biomarkers and any cardiac effect may have been overlooked.Hepatorenal effectsPrescribing information from the FDA lists nitazoxanide safety as unstudied in patients with hepatic and renal impairment [19] .", [["cardiovascular", "ANATOMY", 62, 76], ["cardiac", "ANATOMY", 167, 174], ["Hepatorenal", "ANATOMY", 207, 218], ["hepatic", "ANATOMY", 319, 326], ["renal", "ANATOMY", 331, 336], ["cardiovascular Aes", "DISEASE", 62, 80], ["nitazoxanide", "CHEMICAL", 269, 281], ["hepatic and renal impairment", "DISEASE", 319, 347], ["nitazoxanide", "CHEMICAL", 269, 281], ["cardiac", "ORGAN", 167, 174], ["nitazoxanide", "SIMPLE_CHEMICAL", 269, 281], ["patients", "ORGANISM", 305, 313], ["hepatic", "ORGAN", 319, 326], ["renal", "ORGAN", 331, 336], ["patients", "SPECIES", 305, 313], ["the nine studies", "TEST", 8, 24], ["relevant biomarkers", "TEST", 139, 158], ["any cardiac effect", "PROBLEM", 163, 181], ["Hepatorenal effects", "PROBLEM", 207, 226], ["nitazoxanide safety", "TREATMENT", 269, 288], ["hepatic and renal impairment", "PROBLEM", 319, 347], ["effects", "OBSERVATION", 219, 226], ["hepatic", "ANATOMY", 319, 326], ["renal", "ANATOMY", 331, 336], ["impairment", "OBSERVATION", 337, 347]]], ["COviD-19 is known to cause liver damage, renal failure and dehydration [21, 22] . in particular, COviD-19 patients are prone to hepatic transaminitis, proteinuria and increased serum creatinine and uric acid [21, 22] . in the nitazoxanide studies reviewed, none of these markers were reported except for deranged liver function tests in two.", [["liver", "ANATOMY", 27, 32], ["renal", "ANATOMY", 41, 46], ["hepatic", "ANATOMY", 128, 135], ["serum", "ANATOMY", 177, 182], ["liver", "ANATOMY", 313, 318], ["COviD-19", "CHEMICAL", 0, 8], ["liver damage", "DISEASE", 27, 39], ["renal failure", "DISEASE", 41, 54], ["dehydration", "DISEASE", 59, 70], ["hepatic transaminitis", "DISEASE", 128, 149], ["proteinuria", "DISEASE", 151, 162], ["creatinine", "CHEMICAL", 183, 193], ["uric acid", "CHEMICAL", 198, 207], ["COviD-19", "CHEMICAL", 0, 8], ["creatinine", "CHEMICAL", 183, 193], ["uric acid", "CHEMICAL", 198, 207], ["nitazoxanide", "CHEMICAL", 226, 238], ["COviD-19", "GENE_OR_GENE_PRODUCT", 0, 8], ["liver", "ORGAN", 27, 32], ["renal", "ORGAN", 41, 46], ["patients", "ORGANISM", 106, 114], ["hepatic", "ORGAN", 128, 135], ["serum", "ORGANISM_SUBSTANCE", 177, 182], ["creatinine", "SIMPLE_CHEMICAL", 183, 193], ["uric acid", "SIMPLE_CHEMICAL", 198, 207], ["liver", "ORGAN", 313, 318], ["patients", "SPECIES", 106, 114], ["COviD", "TEST", 0, 5], ["liver damage", "PROBLEM", 27, 39], ["renal failure", "PROBLEM", 41, 54], ["dehydration", "PROBLEM", 59, 70], ["COviD", "TEST", 97, 102], ["hepatic transaminitis", "PROBLEM", 128, 149], ["proteinuria", "PROBLEM", 151, 162], ["increased serum creatinine", "PROBLEM", 167, 193], ["uric acid", "TEST", 198, 207], ["the nitazoxanide studies", "TEST", 222, 246], ["these markers", "TEST", 265, 278], ["deranged liver function tests", "PROBLEM", 304, 333], ["liver", "ANATOMY", 27, 32], ["damage", "OBSERVATION", 33, 39], ["renal", "ANATOMY", 41, 46], ["failure", "OBSERVATION", 47, 54], ["dehydration", "OBSERVATION_MODIFIER", 59, 70], ["hepatic", "ANATOMY", 128, 135], ["transaminitis", "OBSERVATION", 136, 149], ["proteinuria", "OBSERVATION", 151, 162], ["increased", "OBSERVATION_MODIFIER", 167, 176], ["liver", "ANATOMY", 313, 318]]], ["As such, we call for reporting of hepatorenal endpoints in future studies of nitazoxanide, especially those undertaken in COviD-19 patients.Pregnancy and breastfeedingRegarding the potential for teratogenic effects of nitazoxanide, the existent evidence base is limited. in early animal studies, nitazoxanide did not adversely affect fertility, even at high doses in rats.", [["hepatorenal", "DISEASE", 34, 45], ["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 218, 230], ["nitazoxanide", "CHEMICAL", 296, 308], ["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 218, 230], ["nitazoxanide", "CHEMICAL", 296, 308], ["nitazoxanide", "SIMPLE_CHEMICAL", 77, 89], ["patients", "ORGANISM", 131, 139], ["nitazoxanide", "SIMPLE_CHEMICAL", 218, 230], ["nitazoxanide", "SIMPLE_CHEMICAL", 296, 308], ["rats", "ORGANISM", 367, 371], ["patients", "SPECIES", 131, 139], ["rats", "SPECIES", 367, 371], ["hepatorenal endpoints", "PROBLEM", 34, 55], ["nitazoxanide", "TREATMENT", 77, 89], ["breastfeeding", "TREATMENT", 154, 167], ["teratogenic effects", "PROBLEM", 195, 214], ["nitazoxanide", "TREATMENT", 218, 230], ["early animal studies", "TEST", 274, 294], ["nitazoxanide", "TREATMENT", 296, 308], ["hepatorenal", "ANATOMY", 34, 45], ["base", "ANATOMY_MODIFIER", 254, 258]]], ["There was also no evidence of harm to the fetus in rats or rabbits, despite high-dose regimens.", [["fetus", "ANATOMY", 42, 47], ["fetus", "ORGANISM", 42, 47], ["rats", "ORGANISM", 51, 55], ["rabbits", "ORGANISM", 59, 66], ["rats", "SPECIES", 51, 55], ["rabbits", "SPECIES", 59, 66], ["rabbits", "SPECIES", 59, 66], ["harm to the fetus in rats", "PROBLEM", 30, 55], ["high-dose regimens", "TREATMENT", 76, 94], ["no evidence of", "UNCERTAINTY", 15, 29], ["harm", "OBSERVATION", 30, 34]]], ["However, there are no adequate studies assessing the effects of nitazoxanide in pregnant women, and it is not known whether nitazoxanide is excreted in human breast milk [20] .", [["breast milk", "ANATOMY", 158, 169], ["nitazoxanide", "CHEMICAL", 64, 76], ["nitazoxanide", "CHEMICAL", 124, 136], ["nitazoxanide", "CHEMICAL", 64, 76], ["nitazoxanide", "CHEMICAL", 124, 136], ["nitazoxanide", "SIMPLE_CHEMICAL", 64, 76], ["women", "ORGANISM", 89, 94], ["nitazoxanide", "SIMPLE_CHEMICAL", 124, 136], ["human", "ORGANISM", 152, 157], ["breast milk", "ORGANISM_SUBSTANCE", 158, 169], ["women", "SPECIES", 89, 94], ["human", "SPECIES", 152, 157], ["human", "SPECIES", 152, 157], ["adequate studies", "TEST", 22, 38], ["nitazoxanide", "TREATMENT", 64, 76], ["nitazoxanide", "TREATMENT", 124, 136], ["no", "UNCERTAINTY", 19, 21]]], ["Therefore, the FDA catagorises the potential of teratogenic effects as 'Category B' [19] , denoting no particular cause for concern but an inadequate evidence base to draw a complete conclusion on safety.", [["teratogenic effects", "PROBLEM", 48, 67], ["no particular", "UNCERTAINTY", 100, 113]]], ["Caution continues to be advised in both pregnant women and nursing mothers.Dose-dependent effectsMuch higher doses than used in studies included in this review may be indicated for in vivo inhibition of SARS-Cov-2.", [["SARS", "DISEASE", 203, 207], ["women", "ORGANISM", 49, 54], ["SARS-Cov-2", "GENE_OR_GENE_PRODUCT", 203, 213], ["women", "SPECIES", 49, 54], ["dependent effects", "PROBLEM", 80, 97]]], ["Although no serious dose-dependent Aes have been noted in the literature for nitazoxanide, there are limited data on the use of nitazoxanide at higher doses.", [["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 128, 140], ["nitazoxanide", "CHEMICAL", 77, 89], ["nitazoxanide", "CHEMICAL", 128, 140], ["nitazoxanide", "SIMPLE_CHEMICAL", 77, 89], ["nitazoxanide", "SIMPLE_CHEMICAL", 128, 140], ["nitazoxanide", "TREATMENT", 77, 89], ["nitazoxanide", "TREATMENT", 128, 140], ["no", "UNCERTAINTY", 9, 11], ["serious", "OBSERVATION_MODIFIER", 12, 19]]], ["At a higher dose, nitazoxanide has been shown to cause mild Gi Aes, but not to prolongate QT interval.Costs of productionAs expected, our estimated cost of production, both for a 14-day period and on a daily basis, is very low and in line with potential COviD-19 treatments already analysed [14] .", [["nitazoxanide", "CHEMICAL", 18, 30], ["nitazoxanide", "CHEMICAL", 18, 30], ["nitazoxanide", "SIMPLE_CHEMICAL", 18, 30], ["Gi Aes", "GENE_OR_GENE_PRODUCT", 60, 66], ["nitazoxanide", "TREATMENT", 18, 30], ["mild Gi Aes", "PROBLEM", 55, 66], ["potential COviD-19 treatments", "TREATMENT", 244, 273]]], ["Therefore, should future clinical trial data support the use of nitazoxanide therapy for COviD-19, it could be mass produced at a minimal cost to ensure wide access especially for low-and middle-income countries.Costs of productionit is worth noting, however, that our estimated costs presume that production is carried out by a generic manufacturer, for example in india (which is the leading centre of generic drug manufacturing), where associated costs of capital investment, overhead and labour are significantly less than originator companies, in this case Romark Laboratories.", [["nitazoxanide", "CHEMICAL", 64, 76], ["nitazoxanide", "CHEMICAL", 64, 76], ["COviD-19", "CHEMICAL", 89, 97], ["nitazoxanide", "SIMPLE_CHEMICAL", 64, 76], ["nitazoxanide therapy", "TREATMENT", 64, 84], ["COviD", "TEST", 89, 94], ["mass", "PROBLEM", 111, 115], ["wide access", "TREATMENT", 153, 164], ["overhead and labour", "PROBLEM", 479, 498], ["mass", "OBSERVATION", 111, 115], ["capital investment", "OBSERVATION", 459, 477]]], ["Additionally, when comparing against current list prices, the 'real' list price in countries may be lower because of in-country negotiated discounts.ConclusionNitazoxanide demonstrates an overall favourable safety profile, with no significant difference in the occurrence of total Aes, serious or gastrointestinal Aes compared with other antimicrobial regimens or with placebo control.", [["gastrointestinal", "ANATOMY", 297, 313], ["Nitazoxanide", "CHEMICAL", 159, 171], ["Aes", "DISEASE", 281, 284], ["Nitazoxanide", "CHEMICAL", 159, 171], ["Nitazoxanide", "SIMPLE_CHEMICAL", 159, 171], ["Nitazoxanide", "TREATMENT", 159, 171], ["total Aes", "PROBLEM", 275, 284], ["other antimicrobial regimens", "TREATMENT", 332, 360], ["placebo control", "TREATMENT", 369, 384], ["gastrointestinal", "ANATOMY", 297, 313]]], ["Further evidence is required regarding specific hepatorenal and cardiovascular effects, as well as the potential for teratogenicity, but existing evidence provides no particular cause for concern.", [["hepatorenal", "ANATOMY", 48, 59], ["cardiovascular", "ANATOMY", 64, 78], ["hepatorenal", "DISEASE", 48, 59], ["cardiovascular", "ANATOMICAL_SYSTEM", 64, 78], ["specific hepatorenal and cardiovascular effects", "PROBLEM", 39, 86], ["teratogenicity", "PROBLEM", 117, 131], ["hepatorenal", "OBSERVATION", 48, 59], ["no particular", "UNCERTAINTY", 164, 177]]], ["However, we recommend caution and careful monitoring in hepatorenally impaired patients.Conclusionwe estimate that it would be possible to manufacture nitazoxanide as generic for $1.41 for a 14-day treatment course at 500 mg BD, up to $4.08 at 1100 mg TDS.", [["hepatorenally impaired", "DISEASE", 56, 78], ["nitazoxanide", "CHEMICAL", 151, 163], ["nitazoxanide", "CHEMICAL", 151, 163], ["patients", "ORGANISM", 79, 87], ["nitazoxanide", "SIMPLE_CHEMICAL", 151, 163], ["patients", "SPECIES", 79, 87], ["careful monitoring", "TEST", 34, 52], ["nitazoxanide", "TREATMENT", 151, 163], ["a 14-day treatment course", "TREATMENT", 189, 214]]], ["A Mexican study comparing nitazoxanide with hydroxychloroquine for COviD-19 is currently recruiting (US Clinical Trials registry number NCT04341493) participants.", [["nitazoxanide", "CHEMICAL", 26, 38], ["hydroxychloroquine", "CHEMICAL", 44, 62], ["COviD-19", "CHEMICAL", 67, 75], ["nitazoxanide", "CHEMICAL", 26, 38], ["hydroxychloroquine", "CHEMICAL", 44, 62], ["COviD-19", "CHEMICAL", 67, 75], ["nitazoxanide", "SIMPLE_CHEMICAL", 26, 38], ["hydroxychloroquine", "SIMPLE_CHEMICAL", 44, 62], ["participants", "SPECIES", 149, 161], ["A Mexican study", "TEST", 0, 15], ["nitazoxanide", "TREATMENT", 26, 38], ["hydroxychloroquine", "TREATMENT", 44, 62], ["COviD", "TREATMENT", 67, 72]]], ["Further trials in COviD-19 patients should be initiated, but the high reported in vitro activity of nitazoxanide against SARS-Cov-2 should also be confirmed. if efficacy against SARS-Cov-2 is demonstrated in clinical studies, nitazoxanide may represent a safe and affordable treatment in the ongoing pandemic.FundingFunding received from the international Treatment Preparedness Coalition as part of the Unitaid-supported project 'Affordable Medicines for Developing Countries'.Conflicts of interestvP and TP have no conflicts of interest to declare.", [["nitazoxanide", "CHEMICAL", 100, 112], ["SARS", "DISEASE", 121, 125], ["SARS", "DISEASE", 178, 182], ["nitazoxanide", "CHEMICAL", 226, 238], ["nitazoxanide", "CHEMICAL", 100, 112], ["nitazoxanide", "CHEMICAL", 226, 238], ["COviD-19", "ORGANISM", 18, 26], ["patients", "ORGANISM", 27, 35], ["nitazoxanide", "SIMPLE_CHEMICAL", 100, 112], ["nitazoxanide", "SIMPLE_CHEMICAL", 226, 238], ["TP", "GENE_OR_GENE_PRODUCT", 506, 508], ["patients", "SPECIES", 27, 35], ["Further trials in COviD", "TREATMENT", 0, 23], ["nitazoxanide", "TREATMENT", 100, 112], ["SARS", "PROBLEM", 121, 125], ["SARS", "PROBLEM", 178, 182], ["Cov", "TEST", 183, 186], ["clinical studies", "TEST", 208, 224], ["nitazoxanide", "TREATMENT", 226, 238], ["affordable treatment", "TREATMENT", 264, 284]]], ["He is a Director for Tandem Nano Ltd, which is not related to this project.", [["Tandem Nano Ltd", "TREATMENT", 21, 36], ["Nano Ltd", "OBSERVATION", 28, 36], ["not related to", "UNCERTAINTY", 47, 61]]]], "834b1aa5fa0430400f66e2434dfad1838ead778b": [["INTRODUCTIONMetabolic syndrome (MetS) is a cluster of metabolic abnormalities, including obesity, type 2 diabetic mellitus (T2DM), and dyslipidemia.", [["INTRODUCTIONMetabolic syndrome", "DISEASE", 0, 30], ["MetS", "DISEASE", 32, 36], ["metabolic abnormalities", "DISEASE", 54, 77], ["obesity", "DISEASE", 89, 96], ["type 2 diabetic mellitus", "DISEASE", 98, 122], ["T2DM", "DISEASE", 124, 128], ["dyslipidemia", "DISEASE", 135, 147], ["INTRODUCTIONMetabolic syndrome", "PROBLEM", 0, 30], ["MetS", "PROBLEM", 32, 36], ["metabolic abnormalities", "PROBLEM", 54, 77], ["obesity", "PROBLEM", 89, 96], ["type 2 diabetic mellitus", "PROBLEM", 98, 122], ["T2DM)", "PROBLEM", 124, 129], ["dyslipidemia", "PROBLEM", 135, 147], ["MetS", "OBSERVATION", 32, 36], ["cluster", "OBSERVATION_MODIFIER", 43, 50], ["metabolic abnormalities", "OBSERVATION", 54, 77], ["obesity", "OBSERVATION", 89, 96], ["diabetic", "OBSERVATION_MODIFIER", 105, 113], ["mellitus", "OBSERVATION", 114, 122], ["dyslipidemia", "OBSERVATION", 135, 147]]], ["The prevalence of both obesity and MetS continues to rise worldwide.", [["obesity", "DISEASE", 23, 30], ["MetS", "DISEASE", 35, 39], ["both obesity", "PROBLEM", 18, 30], ["MetS", "PROBLEM", 35, 39], ["both", "OBSERVATION_MODIFIER", 18, 22], ["obesity", "OBSERVATION", 23, 30], ["MetS", "OBSERVATION", 35, 39]]], ["Non-alcoholic fatty-liver disease (NAFLD) consists of a spectrum of chronic liver disorders from simple hepatic steatosis, steatohepatitis, and fibrosis to cirrhosis, and even carcinoma.", [["Non-alcoholic fatty-liver", "ANATOMY", 0, 25], ["liver", "ANATOMY", 76, 81], ["hepatic", "ANATOMY", 104, 111], ["carcinoma", "ANATOMY", 176, 185], ["fatty-liver disease", "DISEASE", 14, 33], ["NAFLD", "DISEASE", 35, 40], ["liver disorders", "DISEASE", 76, 91], ["hepatic steatosis", "DISEASE", 104, 121], ["steatohepatitis", "DISEASE", 123, 138], ["fibrosis", "DISEASE", 144, 152], ["cirrhosis", "DISEASE", 156, 165], ["carcinoma", "DISEASE", 176, 185], ["liver", "ORGAN", 20, 25], ["liver", "ORGAN", 76, 81], ["hepatic", "ORGAN", 104, 111], ["carcinoma", "CANCER", 176, 185], ["Non-alcoholic fatty-liver disease (NAFLD)", "PROBLEM", 0, 41], ["chronic liver disorders", "PROBLEM", 68, 91], ["simple hepatic steatosis", "PROBLEM", 97, 121], ["steatohepatitis", "PROBLEM", 123, 138], ["fibrosis to cirrhosis", "PROBLEM", 144, 165], ["even carcinoma", "PROBLEM", 171, 185], ["liver", "ANATOMY", 20, 25], ["disease", "OBSERVATION", 26, 33], ["chronic", "OBSERVATION_MODIFIER", 68, 75], ["liver", "ANATOMY", 76, 81], ["disorders", "OBSERVATION", 82, 91], ["simple", "OBSERVATION_MODIFIER", 97, 103], ["hepatic", "ANATOMY", 104, 111], ["steatosis", "OBSERVATION", 112, 121], ["steatohepatitis", "OBSERVATION", 123, 138], ["fibrosis", "OBSERVATION", 144, 152], ["cirrhosis", "OBSERVATION", 156, 165], ["carcinoma", "OBSERVATION", 176, 185]]], ["NAFLD is expected to become the most common cause of chronic liver diseases, may be affecting >30% of the general population [1] .", [["liver", "ANATOMY", 61, 66], ["NAFLD", "DISEASE", 0, 5], ["chronic liver diseases", "DISEASE", 53, 75], ["liver", "ORGAN", 61, 66], ["NAFLD", "PROBLEM", 0, 5], ["chronic liver diseases", "PROBLEM", 53, 75], ["chronic", "OBSERVATION_MODIFIER", 53, 60], ["liver", "ANATOMY", 61, 66], ["diseases", "OBSERVATION", 67, 75]]], ["NAFLD may be viewed as a hepatic form of MetS [2] [3] [4] [5] .", [["hepatic", "ANATOMY", 25, 32], ["NAFLD", "DISEASE", 0, 5], ["MetS", "DISEASE", 41, 45], ["MetS [2] [3] [4] [5]", "SIMPLE_CHEMICAL", 41, 61], ["MetS", "TEST", 41, 45], ["hepatic", "ANATOMY", 25, 32]]], ["Glucose and triglycerides (TG) represent two key Mets components, and a fatty liver may secrete more glucose and TG in addition to hepatic accumulation.", [["fatty liver", "ANATOMY", 72, 83], ["hepatic", "ANATOMY", 131, 138], ["Glucose", "CHEMICAL", 0, 7], ["fatty liver", "DISEASE", 72, 83], ["glucose", "CHEMICAL", 101, 108], ["TG", "DISEASE", 113, 115], ["Glucose", "CHEMICAL", 0, 7], ["triglycerides", "CHEMICAL", 12, 25], ["glucose", "CHEMICAL", 101, 108], ["Glucose", "SIMPLE_CHEMICAL", 0, 7], ["triglycerides", "SIMPLE_CHEMICAL", 12, 25], ["TG", "SIMPLE_CHEMICAL", 27, 29], ["Mets", "GENE_OR_GENE_PRODUCT", 49, 53], ["liver", "ORGAN", 78, 83], ["glucose", "SIMPLE_CHEMICAL", 101, 108], ["TG", "SIMPLE_CHEMICAL", 113, 115], ["hepatic", "ORGAN", 131, 138], ["Glucose", "TEST", 0, 7], ["triglycerides", "TEST", 12, 25], ["TG", "TEST", 27, 29], ["two key Mets components", "PROBLEM", 41, 64], ["a fatty liver", "PROBLEM", 70, 83], ["TG", "TEST", 113, 115], ["hepatic accumulation", "PROBLEM", 131, 151], ["two", "OBSERVATION_MODIFIER", 41, 44], ["key", "OBSERVATION_MODIFIER", 45, 48], ["Mets", "OBSERVATION", 49, 53], ["liver", "ANATOMY", 78, 83], ["hepatic", "ANATOMY", 131, 138], ["accumulation", "OBSERVATION", 139, 151]]], ["The liver is therefore a key participant in metabolic abnormalities [6] .", [["liver", "ANATOMY", 4, 9], ["metabolic abnormalities", "DISEASE", 44, 67], ["liver", "ORGAN", 4, 9], ["metabolic abnormalities", "PROBLEM", 44, 67], ["liver", "ANATOMY", 4, 9], ["metabolic abnormalities", "OBSERVATION", 44, 67]]], ["Insulin resistance is progressively recognized as a link between MetS and NAFLD [3, 7, 8] and is associated with excessive lipid accumulation in the liver (steatosis), which may further augment insulin resistance.", [["liver", "ANATOMY", 149, 154], ["Insulin", "CHEMICAL", 0, 7], ["MetS", "DISEASE", 65, 69], ["NAFLD", "DISEASE", 74, 79], ["steatosis", "DISEASE", 156, 165], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["lipid", "SIMPLE_CHEMICAL", 123, 128], ["liver", "ORGAN", 149, 154], ["insulin", "GENE_OR_GENE_PRODUCT", 194, 201], ["Insulin resistance", "TREATMENT", 0, 18], ["MetS", "PROBLEM", 65, 69], ["excessive lipid accumulation in the liver", "PROBLEM", 113, 154], ["steatosis", "PROBLEM", 156, 165], ["excessive", "OBSERVATION_MODIFIER", 113, 122], ["lipid accumulation", "OBSERVATION", 123, 141], ["liver", "ANATOMY", 149, 154], ["steatosis", "OBSERVATION", 156, 165], ["insulin resistance", "OBSERVATION", 194, 212]]], ["This favors the use of insulin sensitizers for treating both MetS and NAFLD.INTRODUCTIONThe drug targets for insulin sensitizers include PPAR\u03b3 [9] and PTP1B [10] .", [["insulin sensitizers", "CHEMICAL", 23, 42], ["MetS", "DISEASE", 61, 65], ["NAFLD", "DISEASE", 70, 75], ["insulin", "GENE_OR_GENE_PRODUCT", 23, 30], ["insulin", "GENE_OR_GENE_PRODUCT", 109, 116], ["PPAR\u03b3 [9]", "GENE_OR_GENE_PRODUCT", 137, 146], ["PTP1B", "GENE_OR_GENE_PRODUCT", 151, 156], ["PPAR\u03b3 [9]", "PROTEIN", 137, 146], ["PTP1B", "PROTEIN", 151, 156], ["insulin sensitizers", "TREATMENT", 23, 42], ["both MetS", "PROBLEM", 56, 65], ["NAFLD", "PROBLEM", 70, 75], ["insulin sensitizers", "TREATMENT", 109, 128], ["MetS", "OBSERVATION", 61, 65], ["NAFLD", "OBSERVATION", 70, 75]]], ["PPAR\u03b3 agonists are not on the recommendation list, while PTP1B inhibitors need regulatory approval for clinical applications.", [["PPAR\u03b3", "GENE_OR_GENE_PRODUCT", 0, 5], ["PTP1B", "GENE_OR_GENE_PRODUCT", 57, 62], ["PTP1B", "PROTEIN", 57, 62], ["PTP1B inhibitors", "TREATMENT", 57, 73], ["clinical applications", "TREATMENT", 103, 124]]], ["Accumulated evidence over the last decade suggests that bone also functions as an endocrine organ regulating wholebody glucose and energy metabolism.", [["bone", "ANATOMY", 56, 60], ["endocrine organ", "ANATOMY", 82, 97], ["wholebody", "ANATOMY", 109, 118], ["glucose", "CHEMICAL", 119, 126], ["glucose", "CHEMICAL", 119, 126], ["bone", "TISSUE", 56, 60], ["endocrine organ", "TISSUE", 82, 97], ["glucose", "SIMPLE_CHEMICAL", 119, 126], ["bone also functions", "PROBLEM", 56, 75], ["an endocrine organ", "TEST", 79, 97], ["bone", "ANATOMY", 56, 60], ["energy metabolism", "OBSERVATION", 131, 148]]], ["Osteoblasts in the bone marrow express osteocalcin, which undergoes post-translational carboxylation and deposits in mineralized bone matrix.", [["Osteoblasts", "ANATOMY", 0, 11], ["bone marrow", "ANATOMY", 19, 30], ["bone matrix", "ANATOMY", 129, 140], ["Osteoblasts", "CELL", 0, 11], ["bone marrow", "MULTI-TISSUE_STRUCTURE", 19, 30], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 39, 50], ["bone", "TISSUE", 129, 133], ["matrix", "CELLULAR_COMPONENT", 134, 140], ["Osteoblasts", "CELL_TYPE", 0, 11], ["osteocalcin", "PROTEIN", 39, 50], ["Osteoblasts in the bone marrow express osteocalcin", "PROBLEM", 0, 50], ["post-translational carboxylation and deposits in mineralized bone matrix", "TREATMENT", 68, 140], ["bone marrow", "ANATOMY", 19, 30], ["osteocalcin", "OBSERVATION", 39, 50], ["deposits", "OBSERVATION", 105, 113], ["mineralized bone matrix", "OBSERVATION", 117, 140]]], ["A portion of osteocalcin remains uncarboxylated (uncarboxylated osteocalcin, GluOC) and can be released into blood, where it functions as a hormone to regulate insulin secretion and insulin sensitivity [11] [12] [13] .", [["blood", "ANATOMY", 109, 114], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 13, 24], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 64, 75], ["GluOC", "GENE_OR_GENE_PRODUCT", 77, 82], ["blood", "ORGANISM_SUBSTANCE", 109, 114], ["insulin", "GENE_OR_GENE_PRODUCT", 160, 167], ["insulin", "GENE_OR_GENE_PRODUCT", 182, 189], ["[11] [12] [13]", "SIMPLE_CHEMICAL", 202, 216], ["osteocalcin", "PROTEIN", 13, 24], ["uncarboxylated osteocalcin", "PROTEIN", 49, 75], ["GluOC", "PROTEIN", 77, 82], ["osteocalcin", "TEST", 13, 24], ["a hormone", "TREATMENT", 138, 147], ["insulin secretion", "TEST", 160, 177], ["insulin sensitivity", "TEST", 182, 201], ["osteocalcin", "OBSERVATION", 13, 24]]], ["For instance, elevated blood glucose, impaired glucose tolerance, insulin resistance, lower energy expenditure, and impaired \u03b2-cell function were observed in osteocalcin knockout mice (Ocn -/-) [12] .", [["blood", "ANATOMY", 23, 28], ["\u03b2-cell", "ANATOMY", 125, 131], ["glucose", "CHEMICAL", 29, 36], ["glucose", "CHEMICAL", 47, 54], ["glucose", "CHEMICAL", 29, 36], ["glucose", "CHEMICAL", 47, 54], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["glucose", "SIMPLE_CHEMICAL", 29, 36], ["glucose", "SIMPLE_CHEMICAL", 47, 54], ["insulin", "GENE_OR_GENE_PRODUCT", 66, 73], ["\u03b2-cell", "MULTI-TISSUE_STRUCTURE", 125, 131], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 158, 169], ["mice", "ORGANISM", 179, 183], ["osteocalcin", "PROTEIN", 158, 169], ["mice", "SPECIES", 179, 183], ["elevated blood glucose", "PROBLEM", 14, 36], ["impaired glucose tolerance", "PROBLEM", 38, 64], ["insulin resistance", "PROBLEM", 66, 84], ["lower energy expenditure", "PROBLEM", 86, 110], ["impaired \u03b2-cell function", "PROBLEM", 116, 140], ["elevated", "OBSERVATION", 14, 22], ["glucose tolerance", "OBSERVATION", 47, 64]]], ["Osteocalcin exerts its biological function by binding to G proteincoupled receptor family C member A (GPRC6A) in target organs.", [["organs", "ANATOMY", 120, 126], ["Osteocalcin", "GENE_OR_GENE_PRODUCT", 0, 11], ["G proteincoupled receptor family C member A", "GENE_OR_GENE_PRODUCT", 57, 100], ["GPRC6A", "GENE_OR_GENE_PRODUCT", 102, 108], ["organs", "ORGAN", 120, 126], ["Osteocalcin", "PROTEIN", 0, 11], ["G proteincoupled receptor family C member A", "PROTEIN", 57, 100], ["GPRC6A", "PROTEIN", 102, 108], ["organs", "ANATOMY", 120, 126]]], ["GPRC6A involvement was demonstrated by GPRC6A -/mice, which displayed the phenotype of hepatic steatosis, hyperglycemia, glucose intolerance, and insulin resistance [14] .", [["hepatic", "ANATOMY", 87, 94], ["hepatic steatosis", "DISEASE", 87, 104], ["hyperglycemia", "DISEASE", 106, 119], ["glucose intolerance", "DISEASE", 121, 140], ["glucose", "CHEMICAL", 121, 128], ["GPRC6A", "GENE_OR_GENE_PRODUCT", 0, 6], ["GPRC6A", "GENE_OR_GENE_PRODUCT", 39, 45], ["mice", "ORGANISM", 48, 52], ["hepatic", "ORGAN", 87, 94], ["glucose", "SIMPLE_CHEMICAL", 121, 128], ["insulin", "GENE_OR_GENE_PRODUCT", 146, 153], ["GPRC6A", "PROTEIN", 0, 6], ["GPRC6A", "PROTEIN", 39, 45], ["mice", "SPECIES", 48, 52], ["GPRC6A involvement", "PROBLEM", 0, 18], ["GPRC6A", "TEST", 39, 45], ["hepatic steatosis", "PROBLEM", 87, 104], ["hyperglycemia", "PROBLEM", 106, 119], ["glucose intolerance", "PROBLEM", 121, 140], ["insulin resistance", "TREATMENT", 146, 164], ["hepatic", "ANATOMY", 87, 94], ["steatosis", "OBSERVATION", 95, 104], ["hyperglycemia", "OBSERVATION", 106, 119], ["glucose intolerance", "OBSERVATION", 121, 140], ["insulin resistance", "OBSERVATION", 146, 164]]], ["An increase in the serum osteocalcin level through administration of exogenous osteocalcin mitigated obesity and glucose intolerance in chow-or high-fat diet (HFD)-fed mice [15] [16] [17] .", [["serum", "ANATOMY", 19, 24], ["obesity", "DISEASE", 101, 108], ["glucose intolerance", "DISEASE", 113, 132], ["glucose", "CHEMICAL", 113, 120], ["serum", "ORGANISM_SUBSTANCE", 19, 24], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 25, 36], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 79, 90], ["glucose", "SIMPLE_CHEMICAL", 113, 120], ["HFD", "SIMPLE_CHEMICAL", 159, 162], ["mice", "ORGANISM", 168, 172], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 173, 187], ["osteocalcin", "PROTEIN", 25, 36], ["osteocalcin", "PROTEIN", 79, 90], ["mice", "SPECIES", 168, 172], ["An increase", "PROBLEM", 0, 11], ["the serum osteocalcin level", "TEST", 15, 42], ["exogenous osteocalcin mitigated obesity", "PROBLEM", 69, 108], ["glucose intolerance", "PROBLEM", 113, 132], ["chow", "TEST", 136, 140], ["high-fat diet (HFD)", "TREATMENT", 144, 163], ["increase", "OBSERVATION_MODIFIER", 3, 11]]], ["It has been accepted that the insulin sensitivity in adipose tissue and muscle could be increased by osteocalcin, but its insulin-sensitizing function in the liver remains to be established [11, 18] .", [["adipose tissue", "ANATOMY", 53, 67], ["muscle", "ANATOMY", 72, 78], ["liver", "ANATOMY", 158, 163], ["insulin", "GENE_OR_GENE_PRODUCT", 30, 37], ["adipose tissue", "TISSUE", 53, 67], ["muscle", "ORGAN", 72, 78], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 101, 112], ["insulin", "GENE_OR_GENE_PRODUCT", 122, 129], ["liver", "ORGAN", 158, 163], ["osteocalcin", "PROTEIN", 101, 112], ["the insulin sensitivity", "TEST", 26, 49], ["osteocalcin", "TEST", 101, 112], ["its insulin", "TREATMENT", 118, 129], ["adipose tissue", "ANATOMY", 53, 67], ["muscle", "ANATOMY", 72, 78], ["increased", "OBSERVATION_MODIFIER", 88, 97], ["liver", "ANATOMY", 158, 163]]], ["Osteocalcin reduced hepatic steatosis in high-fat diet-fed wild-type mice or high-fat and high-cholesterol diet (WHFD)-fed Ldlr -/male mice [16, 19] .", [["hepatic", "ANATOMY", 20, 27], ["steatosis", "DISEASE", 28, 37], ["cholesterol", "CHEMICAL", 95, 106], ["cholesterol", "CHEMICAL", 95, 106], ["Osteocalcin", "GENE_OR_GENE_PRODUCT", 0, 11], ["hepatic steatosis", "PATHOLOGICAL_FORMATION", 20, 37], ["mice", "ORGANISM", 69, 73], ["fat", "TISSUE", 82, 85], ["high-cholesterol diet", "SIMPLE_CHEMICAL", 90, 111], ["WHFD", "SIMPLE_CHEMICAL", 113, 117], ["Ldlr -/male mice", "ORGANISM", 123, 139], ["Osteocalcin", "PROTEIN", 0, 11], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 135, 139], ["mice", "SPECIES", 135, 139], ["Osteocalcin reduced hepatic steatosis", "PROBLEM", 0, 37], ["high-fat diet", "TREATMENT", 41, 54], ["high-cholesterol diet", "TREATMENT", 90, 111], ["hepatic", "ANATOMY", 20, 27], ["steatosis", "OBSERVATION", 28, 37], ["high", "OBSERVATION_MODIFIER", 41, 45]]], ["However, these studies did not characterize the mechanisms by which osteocalcin regulated glucose and lipid metabolism in the liver.INTRODUCTIONIn this study, we tested the impact of GluOC on glucose and lipid metabolism in KKAy mice, a T2DM animal model of MetS that displays obesity, hyperglycemia, hyperinsulinemia, insulin resistance, and hepatic steatosis [20] .", [["liver", "ANATOMY", 126, 131], ["hepatic", "ANATOMY", 343, 350], ["glucose", "CHEMICAL", 90, 97], ["GluOC", "CHEMICAL", 183, 188], ["glucose", "CHEMICAL", 192, 199], ["T2DM", "DISEASE", 237, 241], ["MetS", "DISEASE", 258, 262], ["obesity", "DISEASE", 277, 284], ["hyperglycemia", "DISEASE", 286, 299], ["hyperinsulinemia", "DISEASE", 301, 317], ["hepatic steatosis", "DISEASE", 343, 360], ["glucose", "CHEMICAL", 90, 97], ["GluOC", "CHEMICAL", 183, 188], ["glucose", "CHEMICAL", 192, 199], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 68, 79], ["glucose", "SIMPLE_CHEMICAL", 90, 97], ["lipid", "SIMPLE_CHEMICAL", 102, 107], ["liver", "ORGAN", 126, 131], ["GluOC", "SIMPLE_CHEMICAL", 183, 188], ["glucose", "SIMPLE_CHEMICAL", 192, 199], ["lipid", "SIMPLE_CHEMICAL", 204, 209], ["KKAy mice", "ORGANISM", 224, 233], ["insulin", "GENE_OR_GENE_PRODUCT", 319, 326], ["hepatic", "ORGAN", 343, 350], ["osteocalcin", "PROTEIN", 68, 79], ["mice", "SPECIES", 229, 233], ["mice", "SPECIES", 229, 233], ["these studies", "TEST", 9, 22], ["osteocalcin regulated glucose", "TEST", 68, 97], ["lipid metabolism in the liver", "PROBLEM", 102, 131], ["this study", "TEST", 147, 157], ["glucose", "TEST", 192, 199], ["a T2DM animal model of MetS", "PROBLEM", 235, 262], ["obesity", "PROBLEM", 277, 284], ["hyperglycemia", "PROBLEM", 286, 299], ["hyperinsulinemia", "PROBLEM", 301, 317], ["insulin resistance", "PROBLEM", 319, 337], ["hepatic steatosis", "PROBLEM", 343, 360], ["lipid metabolism", "OBSERVATION", 102, 118], ["liver", "ANATOMY", 126, 131], ["obesity", "OBSERVATION", 277, 284], ["hyperglycemia", "OBSERVATION", 286, 299], ["hyperinsulinemia", "OBSERVATION", 301, 317], ["insulin resistance", "OBSERVATION", 319, 337], ["hepatic", "ANATOMY", 343, 350], ["steatosis", "OBSERVATION", 351, 360]]], ["Fascinatingly, KKAy mice had significantly lower serum GluOC than C57BL/6 mice, as demonstrated by our earlier study [21] , suggesting a GluOC deficiency that may underlie the abnormal phenotype.", [["serum", "ANATOMY", 49, 54], ["KKAy mice", "ORGANISM", 15, 24], ["serum", "ORGANISM_SUBSTANCE", 49, 54], ["GluOC", "GENE_OR_GENE_PRODUCT", 55, 60], ["C57BL/6 mice", "ORGANISM", 66, 78], ["GluOC", "GENE_OR_GENE_PRODUCT", 137, 142], ["serum GluOC", "PROTEIN", 49, 60], ["GluOC", "PROTEIN", 137, 142], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 20, 24], ["mice", "SPECIES", 74, 78], ["significantly lower serum GluOC", "PROBLEM", 29, 60], ["our earlier study", "TEST", 99, 116], ["a GluOC deficiency", "PROBLEM", 135, 153], ["the abnormal phenotype", "PROBLEM", 172, 194], ["GluOC deficiency", "OBSERVATION", 137, 153], ["abnormal phenotype", "OBSERVATION", 176, 194]]], ["Our results confirmed that GluOC treatment made hepatocytes more responsive to insulin and improved glucose and lipid metabolism in KKAy mice.Chemicals and reagentsRecombinant mouse GST-osteocalcin fusion protein was expressed in BL21 (DE3) (TransGen Biotech, Beijing, China) with the expression plasmid pGEX-6p-1, which encodes human BGLAP2.", [["hepatocytes", "ANATOMY", 48, 59], ["GluOC", "CHEMICAL", 27, 32], ["glucose", "CHEMICAL", 100, 107], ["GluOC", "CHEMICAL", 27, 32], ["glucose", "CHEMICAL", 100, 107], ["GluOC", "SIMPLE_CHEMICAL", 27, 32], ["hepatocytes", "CELL", 48, 59], ["insulin", "GENE_OR_GENE_PRODUCT", 79, 86], ["glucose", "SIMPLE_CHEMICAL", 100, 107], ["lipid", "SIMPLE_CHEMICAL", 112, 117], ["KKAy mice", "ORGANISM", 132, 141], ["mouse", "ORGANISM", 176, 181], ["GST", "GENE_OR_GENE_PRODUCT", 182, 185], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 186, 197], ["pGEX-6p-1", "GENE_OR_GENE_PRODUCT", 304, 313], ["human", "ORGANISM", 329, 334], ["BGLAP2", "GENE_OR_GENE_PRODUCT", 335, 341], ["GluOC", "PROTEIN", 27, 32], ["hepatocytes", "CELL_TYPE", 48, 59], ["insulin", "PROTEIN", 79, 86], ["GST", "PROTEIN", 182, 185], ["osteocalcin fusion protein", "PROTEIN", 186, 212], ["BL21", "CELL_LINE", 230, 234], ["expression plasmid", "DNA", 285, 303], ["pGEX", "DNA", 304, 308], ["6p-1", "DNA", 309, 313], ["human BGLAP2", "PROTEIN", 329, 341], ["mice", "SPECIES", 137, 141], ["mouse", "SPECIES", 176, 181], ["human", "SPECIES", 329, 334], ["mice", "SPECIES", 137, 141], ["mouse", "SPECIES", 176, 181], ["BL21", "SPECIES", 230, 234], ["human", "SPECIES", 329, 334], ["GluOC treatment", "TREATMENT", 27, 42], ["hepatocytes", "PROBLEM", 48, 59], ["insulin", "TREATMENT", 79, 86], ["glucose", "TEST", 100, 107], ["lipid metabolism", "TEST", 112, 128], ["Recombinant mouse GST", "TEST", 164, 185], ["osteocalcin fusion protein", "PROBLEM", 186, 212]]], ["GST-osteocalcin fusion protein in the bacterial extract was purified using Glutathione Sepharose 4B (GE Healthcare Life Sciences, Piscataway Township, NJ, USA) and cleaved from the GST moiety using PreScission Protease.", [["extract", "ANATOMY", 48, 55], ["Glutathione", "CHEMICAL", 75, 86], ["Glutathione", "CHEMICAL", 75, 86], ["GST", "GENE_OR_GENE_PRODUCT", 0, 3], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 4, 15], ["Glutathione", "SIMPLE_CHEMICAL", 75, 86], ["GST", "GENE_OR_GENE_PRODUCT", 181, 184], ["PreScission Protease", "GENE_OR_GENE_PRODUCT", 198, 218], ["GST", "PROTEIN", 0, 3], ["osteocalcin fusion protein", "PROTEIN", 4, 30], ["GST moiety", "PROTEIN", 181, 191], ["PreScission Protease", "PROTEIN", 198, 218], ["GST", "TEST", 0, 3], ["osteocalcin fusion protein", "TREATMENT", 4, 30], ["the bacterial extract", "TREATMENT", 34, 55], ["Glutathione Sepharose 4B", "TREATMENT", 75, 99], ["the GST moiety", "TREATMENT", 177, 191], ["PreScission Protease", "TREATMENT", 198, 218], ["osteocalcin fusion", "OBSERVATION", 4, 22]]], ["Then the digested sample was loaded onto Glutathione Sepharose 4B again to remove GST and GST-osteocalcin fusion protein.", [["sample", "ANATOMY", 18, 24], ["Glutathione", "CHEMICAL", 41, 52], ["Glutathione", "SIMPLE_CHEMICAL", 41, 52], ["GST", "GENE_OR_GENE_PRODUCT", 82, 85], ["GST", "GENE_OR_GENE_PRODUCT", 90, 93], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 94, 105], ["GST", "PROTEIN", 82, 85], ["GST", "PROTEIN", 90, 93], ["osteocalcin fusion protein", "PROTEIN", 94, 120], ["the digested sample", "TREATMENT", 5, 24], ["Glutathione Sepharose 4B", "TREATMENT", 41, 65], ["GST", "TEST", 82, 85], ["GST", "TEST", 90, 93], ["osteocalcin fusion protein", "TREATMENT", 94, 120]]], ["The GE AKTA Purifier Purification system was used for purification procedures.", [["AKTA", "PROTEIN", 7, 11], ["The GE AKTA Purifier Purification system", "TREATMENT", 0, 40], ["purification procedures", "TREATMENT", 54, 77]]], ["The relative purity of the osteocalcin was assessed by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and Coomassie blue staining.", [["sodium dodecyl sulfate", "CHEMICAL", 55, 77], ["sodium dodecyl sulfate", "CHEMICAL", 55, 77], ["polyacrylamide", "CHEMICAL", 78, 92], ["Coomassie blue", "CHEMICAL", 128, 142], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 27, 38], ["sodium dodecyl sulfate", "SIMPLE_CHEMICAL", 55, 77], ["Coomassie", "SIMPLE_CHEMICAL", 128, 137], ["osteocalcin", "PROTEIN", 27, 38], ["the osteocalcin", "TEST", 23, 38], ["sodium dodecyl sulfate", "TREATMENT", 55, 77], ["polyacrylamide gel electrophoresis", "TREATMENT", 78, 112], ["Coomassie blue staining", "PROBLEM", 128, 151], ["purity", "OBSERVATION_MODIFIER", 13, 19]]], ["The specificity of the recombinant osteocalcin was probed by osteocalcin antibody (Abcam, Cambridge, MA, USA) after SDS-PAGE separation.", [["osteocalcin", "GENE_OR_GENE_PRODUCT", 35, 46], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 61, 72], ["recombinant osteocalcin", "PROTEIN", 23, 46], ["osteocalcin antibody", "PROTEIN", 61, 81], ["Abcam", "PROTEIN", 83, 88], ["the recombinant osteocalcin", "TEST", 19, 46], ["osteocalcin antibody", "TEST", 61, 81]]], ["For blood uncarboxylated OC level determination, the serum was collected 24 h after the last oral dose of 14-day OC administration, and a Mouse Glu-Osteocalcin High Sensitive EIA Kit (Takara, Tokyo, Japan) was used.Chemicals and reagentsGeneral reagents were purchased from Sigma-Aldrich (St. Louis., MO, USA).", [["blood", "ANATOMY", 4, 9], ["serum", "ANATOMY", 53, 58], ["oral", "ANATOMY", 93, 97], ["OC", "CHEMICAL", 25, 27], ["OC", "CHEMICAL", 113, 115], ["blood", "ORGANISM_SUBSTANCE", 4, 9], ["OC", "SIMPLE_CHEMICAL", 25, 27], ["serum", "ORGANISM_SUBSTANCE", 53, 58], ["oral", "ORGANISM_SUBDIVISION", 93, 97], ["OC", "SIMPLE_CHEMICAL", 113, 115], ["Sigma-Aldrich", "ORGANISM", 274, 287], ["St. Louis.", "ORGANISM", 289, 299], ["Mouse", "SPECIES", 138, 143], ["Mouse", "SPECIES", 138, 143], ["blood uncarboxylated OC level determination", "TEST", 4, 47], ["the serum", "TEST", 49, 58], ["a Mouse Glu-Osteocalcin", "TEST", 136, 159]]], ["A mouse insulin ultrasensitive ELISA kit was purchased from ALPCO (Salem, NH, USA).", [["mouse", "ORGANISM", 2, 7], ["insulin", "GENE_OR_GENE_PRODUCT", 8, 15], ["mouse", "SPECIES", 2, 7], ["mouse", "SPECIES", 2, 7], ["A mouse insulin ultrasensitive ELISA kit", "TREATMENT", 0, 40]]], ["The ECL reaction kit was obtained from Tanon Science & Technology (Shanghai, China).", [["The ECL reaction kit", "TEST", 0, 20]]], ["Cell culture media were supplied by GIBCO (Grand Island, NY, USA).", [["Cell", "ANATOMY", 0, 4], ["Cell", "CELL", 0, 4], ["Cell culture media", "TEST", 0, 18]]], ["The following antibodies were used to determine the activity of the insulin signaling pathway and hepatic lipid metabolism pathway: \u03b2-actin, GAPDH, fatty acid synthase (FAS), acetyl-CoA carboxylase (ACC), insulin receptor \u03b2 (IR\u03b2), protein kinase B (PKB/Akt), Akt (pS473), forkhead box O1 (Foxo1), Foxo1 (pS256), glycogen synthase kinase 3 beta (GSK3\u03b2), and GSK3\u03b2 (pS9) from Cell Signaling Technology (Danvers, MA, USA); cluster of differentiation 36 (CD36), carnitine palmitoyltransferase I (CPT1), and medium-chain acyl-CoA dehydrogenase (MCAD) from Abcam; and SREBP1c and IR\u03b2 (pY1162/1163) from Santa Cruz Biotechnology (Santa Cruz, CA, USA). and randomly divided into three groups (n = 10): phosphate buffered saline (PBS) control, OC-L (3 ng/g body weight/day) and OC-H (30 ng/g body weight/day).", [["hepatic", "ANATOMY", 98, 105], ["Cell", "ANATOMY", 374, 378], ["body", "ANATOMY", 748, 752], ["body", "ANATOMY", 783, 787], ["fatty acid", "CHEMICAL", 148, 158], ["acetyl-CoA", "CHEMICAL", 175, 185], ["carnitine", "CHEMICAL", 458, 467], ["phosphate", "CHEMICAL", 694, 703], ["OC", "CHEMICAL", 735, 737], ["OC-H", "CHEMICAL", 769, 773], ["fatty acid", "CHEMICAL", 148, 158], ["acetyl-CoA", "CHEMICAL", 175, 185], ["carnitine", "CHEMICAL", 458, 467], ["acyl-CoA", "CHEMICAL", 516, 524], ["phosphate", "CHEMICAL", 694, 703], ["insulin", "GENE_OR_GENE_PRODUCT", 68, 75], ["hepatic", "ORGAN", 98, 105], ["lipid", "SIMPLE_CHEMICAL", 106, 111], ["\u03b2-actin", "GENE_OR_GENE_PRODUCT", 132, 139], ["GAPDH", "GENE_OR_GENE_PRODUCT", 141, 146], ["fatty acid synthase", "GENE_OR_GENE_PRODUCT", 148, 167], ["FAS", "GENE_OR_GENE_PRODUCT", 169, 172], ["acetyl-CoA carboxylase", "GENE_OR_GENE_PRODUCT", 175, 197], ["ACC", "SIMPLE_CHEMICAL", 199, 202], ["insulin receptor \u03b2", "GENE_OR_GENE_PRODUCT", 205, 223], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 225, 228], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 231, 247], ["PKB", "GENE_OR_GENE_PRODUCT", 249, 252], ["Akt", "GENE_OR_GENE_PRODUCT", 253, 256], ["Akt", "GENE_OR_GENE_PRODUCT", 259, 262], ["S473", "GENE_OR_GENE_PRODUCT", 265, 269], ["forkhead box O1", "GENE_OR_GENE_PRODUCT", 272, 287], ["Foxo1", "GENE_OR_GENE_PRODUCT", 289, 294], ["Foxo1", "GENE_OR_GENE_PRODUCT", 297, 302], ["pS256", "GENE_OR_GENE_PRODUCT", 304, 309], ["glycogen synthase kinase 3 beta", "GENE_OR_GENE_PRODUCT", 312, 343], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 345, 350], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 357, 362], ["pS9", "GENE_OR_GENE_PRODUCT", 364, 367], ["Cell", "CELL", 374, 378], ["cluster of differentiation 36", "GENE_OR_GENE_PRODUCT", 420, 449], ["CD36", "GENE_OR_GENE_PRODUCT", 451, 455], ["carnitine palmitoyltransferase I", "GENE_OR_GENE_PRODUCT", 458, 490], ["CPT1", "GENE_OR_GENE_PRODUCT", 492, 496], ["medium-chain acyl-CoA dehydrogenase", "GENE_OR_GENE_PRODUCT", 503, 538], ["MCAD", "GENE_OR_GENE_PRODUCT", 540, 544], ["Abcam", "GENE_OR_GENE_PRODUCT", 551, 556], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 562, 569], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 574, 577], ["phosphate buffered saline", "SIMPLE_CHEMICAL", 694, 719], ["OC-L", "SIMPLE_CHEMICAL", 735, 739], ["body", "ORGANISM_SUBDIVISION", 748, 752], ["OC-H", "SIMPLE_CHEMICAL", 769, 773], ["body", "ORGANISM_SUBDIVISION", 783, 787], ["insulin", "PROTEIN", 68, 75], ["\u03b2-actin", "PROTEIN", 132, 139], ["GAPDH", "PROTEIN", 141, 146], ["fatty acid synthase", "PROTEIN", 148, 167], ["FAS", "PROTEIN", 169, 172], ["acetyl-CoA carboxylase", "PROTEIN", 175, 197], ["ACC", "PROTEIN", 199, 202], ["insulin receptor \u03b2", "PROTEIN", 205, 223], ["IR\u03b2", "PROTEIN", 225, 228], ["protein kinase B", "PROTEIN", 231, 247], ["PKB", "PROTEIN", 249, 252], ["Akt", "PROTEIN", 253, 256], ["Akt", "PROTEIN", 259, 262], ["pS473", "PROTEIN", 264, 269], ["forkhead box O1", "PROTEIN", 272, 287], ["Foxo1", "PROTEIN", 289, 294], ["Foxo1", "PROTEIN", 297, 302], ["pS256", "PROTEIN", 304, 309], ["glycogen synthase kinase 3 beta", "PROTEIN", 312, 343], ["GSK3\u03b2", "PROTEIN", 345, 350], ["GSK3\u03b2", "PROTEIN", 357, 362], ["pS9", "PROTEIN", 364, 367], ["cluster of differentiation 36", "PROTEIN", 420, 449], ["CD36", "PROTEIN", 451, 455], ["carnitine palmitoyltransferase I", "PROTEIN", 458, 490], ["CPT1", "PROTEIN", 492, 496], ["medium-chain acyl-CoA dehydrogenase", "PROTEIN", 503, 538], ["MCAD", "PROTEIN", 540, 544], ["Abcam", "PROTEIN", 551, 556], ["SREBP1c", "PROTEIN", 562, 569], ["IR\u03b2", "PROTEIN", 574, 577], ["pY1162/1163", "PROTEIN", 579, 590], ["Santa Cruz Biotechnology", "PROTEIN", 597, 621], ["the insulin signaling pathway", "TREATMENT", 64, 93], ["\u03b2-actin", "TREATMENT", 132, 139], ["fatty acid synthase", "TEST", 148, 167], ["FAS", "TEST", 169, 172], ["acetyl-CoA carboxylase (ACC)", "TREATMENT", 175, 203], ["insulin receptor", "TREATMENT", 205, 221], ["protein kinase B (PKB/Akt", "TEST", 231, 256], ["Akt", "TEST", 259, 262], ["forkhead box O1", "TEST", 272, 287], ["glycogen synthase kinase", "TEST", 312, 336], ["carnitine palmitoyltransferase I (CPT1)", "TREATMENT", 458, 497], ["Abcam", "TEST", 551, 556], ["phosphate buffered saline (PBS) control", "TREATMENT", 694, 733], ["OC", "TEST", 735, 737], ["hepatic", "ANATOMY", 98, 105]]], ["Nonfasting glucose, fasting glucose, and body weight were measured before treatment.", [["body", "ANATOMY", 41, 45], ["glucose", "CHEMICAL", 11, 18], ["glucose", "CHEMICAL", 11, 18], ["glucose", "CHEMICAL", 28, 35], ["glucose", "SIMPLE_CHEMICAL", 11, 18], ["fasting", "ORGANISM_SUBSTANCE", 20, 27], ["glucose", "SIMPLE_CHEMICAL", 28, 35], ["body", "ORGANISM_SUBDIVISION", 41, 45], ["Nonfasting glucose", "TEST", 0, 18], ["fasting glucose", "TEST", 20, 35], ["body weight", "TEST", 41, 52], ["treatment", "TREATMENT", 74, 83]]], ["As shown in Table 1 , there were no significant differences in the three markers among the three groups.", [["significant differences", "PROBLEM", 36, 59], ["no", "UNCERTAINTY", 33, 35], ["significant", "OBSERVATION_MODIFIER", 36, 47], ["differences", "OBSERVATION_MODIFIER", 48, 59]]], ["PBS and GluOC were orally administered daily for 4 weeks.", [["GluOC", "CHEMICAL", 8, 13], ["PBS", "SIMPLE_CHEMICAL", 0, 3], ["GluOC", "SIMPLE_CHEMICAL", 8, 13], ["PBS", "TEST", 0, 3], ["GluOC", "TREATMENT", 8, 13]]], ["Aged-matched female C57BL/6 mice fed a standard chow diet (1022, Beijing HFK Bioscience Co. Ltd., China) were orally administered PBS (0.1 mL/10 g body weight) as a normal control (C57).Animals and OC treatmentGlucose metabolism evaluation in mice During administration, nonfasting blood glucose and fasting blood glucose (FBG) were kinetically monitored at days 0, 7, 14, and 24 of GluOC administration.", [["body", "ANATOMY", 147, 151], ["blood", "ANATOMY", 282, 287], ["blood", "ANATOMY", 308, 313], ["OC", "CHEMICAL", 198, 200], ["Glucose", "CHEMICAL", 210, 217], ["glucose", "CHEMICAL", 288, 295], ["glucose", "CHEMICAL", 314, 321], ["GluOC", "CHEMICAL", 383, 388], ["Glucose", "CHEMICAL", 210, 217], ["glucose", "CHEMICAL", 288, 295], ["glucose", "CHEMICAL", 314, 321], ["C57BL/6 mice", "ORGANISM", 20, 32], ["body", "ORGANISM_SUBDIVISION", 147, 151], ["Glucose", "SIMPLE_CHEMICAL", 210, 217], ["mice", "ORGANISM", 243, 247], ["blood", "ORGANISM_SUBSTANCE", 282, 287], ["glucose", "SIMPLE_CHEMICAL", 288, 295], ["blood", "ORGANISM_SUBSTANCE", 308, 313], ["glucose", "SIMPLE_CHEMICAL", 314, 321], ["FBG", "SIMPLE_CHEMICAL", 323, 326], ["GluOC", "GENE_OR_GENE_PRODUCT", 383, 388], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 243, 247], ["mice", "SPECIES", 28, 32], ["mice", "SPECIES", 243, 247], ["OC treatment", "TREATMENT", 198, 210], ["Glucose metabolism evaluation", "TEST", 210, 239], ["nonfasting blood glucose", "TEST", 271, 295], ["fasting blood glucose", "TEST", 300, 321], ["FBG", "TEST", 323, 326], ["GluOC administration", "TREATMENT", 383, 403]]], ["An oral glucose tolerance test (OGTT) was performed on day 28.", [["oral", "ANATOMY", 3, 7], ["glucose", "CHEMICAL", 8, 15], ["glucose", "CHEMICAL", 8, 15], ["oral", "ORGANISM_SUBDIVISION", 3, 7], ["glucose", "SIMPLE_CHEMICAL", 8, 15], ["An oral glucose tolerance test", "TEST", 0, 30], ["OGTT", "TEST", 32, 36]]], ["Blood samples were collected from tails for determination of baseline values of blood glucose (0 min) after 4-h fasting.", [["Blood samples", "ANATOMY", 0, 13], ["blood", "ANATOMY", 80, 85], ["glucose", "CHEMICAL", 86, 93], ["glucose", "CHEMICAL", 86, 93], ["Blood samples", "ORGANISM_SUBSTANCE", 0, 13], ["blood", "ORGANISM_SUBSTANCE", 80, 85], ["glucose", "SIMPLE_CHEMICAL", 86, 93], ["Blood samples", "TEST", 0, 13], ["blood glucose", "TEST", 80, 93]]], ["The mice were then orally administered glucose (2 g/kg body weight), and blood samples were collected at 15, 60, and 120 min.", [["body", "ANATOMY", 55, 59], ["blood samples", "ANATOMY", 73, 86], ["glucose", "CHEMICAL", 39, 46], ["glucose", "CHEMICAL", 39, 46], ["mice", "ORGANISM", 4, 8], ["glucose", "SIMPLE_CHEMICAL", 39, 46], ["body", "ORGANISM_SUBDIVISION", 55, 59], ["blood samples", "ORGANISM_SUBSTANCE", 73, 86], ["mice", "SPECIES", 4, 8], ["mice", "SPECIES", 4, 8], ["The mice", "TREATMENT", 0, 8], ["glucose", "TEST", 39, 46], ["blood samples", "TEST", 73, 86]]], ["A glucose oxidase (GOD) assay was used for blood glucose level measurement.", [["blood", "ANATOMY", 43, 48], ["glucose", "CHEMICAL", 2, 9], ["glucose", "CHEMICAL", 49, 56], ["glucose", "CHEMICAL", 2, 9], ["glucose", "CHEMICAL", 49, 56], ["glucose oxidase", "GENE_OR_GENE_PRODUCT", 2, 17], ["GOD", "SIMPLE_CHEMICAL", 19, 22], ["blood", "ORGANISM_SUBSTANCE", 43, 48], ["glucose", "SIMPLE_CHEMICAL", 49, 56], ["glucose oxidase", "PROTEIN", 2, 17], ["A glucose oxidase", "TEST", 0, 17], ["blood glucose level measurement", "TEST", 43, 74]]], ["The values of the area under the glucose-time curve (AUC) were calculated.Animals and OC treatmentInsulin sensitivity estimation in mice After GluOC administration for 14 days, the fasting plasma insulin (FPI) was determined.", [["plasma", "ANATOMY", 189, 195], ["OC", "CHEMICAL", 86, 88], ["GluOC", "CHEMICAL", 143, 148], ["glucose", "CHEMICAL", 33, 40], ["glucose", "SIMPLE_CHEMICAL", 33, 40], ["Insulin", "GENE_OR_GENE_PRODUCT", 98, 105], ["mice", "ORGANISM", 132, 136], ["GluOC", "SIMPLE_CHEMICAL", 143, 148], ["plasma", "ORGANISM_SUBSTANCE", 189, 195], ["insulin", "GENE_OR_GENE_PRODUCT", 196, 203], ["FPI", "GENE_OR_GENE_PRODUCT", 205, 208], ["fasting plasma insulin", "PROTEIN", 181, 203], ["mice", "SPECIES", 132, 136], ["mice", "SPECIES", 132, 136], ["the glucose", "TEST", 29, 40], ["AUC", "TEST", 53, 56], ["OC treatment", "TREATMENT", 86, 98], ["Insulin sensitivity estimation", "TEST", 98, 128], ["GluOC administration", "TREATMENT", 143, 163], ["the fasting plasma insulin (FPI", "TREATMENT", 177, 208]]], ["The Homeostatic Model Assessment of Insulin Resistance (HOMA-IR) index was calculated with the following formula: HOMA-IR index = (FPI \u00d7 FPG)/22.5, where FPI is fasting plasma insulin concentration (mU/L) and FPG is fasting plasma glucose (mM) [22] .", [["plasma", "ANATOMY", 169, 175], ["plasma", "ANATOMY", 224, 230], ["glucose", "CHEMICAL", 231, 238], ["glucose", "CHEMICAL", 231, 238], ["Insulin", "GENE_OR_GENE_PRODUCT", 36, 43], ["plasma", "ORGANISM_SUBSTANCE", 169, 175], ["insulin", "GENE_OR_GENE_PRODUCT", 176, 183], ["FPG", "SIMPLE_CHEMICAL", 209, 212], ["plasma", "ORGANISM_SUBSTANCE", 224, 230], ["glucose", "SIMPLE_CHEMICAL", 231, 238], ["Insulin Resistance (HOMA-IR) index", "TEST", 36, 70], ["HOMA", "TEST", 114, 118], ["IR index", "TEST", 119, 127], ["FPI", "TEST", 131, 134], ["FPG", "TEST", 137, 140], ["FPI", "TEST", 154, 157], ["fasting plasma insulin concentration", "TEST", 161, 197], ["FPG", "TEST", 209, 212], ["fasting plasma glucose", "TEST", 216, 238]]], ["Animals were fasted for 4 h before FPI/FPG determination.Animals and OC treatmentEvaluation of hepatic lipid accumulation After 4 weeks of GluOC treatment, hepatic histology and TG content were evaluated in KKAy mice.", [["hepatic", "ANATOMY", 95, 102], ["hepatic", "ANATOMY", 156, 163], ["OC", "CHEMICAL", 69, 71], ["GluOC", "CHEMICAL", 139, 144], ["GluOC", "CHEMICAL", 139, 144], ["Animals", "ORGANISM", 0, 7], ["hepatic lipid", "MULTI-TISSUE_STRUCTURE", 95, 108], ["GluOC", "SIMPLE_CHEMICAL", 139, 144], ["hepatic", "ORGAN", 156, 163], ["TG", "SIMPLE_CHEMICAL", 178, 180], ["mice", "ORGANISM", 212, 216], ["mice", "SPECIES", 212, 216], ["mice", "SPECIES", 212, 216], ["FPI/FPG determination", "TEST", 35, 56], ["OC treatment", "TREATMENT", 69, 81], ["Evaluation", "TEST", 81, 91], ["hepatic lipid accumulation", "PROBLEM", 95, 121], ["GluOC treatment", "TREATMENT", 139, 154], ["hepatic histology", "TEST", 156, 173], ["TG content", "TEST", 178, 188], ["hepatic", "ANATOMY", 95, 102], ["lipid accumulation", "OBSERVATION", 103, 121], ["hepatic", "ANATOMY", 156, 163]]], ["Hematoxylin and eosinstained liver sections were used for histology evaluation.", [["liver sections", "ANATOMY", 29, 43], ["Hematoxylin", "CHEMICAL", 0, 11], ["Hematoxylin", "SIMPLE_CHEMICAL", 0, 11], ["liver sections", "CANCER", 29, 43], ["Hematoxylin", "TEST", 0, 11], ["eosinstained liver sections", "TREATMENT", 16, 43], ["histology evaluation", "TEST", 58, 78], ["liver", "ANATOMY", 29, 34]]], ["The scope of steatosis was scored as 0 (no steatosis), 1 (< 25% of hepatocytes), 2 (26%-50%), 3 (51%-75%), and 4 (> 75%) [23] .", [["hepatocytes", "ANATOMY", 67, 78], ["steatosis", "DISEASE", 13, 22], ["steatosis", "DISEASE", 43, 52], ["hepatocytes", "CELL", 67, 78], ["steatosis", "PROBLEM", 13, 22], ["steatosis", "TEST", 43, 52], ["hepatocytes", "TEST", 67, 78], ["steatosis", "OBSERVATION", 13, 22], ["hepatocytes", "ANATOMY", 67, 78]]], ["Hepatic TG was extracted from the left lateral lobe of the liver per the published method [24] and determined with commercial biochemical kits (Biosino Biotechnology Co., Ltd., Beijing, China).Animals and OC treatmentEvaluation of blood lipid panel Blood samples were collected from the tails after 4 h of fasting.", [["Hepatic", "ANATOMY", 0, 7], ["left lateral lobe", "ANATOMY", 34, 51], ["liver", "ANATOMY", 59, 64], ["blood", "ANATOMY", 231, 236], ["Blood samples", "ANATOMY", 249, 262], ["OC", "CHEMICAL", 205, 207], ["Hepatic TG", "MULTI-TISSUE_STRUCTURE", 0, 10], ["lateral lobe", "MULTI-TISSUE_STRUCTURE", 39, 51], ["liver", "ORGAN", 59, 64], ["blood", "ORGANISM_SUBSTANCE", 231, 236], ["Blood samples", "ORGANISM_SUBSTANCE", 249, 262], ["Hepatic TG", "TEST", 0, 10], ["OC treatment", "TREATMENT", 205, 217], ["Evaluation of blood lipid panel", "TEST", 217, 248], ["Blood samples", "TEST", 249, 262], ["fasting", "TEST", 306, 313], ["TG", "OBSERVATION", 8, 10], ["left", "ANATOMY_MODIFIER", 34, 38], ["lateral", "ANATOMY_MODIFIER", 39, 46], ["lobe", "ANATOMY_MODIFIER", 47, 51], ["liver", "ANATOMY", 59, 64]]], ["Serum levels of TG, total cholesterol (TC), high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were quantitatively detected with commercial kits (Biosino Biotechnology Co., Ltd., Beijing, China).Animals and OC treatmentAnalysis of hepatic insulin and glucose metabolism pathways After 4 weeks of GluOC treatment, mice were first fasted overnight and then anesthetized by intraperitoneal injection of 1% sodium pentobarbital (0.1 mL/10 g).", [["Serum", "ANATOMY", 0, 5], ["hepatic", "ANATOMY", 274, 281], ["intraperitoneal", "ANATOMY", 414, 429], ["cholesterol", "CHEMICAL", 26, 37], ["TC", "CHEMICAL", 39, 41], ["cholesterol", "CHEMICAL", 69, 80], ["cholesterol", "CHEMICAL", 118, 129], ["OC", "CHEMICAL", 250, 252], ["glucose", "CHEMICAL", 294, 301], ["GluOC", "CHEMICAL", 339, 344], ["sodium pentobarbital", "CHEMICAL", 446, 466], ["cholesterol", "CHEMICAL", 26, 37], ["cholesterol", "CHEMICAL", 69, 80], ["cholesterol", "CHEMICAL", 118, 129], ["glucose", "CHEMICAL", 294, 301], ["GluOC", "CHEMICAL", 339, 344], ["sodium pentobarbital", "CHEMICAL", 446, 466], ["Serum", "ORGANISM_SUBSTANCE", 0, 5], ["TG", "SIMPLE_CHEMICAL", 16, 18], ["cholesterol", "SIMPLE_CHEMICAL", 26, 37], ["TC", "SIMPLE_CHEMICAL", 39, 41], ["high-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 44, 80], ["HDL-C", "SIMPLE_CHEMICAL", 82, 87], ["low-density lipoprotein cholesterol", "SIMPLE_CHEMICAL", 94, 129], ["LDL-C", "SIMPLE_CHEMICAL", 131, 136], ["hepatic", "MULTI-TISSUE_STRUCTURE", 274, 281], ["insulin", "GENE_OR_GENE_PRODUCT", 282, 289], ["glucose", "SIMPLE_CHEMICAL", 294, 301], ["GluOC", "SIMPLE_CHEMICAL", 339, 344], ["mice", "ORGANISM", 356, 360], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 414, 429], ["sodium", "SIMPLE_CHEMICAL", 446, 452], ["pentobarbital", "SIMPLE_CHEMICAL", 453, 466], ["TG", "PROTEIN", 16, 18], ["HDL", "PROTEIN", 82, 85], ["LDL", "PROTEIN", 131, 134], ["mice", "SPECIES", 356, 360], ["mice", "SPECIES", 356, 360], ["Serum levels", "TEST", 0, 12], ["TG", "TEST", 16, 18], ["total cholesterol", "TEST", 20, 37], ["TC", "TEST", 39, 41], ["high-density lipoprotein cholesterol", "TEST", 44, 80], ["HDL", "TEST", 82, 85], ["low-density lipoprotein cholesterol", "TEST", 94, 129], ["LDL", "TEST", 131, 134], ["OC treatment", "TREATMENT", 250, 262], ["hepatic insulin", "TREATMENT", 274, 289], ["glucose metabolism pathways", "TREATMENT", 294, 321], ["GluOC treatment", "TREATMENT", 339, 354], ["1% sodium pentobarbital", "TREATMENT", 443, 466], ["hepatic", "ANATOMY", 274, 281]]], ["Five animals in each group were randomly selected and injected with quick-acting insulin (Lispro, Eli Lilly and Co., Indianapolis, Indiana, USA) 1 U/kg into the inferior vena cava, and the liver was separated 3 min after insulin injection and immediately frozen in liquid nitrogen.", [["inferior vena cava", "ANATOMY", 161, 179], ["liver", "ANATOMY", 189, 194], ["nitrogen", "CHEMICAL", 272, 280], ["insulin", "GENE_OR_GENE_PRODUCT", 81, 88], ["Lispro", "SIMPLE_CHEMICAL", 90, 96], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 161, 179], ["liver", "ORGAN", 189, 194], ["insulin", "GENE_OR_GENE_PRODUCT", 221, 228], ["insulin", "PROTEIN", 221, 228], ["quick-acting insulin (Lispro", "TREATMENT", 68, 96], ["insulin injection", "TREATMENT", 221, 238], ["liquid nitrogen", "TREATMENT", 265, 280], ["inferior vena cava", "ANATOMY", 161, 179], ["liver", "ANATOMY", 189, 194]]], ["The other five mice .", [["mice", "ORGANISM", 15, 19], ["mice", "SPECIES", 15, 19], ["mice", "SPECIES", 15, 19]]], ["Western blot was conducted to detect the expression of proteins related to hepatic insulin and glucose metabolism pathways as previously described [25] .", [["hepatic", "ANATOMY", 75, 82], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 95, 102], ["hepatic", "MULTI-TISSUE_STRUCTURE", 75, 82], ["insulin", "GENE_OR_GENE_PRODUCT", 83, 90], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["the expression of proteins", "PROBLEM", 37, 63], ["hepatic insulin", "TREATMENT", 75, 90], ["glucose metabolism pathways", "PROBLEM", 95, 122], ["hepatic", "ANATOMY", 75, 82]]], ["The images were acquired on a Tanon-5200 Chemiluminescent Imaging System (Tanon Science & Technology, Shanghai, China).Animals and OC treatmentAnalysis of hepatic lipid metabolism pathways After 4 weeks of GluOC treatment, liver tissues were removed under anesthetization conditions from mice after overnight fasting for protein analysis.", [["hepatic", "ANATOMY", 155, 162], ["liver tissues", "ANATOMY", 223, 236], ["OC", "CHEMICAL", 131, 133], ["GluOC", "CHEMICAL", 206, 211], ["Tanon-5200", "CHEMICAL", 30, 40], ["GluOC", "CHEMICAL", 206, 211], ["hepatic lipid", "MULTI-TISSUE_STRUCTURE", 155, 168], ["GluOC", "SIMPLE_CHEMICAL", 206, 211], ["liver tissues", "TISSUE", 223, 236], ["mice", "ORGANISM", 288, 292], ["mice", "SPECIES", 288, 292], ["mice", "SPECIES", 288, 292], ["The images", "TEST", 0, 10], ["a Tanon", "TEST", 28, 35], ["OC treatment", "TREATMENT", 131, 143], ["hepatic lipid metabolism pathways", "PROBLEM", 155, 188], ["GluOC treatment", "TREATMENT", 206, 221], ["liver tissues", "TREATMENT", 223, 236], ["anesthetization conditions", "TREATMENT", 256, 282], ["protein analysis", "TEST", 321, 337], ["hepatic", "ANATOMY", 155, 162], ["lipid", "ANATOMY_MODIFIER", 163, 168], ["liver", "ANATOMY", 223, 228]]], ["Total proteins from liver lysates were separated by SDS-PAGE, transferred to polyvinylidene difluoride membranes (Merck Millipore, Billerica, Massachusetts, USA), and then probed with anti-SREBP1c, FAS, ACC, CPT1, MCAD, and CD36 antibodies.Animals and OC treatmentEvaluation of glucose metabolism in primary cultured hepatocytes Mouse primary hepatocytes were prepared using the established procedure [26] .", [["liver lysates", "ANATOMY", 20, 33], ["hepatocytes", "ANATOMY", 317, 328], ["primary hepatocytes", "ANATOMY", 335, 354], ["OC", "CHEMICAL", 252, 254], ["glucose", "CHEMICAL", 278, 285], ["polyvinylidene difluoride", "CHEMICAL", 77, 102], ["glucose", "CHEMICAL", 278, 285], ["liver lysates", "ORGANISM_SUBSTANCE", 20, 33], ["membranes", "CELLULAR_COMPONENT", 103, 112], ["anti-SREBP1c", "GENE_OR_GENE_PRODUCT", 184, 196], ["FAS", "GENE_OR_GENE_PRODUCT", 198, 201], ["ACC", "GENE_OR_GENE_PRODUCT", 203, 206], ["CPT1", "GENE_OR_GENE_PRODUCT", 208, 212], ["MCAD", "GENE_OR_GENE_PRODUCT", 214, 218], ["CD36", "GENE_OR_GENE_PRODUCT", 224, 228], ["glucose", "SIMPLE_CHEMICAL", 278, 285], ["hepatocytes", "CELL", 317, 328], ["Mouse", "ORGANISM", 329, 334], ["hepatocytes", "CELL", 343, 354], ["anti-SREBP1c", "PROTEIN", 184, 196], ["FAS", "PROTEIN", 198, 201], ["ACC", "PROTEIN", 203, 206], ["CPT1", "PROTEIN", 208, 212], ["MCAD", "PROTEIN", 214, 218], ["CD36 antibodies", "PROTEIN", 224, 239], ["primary cultured hepatocytes", "CELL_TYPE", 300, 328], ["primary hepatocytes", "CELL_TYPE", 335, 354], ["Mouse", "SPECIES", 329, 334], ["Total proteins", "TEST", 0, 14], ["liver lysates", "TEST", 20, 33], ["polyvinylidene difluoride membranes", "TREATMENT", 77, 112], ["anti-SREBP1c", "TREATMENT", 184, 196], ["CPT1", "TEST", 208, 212], ["MCAD", "TEST", 214, 218], ["CD36 antibodies", "TEST", 224, 239], ["OC treatment", "TREATMENT", 252, 264], ["Evaluation of glucose metabolism", "TEST", 264, 296], ["the established procedure", "TREATMENT", 375, 400], ["liver", "ANATOMY", 20, 25], ["MCAD", "ANATOMY", 214, 218], ["glucose metabolism", "OBSERVATION", 278, 296]]], ["Briefly, the livers from male C57BL/6 mice were retrograde-perfused using collagenase I (Sigma-Aldrich, St. Louis., MO, USA) through the inferior vena cava under anesthesia to isolate primary hepatocytes.", [["livers", "ANATOMY", 13, 19], ["inferior vena cava", "ANATOMY", 137, 155], ["primary hepatocytes", "ANATOMY", 184, 203], ["livers", "ORGAN", 13, 19], ["C57BL/6 mice", "ORGANISM", 30, 42], ["collagenase", "GENE_OR_GENE_PRODUCT", 74, 85], ["Sigma-Aldrich", "SIMPLE_CHEMICAL", 89, 102], ["inferior vena cava", "MULTI-TISSUE_STRUCTURE", 137, 155], ["hepatocytes", "CELL", 192, 203], ["collagenase I", "PROTEIN", 74, 87], ["primary hepatocytes", "CELL_TYPE", 184, 203], ["mice", "SPECIES", 38, 42], ["mice", "SPECIES", 38, 42], ["anesthesia", "TREATMENT", 162, 172], ["livers", "ANATOMY", 13, 19], ["inferior vena cava", "ANATOMY", 137, 155], ["anesthesia", "OBSERVATION", 162, 172], ["primary hepatocytes", "OBSERVATION", 184, 203]]], ["Trypan blue staining was used to estimate cell viability.", [["cell", "ANATOMY", 42, 46], ["Trypan blue", "CHEMICAL", 0, 11], ["Trypan blue", "CHEMICAL", 0, 11], ["Trypan", "SIMPLE_CHEMICAL", 0, 6], ["cell", "CELL", 42, 46], ["Trypan blue staining", "TEST", 0, 20], ["cell viability", "OBSERVATION", 42, 56]]], ["The isolated cells with viability > 95% were eligible for plating.Animals and OC treatmentFor the glucose output assay, hepatocytes were seeded in six-well plates and incubated for 24 h in Williams' medium E supplemented with 100 \u03bcg/mL penicillin and 100 U/mL streptomycin, 1% (v/v) 200 mM L-glutamine (Sigma), and 10% (v/v) fetal bovine serum.", [["cells", "ANATOMY", 13, 18], ["hepatocytes", "ANATOMY", 120, 131], ["fetal bovine serum", "ANATOMY", 325, 343], ["OC", "CHEMICAL", 78, 80], ["glucose", "CHEMICAL", 98, 105], ["penicillin", "CHEMICAL", 236, 246], ["streptomycin", "CHEMICAL", 260, 272], ["L-glutamine", "CHEMICAL", 290, 301], ["glucose", "CHEMICAL", 98, 105], ["penicillin", "CHEMICAL", 236, 246], ["streptomycin", "CHEMICAL", 260, 272], ["L-glutamine", "CHEMICAL", 290, 301], ["cells", "CELL", 13, 18], ["glucose", "SIMPLE_CHEMICAL", 98, 105], ["hepatocytes", "CELL", 120, 131], ["penicillin", "SIMPLE_CHEMICAL", 236, 246], ["streptomycin", "SIMPLE_CHEMICAL", 260, 272], ["L-glutamine", "SIMPLE_CHEMICAL", 290, 301], ["bovine", "ORGANISM", 331, 337], ["serum", "ORGANISM_SUBSTANCE", 338, 343], ["hepatocytes", "CELL_TYPE", 120, 131], ["bovine", "SPECIES", 331, 337], ["bovine", "SPECIES", 331, 337], ["viability", "TEST", 24, 33], ["plating", "TREATMENT", 58, 65], ["OC treatment", "TREATMENT", 78, 90], ["the glucose output assay", "TEST", 94, 118], ["hepatocytes", "TEST", 120, 131], ["penicillin", "TREATMENT", 236, 246], ["streptomycin", "TREATMENT", 260, 272], ["mM L-glutamine (Sigma)", "TREATMENT", 287, 309], ["fetal bovine serum", "TEST", 325, 343], ["isolated cells", "OBSERVATION", 4, 18], ["viability", "OBSERVATION_MODIFIER", 24, 33], ["hepatocytes", "ANATOMY", 120, 131]]], ["Then cells were treated with GluOC (0, 3, 30 ng/mL) for 24 h, washed with PBS and incubated in glucose production medium (glucose-and phenol red-free Dulbecco's Modified Eagle\u02bcs Medium, containing 2 mM sodium pyruvate and 20 mM sodium lactate) for 4 h.", [["cells", "ANATOMY", 5, 10], ["GluOC", "CHEMICAL", 29, 34], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 122, 129], ["phenol", "CHEMICAL", 134, 140], ["sodium pyruvate", "CHEMICAL", 202, 217], ["sodium lactate", "CHEMICAL", 228, 242], ["GluOC", "CHEMICAL", 29, 34], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 122, 129], ["phenol", "CHEMICAL", 134, 140], ["sodium pyruvate", "CHEMICAL", 202, 217], ["sodium lactate", "CHEMICAL", 228, 242], ["cells", "CELL", 5, 10], ["GluOC", "SIMPLE_CHEMICAL", 29, 34], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["glucose", "SIMPLE_CHEMICAL", 122, 129], ["phenol", "SIMPLE_CHEMICAL", 134, 140], ["sodium pyruvate", "SIMPLE_CHEMICAL", 202, 217], ["sodium lactate", "SIMPLE_CHEMICAL", 228, 242], ["GluOC", "TREATMENT", 29, 34], ["PBS", "TREATMENT", 74, 77], ["glucose", "TEST", 122, 129], ["phenol red-free Dulbecco's Modified Eagle\u02bcs Medium", "TREATMENT", 134, 184], ["2 mM sodium pyruvate", "TREATMENT", 197, 217], ["mM sodium lactate", "TEST", 225, 242]]], ["The medium was harvested to measure the glucose concentration.Animals and OC treatmentTo evaluate the impact of GluOC on glycogen synthesis, cells were serum-starved for 6 h and then treated with GluOC (0, 3, 30 ng/mL) for 24 h followed by 10 nM insulin treatment for 5 min.", [["cells", "ANATOMY", 141, 146], ["serum", "ANATOMY", 152, 157], ["glucose", "CHEMICAL", 40, 47], ["OC", "CHEMICAL", 74, 76], ["GluOC", "CHEMICAL", 112, 117], ["glycogen", "CHEMICAL", 121, 129], ["GluOC", "CHEMICAL", 196, 201], ["insulin", "CHEMICAL", 246, 253], ["glucose", "CHEMICAL", 40, 47], ["GluOC", "CHEMICAL", 196, 201], ["glucose", "SIMPLE_CHEMICAL", 40, 47], ["GluOC", "SIMPLE_CHEMICAL", 112, 117], ["glycogen", "SIMPLE_CHEMICAL", 121, 129], ["cells", "CELL", 141, 146], ["serum", "ORGANISM_SUBSTANCE", 152, 157], ["GluOC", "SIMPLE_CHEMICAL", 196, 201], ["insulin", "GENE_OR_GENE_PRODUCT", 246, 253], ["GluOC", "PROTEIN", 112, 117], ["the glucose concentration", "TEST", 36, 61], ["OC treatment", "TREATMENT", 74, 86], ["glycogen synthesis", "TREATMENT", 121, 139], ["serum", "TEST", 152, 157], ["GluOC", "TREATMENT", 196, 201], ["10 nM insulin treatment", "TREATMENT", 240, 263], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["harvested", "OBSERVATION", 15, 24]]], ["The phosphorylation of GSK3\u03b2 was determined by immunoblotting.Animals and OC treatmentLiquid chromatography-tandem mass spectrometry (LC-MS/MS) analysis of mouse liver samples Total liver proteins were isolated from individual mouse livers (n = 3 for the KKAy and OC-L groups) using the SDT buffer (4% SDS, 100 mM DTT, 150 mM Tris-HCl pH 7.6).", [["liver samples", "ANATOMY", 162, 175], ["liver", "ANATOMY", 182, 187], ["livers", "ANATOMY", 233, 239], ["OC", "CHEMICAL", 74, 76], ["OC", "CHEMICAL", 264, 266], ["Tris-HCl", "CHEMICAL", 326, 334], ["DTT", "CHEMICAL", 314, 317], ["Tris-HCl", "CHEMICAL", 326, 334], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 23, 28], ["mouse", "ORGANISM", 156, 161], ["liver", "ORGAN", 162, 167], ["liver", "ORGAN", 182, 187], ["mouse", "ORGANISM", 227, 232], ["livers", "ORGAN", 233, 239], ["GSK3\u03b2", "PROTEIN", 23, 28], ["liver proteins", "PROTEIN", 182, 196], ["mouse", "SPECIES", 156, 161], ["mouse", "SPECIES", 227, 232], ["mouse", "SPECIES", 156, 161], ["mouse", "SPECIES", 227, 232], ["OC treatmentLiquid chromatography", "TEST", 74, 107], ["tandem mass spectrometry", "TEST", 108, 132], ["LC", "TEST", 134, 136], ["MS/MS)", "TEST", 137, 143], ["mouse liver samples", "TEST", 156, 175], ["Total liver proteins", "TEST", 176, 196], ["the KKAy", "TEST", 251, 259], ["OC", "TEST", 264, 266], ["the SDT buffer", "TREATMENT", 283, 297], ["SDS", "TEST", 302, 305], ["DTT", "TEST", 314, 317], ["Tris", "TEST", 326, 330], ["HCl pH", "TEST", 331, 337], ["liver", "ANATOMY", 162, 167], ["liver", "ANATOMY", 182, 187], ["livers", "ANATOMY", 233, 239]]], ["Each protein sample was subjected to the filter-aided sample preparation (FASP) described by Wisniewski [27] and digestion.", [["sample", "ANATOMY", 13, 19], ["sample", "ANATOMY", 54, 60], ["Each protein sample", "TEST", 0, 19], ["the filter", "TREATMENT", 37, 47]]], ["The peptide mixture was transferred to a reverse-phase trap column (Thermo Scientific Acclaim PepMap100, 100 \u00b5m \u00d7 2 cm, nanoViper C18) that was coupled with a C18 reversed-phase analytical column (Thermo Scientific Easy Column, 10 cm long, 75-\u00b5m inner diameter, 3-\u00b5m resin) in buffer A (0.1% formic acid).", [["formic acid", "CHEMICAL", 292, 303], ["formic acid", "CHEMICAL", 292, 303], ["formic acid", "SIMPLE_CHEMICAL", 292, 303], ["Thermo Scientific Acclaim PepMap", "TREATMENT", 68, 100], ["a C18 reversed-phase analytical column", "TREATMENT", 157, 195], ["Thermo Scientific Easy Column", "TREATMENT", 197, 226], ["buffer A", "TREATMENT", 277, 285]]], ["The mix was separated with buffer B (84% acetonitrile and 0.1% formic acid) at a flow rate of 300 nL/min for 2 h.", [["acetonitrile", "CHEMICAL", 41, 53], ["formic acid", "CHEMICAL", 63, 74], ["acetonitrile", "CHEMICAL", 41, 53], ["formic acid", "CHEMICAL", 63, 74], ["acetonitrile", "SIMPLE_CHEMICAL", 41, 53], ["formic acid", "SIMPLE_CHEMICAL", 63, 74], ["buffer B (84% acetonitrile", "TREATMENT", 27, 53], ["a flow rate", "TEST", 79, 90]]], ["The label-free quantification was carried out using MaxQuant as previously described [28] , and the MS raw data were matched to the UniProt Mus musculus database on 4/20/2018.", [["Mus musculus", "SPECIES", 140, 152], ["Mus musculus", "SPECIES", 140, 152], ["The label-free quantification", "TEST", 0, 29], ["MaxQuant", "TREATMENT", 52, 60], ["the MS raw data", "TEST", 96, 111]]], ["To determine the ontology and biological properties of the identified proteins, the protein sequences were mapped to GO parameters in BLAS-T2GO (Version 3.3.5, BioBam, Valencia, Spain).", [["the protein sequences", "TEST", 80, 101], ["BLAS", "TEST", 134, 138]]], ["Proteins that were identified in functional categories and pathways with P-values < 0.05 were considered significantly enriched.Statistical analysisThe data were analyzed by one-way ANOVA.", [["Proteins", "TEST", 0, 8], ["P-values", "TEST", 73, 81], ["Statistical analysis", "TEST", 128, 148], ["The data", "TEST", 148, 156]]], ["All values are presented as means \u00b1 SD or SEM, and statistical significance was considered when P < 0.05.RESULTSGluOC treatment improves hyperglycemia, glucose intolerance, and whole-body insulin resistance in KKAy mice The blood uncarboxylated OC levels were1.6-fold higher in the OC-L and OC-H groups compared with the PBS group, respectively (Fig. 1a) .", [["body", "ANATOMY", 183, 187], ["blood", "ANATOMY", 224, 229], ["RESULTSGluOC", "CHEMICAL", 105, 117], ["hyperglycemia", "DISEASE", 137, 150], ["glucose intolerance", "DISEASE", 152, 171], ["OC", "CHEMICAL", 245, 247], ["OC", "CHEMICAL", 282, 284], ["OC-H", "CHEMICAL", 291, 295], ["RESULTSGluOC", "CHEMICAL", 105, 117], ["glucose", "CHEMICAL", 152, 159], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 105, 117], ["glucose", "SIMPLE_CHEMICAL", 152, 159], ["body", "ORGANISM_SUBDIVISION", 183, 187], ["insulin", "GENE_OR_GENE_PRODUCT", 188, 195], ["mice", "ORGANISM", 215, 219], ["blood", "ORGANISM_SUBSTANCE", 224, 229], ["OC", "SIMPLE_CHEMICAL", 245, 247], ["OC-L", "SIMPLE_CHEMICAL", 282, 286], ["OC-H", "SIMPLE_CHEMICAL", 291, 295], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 215, 219], ["All values", "TEST", 0, 10], ["RESULTSGluOC treatment", "TREATMENT", 105, 127], ["hyperglycemia", "PROBLEM", 137, 150], ["glucose intolerance", "PROBLEM", 152, 171], ["whole-body insulin resistance", "TREATMENT", 177, 206], ["The blood uncarboxylated OC levels", "TEST", 220, 254], ["the OC", "TEST", 278, 284], ["the PBS group", "TEST", 317, 330], ["glucose intolerance", "OBSERVATION", 152, 171]]], ["Nonfasting and fasting blood glucose (FBG) levels were significantly higher in the PBS-treated KKAy mice compared with C57 mice, and both were significantly lower in the GluOC-treated groups, especially FBG (Fig. 1b, c) .", [["blood", "ANATOMY", 23, 28], ["glucose", "CHEMICAL", 29, 36], ["GluOC", "CHEMICAL", 170, 175], ["glucose", "CHEMICAL", 29, 36], ["GluOC", "CHEMICAL", 170, 175], ["blood", "ORGANISM_SUBSTANCE", 23, 28], ["glucose", "SIMPLE_CHEMICAL", 29, 36], ["FBG", "SIMPLE_CHEMICAL", 38, 41], ["PBS", "SIMPLE_CHEMICAL", 83, 86], ["KKAy", "ORGANISM", 95, 99], ["mice", "ORGANISM", 100, 104], ["C57 mice", "ORGANISM", 119, 127], ["GluOC", "SIMPLE_CHEMICAL", 170, 175], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 123, 127], ["mice", "SPECIES", 100, 104], ["mice", "SPECIES", 123, 127], ["Nonfasting", "TEST", 0, 10], ["fasting blood glucose", "TEST", 15, 36], ["FBG) levels", "TEST", 38, 49], ["FBG", "TEST", 203, 206], ["significantly", "OBSERVATION_MODIFIER", 143, 156], ["lower", "OBSERVATION_MODIFIER", 157, 162]]], ["A 14-day treatment led FBG to be 20.2% and 21.9% lower in the OC-L and OC-H groups, respectively, compared to the PBS-treated KKAy mice; 27.3% and 26.5% lower FBG was observed after 24-day treatment.", [["OC", "CHEMICAL", 62, 64], ["OC-H", "CHEMICAL", 71, 75], ["OC-H", "SIMPLE_CHEMICAL", 71, 75], ["PBS", "SIMPLE_CHEMICAL", 114, 117], ["KKAy", "ORGANISM", 126, 130], ["mice", "ORGANISM", 131, 135], ["mice", "SPECIES", 131, 135], ["mice", "SPECIES", 131, 135], ["FBG", "TEST", 23, 26], ["the OC", "TEST", 58, 64], ["the PBS", "TEST", 110, 117], ["lower FBG", "TEST", 153, 162]]], ["In OGTT, the blood glucose levels after glucose loading in the PBS-treated KKAy mice were significantly higher than those in C57 mice (Fig. 1d) , which indicated impaired glucose tolerance (IGT).", [["blood", "ANATOMY", 13, 18], ["glucose", "CHEMICAL", 19, 26], ["glucose", "CHEMICAL", 40, 47], ["impaired glucose tolerance", "DISEASE", 162, 188], ["IGT", "DISEASE", 190, 193], ["glucose", "CHEMICAL", 19, 26], ["glucose", "CHEMICAL", 40, 47], ["glucose", "CHEMICAL", 171, 178], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["glucose", "SIMPLE_CHEMICAL", 19, 26], ["glucose", "SIMPLE_CHEMICAL", 40, 47], ["PBS", "SIMPLE_CHEMICAL", 63, 66], ["KKAy", "ORGANISM", 75, 79], ["mice", "ORGANISM", 80, 84], ["C57 mice", "ORGANISM", 125, 133], ["glucose", "SIMPLE_CHEMICAL", 171, 178], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 129, 133], ["mice", "SPECIES", 80, 84], ["mice", "SPECIES", 129, 133], ["OGTT", "TEST", 3, 7], ["the blood glucose levels", "TEST", 9, 33], ["glucose loading", "TEST", 40, 55], ["the PBS", "TEST", 59, 66], ["impaired glucose tolerance", "PROBLEM", 162, 188], ["impaired", "OBSERVATION_MODIFIER", 162, 170], ["glucose tolerance", "OBSERVATION", 171, 188]]], ["GluOC treatment improved glucose intolerance in the OC-H group, as seen by a\u00f1 11% decrease in AUC ogtt (Fig. 1e) .", [["GluOC", "CHEMICAL", 0, 5], ["glucose intolerance", "DISEASE", 25, 44], ["OC-H", "CHEMICAL", 52, 56], ["GluOC", "CHEMICAL", 0, 5], ["glucose", "CHEMICAL", 25, 32], ["GluOC", "SIMPLE_CHEMICAL", 0, 5], ["glucose", "SIMPLE_CHEMICAL", 25, 32], ["OC-H", "SIMPLE_CHEMICAL", 52, 56], ["GluOC treatment", "TREATMENT", 0, 15], ["glucose intolerance", "PROBLEM", 25, 44], ["AUC ogtt", "TEST", 94, 102], ["glucose intolerance", "OBSERVATION", 25, 44]]], ["KKAy mice displayed severe insulin resistance, showing significantly higher FPI and HOMA-IR compared with C57 mice.", [["KKAy mice", "ORGANISM", 0, 9], ["insulin", "GENE_OR_GENE_PRODUCT", 27, 34], ["C57 mice", "ORGANISM", 106, 114], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 5, 9], ["mice", "SPECIES", 110, 114], ["severe insulin resistance", "PROBLEM", 20, 45], ["significantly higher FPI", "PROBLEM", 55, 79], ["HOMA", "TEST", 84, 88], ["severe", "OBSERVATION_MODIFIER", 20, 26], ["insulin resistance", "OBSERVATION", 27, 45]]], ["The high FPI and HOMA-IR were both reduced by GluOC treatment (Fig. 1f, g) .", [["GluOC", "CHEMICAL", 46, 51], ["GluOC", "CHEMICAL", 46, 51], ["GluOC", "SIMPLE_CHEMICAL", 46, 51], ["HOMA-IR", "TREATMENT", 17, 24], ["GluOC treatment", "TREATMENT", 46, 61], ["high", "OBSERVATION_MODIFIER", 4, 8]]], ["These findings suggest that treatment with both GluOC doses (3 and 30 ng/g BW) delivered hypoglycemic and insulin-sensitizing effects in KKAy mice.RESULTSGluOC treatment prevents hepatic steatosis in KKAy mice KKAy mice developed prominent hepatocyte lipidosis and hepatic steatosis throughout the entire lobule, and the hepatic cord structure was not distorted.", [["hepatic", "ANATOMY", 179, 186], ["hepatocyte", "ANATOMY", 240, 250], ["hepatic", "ANATOMY", 265, 272], ["lobule", "ANATOMY", 305, 311], ["hepatic cord", "ANATOMY", 321, 333], ["GluOC", "CHEMICAL", 48, 53], ["hypoglycemic", "DISEASE", 89, 101], ["RESULTSGluOC", "CHEMICAL", 147, 159], ["steatosis", "DISEASE", 187, 196], ["steatosis", "DISEASE", 273, 282], ["GluOC", "CHEMICAL", 48, 53], ["RESULTSGluOC", "CHEMICAL", 147, 159], ["GluOC", "SIMPLE_CHEMICAL", 48, 53], ["insulin", "GENE_OR_GENE_PRODUCT", 106, 113], ["KKAy mice", "ORGANISM", 137, 146], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 147, 159], ["hepatic steatosis", "PATHOLOGICAL_FORMATION", 179, 196], ["KKAy mice", "ORGANISM", 200, 209], ["KKAy mice", "ORGANISM", 210, 219], ["hepatocyte lipidosis", "PATHOLOGICAL_FORMATION", 240, 260], ["hepatic steatosis", "PATHOLOGICAL_FORMATION", 265, 282], ["lobule", "ORGAN", 305, 311], ["hepatic cord", "ORGAN", 321, 333], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 215, 219], ["mice", "SPECIES", 142, 146], ["mice", "SPECIES", 205, 209], ["mice", "SPECIES", 215, 219], ["both GluOC doses", "TREATMENT", 43, 59], ["hypoglycemic", "PROBLEM", 89, 101], ["insulin", "TREATMENT", 106, 113], ["RESULTSGluOC treatment", "TREATMENT", 147, 169], ["hepatic steatosis", "PROBLEM", 179, 196], ["prominent hepatocyte lipidosis", "PROBLEM", 230, 260], ["hepatic steatosis", "PROBLEM", 265, 282], ["hepatic", "ANATOMY", 179, 186], ["steatosis", "OBSERVATION", 187, 196], ["prominent", "OBSERVATION_MODIFIER", 230, 239], ["hepatocyte lipidosis", "OBSERVATION", 240, 260], ["hepatic", "ANATOMY", 265, 272], ["steatosis", "OBSERVATION", 273, 282], ["entire", "OBSERVATION_MODIFIER", 298, 304], ["lobule", "OBSERVATION_MODIFIER", 305, 311], ["hepatic cord", "ANATOMY", 321, 333], ["not", "UNCERTAINTY", 348, 351], ["distorted", "OBSERVATION", 352, 361]]], ["After 4 weeks of GluOC treatment, hepatocyte lipidosis was significantly ameliorated, especially in the OC-H group (Fig. 2a, b) .", [["hepatocyte", "ANATOMY", 34, 44], ["GluOC", "CHEMICAL", 17, 22], ["OC-H", "CHEMICAL", 104, 108], ["GluOC", "CHEMICAL", 17, 22], ["GluOC", "SIMPLE_CHEMICAL", 17, 22], ["hepatocyte", "CELL", 34, 44], ["OC-H", "SIMPLE_CHEMICAL", 104, 108], ["GluOC treatment", "TREATMENT", 17, 32], ["hepatocyte lipidosis", "PROBLEM", 34, 54], ["hepatocyte", "ANATOMY", 34, 44], ["lipidosis", "OBSERVATION", 45, 54]]], ["The hepatic TG content in KKAy mice was 10.8-fold higher than in C57 mice.", [["hepatic", "ANATOMY", 4, 11], ["hepatic TG", "MULTI-TISSUE_STRUCTURE", 4, 14], ["KKAy mice", "ORGANISM", 26, 35], ["C57 mice", "ORGANISM", 65, 73], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 69, 73], ["mice", "SPECIES", 31, 35], ["mice", "SPECIES", 69, 73], ["The hepatic TG content", "TEST", 0, 22], ["KKAy mice", "TEST", 26, 35], ["hepatic", "ANATOMY", 4, 11], ["TG content", "OBSERVATION", 12, 22]]], ["The GluOC treatment significantly lowered the high TG content by as much as 58.3% in the OC-H group (Fig. 2c) .RESULTSGluOC treatment ameliorates dyslipidemia in KKAy mice by decreasing blood TG and TC levels KKAy mice developed prominent dyslipidemia, showing higher serum TC, TG, HDL-C, and LDL-C compared with C57 mice.", [["blood", "ANATOMY", 186, 191], ["serum", "ANATOMY", 268, 273], ["GluOC", "CHEMICAL", 4, 9], ["TG", "DISEASE", 51, 53], ["OC-H", "CHEMICAL", 89, 93], ["RESULTSGluOC", "CHEMICAL", 111, 123], ["dyslipidemia", "DISEASE", 146, 158], ["dyslipidemia", "DISEASE", 239, 251], ["GluOC", "CHEMICAL", 4, 9], ["RESULTSGluOC", "CHEMICAL", 111, 123], ["GluOC", "SIMPLE_CHEMICAL", 4, 9], ["TG", "SIMPLE_CHEMICAL", 51, 53], ["OC-H", "SIMPLE_CHEMICAL", 89, 93], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 111, 123], ["KKAy mice", "ORGANISM", 162, 171], ["blood", "ORGANISM_SUBSTANCE", 186, 191], ["TG", "SIMPLE_CHEMICAL", 192, 194], ["TC", "SIMPLE_CHEMICAL", 199, 201], ["mice", "ORGANISM", 214, 218], ["serum", "ORGANISM_SUBSTANCE", 268, 273], ["TC", "SIMPLE_CHEMICAL", 274, 276], ["TG", "SIMPLE_CHEMICAL", 278, 280], ["HDL-C", "SIMPLE_CHEMICAL", 282, 287], ["LDL-C", "SIMPLE_CHEMICAL", 293, 298], ["C57 mice", "ORGANISM", 313, 321], ["HDL", "PROTEIN", 282, 285], ["LDL", "PROTEIN", 293, 296], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 214, 218], ["mice", "SPECIES", 317, 321], ["mice", "SPECIES", 167, 171], ["mice", "SPECIES", 214, 218], ["mice", "SPECIES", 317, 321], ["The GluOC treatment", "TREATMENT", 0, 19], ["the high TG content", "PROBLEM", 42, 61], ["dyslipidemia", "PROBLEM", 146, 158], ["blood TG", "TEST", 186, 194], ["TC levels", "TEST", 199, 208], ["prominent dyslipidemia", "PROBLEM", 229, 251], ["serum TC", "TEST", 268, 276], ["TG", "TEST", 278, 280], ["HDL", "TEST", 282, 285], ["LDL", "TEST", 293, 296], ["prominent", "OBSERVATION_MODIFIER", 229, 238], ["dyslipidemia", "OBSERVATION", 239, 251], ["LDL", "ANATOMY", 293, 296]]], ["As shown in Fig. 3 , the serum TC and TG levels became lower in response to GluOC treatment without altering food intake or body weight in KKAy mice.RESULTSGluOC treatment enhances insulin sensitivity by activating the hepatic IR\u03b2/PI3K/Akt pathway in KKAy mice Insulin function is mediated by activating the insulin receptor and downstream signaling molecules.", [["serum", "ANATOMY", 25, 30], ["body", "ANATOMY", 124, 128], ["hepatic", "ANATOMY", 219, 226], ["GluOC", "CHEMICAL", 76, 81], ["RESULTSGluOC", "CHEMICAL", 149, 161], ["GluOC", "CHEMICAL", 76, 81], ["RESULTSGluOC", "CHEMICAL", 149, 161], ["serum", "ORGANISM_SUBSTANCE", 25, 30], ["TC", "SIMPLE_CHEMICAL", 31, 33], ["TG", "SIMPLE_CHEMICAL", 38, 40], ["GluOC", "SIMPLE_CHEMICAL", 76, 81], ["food", "ORGANISM_SUBDIVISION", 109, 113], ["body", "ORGANISM_SUBDIVISION", 124, 128], ["KKAy mice", "ORGANISM", 139, 148], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 149, 161], ["insulin", "GENE_OR_GENE_PRODUCT", 181, 188], ["\u03b2", "GENE_OR_GENE_PRODUCT", 229, 230], ["PI3K", "GENE_OR_GENE_PRODUCT", 231, 235], ["Akt", "GENE_OR_GENE_PRODUCT", 236, 239], ["KKAy mice", "ORGANISM", 251, 260], ["Insulin", "GENE_OR_GENE_PRODUCT", 261, 268], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 308, 324], ["hepatic IR\u03b2", "PROTEIN", 219, 230], ["PI3K", "PROTEIN", 231, 235], ["Akt", "PROTEIN", 236, 239], ["insulin receptor", "PROTEIN", 308, 324], ["downstream signaling molecules", "PROTEIN", 329, 359], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 256, 260], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 256, 260], ["the serum TC", "TEST", 21, 33], ["TG levels", "TEST", 38, 47], ["GluOC treatment", "TREATMENT", 76, 91], ["RESULTSGluOC treatment enhances insulin sensitivity", "TREATMENT", 149, 200], ["the hepatic IR", "TEST", 215, 229], ["Akt pathway", "TREATMENT", 236, 247], ["KKAy mice Insulin function", "TREATMENT", 251, 277], ["the insulin receptor", "TREATMENT", 304, 324], ["hepatic", "ANATOMY", 219, 226]]], ["To understand the underlying mechanisms responsible for the improved insulin sensitivity in GluOC-treated mice, insulin signaling molecules in liver tissues were investigated.", [["liver tissues", "ANATOMY", 143, 156], ["GluOC", "CHEMICAL", 92, 97], ["insulin", "GENE_OR_GENE_PRODUCT", 69, 76], ["GluOC", "SIMPLE_CHEMICAL", 92, 97], ["mice", "ORGANISM", 106, 110], ["insulin", "GENE_OR_GENE_PRODUCT", 112, 119], ["liver tissues", "TISSUE", 143, 156], ["GluOC", "PROTEIN", 92, 97], ["insulin signaling molecules", "PROTEIN", 112, 139], ["mice", "SPECIES", 106, 110], ["mice", "SPECIES", 106, 110], ["the improved insulin sensitivity", "PROBLEM", 56, 88], ["GluOC", "TEST", 92, 97], ["insulin signaling molecules", "TREATMENT", 112, 139], ["liver tissues", "ANATOMY", 143, 156]]], ["As shown in Fig. 4 , the insulin signaling pathway was suppressed in KKAy mice, showing a downregulated phosphorylation of IR\u03b2, PI3K, and Akt after insulin administration in C57 mice.", [["insulin", "GENE_OR_GENE_PRODUCT", 25, 32], ["KKAy mice", "ORGANISM", 69, 78], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 123, 126], ["PI3K", "GENE_OR_GENE_PRODUCT", 128, 132], ["Akt", "GENE_OR_GENE_PRODUCT", 138, 141], ["insulin", "GENE_OR_GENE_PRODUCT", 148, 155], ["C57 mice", "ORGANISM", 174, 182], ["insulin", "PROTEIN", 25, 32], ["IR\u03b2", "PROTEIN", 123, 126], ["PI3K", "PROTEIN", 128, 132], ["Akt", "PROTEIN", 138, 141], ["insulin", "PROTEIN", 148, 155], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 178, 182], ["mice", "SPECIES", 74, 78], ["mice", "SPECIES", 178, 182], ["the insulin signaling pathway", "TREATMENT", 21, 50], ["a downregulated phosphorylation of IR\u03b2", "PROBLEM", 88, 126], ["PI3K", "TEST", 128, 132], ["insulin administration", "TREATMENT", 148, 170]]], ["After 4 weeks of treatment, the insulin-induced phosphorylation of IR\u03b2 and Akt was upregulated in OC-L-and OC-H-treated mice compared with KKAy mice, suggesting that GluOC treatment enhanced the hepatic insulin signaling pathway in KKAy mice.RESULTSGluOC treatment ameliorates hyperglycemia by suppressing gluconeogenesis and promoting glycogen synthesis in KKAy mice The activation of the IR\u03b2/PI3K/Akt pathway was accompanied by upregulated insulin-stimulated phosphorylation of Foxo1 (Ser253) and GSK3\u03b2 (Ser9), which are involved in glucose metabolism downstream (Fig. 5a-d) .", [["hepatic", "ANATOMY", 195, 202], ["OC", "CHEMICAL", 98, 100], ["OC", "CHEMICAL", 107, 109], ["GluOC", "CHEMICAL", 166, 171], ["RESULTSGluOC", "CHEMICAL", 242, 254], ["hyperglycemia", "DISEASE", 277, 290], ["glycogen", "CHEMICAL", 336, 344], ["glucose", "CHEMICAL", 535, 542], ["GluOC", "CHEMICAL", 166, 171], ["RESULTSGluOC", "CHEMICAL", 242, 254], ["glucose", "CHEMICAL", 535, 542], ["insulin", "GENE_OR_GENE_PRODUCT", 32, 39], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 67, 70], ["Akt", "GENE_OR_GENE_PRODUCT", 75, 78], ["OC-L", "SIMPLE_CHEMICAL", 98, 102], ["OC-H-", "SIMPLE_CHEMICAL", 107, 112], ["mice", "ORGANISM", 120, 124], ["KKAy mice", "ORGANISM", 139, 148], ["GluOC", "GENE_OR_GENE_PRODUCT", 166, 171], ["hepatic", "ORGAN", 195, 202], ["insulin", "GENE_OR_GENE_PRODUCT", 203, 210], ["KKAy mice", "ORGANISM", 232, 241], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 242, 254], ["glycogen", "SIMPLE_CHEMICAL", 336, 344], ["KKAy mice", "ORGANISM", 358, 367], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 390, 393], ["PI3K", "GENE_OR_GENE_PRODUCT", 394, 398], ["Akt", "GENE_OR_GENE_PRODUCT", 399, 402], ["insulin", "GENE_OR_GENE_PRODUCT", 442, 449], ["Foxo1", "GENE_OR_GENE_PRODUCT", 480, 485], ["Ser253", "GENE_OR_GENE_PRODUCT", 487, 493], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 499, 504], ["Ser9", "GENE_OR_GENE_PRODUCT", 506, 510], ["glucose", "SIMPLE_CHEMICAL", 535, 542], ["insulin", "PROTEIN", 32, 39], ["IR\u03b2", "PROTEIN", 67, 70], ["Akt", "PROTEIN", 75, 78], ["IR\u03b2", "PROTEIN", 390, 393], ["PI3K", "PROTEIN", 394, 398], ["Akt", "PROTEIN", 399, 402], ["insulin", "PROTEIN", 442, 449], ["Foxo1", "PROTEIN", 480, 485], ["Ser253", "PROTEIN", 487, 493], ["GSK3\u03b2", "PROTEIN", 499, 504], ["Ser9", "PROTEIN", 506, 510], ["mice", "SPECIES", 120, 124], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 363, 367], ["mice", "SPECIES", 144, 148], ["mice", "SPECIES", 237, 241], ["mice", "SPECIES", 363, 367], ["treatment", "TREATMENT", 17, 26], ["the insulin", "TREATMENT", 28, 39], ["GluOC treatment", "TREATMENT", 166, 181], ["hyperglycemia", "PROBLEM", 277, 290], ["suppressing gluconeogenesis", "PROBLEM", 294, 321], ["glycogen synthesis", "TREATMENT", 336, 354], ["the IR", "TEST", 386, 392], ["Akt pathway", "TEST", 399, 410], ["upregulated insulin", "TREATMENT", 430, 449], ["Foxo1", "TEST", 480, 485], ["GSK3\u03b2 (Ser9", "TEST", 499, 510], ["hepatic", "ANATOMY", 195, 202], ["glycogen synthesis", "OBSERVATION", 336, 354]]], ["Foxo1 is the key transcription factor in gluconeogenesis, and GSK3\u03b2 is involved in glycogen synthesis.", [["glycogen", "CHEMICAL", 83, 91], ["Foxo1", "GENE_OR_GENE_PRODUCT", 0, 5], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 62, 67], ["glycogen", "SIMPLE_CHEMICAL", 83, 91], ["Foxo1", "PROTEIN", 0, 5], ["transcription factor", "PROTEIN", 17, 37], ["GSK3\u03b2", "PROTEIN", 62, 67], ["glycogen synthesis", "PROBLEM", 83, 101], ["glycogen synthesis", "OBSERVATION", 83, 101]]], ["Remarkably, the total Foxo1 expression was significantly higher in KKAy mice but was significantly lower in GluOC-treated mice compared to C57 mice (Fig. 5b) .", [["GluOC", "CHEMICAL", 108, 113], ["GluOC", "CHEMICAL", 108, 113], ["Foxo1", "GENE_OR_GENE_PRODUCT", 22, 27], ["KKAy mice", "ORGANISM", 67, 76], ["GluOC", "SIMPLE_CHEMICAL", 108, 113], ["mice", "ORGANISM", 122, 126], ["C57 mice", "ORGANISM", 139, 147], ["Foxo1", "PROTEIN", 22, 27], ["GluOC", "PROTEIN", 108, 113], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 122, 126], ["mice", "SPECIES", 143, 147], ["mice", "SPECIES", 72, 76], ["mice", "SPECIES", 143, 147], ["the total Foxo1 expression", "TEST", 12, 38]]], ["These results suggested that GluOC Uncarboxylated osteocalcin for treating metabolic syndrome XL Zhang et al.RESULTSenhanced both hepatic insulin signaling and glycometabolic pathways involved in gluconeogenesis and glycogen synthesis.RESULTSBoth glycogenolysis and gluconeogenesis lead to hepatic glucose production (HGP), contributing to blood glucose homeostasis, especially in the starving state (FBG).", [["hepatic", "ANATOMY", 130, 137], ["hepatic", "ANATOMY", 290, 297], ["blood", "ANATOMY", 340, 345], ["GluOC", "CHEMICAL", 29, 34], ["metabolic syndrome", "DISEASE", 75, 93], ["glycogen", "CHEMICAL", 216, 224], ["glucose", "CHEMICAL", 298, 305], ["glucose", "CHEMICAL", 346, 353], ["glucose", "CHEMICAL", 298, 305], ["glucose", "CHEMICAL", 346, 353], ["GluOC", "SIMPLE_CHEMICAL", 29, 34], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 50, 61], ["hepatic", "MULTI-TISSUE_STRUCTURE", 130, 137], ["insulin", "GENE_OR_GENE_PRODUCT", 138, 145], ["glycogen", "SIMPLE_CHEMICAL", 216, 224], ["hepatic", "ORGAN", 290, 297], ["glucose", "SIMPLE_CHEMICAL", 298, 305], ["blood", "ORGANISM_SUBSTANCE", 340, 345], ["glucose", "SIMPLE_CHEMICAL", 346, 353], ["osteocalcin", "PROTEIN", 50, 61], ["GluOC Uncarboxylated osteocalcin", "TREATMENT", 29, 61], ["metabolic syndrome", "PROBLEM", 75, 93], ["both hepatic insulin signaling", "TREATMENT", 125, 155], ["glycometabolic pathways", "PROBLEM", 160, 183], ["glycogen synthesis", "TREATMENT", 216, 234], ["RESULTSBoth glycogenolysis", "PROBLEM", 235, 261], ["gluconeogenesis", "PROBLEM", 266, 281], ["hepatic glucose production", "PROBLEM", 290, 316], ["blood glucose homeostasis", "PROBLEM", 340, 365], ["FBG", "TEST", 401, 404], ["hepatic", "ANATOMY", 130, 137], ["insulin signaling", "OBSERVATION", 138, 155], ["glycogen synthesis", "OBSERVATION", 216, 234], ["hepatic", "ANATOMY", 290, 297], ["glucose production", "OBSERVATION", 298, 316], ["glucose homeostasis", "OBSERVATION", 346, 365]]], ["Gluconeogenesis is mainly regulated by insulin, while glycogenolysis is stimulated by glucagon.", [["Gluconeogenesis", "DISEASE", 0, 15], ["glucagon", "CHEMICAL", 86, 94], ["insulin", "GENE_OR_GENE_PRODUCT", 39, 46], ["glucagon", "GENE_OR_GENE_PRODUCT", 86, 94], ["insulin", "PROTEIN", 39, 46], ["Gluconeogenesis", "TREATMENT", 0, 15], ["insulin", "TREATMENT", 39, 46], ["glucagon", "TREATMENT", 86, 94]]], ["The data in primary cultured hepatocytes (Fig. 5e, f) showed that GluOC treatment triggered a concentration-dependent inhibition of HGP under both insulin-free and insulin-stimulated conditions.", [["hepatocytes", "ANATOMY", 29, 40], ["GluOC", "CHEMICAL", 66, 71], ["GluOC", "CHEMICAL", 66, 71], ["hepatocytes", "CELL", 29, 40], ["GluOC", "SIMPLE_CHEMICAL", 66, 71], ["HGP", "SIMPLE_CHEMICAL", 132, 135], ["insulin", "GENE_OR_GENE_PRODUCT", 147, 154], ["insulin", "GENE_OR_GENE_PRODUCT", 164, 171], ["primary cultured hepatocytes", "CELL_TYPE", 12, 40], ["HGP", "PROTEIN", 132, 135], ["insulin", "PROTEIN", 147, 154], ["insulin", "PROTEIN", 164, 171], ["The data", "TEST", 0, 8], ["primary cultured hepatocytes", "TEST", 12, 40], ["GluOC treatment", "TREATMENT", 66, 81], ["a concentration-dependent inhibition of HGP", "PROBLEM", 92, 135], ["both insulin", "TREATMENT", 142, 154], ["insulin", "TREATMENT", 164, 171], ["hepatocytes", "ANATOMY", 29, 40]]], ["This finding was in accordance with the suppressed hepatic Foxo1 expression without insulin stimulation and the enhanced Foxo1 phosphorylation with insulin stimulation by GluOC treatment in KKAy mice.", [["hepatic", "ANATOMY", 51, 58], ["GluOC", "CHEMICAL", 171, 176], ["GluOC", "CHEMICAL", 171, 176], ["hepatic", "ORGAN", 51, 58], ["Foxo1", "GENE_OR_GENE_PRODUCT", 59, 64], ["insulin", "GENE_OR_GENE_PRODUCT", 84, 91], ["Foxo1", "GENE_OR_GENE_PRODUCT", 121, 126], ["insulin", "GENE_OR_GENE_PRODUCT", 148, 155], ["GluOC", "SIMPLE_CHEMICAL", 171, 176], ["KKAy mice", "ORGANISM", 190, 199], ["Foxo1", "PROTEIN", 59, 64], ["Foxo1", "PROTEIN", 121, 126], ["insulin", "PROTEIN", 148, 155], ["mice", "SPECIES", 195, 199], ["mice", "SPECIES", 195, 199], ["insulin stimulation", "TREATMENT", 84, 103], ["the enhanced Foxo1 phosphorylation", "TREATMENT", 108, 142], ["insulin stimulation", "TREATMENT", 148, 167], ["hepatic", "ANATOMY", 51, 58], ["Foxo1 expression", "OBSERVATION", 59, 75]]], ["Fig. 1 GluOC treatment improves hyperglycemia, glucose intolerance, and whole-body insulin resistance in KKAy mice.", [["body", "ANATOMY", 78, 82], ["GluOC", "CHEMICAL", 7, 12], ["hyperglycemia", "DISEASE", 32, 45], ["glucose intolerance", "DISEASE", 47, 66], ["glucose", "CHEMICAL", 47, 54], ["GluOC", "SIMPLE_CHEMICAL", 7, 12], ["glucose", "SIMPLE_CHEMICAL", 47, 54], ["body", "ORGANISM_SUBDIVISION", 78, 82], ["insulin", "GENE_OR_GENE_PRODUCT", 83, 90], ["KKAy mice", "ORGANISM", 105, 114], ["mice", "SPECIES", 110, 114], ["mice", "SPECIES", 110, 114], ["hyperglycemia", "PROBLEM", 32, 45], ["glucose intolerance", "PROBLEM", 47, 66], ["whole-body insulin resistance", "TREATMENT", 72, 101], ["hyperglycemia", "OBSERVATION", 32, 45], ["glucose intolerance", "OBSERVATION", 47, 66]]], ["Animals were treated with GluOC (3 or 30 ng/g BW) for 28 days. a Blood uncarboxylated osteocalcin levels; b Nonfasting blood glucose; c Fasting blood glucose; d Blood glucose levels after the glucose loading; e Area under the curve in OGTT; f Fasting plasma insulin levels; g HOMA-IR.", [["Blood", "ANATOMY", 65, 70], ["blood", "ANATOMY", 119, 124], ["blood", "ANATOMY", 144, 149], ["Blood", "ANATOMY", 161, 166], ["plasma", "ANATOMY", 251, 257], ["GluOC", "CHEMICAL", 26, 31], ["glucose", "CHEMICAL", 125, 132], ["glucose", "CHEMICAL", 167, 174], ["glucose", "CHEMICAL", 192, 199], ["GluOC", "CHEMICAL", 26, 31], ["glucose", "CHEMICAL", 125, 132], ["glucose", "CHEMICAL", 150, 157], ["glucose", "CHEMICAL", 167, 174], ["glucose", "CHEMICAL", 192, 199], ["Animals", "ORGANISM", 0, 7], ["GluOC", "SIMPLE_CHEMICAL", 26, 31], ["Blood", "ORGANISM_SUBSTANCE", 65, 70], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 86, 97], ["blood", "ORGANISM_SUBSTANCE", 119, 124], ["glucose", "SIMPLE_CHEMICAL", 125, 132], ["blood", "ORGANISM_SUBSTANCE", 144, 149], ["glucose", "SIMPLE_CHEMICAL", 150, 157], ["Blood", "ORGANISM_SUBSTANCE", 161, 166], ["glucose", "SIMPLE_CHEMICAL", 167, 174], ["glucose", "SIMPLE_CHEMICAL", 192, 199], ["Fasting", "ORGANISM_SUBSTANCE", 243, 250], ["plasma", "ORGANISM_SUBSTANCE", 251, 257], ["insulin", "GENE_OR_GENE_PRODUCT", 258, 265], ["osteocalcin", "PROTEIN", 86, 97], ["GluOC", "TREATMENT", 26, 31], ["a Blood uncarboxylated osteocalcin levels", "TEST", 63, 104], ["Nonfasting blood glucose", "TEST", 108, 132], ["Fasting blood glucose", "TEST", 136, 157], ["Blood glucose levels", "TEST", 161, 181], ["the glucose loading", "TREATMENT", 188, 207], ["OGTT", "TEST", 235, 239], ["Fasting plasma insulin levels", "TEST", 243, 272]]], ["Data are expressed as mean \u00b1 SEM (n = 10). ### P < 0.001 vs. C57; P < 0.001 vs. KKAyRESULTSThe effect of GluOC on glycogen synthesis was also evaluated in primary cultured hepatocytes.", [["hepatocytes", "ANATOMY", 172, 183], ["GluOC", "CHEMICAL", 105, 110], ["glycogen", "CHEMICAL", 114, 122], ["GluOC", "SIMPLE_CHEMICAL", 105, 110], ["glycogen", "SIMPLE_CHEMICAL", 114, 122], ["hepatocytes", "CELL", 172, 183], ["primary cultured hepatocytes", "CELL_TYPE", 155, 183], ["P", "TEST", 47, 48], ["C57", "TEST", 61, 64], ["P", "TEST", 66, 67], ["GluOC", "PROBLEM", 105, 110], ["glycogen synthesis", "TREATMENT", 114, 132], ["hepatocytes", "ANATOMY", 172, 183]]], ["As shown in Fig. 5g , h, GluOC promoted insulin-stimulated GSK3\u03b2 phosphorylation, suggesting that OC could enhance glycogen synthesis in vitro.", [["GluOC", "CHEMICAL", 25, 30], ["OC", "CHEMICAL", 98, 100], ["glycogen", "CHEMICAL", 115, 123], ["GluOC", "CHEMICAL", 25, 30], ["GluOC", "SIMPLE_CHEMICAL", 25, 30], ["insulin", "GENE_OR_GENE_PRODUCT", 40, 47], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 59, 64], ["OC", "SIMPLE_CHEMICAL", 98, 100], ["glycogen", "SIMPLE_CHEMICAL", 115, 123], ["GSK3\u03b2", "PROTEIN", 59, 64], ["insulin", "TREATMENT", 40, 47], ["phosphorylation", "PROBLEM", 65, 80], ["glycogen synthesis", "TREATMENT", 115, 133], ["glycogen synthesis", "OBSERVATION", 115, 133]]], ["This result was consistent with the improved nonfasting blood glucose after OC administration in KKAy mice.RESULTSGluOC treatment ameliorates hepatic steatosis by inhibiting de novo lipogenesis and enhancing fatty-acid \u03b2-oxidation in KKAy mice Hepatic lipid metabolism pathways, including fatty acid uptake (CD36), fatty-acid \u03b2-oxidation (CPT1, MCAD), and de novo lipogenesis (SREBP1c, ACC, FAS), were evaluated by western blot.", [["blood", "ANATOMY", 56, 61], ["hepatic", "ANATOMY", 142, 149], ["Hepatic", "ANATOMY", 244, 251], ["glucose", "CHEMICAL", 62, 69], ["OC", "CHEMICAL", 76, 78], ["RESULTSGluOC", "CHEMICAL", 107, 119], ["steatosis", "DISEASE", 150, 159], ["fatty-acid", "CHEMICAL", 208, 218], ["fatty acid", "CHEMICAL", 289, 299], ["fatty-acid", "CHEMICAL", 315, 325], ["glucose", "CHEMICAL", 62, 69], ["RESULTSGluOC", "CHEMICAL", 107, 119], ["fatty-acid", "CHEMICAL", 208, 218], ["fatty acid", "CHEMICAL", 289, 299], ["fatty-acid", "CHEMICAL", 315, 325], ["blood", "ORGANISM_SUBSTANCE", 56, 61], ["glucose", "SIMPLE_CHEMICAL", 62, 69], ["OC", "SIMPLE_CHEMICAL", 76, 78], ["KKAy mice", "ORGANISM", 97, 106], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 107, 119], ["hepatic steatosis", "PATHOLOGICAL_FORMATION", 142, 159], ["fatty-acid", "SIMPLE_CHEMICAL", 208, 218], ["KKAy mice", "ORGANISM", 234, 243], ["Hepatic lipid", "MULTI-TISSUE_STRUCTURE", 244, 257], ["fatty acid", "SIMPLE_CHEMICAL", 289, 299], ["CD36", "GENE_OR_GENE_PRODUCT", 308, 312], ["fatty-acid \u03b2-oxidation", "GENE_OR_GENE_PRODUCT", 315, 337], ["CPT1", "GENE_OR_GENE_PRODUCT", 339, 343], ["MCAD", "GENE_OR_GENE_PRODUCT", 345, 349], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 377, 384], ["ACC", "GENE_OR_GENE_PRODUCT", 386, 389], ["FAS", "GENE_OR_GENE_PRODUCT", 391, 394], ["CD36", "PROTEIN", 308, 312], ["CPT1", "PROTEIN", 339, 343], ["MCAD", "PROTEIN", 345, 349], ["SREBP1c", "PROTEIN", 377, 384], ["ACC", "PROTEIN", 386, 389], ["FAS", "PROTEIN", 391, 394], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 239, 243], ["mice", "SPECIES", 102, 106], ["mice", "SPECIES", 239, 243], ["blood glucose", "TEST", 56, 69], ["hepatic steatosis", "PROBLEM", 142, 159], ["novo lipogenesis", "PROBLEM", 177, 193], ["enhancing fatty-acid \u03b2-oxidation", "PROBLEM", 198, 230], ["Hepatic lipid metabolism pathways", "PROBLEM", 244, 277], ["fatty acid uptake", "PROBLEM", 289, 306], ["CD36", "TEST", 308, 312], ["fatty-acid \u03b2-oxidation", "PROBLEM", 315, 337], ["de novo lipogenesis", "PROBLEM", 356, 375], ["consistent with", "UNCERTAINTY", 16, 31], ["hepatic", "ANATOMY", 142, 149], ["steatosis", "OBSERVATION", 150, 159], ["novo lipogenesis", "OBSERVATION", 177, 193], ["enhancing", "OBSERVATION_MODIFIER", 198, 207], ["fatty", "OBSERVATION_MODIFIER", 208, 213], ["Hepatic", "ANATOMY", 244, 251], ["lipid metabolism", "OBSERVATION", 252, 268], ["fatty acid uptake", "OBSERVATION", 289, 306], ["MCAD", "ANATOMY", 345, 349], ["novo lipogenesis", "OBSERVATION", 359, 375]]], ["As shown in Fig. 6a , b, the hepatic expression of SREBP1c and FAS was upregulated in KKAy mice, indicating increased hepatic lipogenesis.", [["hepatic", "ANATOMY", 29, 36], ["hepatic", "ANATOMY", 118, 125], ["hepatic", "MULTI-TISSUE_STRUCTURE", 29, 36], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 51, 58], ["FAS", "GENE_OR_GENE_PRODUCT", 63, 66], ["KKAy mice", "ORGANISM", 86, 95], ["hepatic", "ORGAN", 118, 125], ["SREBP1c", "PROTEIN", 51, 58], ["FAS", "PROTEIN", 63, 66], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["FAS", "TEST", 63, 66], ["increased hepatic lipogenesis", "PROBLEM", 108, 137], ["hepatic", "ANATOMY", 29, 36], ["increased", "OBSERVATION_MODIFIER", 108, 117], ["hepatic", "ANATOMY", 118, 125], ["lipogenesis", "OBSERVATION", 126, 137]]], ["Remarkably, hepatic lipogenesis was inhibited by OC treatment, which downregulated the expression of SREBP1c, ACC and FAS, especially in the OC-H group.", [["hepatic", "ANATOMY", 12, 19], ["OC", "CHEMICAL", 49, 51], ["OC-H", "CHEMICAL", 141, 145], ["hepatic", "ORGAN", 12, 19], ["OC", "SIMPLE_CHEMICAL", 49, 51], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 101, 108], ["ACC", "GENE_OR_GENE_PRODUCT", 110, 113], ["FAS", "GENE_OR_GENE_PRODUCT", 118, 121], ["OC-H", "GENE_OR_GENE_PRODUCT", 141, 145], ["SREBP1c", "PROTEIN", 101, 108], ["ACC", "PROTEIN", 110, 113], ["FAS", "PROTEIN", 118, 121], ["hepatic lipogenesis", "PROBLEM", 12, 31], ["OC treatment", "TREATMENT", 49, 61], ["hepatic", "ANATOMY", 12, 19], ["lipogenesis", "OBSERVATION", 20, 31]]], ["The fatty-acid \u03b2-oxidation in KKAy mice was significantly lower, but it was significantly higher following GluOC treatment (Fig. 6c, d) .", [["fatty-acid", "CHEMICAL", 4, 14], ["GluOC", "CHEMICAL", 107, 112], ["fatty-acid", "CHEMICAL", 4, 14], ["GluOC", "CHEMICAL", 107, 112], ["fatty-acid", "SIMPLE_CHEMICAL", 4, 14], ["KKAy mice", "ORGANISM", 30, 39], ["GluOC", "SIMPLE_CHEMICAL", 107, 112], ["mice", "SPECIES", 35, 39], ["mice", "SPECIES", 35, 39], ["The fatty-acid \u03b2-oxidation", "TEST", 0, 26], ["GluOC treatment", "TREATMENT", 107, 122], ["fatty", "OBSERVATION_MODIFIER", 4, 9], ["significantly", "OBSERVATION_MODIFIER", 44, 57], ["lower", "OBSERVATION_MODIFIER", 58, 63]]], ["Interestingly, CD36 expression was upregulated in the GluOC-treated group, which might be compensatory to the decreased de novo lipogenesis.RESULTSGluOC treatment changes hepatic fatty-acid metabolic processes in KKAy mice GO enrichment analysis of the expressed hepatic proteins suggested that the hepatic proteins that were differentially expressed were mainly correlated with biological processes and functions and cellular components (Fig. 7a) .", [["hepatic", "ANATOMY", 171, 178], ["hepatic", "ANATOMY", 263, 270], ["hepatic", "ANATOMY", 299, 306], ["cellular", "ANATOMY", 418, 426], ["GluOC", "CHEMICAL", 54, 59], ["RESULTSGluOC", "CHEMICAL", 140, 152], ["GluOC", "CHEMICAL", 54, 59], ["RESULTSGluOC", "CHEMICAL", 140, 152], ["fatty-acid", "CHEMICAL", 179, 189], ["CD36", "GENE_OR_GENE_PRODUCT", 15, 19], ["GluOC", "SIMPLE_CHEMICAL", 54, 59], ["RESULTSGluOC", "SIMPLE_CHEMICAL", 140, 152], ["hepatic fatty", "PATHOLOGICAL_FORMATION", 171, 184], ["mice", "ORGANISM", 218, 222], ["hepatic", "MULTI-TISSUE_STRUCTURE", 263, 270], ["hepatic", "MULTI-TISSUE_STRUCTURE", 299, 306], ["cellular", "CELL", 418, 426], ["CD36", "PROTEIN", 15, 19], ["GluOC-treated group", "CELL_LINE", 54, 73], ["hepatic proteins", "PROTEIN", 263, 279], ["hepatic proteins", "PROTEIN", 299, 315], ["mice", "SPECIES", 218, 222], ["mice", "SPECIES", 218, 222], ["the decreased de novo lipogenesis", "PROBLEM", 106, 139], ["RESULTSGluOC treatment", "TREATMENT", 140, 162], ["hepatic fatty-acid metabolic processes", "PROBLEM", 171, 209], ["enrichment analysis", "TEST", 226, 245], ["the hepatic proteins", "PROBLEM", 295, 315], ["decreased", "OBSERVATION_MODIFIER", 110, 119], ["novo lipogenesis", "OBSERVATION", 123, 139], ["hepatic", "ANATOMY", 171, 178], ["fatty", "OBSERVATION_MODIFIER", 179, 184], ["hepatic", "ANATOMY", 263, 270], ["hepatic", "ANATOMY", 299, 306]]], ["Fatty-acid metabolic processes and responses to endoplasmic reticulum stress were strongly affected by GluOC treatment.", [["endoplasmic reticulum", "ANATOMY", 48, 69], ["GluOC", "CHEMICAL", 103, 108], ["Fatty-acid", "CHEMICAL", 0, 10], ["GluOC", "CHEMICAL", 103, 108], ["Fatty-acid", "SIMPLE_CHEMICAL", 0, 10], ["endoplasmic reticulum", "CELLULAR_COMPONENT", 48, 69], ["GluOC", "SIMPLE_CHEMICAL", 103, 108], ["Fatty-acid metabolic processes", "PROBLEM", 0, 30], ["endoplasmic reticulum stress", "PROBLEM", 48, 76], ["GluOC treatment", "TREATMENT", 103, 118], ["endoplasmic reticulum stress", "OBSERVATION", 48, 76]]], ["The representatives of differentially expressed proteins in the fatty-acid metabolic process are shown in Fig. 7b .", [["fatty-acid", "CHEMICAL", 64, 74], ["the fatty-acid metabolic process", "PROBLEM", 60, 92]]], ["Interestingly, the hepatic expression of malonyl-CoA-acyl carrier protein transacylase (MCAT) was significantly downregulated by GluOC treatment.", [["hepatic", "ANATOMY", 19, 26], ["malonyl-CoA-acyl", "CHEMICAL", 41, 57], ["GluOC", "CHEMICAL", 129, 134], ["malonyl-CoA", "CHEMICAL", 41, 52], ["acyl", "CHEMICAL", 53, 57], ["GluOC", "CHEMICAL", 129, 134], ["hepatic", "MULTI-TISSUE_STRUCTURE", 19, 26], ["malonyl-CoA-acyl carrier protein transacylase", "GENE_OR_GENE_PRODUCT", 41, 86], ["MCAT", "GENE_OR_GENE_PRODUCT", 88, 92], ["GluOC", "SIMPLE_CHEMICAL", 129, 134], ["malonyl-CoA-acyl carrier protein transacylase", "PROTEIN", 41, 86], ["MCAT", "PROTEIN", 88, 92], ["GluOC", "PROTEIN", 129, 134], ["malonyl-CoA-acyl carrier protein transacylase", "TEST", 41, 86], ["GluOC treatment", "TREATMENT", 129, 144], ["hepatic", "ANATOMY", 19, 26], ["CoA", "OBSERVATION_MODIFIER", 49, 52]]], ["Indeed, immunoblot analysis revealed the suppressed hepatic expression of MCAT (Fig. 7c) .DISCUSSIONThe liver is the most important organ for glucose and lipid metabolism.", [["hepatic", "ANATOMY", 52, 59], ["liver", "ANATOMY", 104, 109], ["organ", "ANATOMY", 132, 137], ["glucose", "CHEMICAL", 142, 149], ["glucose", "CHEMICAL", 142, 149], ["hepatic", "MULTI-TISSUE_STRUCTURE", 52, 59], ["MCAT", "GENE_OR_GENE_PRODUCT", 74, 78], ["liver", "ORGAN", 104, 109], ["organ", "ORGAN", 132, 137], ["glucose", "SIMPLE_CHEMICAL", 142, 149], ["lipid", "SIMPLE_CHEMICAL", 154, 159], ["MCAT", "PROTEIN", 74, 78], ["immunoblot analysis", "TEST", 8, 27], ["glucose", "TEST", 142, 149], ["lipid metabolism", "TEST", 154, 170], ["hepatic", "ANATOMY", 52, 59], ["liver", "ANATOMY", 104, 109], ["lipid metabolism", "OBSERVATION", 154, 170]]], ["Under physiological conditions, the hepatic response to insulin includes inhibition of gluconeogenesis and facilitation of lipogenesis.", [["hepatic", "ANATOMY", 36, 43], ["hepatic", "MULTI-TISSUE_STRUCTURE", 36, 43], ["insulin", "GENE_OR_GENE_PRODUCT", 56, 63], ["insulin", "PROTEIN", 56, 63], ["insulin", "TREATMENT", 56, 63], ["inhibition of gluconeogenesis", "TREATMENT", 73, 102], ["facilitation of lipogenesis", "TREATMENT", 107, 134], ["physiological conditions", "OBSERVATION", 6, 30], ["hepatic", "ANATOMY", 36, 43]]], ["However, hepatic lipogenesis remains functional while gluconeogenesis is no longer inhibited in the insulin-resistant state.", [["hepatic", "ANATOMY", 9, 16], ["hepatic", "MULTI-TISSUE_STRUCTURE", 9, 16], ["insulin", "GENE_OR_GENE_PRODUCT", 100, 107], ["insulin", "PROTEIN", 100, 107], ["hepatic lipogenesis", "PROBLEM", 9, 28], ["hepatic", "ANATOMY", 9, 16], ["lipogenesis", "OBSERVATION", 17, 28], ["no longer", "UNCERTAINTY", 73, 82]]], ["An increased blood insulin level, as a result of failing to bring down blood glucose, continuously favors hepatic lipogenesis, resulting in fat accumulation or steatosis.", [["blood", "ANATOMY", 13, 18], ["blood", "ANATOMY", 71, 76], ["hepatic", "ANATOMY", 106, 113], ["fat", "ANATOMY", 140, 143], ["glucose", "CHEMICAL", 77, 84], ["steatosis", "DISEASE", 160, 169], ["glucose", "CHEMICAL", 77, 84], ["blood", "ORGANISM_SUBSTANCE", 13, 18], ["insulin", "GENE_OR_GENE_PRODUCT", 19, 26], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["hepatic", "ORGAN", 106, 113], ["fat", "TISSUE", 140, 143], ["An increased blood insulin level", "PROBLEM", 0, 32], ["blood glucose", "TEST", 71, 84], ["hepatic lipogenesis", "PROBLEM", 106, 125], ["fat accumulation", "PROBLEM", 140, 156], ["steatosis", "PROBLEM", 160, 169], ["increased", "OBSERVATION_MODIFIER", 3, 12], ["blood insulin", "OBSERVATION", 13, 26], ["hepatic", "ANATOMY", 106, 113], ["lipogenesis", "OBSERVATION", 114, 125], ["fat accumulation", "OBSERVATION", 140, 156], ["steatosis", "OBSERVATION", 160, 169]]], ["Thus, insulin resistance is a culprit in the pathogenesis of fatty liver.", [["fatty liver", "ANATOMY", 61, 72], ["fatty liver", "DISEASE", 61, 72], ["insulin", "GENE_OR_GENE_PRODUCT", 6, 13], ["liver", "ORGAN", 67, 72], ["insulin resistance", "TREATMENT", 6, 24], ["fatty liver", "PROBLEM", 61, 72], ["insulin resistance", "OBSERVATION", 6, 24], ["fatty", "OBSERVATION", 61, 66], ["liver", "ANATOMY", 67, 72]]], ["Previous studies suggested that insulin sensitivity can be improved in adipose tissue and muscle by GluOC administration [15] [16] [17] .", [["adipose tissue", "ANATOMY", 71, 85], ["muscle", "ANATOMY", 90, 96], ["GluOC", "CHEMICAL", 100, 105], ["GluOC", "CHEMICAL", 100, 105], ["insulin", "GENE_OR_GENE_PRODUCT", 32, 39], ["adipose tissue", "TISSUE", 71, 85], ["muscle", "ORGAN", 90, 96], ["GluOC", "SIMPLE_CHEMICAL", 100, 105], ["[15] [16] [17]", "SIMPLE_CHEMICAL", 121, 135], ["Previous studies", "TEST", 0, 16], ["insulin sensitivity", "PROBLEM", 32, 51], ["muscle", "ANATOMY", 90, 96]]], ["This study investigated the insulinsensitizing effect in the liver of KKAy mice.", [["liver", "ANATOMY", 61, 66], ["liver", "ORGAN", 61, 66], ["KKAy mice", "ORGANISM", 70, 79], ["mice", "SPECIES", 75, 79], ["mice", "SPECIES", 75, 79], ["This study", "TEST", 0, 10], ["liver", "ANATOMY", 61, 66]]], ["We found that osteocalcin treatment improved hepatic glucose and lipid metabolism, which was likely mediated through activating the insulin signaling pathway.DISCUSSIONGluOC enhances hepatic insulin sensitivity in KKAy mice Insulin functions by activating the insulin receptor and the downstream signaling molecules of the insulin signaling pathway.", [["hepatic", "ANATOMY", 45, 52], ["hepatic", "ANATOMY", 183, 190], ["glucose", "CHEMICAL", 53, 60], ["glucose", "CHEMICAL", 53, 60], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 14, 25], ["hepatic", "MULTI-TISSUE_STRUCTURE", 45, 52], ["glucose", "SIMPLE_CHEMICAL", 53, 60], ["lipid", "SIMPLE_CHEMICAL", 65, 70], ["insulin", "GENE_OR_GENE_PRODUCT", 132, 139], ["hepatic", "ORGAN", 183, 190], ["insulin", "GENE_OR_GENE_PRODUCT", 191, 198], ["KKAy mice", "ORGANISM", 214, 223], ["Insulin", "GENE_OR_GENE_PRODUCT", 224, 231], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 260, 276], ["insulin", "GENE_OR_GENE_PRODUCT", 323, 330], ["osteocalcin", "PROTEIN", 14, 25], ["insulin receptor", "PROTEIN", 260, 276], ["downstream signaling molecules", "PROTEIN", 285, 315], ["mice", "SPECIES", 219, 223], ["mice", "SPECIES", 219, 223], ["osteocalcin treatment", "TREATMENT", 14, 35], ["hepatic glucose", "TEST", 45, 60], ["lipid metabolism", "PROBLEM", 65, 81], ["the insulin signaling pathway", "TREATMENT", 128, 157], ["hepatic insulin sensitivity", "TREATMENT", 183, 210], ["KKAy mice Insulin functions", "TREATMENT", 214, 241], ["the insulin receptor", "TREATMENT", 256, 276], ["the insulin signaling pathway", "TREATMENT", 319, 348], ["osteocalcin", "OBSERVATION", 14, 25], ["hepatic", "ANATOMY", 45, 52], ["lipid metabolism", "OBSERVATION", 65, 81], ["hepatic", "ANATOMY", 183, 190], ["insulin sensitivity", "OBSERVATION", 191, 210]]], ["The binding of insulin to insulin receptor (IR) triggers phosphorylation of insulin receptor \u03b2 (IR\u03b2) and its substrate (IRS), which activates the phosphatidylinositol 3-kinase (PI3K)-Akt/protein kinase B (PKB) pathway, contributing to glucose uptake, glycogen synthesis, and inhibition of gluconeogenesis [29, 30] .", [["glucose", "CHEMICAL", 235, 242], ["glycogen", "CHEMICAL", 251, 259], ["phosphatidylinositol", "CHEMICAL", 146, 166], ["glucose", "CHEMICAL", 235, 242], ["insulin", "GENE_OR_GENE_PRODUCT", 15, 22], ["insulin receptor", "GENE_OR_GENE_PRODUCT", 26, 42], ["IR", "GENE_OR_GENE_PRODUCT", 44, 46], ["insulin receptor \u03b2", "GENE_OR_GENE_PRODUCT", 76, 94], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 96, 99], ["IRS", "GENE_OR_GENE_PRODUCT", 120, 123], ["phosphatidylinositol 3-kinase", "GENE_OR_GENE_PRODUCT", 146, 175], ["PI3K", "GENE_OR_GENE_PRODUCT", 177, 181], ["Akt", "GENE_OR_GENE_PRODUCT", 183, 186], ["protein kinase B", "GENE_OR_GENE_PRODUCT", 187, 203], ["PKB", "GENE_OR_GENE_PRODUCT", 205, 208], ["glucose", "SIMPLE_CHEMICAL", 235, 242], ["glycogen", "SIMPLE_CHEMICAL", 251, 259], ["insulin", "PROTEIN", 15, 22], ["insulin receptor", "PROTEIN", 26, 42], ["IR", "PROTEIN", 44, 46], ["insulin receptor \u03b2", "PROTEIN", 76, 94], ["IR\u03b2", "PROTEIN", 96, 99], ["IRS", "PROTEIN", 120, 123], ["phosphatidylinositol 3-kinase", "PROTEIN", 146, 175], ["PI3K", "PROTEIN", 177, 181], ["Akt", "PROTEIN", 183, 186], ["protein kinase B", "PROTEIN", 187, 203], ["PKB", "PROTEIN", 205, 208], ["insulin to insulin receptor (IR)", "TREATMENT", 15, 47], ["phosphorylation of insulin receptor", "TREATMENT", 57, 92], ["the phosphatidylinositol", "TEST", 142, 166], ["PI3K", "TEST", 177, 181], ["Akt/protein kinase B (PKB) pathway", "TEST", 183, 217], ["glucose uptake", "PROBLEM", 235, 249], ["glycogen synthesis", "TREATMENT", 251, 269], ["gluconeogenesis", "TEST", 289, 304]]], ["In this study, both hyperinsulinemia and the elevated HOMA-IR index in KKAy mice were reduced by GluOC treatment (Fig. 1f, g) .", [["hyperinsulinemia", "DISEASE", 20, 36], ["GluOC", "CHEMICAL", 97, 102], ["GluOC", "CHEMICAL", 97, 102], ["mice", "ORGANISM", 76, 80], ["GluOC", "SIMPLE_CHEMICAL", 97, 102], ["mice", "SPECIES", 76, 80], ["mice", "SPECIES", 76, 80], ["this study", "TEST", 3, 13], ["both hyperinsulinemia", "PROBLEM", 15, 36], ["the elevated HOMA", "PROBLEM", 41, 58], ["GluOC treatment", "TREATMENT", 97, 112], ["hyperinsulinemia", "OBSERVATION", 20, 36], ["elevated", "OBSERVATION_MODIFIER", 45, 53]]], ["In OGTT, the IGT was also improved (Fig. 1d, e) .", [["OGTT", "TEST", 3, 7], ["improved", "OBSERVATION_MODIFIER", 26, 34]]], ["Thus, GluOC treatment mitigated hepatic insulin resistance, as evidenced by the increased hepatic insulinstimulated phosphorylation of IR\u03b2, PI3K, and Akt (Fig. 4) .", [["hepatic", "ANATOMY", 32, 39], ["hepatic", "ANATOMY", 90, 97], ["GluOC", "CHEMICAL", 6, 11], ["GluOC", "CHEMICAL", 6, 11], ["GluOC", "SIMPLE_CHEMICAL", 6, 11], ["hepatic", "ORGAN", 32, 39], ["insulin", "GENE_OR_GENE_PRODUCT", 40, 47], ["IR\u03b2", "GENE_OR_GENE_PRODUCT", 135, 138], ["PI3K", "GENE_OR_GENE_PRODUCT", 140, 144], ["Akt", "GENE_OR_GENE_PRODUCT", 150, 153], ["IR\u03b2", "PROTEIN", 135, 138], ["PI3K", "PROTEIN", 140, 144], ["Akt", "PROTEIN", 150, 153], ["GluOC treatment", "TREATMENT", 6, 21], ["hepatic insulin resistance", "TREATMENT", 32, 58], ["the increased hepatic insulinstimulated phosphorylation of IR\u03b2", "PROBLEM", 76, 138], ["PI3K", "TEST", 140, 144], ["hepatic", "ANATOMY", 32, 39], ["insulin resistance", "OBSERVATION", 40, 58], ["increased", "OBSERVATION_MODIFIER", 80, 89], ["hepatic", "ANATOMY", 90, 97], ["insulinstimulated phosphorylation", "OBSERVATION", 98, 131]]], ["KKAy. e and f GluOC inhibits glucose output in primary cultured hepatocytes.", [["hepatocytes", "ANATOMY", 64, 75], ["GluOC", "CHEMICAL", 14, 19], ["glucose", "CHEMICAL", 29, 36], ["GluOC", "CHEMICAL", 14, 19], ["glucose", "CHEMICAL", 29, 36], ["f GluOC", "SIMPLE_CHEMICAL", 12, 19], ["glucose", "SIMPLE_CHEMICAL", 29, 36], ["hepatocytes", "CELL", 64, 75], ["KKAy", "PROTEIN", 0, 4], ["primary cultured hepatocytes", "CELL_TYPE", 47, 75], ["e and f GluOC", "TEST", 6, 19], ["glucose output", "TEST", 29, 43], ["primary cultured hepatocytes", "PROBLEM", 47, 75], ["glucose output", "OBSERVATION", 29, 43], ["hepatocytes", "ANATOMY", 64, 75]]], ["Primary hepatocytes were isolated from male C57BL/6 mice, seeded in six-well plate in William\u02bcs E medium for 24 h, and starved for 4 h; then cells were treated with GluOC for 24 h, washed with PBS, and incubated in glucose-and phenol red-free medium containing 2 mM sodium pyruvate, 20 mM sodium lactate for 4 h.", [["Primary hepatocytes", "ANATOMY", 0, 19], ["cells", "ANATOMY", 141, 146], ["GluOC", "CHEMICAL", 165, 170], ["glucose", "CHEMICAL", 215, 222], ["phenol", "CHEMICAL", 227, 233], ["sodium pyruvate", "CHEMICAL", 266, 281], ["sodium lactate", "CHEMICAL", 289, 303], ["GluOC", "CHEMICAL", 165, 170], ["glucose", "CHEMICAL", 215, 222], ["phenol", "CHEMICAL", 227, 233], ["sodium pyruvate", "CHEMICAL", 266, 281], ["sodium lactate", "CHEMICAL", 289, 303], ["hepatocytes", "CELL", 8, 19], ["C57BL/6 mice", "ORGANISM", 44, 56], ["cells", "CELL", 141, 146], ["GluOC", "SIMPLE_CHEMICAL", 165, 170], ["glucose", "SIMPLE_CHEMICAL", 215, 222], ["phenol", "SIMPLE_CHEMICAL", 227, 233], ["sodium pyruvate", "SIMPLE_CHEMICAL", 266, 281], ["sodium lactate", "SIMPLE_CHEMICAL", 289, 303], ["Primary hepatocytes", "CELL_TYPE", 0, 19], ["mice", "SPECIES", 52, 56], ["mice", "SPECIES", 52, 56], ["Primary hepatocytes", "PROBLEM", 0, 19], ["William\u02bcs E medium", "TREATMENT", 86, 104], ["GluOC", "TREATMENT", 165, 170], ["PBS", "TREATMENT", 193, 196], ["glucose", "TEST", 215, 222], ["phenol red-free medium", "TREATMENT", 227, 249], ["2 mM sodium pyruvate", "TREATMENT", 261, 281], ["mM sodium lactate", "TEST", 286, 303], ["hepatocytes", "ANATOMY", 8, 19]]], ["The medium was withdrawn for measure of glucose concentration. e Images of primary cultured hepatocytes 24 h after seeding; f Glucose output was suppressed by GluOC.", [["hepatocytes", "ANATOMY", 92, 103], ["glucose", "CHEMICAL", 40, 47], ["Glucose", "CHEMICAL", 126, 133], ["GluOC", "CHEMICAL", 159, 164], ["glucose", "CHEMICAL", 40, 47], ["Glucose", "CHEMICAL", 126, 133], ["GluOC", "CHEMICAL", 159, 164], ["glucose", "SIMPLE_CHEMICAL", 40, 47], ["hepatocytes", "CELL", 92, 103], ["Glucose", "SIMPLE_CHEMICAL", 126, 133], ["GluOC", "SIMPLE_CHEMICAL", 159, 164], ["primary cultured hepatocytes", "CELL_TYPE", 75, 103], ["GluOC", "PROTEIN", 159, 164], ["glucose concentration", "TREATMENT", 40, 61], ["primary cultured hepatocytes", "TEST", 75, 103], ["Glucose output", "TEST", 126, 140], ["medium", "OBSERVATION_MODIFIER", 4, 10], ["hepatocytes", "ANATOMY", 92, 103]]], ["Data are expressed as mean \u00b1 SD (n = 6). ### P < 0.001 vs. 0 ng/mL in insulin-free group; &&& P < 0.001 vs. 0 ng/mL in insulin-free group; **P < 0.05 vs. 0 ng/mL in insulin-stimulated group GluOC ameliorates hyperglycemia through the glycometabolic pathway in KKAy mice Fasting blood glucose (FBG) was significantly improved in the GluOC-treated group.", [["blood", "ANATOMY", 278, 283], ["GluOC", "CHEMICAL", 190, 195], ["hyperglycemia", "DISEASE", 208, 221], ["glucose", "CHEMICAL", 284, 291], ["GluOC", "CHEMICAL", 332, 337], ["glucose", "CHEMICAL", 284, 291], ["GluOC", "CHEMICAL", 332, 337], ["insulin", "GENE_OR_GENE_PRODUCT", 70, 77], ["insulin", "GENE_OR_GENE_PRODUCT", 119, 126], ["insulin", "GENE_OR_GENE_PRODUCT", 165, 172], ["GluOC", "SIMPLE_CHEMICAL", 190, 195], ["mice", "ORGANISM", 265, 269], ["blood", "ORGANISM_SUBSTANCE", 278, 283], ["glucose", "SIMPLE_CHEMICAL", 284, 291], ["GluOC", "SIMPLE_CHEMICAL", 332, 337], ["insulin", "PROTEIN", 70, 77], ["insulin", "PROTEIN", 119, 126], ["insulin", "PROTEIN", 165, 172], ["mice", "SPECIES", 265, 269], ["mice", "SPECIES", 265, 269], ["P", "PROBLEM", 45, 46], ["insulin", "TREATMENT", 70, 77], ["insulin", "TREATMENT", 119, 126], ["insulin", "TREATMENT", 165, 172], ["hyperglycemia", "PROBLEM", 208, 221], ["the glycometabolic pathway", "TEST", 230, 256], ["Fasting blood glucose", "TEST", 270, 291], ["FBG", "TEST", 293, 296], ["improved", "OBSERVATION_MODIFIER", 316, 324]]], ["However, the decrease in nonfasting blood glucose was not as efficient as FBG (Fig. 1b, c) .", [["blood", "ANATOMY", 36, 41], ["glucose", "CHEMICAL", 42, 49], ["glucose", "CHEMICAL", 42, 49], ["blood", "ORGANISM_SUBSTANCE", 36, 41], ["glucose", "SIMPLE_CHEMICAL", 42, 49], ["nonfasting blood glucose", "TEST", 25, 49], ["FBG", "TEST", 74, 77], ["decrease", "OBSERVATION_MODIFIER", 13, 21]]], ["FBG is mainly maintained by hepatic glycogenolysis and gluconeogenesis, while nonfasting blood glucose is mainly regulated by the utilization of glucose by muscle/adipose tissues and glycogen synthesis in liver.", [["hepatic", "ANATOMY", 28, 35], ["blood", "ANATOMY", 89, 94], ["muscle", "ANATOMY", 156, 162], ["adipose tissues", "ANATOMY", 163, 178], ["liver", "ANATOMY", 205, 210], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 145, 152], ["glycogen", "CHEMICAL", 183, 191], ["glucose", "CHEMICAL", 95, 102], ["glucose", "CHEMICAL", 145, 152], ["hepatic", "MULTI-TISSUE_STRUCTURE", 28, 35], ["blood", "ORGANISM_SUBSTANCE", 89, 94], ["glucose", "SIMPLE_CHEMICAL", 95, 102], ["glucose", "SIMPLE_CHEMICAL", 145, 152], ["muscle", "TISSUE", 156, 162], ["adipose tissues", "TISSUE", 163, 178], ["glycogen", "SIMPLE_CHEMICAL", 183, 191], ["liver", "ORGAN", 205, 210], ["FBG", "TEST", 0, 3], ["gluconeogenesis", "TEST", 55, 70], ["nonfasting blood glucose", "TEST", 78, 102], ["glucose", "TEST", 145, 152], ["glycogen synthesis in liver", "PROBLEM", 183, 210], ["hepatic", "ANATOMY", 28, 35], ["glycogenolysis", "OBSERVATION", 36, 50], ["muscle", "ANATOMY", 156, 162], ["adipose tissues", "ANATOMY", 163, 178], ["glycogen synthesis", "OBSERVATION", 183, 201], ["liver", "ANATOMY", 205, 210]]], ["In type 2 diabetes mellitus, augmented gluconeogenesis leads to higher blood glucose (especially FBG) and is also a therapeutic target for type 2 diabetes.", [["blood", "ANATOMY", 71, 76], ["type 2 diabetes mellitus", "DISEASE", 3, 27], ["glucose", "CHEMICAL", 77, 84], ["type 2 diabetes", "DISEASE", 139, 154], ["glucose", "CHEMICAL", 77, 84], ["blood", "ORGANISM_SUBSTANCE", 71, 76], ["glucose", "SIMPLE_CHEMICAL", 77, 84], ["type 2 diabetes mellitus", "PROBLEM", 3, 27], ["augmented gluconeogenesis", "PROBLEM", 29, 54], ["higher blood glucose", "TEST", 64, 84], ["FBG", "TEST", 97, 100], ["type 2 diabetes", "PROBLEM", 139, 154], ["type 2", "OBSERVATION_MODIFIER", 3, 9], ["diabetes mellitus", "OBSERVATION", 10, 27], ["diabetes", "OBSERVATION", 146, 154]]], ["It is assumed that the liver is the main target organ of GluOC, resulting in increasing hepatic insulin sensitivity, inhibiting HGP and lowering FBG level.", [["liver", "ANATOMY", 23, 28], ["organ", "ANATOMY", 48, 53], ["hepatic", "ANATOMY", 88, 95], ["liver", "ORGAN", 23, 28], ["organ", "ORGAN", 48, 53], ["GluOC", "GENE_OR_GENE_PRODUCT", 57, 62], ["hepatic", "MULTI-TISSUE_STRUCTURE", 88, 95], ["insulin", "GENE_OR_GENE_PRODUCT", 96, 103], ["HGP", "SIMPLE_CHEMICAL", 128, 131], ["FBG", "GENE_OR_GENE_PRODUCT", 145, 148], ["GluOC", "PROTEIN", 57, 62], ["FBG", "PROTEIN", 145, 148], ["increasing hepatic insulin sensitivity", "PROBLEM", 77, 115], ["HGP", "TEST", 128, 131], ["lowering FBG level", "TEST", 136, 154], ["liver", "ANATOMY", 23, 28], ["main", "OBSERVATION_MODIFIER", 36, 40], ["increasing", "OBSERVATION_MODIFIER", 77, 87], ["hepatic", "ANATOMY", 88, 95], ["insulin sensitivity", "OBSERVATION", 96, 115], ["lowering FBG", "OBSERVATION", 136, 148]]], ["Hepatic gluconeogenesis is regulated by Foxo1, and glycogen synthesis is regulated by GSK3\u03b2.", [["Hepatic", "ANATOMY", 0, 7], ["glycogen", "CHEMICAL", 51, 59], ["Hepatic", "MULTI-TISSUE_STRUCTURE", 0, 7], ["Foxo1", "GENE_OR_GENE_PRODUCT", 40, 45], ["glycogen", "SIMPLE_CHEMICAL", 51, 59], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 86, 91], ["Foxo1", "PROTEIN", 40, 45], ["GSK3\u03b2", "PROTEIN", 86, 91], ["Hepatic gluconeogenesis", "PROBLEM", 0, 23], ["glycogen synthesis", "TREATMENT", 51, 69], ["gluconeogenesis", "OBSERVATION", 8, 23]]], ["Insulin normally suppresses hepatic Foxo1 function by activating the protein kinase Akt, which phosphorylates Foxo1, which remains inactive in the cytoplasm [31] .", [["hepatic", "ANATOMY", 28, 35], ["cytoplasm", "ANATOMY", 147, 156], ["Insulin", "CHEMICAL", 0, 7], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["hepatic", "ORGAN", 28, 35], ["Foxo1", "GENE_OR_GENE_PRODUCT", 36, 41], ["Akt", "GENE_OR_GENE_PRODUCT", 84, 87], ["Foxo1", "GENE_OR_GENE_PRODUCT", 110, 115], ["cytoplasm", "ORGANISM_SUBSTANCE", 147, 156], ["Foxo1", "PROTEIN", 36, 41], ["protein kinase Akt", "PROTEIN", 69, 87], ["Foxo1", "PROTEIN", 110, 115], ["Insulin", "TREATMENT", 0, 7], ["the protein kinase Akt", "TEST", 65, 87], ["phosphorylates Foxo1", "TEST", 95, 115], ["hepatic", "ANATOMY", 28, 35], ["Foxo1 function", "OBSERVATION", 36, 50]]], ["In this study, GluOC treatment increased the insulin-induced phosphorylation of Foxo1 (Fig. 5a, b) , which suppressed gluconeogenesis, as demonstrated by the hepatic glucose output assays of the primary cultured hepatocytes (Fig. 5e, f) .", [["hepatic", "ANATOMY", 158, 165], ["hepatocytes", "ANATOMY", 212, 223], ["GluOC", "CHEMICAL", 15, 20], ["glucose", "CHEMICAL", 166, 173], ["GluOC", "CHEMICAL", 15, 20], ["glucose", "CHEMICAL", 166, 173], ["GluOC", "SIMPLE_CHEMICAL", 15, 20], ["insulin", "GENE_OR_GENE_PRODUCT", 45, 52], ["Foxo1", "GENE_OR_GENE_PRODUCT", 80, 85], ["b", "GENE_OR_GENE_PRODUCT", 96, 97], ["hepatic", "MULTI-TISSUE_STRUCTURE", 158, 165], ["glucose", "SIMPLE_CHEMICAL", 166, 173], ["hepatocytes", "CELL", 212, 223], ["insulin", "PROTEIN", 45, 52], ["Foxo1", "PROTEIN", 80, 85], ["Fig. 5a, b)", "PROTEIN", 87, 98], ["primary cultured hepatocytes", "CELL_TYPE", 195, 223], ["this study", "TEST", 3, 13], ["GluOC treatment", "TREATMENT", 15, 30], ["the insulin", "TREATMENT", 41, 52], ["the hepatic glucose output assays", "TEST", 154, 187], ["hepatic", "ANATOMY", 158, 165], ["glucose output", "OBSERVATION", 166, 180], ["hepatocytes", "ANATOMY", 212, 223]]], ["This explains the significantly decreased FBG in GluOC-treated KKAy mice (Fig. 1c) .", [["GluOC", "CHEMICAL", 49, 54], ["GluOC", "CHEMICAL", 49, 54], ["FBG", "SIMPLE_CHEMICAL", 42, 45], ["GluOC", "SIMPLE_CHEMICAL", 49, 54], ["KKAy mice", "ORGANISM", 63, 72], ["FBG", "PROTEIN", 42, 45], ["GluOC", "PROTEIN", 49, 54], ["mice", "SPECIES", 68, 72], ["the significantly decreased FBG in GluOC", "PROBLEM", 14, 54], ["significantly", "OBSERVATION_MODIFIER", 18, 31], ["decreased", "OBSERVATION_MODIFIER", 32, 41], ["FBG", "OBSERVATION_MODIFIER", 42, 45]]], ["As expected, the hepatic Foxo1 expression in KKAy mice was significantly higher before GluOC treatment and lower after it treatment compared with C57 mice (Fig. 5b) .", [["hepatic", "ANATOMY", 17, 24], ["GluOC", "CHEMICAL", 87, 92], ["GluOC", "CHEMICAL", 87, 92], ["hepatic", "MULTI-TISSUE_STRUCTURE", 17, 24], ["Foxo1", "GENE_OR_GENE_PRODUCT", 25, 30], ["KKAy mice", "ORGANISM", 45, 54], ["GluOC", "SIMPLE_CHEMICAL", 87, 92], ["C57 mice", "ORGANISM", 146, 154], ["Foxo1", "PROTEIN", 25, 30], ["GluOC", "PROTEIN", 87, 92], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 150, 154], ["mice", "SPECIES", 50, 54], ["mice", "SPECIES", 150, 154], ["GluOC treatment", "TREATMENT", 87, 102], ["it treatment", "TREATMENT", 119, 131], ["hepatic", "ANATOMY", 17, 24], ["Foxo1 expression", "OBSERVATION", 25, 41], ["significantly", "OBSERVATION_MODIFIER", 59, 72], ["higher", "OBSERVATION_MODIFIER", 73, 79]]], ["As reported, a higher hepatic Foxo1 level was an indication of insulin resistance in obese mice, leading to augmented hepatic gluconeogenesis [32, 33] .", [["hepatic", "ANATOMY", 22, 29], ["hepatic", "ANATOMY", 118, 125], ["hepatic", "ORGAN", 22, 29], ["Foxo1", "GENE_OR_GENE_PRODUCT", 30, 35], ["insulin", "GENE_OR_GENE_PRODUCT", 63, 70], ["mice", "ORGANISM", 91, 95], ["hepatic", "ORGAN", 118, 125], ["Foxo1", "PROTEIN", 30, 35], ["mice", "SPECIES", 91, 95], ["mice", "SPECIES", 91, 95], ["a higher hepatic Foxo1 level", "PROBLEM", 13, 41], ["insulin resistance", "TREATMENT", 63, 81], ["augmented hepatic gluconeogenesis", "PROBLEM", 108, 141], ["hepatic", "ANATOMY", 22, 29], ["Foxo1 level", "OBSERVATION", 30, 41], ["insulin resistance", "OBSERVATION", 63, 81], ["hepatic", "ANATOMY", 118, 125]]], ["The suppressed Foxo1 expression could be a mechanism for the observed hypoglycemic effect of GluOC treatment.", [["hypoglycemic", "DISEASE", 70, 82], ["GluOC", "CHEMICAL", 93, 98], ["GluOC", "CHEMICAL", 93, 98], ["Foxo1", "GENE_OR_GENE_PRODUCT", 15, 20], ["GluOC", "SIMPLE_CHEMICAL", 93, 98], ["Foxo1", "PROTEIN", 15, 20], ["GluOC treatment", "TREATMENT", 93, 108], ["Foxo1 expression", "OBSERVATION", 15, 31]]], ["Insulin also induces GSK3\u03b2 phosphorylation and inactivation, consequently leading to decreased phosphorylation and increased activation of glycogen synthase (GS).", [["Insulin", "CHEMICAL", 0, 7], ["glycogen", "CHEMICAL", 139, 147], ["Insulin", "GENE_OR_GENE_PRODUCT", 0, 7], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 21, 26], ["glycogen synthase", "GENE_OR_GENE_PRODUCT", 139, 156], ["GS", "GENE_OR_GENE_PRODUCT", 158, 160], ["GSK3\u03b2", "PROTEIN", 21, 26], ["glycogen synthase", "PROTEIN", 139, 156], ["GS", "PROTEIN", 158, 160], ["Insulin", "TREATMENT", 0, 7], ["phosphorylation", "PROBLEM", 27, 42], ["decreased phosphorylation", "PROBLEM", 85, 110], ["glycogen synthase", "TREATMENT", 139, 156]]], ["This step is rate-limiting for glycogen synthesis [34] .", [["glycogen", "CHEMICAL", 31, 39], ["glycogen", "SIMPLE_CHEMICAL", 31, 39], ["glycogen synthesis", "PROBLEM", 31, 49]]], ["In this study, the insulin-induced phosphorylation of GSK3\u03b2 was significantly higher both in GluOC-treated mice liver (Fig. 5c, d) and in primary cultured hepatocytes (Fig. 5g, h) , suggesting the promotion of glycogen synthesis and the reduction of nonfasting blood glucose by GluOC administration.DISCUSSIONGluOC ameliorates hepatic steatosis by regulating hepatic de novo lipogenesis (DNL) and enhancing fatty-acid \u03b2-oxidation in KKAy mice Insulin resistance is implicated in the pathogenesis of fatty liver [4, 35, 36] .", [["liver", "ANATOMY", 112, 117], ["hepatocytes", "ANATOMY", 155, 166], ["blood", "ANATOMY", 261, 266], ["hepatic", "ANATOMY", 327, 334], ["hepatic", "ANATOMY", 359, 366], ["fatty liver", "ANATOMY", 499, 510], ["GluOC", "CHEMICAL", 93, 98], ["glycogen", "CHEMICAL", 210, 218], ["glucose", "CHEMICAL", 267, 274], ["GluOC", "CHEMICAL", 278, 283], ["steatosis", "DISEASE", 335, 344], ["fatty-acid", "CHEMICAL", 407, 417], ["Insulin", "CHEMICAL", 443, 450], ["fatty liver", "DISEASE", 499, 510], ["GluOC", "CHEMICAL", 93, 98], ["glucose", "CHEMICAL", 267, 274], ["GluOC", "CHEMICAL", 278, 283], ["fatty-acid", "CHEMICAL", 407, 417], ["insulin", "GENE_OR_GENE_PRODUCT", 19, 26], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 54, 59], ["GluOC", "SIMPLE_CHEMICAL", 93, 98], ["mice", "ORGANISM", 107, 111], ["liver", "ORGAN", 112, 117], ["hepatocytes", "CELL", 155, 166], ["glycogen", "SIMPLE_CHEMICAL", 210, 218], ["blood", "ORGANISM_SUBSTANCE", 261, 266], ["glucose", "SIMPLE_CHEMICAL", 267, 274], ["GluOC", "SIMPLE_CHEMICAL", 278, 283], ["hepatic", "ORGAN", 327, 334], ["DNL", "SIMPLE_CHEMICAL", 388, 391], ["fatty-acid", "SIMPLE_CHEMICAL", 407, 417], ["KKAy mice", "ORGANISM", 433, 442], ["Insulin", "GENE_OR_GENE_PRODUCT", 443, 450], ["liver", "ORGAN", 505, 510], ["insulin", "PROTEIN", 19, 26], ["GSK3\u03b2", "PROTEIN", 54, 59], ["GluOC", "PROTEIN", 93, 98], ["primary cultured hepatocytes", "CELL_TYPE", 138, 166], ["mice", "SPECIES", 107, 111], ["mice", "SPECIES", 438, 442], ["mice", "SPECIES", 438, 442], ["this study", "TEST", 3, 13], ["the insulin", "TREATMENT", 15, 26], ["GSK3", "TEST", 54, 58], ["GluOC", "TEST", 93, 98], ["glycogen synthesis", "TREATMENT", 210, 228], ["nonfasting blood glucose", "TREATMENT", 250, 274], ["GluOC administration", "TREATMENT", 278, 298], ["hepatic steatosis", "PROBLEM", 327, 344], ["enhancing fatty-acid \u03b2-oxidation", "PROBLEM", 397, 429], ["KKAy mice Insulin resistance", "TREATMENT", 433, 461], ["fatty liver", "PROBLEM", 499, 510], ["liver", "ANATOMY", 112, 117], ["hepatocytes", "ANATOMY", 155, 166], ["glycogen synthesis", "OBSERVATION", 210, 228], ["hepatic", "ANATOMY", 327, 334], ["steatosis", "OBSERVATION", 335, 344], ["hepatic", "ANATOMY", 359, 366], ["novo lipogenesis", "OBSERVATION", 370, 386], ["enhancing", "OBSERVATION_MODIFIER", 397, 406], ["fatty", "OBSERVATION_MODIFIER", 407, 412], ["Insulin resistance", "OBSERVATION", 443, 461], ["fatty", "OBSERVATION", 499, 504], ["liver", "ANATOMY", 505, 510]]], ["Hepatic steatosis, an early stage of NAFLD, reflects imbalanced lipid storage and lipid secretion, leading to increased lipid accumulation in the liver.", [["Hepatic", "ANATOMY", 0, 7], ["liver", "ANATOMY", 146, 151], ["steatosis", "DISEASE", 8, 17], ["NAFLD", "DISEASE", 37, 42], ["Hepatic", "ORGAN", 0, 7], ["lipid", "SIMPLE_CHEMICAL", 64, 69], ["lipid", "SIMPLE_CHEMICAL", 82, 87], ["lipid", "SIMPLE_CHEMICAL", 120, 125], ["liver", "ORGAN", 146, 151], ["Hepatic steatosis", "PROBLEM", 0, 17], ["NAFLD", "PROBLEM", 37, 42], ["imbalanced lipid storage", "PROBLEM", 53, 77], ["lipid secretion", "PROBLEM", 82, 97], ["increased lipid accumulation in the liver", "PROBLEM", 110, 151], ["steatosis", "OBSERVATION", 8, 17], ["early", "OBSERVATION_MODIFIER", 22, 27], ["stage", "OBSERVATION_MODIFIER", 28, 33], ["NAFLD", "OBSERVATION", 37, 42], ["lipid storage", "OBSERVATION", 64, 77], ["lipid secretion", "OBSERVATION", 82, 97], ["increased", "OBSERVATION_MODIFIER", 110, 119], ["lipid accumulation", "OBSERVATION", 120, 138], ["liver", "ANATOMY", 146, 151]]], ["Lipid storage includes both the uptake of free fatty acids and DNL in the liver.", [["liver", "ANATOMY", 74, 79], ["fatty acids", "CHEMICAL", 47, 58], ["fatty acids", "CHEMICAL", 47, 58], ["Lipid", "SIMPLE_CHEMICAL", 0, 5], ["free fatty acids", "SIMPLE_CHEMICAL", 42, 58], ["DNL", "SIMPLE_CHEMICAL", 63, 66], ["liver", "ORGAN", 74, 79], ["Lipid storage", "TEST", 0, 13], ["free fatty acids", "TEST", 42, 58], ["fatty acids", "OBSERVATION", 47, 58], ["liver", "ANATOMY", 74, 79]]], ["The pancreas senses insulin resistance by increasing insulin production, which results in hyperinsulinemia.", [["pancreas", "ANATOMY", 4, 12], ["hyperinsulinemia", "DISEASE", 90, 106], ["pancreas", "ORGAN", 4, 12], ["insulin", "GENE_OR_GENE_PRODUCT", 20, 27], ["insulin", "GENE_OR_GENE_PRODUCT", 53, 60], ["increasing insulin production", "TREATMENT", 42, 71], ["hyperinsulinemia", "PROBLEM", 90, 106], ["pancreas", "ANATOMY", 4, 12], ["insulin resistance", "OBSERVATION", 20, 38], ["increasing", "OBSERVATION_MODIFIER", 42, 52], ["insulin production", "OBSERVATION", 53, 71], ["hyperinsulinemia", "OBSERVATION", 90, 106]]], ["The increased insulin level increases DNL, resulting in steatosis if the lipids cannot be efficiently secreted [37] .", [["steatosis", "DISEASE", 56, 65], ["insulin", "GENE_OR_GENE_PRODUCT", 14, 21], ["DNL", "SIMPLE_CHEMICAL", 38, 41], ["lipids", "SIMPLE_CHEMICAL", 73, 79], ["The increased insulin level", "PROBLEM", 0, 27], ["steatosis", "PROBLEM", 56, 65], ["the lipids", "TREATMENT", 69, 79], ["increased", "OBSERVATION_MODIFIER", 4, 13], ["insulin level", "OBSERVATION", 14, 27], ["steatosis", "OBSERVATION", 56, 65]]], ["DNL can be regulated at the transcriptional level by sterol regulatory element binding protein-1c (SREBP1c) [37] [38] [39] [40] .", [["sterol", "CHEMICAL", 53, 59], ["DNL", "GENE_OR_GENE_PRODUCT", 0, 3], ["sterol regulatory element binding protein-1c", "GENE_OR_GENE_PRODUCT", 53, 97], ["DNL", "PROTEIN", 0, 3], ["sterol regulatory element binding protein", "PROTEIN", 53, 94], ["binding protein", "TEST", 79, 94]]], ["Both insulin and hyperinsulinemia upregulate SEREBP1c expression via multiple insulin signaling pathways, such as mTORC1, PI3K-Akt, and others [4, 41, 42] .DISCUSSIONIn this study, we revealed that GluOC ameliorated steatosis by regulating hepatic de novo lipogenesis (DNL) in KKAy mice Consistent with the elevated FPI, hepatic SREBP1c expression was increased by 4-5-fold and was accompanied by elevated DNL in KKAy mice compared with C57 mice (Fig. 6a, b) .", [["hepatic", "ANATOMY", 240, 247], ["hepatic", "ANATOMY", 321, 328], ["hyperinsulinemia", "DISEASE", 17, 33], ["GluOC", "CHEMICAL", 198, 203], ["steatosis", "DISEASE", 216, 225], ["GluOC", "CHEMICAL", 198, 203], ["insulin", "GENE_OR_GENE_PRODUCT", 5, 12], ["hyperinsulinemia", "SIMPLE_CHEMICAL", 17, 33], ["SEREBP1c", "GENE_OR_GENE_PRODUCT", 45, 53], ["insulin", "GENE_OR_GENE_PRODUCT", 78, 85], ["mTORC1", "GENE_OR_GENE_PRODUCT", 114, 120], ["PI3K", "GENE_OR_GENE_PRODUCT", 122, 126], ["Akt", "GENE_OR_GENE_PRODUCT", 127, 130], ["GluOC", "SIMPLE_CHEMICAL", 198, 203], ["KKAy mice", "ORGANISM", 277, 286], ["FPI", "GENE_OR_GENE_PRODUCT", 316, 319], ["hepatic", "MULTI-TISSUE_STRUCTURE", 321, 328], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 329, 336], ["DNL", "SIMPLE_CHEMICAL", 406, 409], ["KKAy mice", "ORGANISM", 413, 422], ["C57 mice", "ORGANISM", 437, 445], ["SEREBP1c", "PROTEIN", 45, 53], ["mTORC1", "PROTEIN", 114, 120], ["PI3K", "PROTEIN", 122, 126], ["Akt", "PROTEIN", 127, 130], ["SREBP1c", "PROTEIN", 329, 336], ["DNL", "PROTEIN", 406, 409], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 418, 422], ["mice", "SPECIES", 441, 445], ["mice", "SPECIES", 282, 286], ["mice", "SPECIES", 418, 422], ["mice", "SPECIES", 441, 445], ["Both insulin", "TREATMENT", 0, 12], ["hyperinsulinemia upregulate", "TREATMENT", 17, 44], ["multiple insulin signaling pathways", "TREATMENT", 69, 104], ["mTORC1", "TEST", 114, 120], ["PI3K", "TEST", 122, 126], ["this study", "TEST", 169, 179], ["GluOC ameliorated steatosis", "PROBLEM", 198, 225], ["the elevated FPI", "PROBLEM", 303, 319], ["hepatic SREBP1c expression", "TEST", 321, 347], ["elevated DNL", "PROBLEM", 397, 409], ["steatosis", "OBSERVATION", 216, 225], ["hepatic", "ANATOMY", 240, 247], ["elevated", "OBSERVATION", 307, 315], ["hepatic", "ANATOMY", 321, 328], ["SREBP1c expression", "OBSERVATION", 329, 347], ["increased", "OBSERVATION_MODIFIER", 352, 361]]], ["GluOC treatment led to the reduction of both FPI and hepatic SREBP1c expression, suggesting that GluOC ameliorated hyperinsulinemia (Fig. 1f) and then suppressed SREBP1c expression.", [["hepatic", "ANATOMY", 53, 60], ["GluOC", "CHEMICAL", 0, 5], ["GluOC", "CHEMICAL", 97, 102], ["hyperinsulinemia", "DISEASE", 115, 131], ["GluOC", "CHEMICAL", 0, 5], ["GluOC", "CHEMICAL", 97, 102], ["GluOC", "SIMPLE_CHEMICAL", 0, 5], ["FPI", "GENE_OR_GENE_PRODUCT", 45, 48], ["hepatic", "ORGAN", 53, 60], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 61, 68], ["GluOC", "SIMPLE_CHEMICAL", 97, 102], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 162, 169], ["SREBP1c", "PROTEIN", 61, 68], ["SREBP1c", "PROTEIN", 162, 169], ["GluOC treatment", "TREATMENT", 0, 15], ["both FPI", "TEST", 40, 48], ["hepatic SREBP1c expression", "TEST", 53, 79], ["GluOC ameliorated hyperinsulinemia", "PROBLEM", 97, 131], ["hepatic", "ANATOMY", 53, 60], ["SREBP1c expression", "OBSERVATION", 61, 79]]], ["We further determined the expression levels of acetyl-CoA carboxylase (ACC) and fatty-acid synthase (FAS), two main enzymes involved in DNL.", [["acetyl-CoA", "CHEMICAL", 47, 57], ["fatty-acid", "CHEMICAL", 80, 90], ["acetyl-CoA", "CHEMICAL", 47, 57], ["fatty-acid", "CHEMICAL", 80, 90], ["acetyl-CoA carboxylase", "GENE_OR_GENE_PRODUCT", 47, 69], ["ACC", "SIMPLE_CHEMICAL", 71, 74], ["fatty-acid synthase", "GENE_OR_GENE_PRODUCT", 80, 99], ["FAS", "GENE_OR_GENE_PRODUCT", 101, 104], ["DNL", "SIMPLE_CHEMICAL", 136, 139], ["acetyl-CoA carboxylase", "PROTEIN", 47, 69], ["ACC", "PROTEIN", 71, 74], ["fatty-acid synthase", "PROTEIN", 80, 99], ["FAS", "PROTEIN", 101, 104], ["DNL", "PROTEIN", 136, 139], ["acetyl-CoA carboxylase", "TREATMENT", 47, 69], ["fatty-acid synthase", "TEST", 80, 99], ["FAS", "TEST", 101, 104], ["two main enzymes", "TEST", 107, 123]]], ["SREBP1c has been reported to activate ACC and FAS [43] [44] [45] .", [["SREBP1c", "CHEMICAL", 0, 7], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 0, 7], ["ACC", "SIMPLE_CHEMICAL", 38, 41], ["SREBP1c", "PROTEIN", 0, 7], ["ACC", "PROTEIN", 38, 41], ["SREBP1c", "TEST", 0, 7]]], ["In this study, ACC and FAS expression was reduced in the GluOC treatment group, which was consistent with the decreased SREBP1c expression, indicating that GluOC improved hepatic steatosis by suppressing hepatic DNL in KKAy mice.", [["GluOC", "ANATOMY", 57, 62], ["hepatic", "ANATOMY", 171, 178], ["hepatic DNL", "ANATOMY", 204, 215], ["GluOC", "CHEMICAL", 57, 62], ["GluOC", "CHEMICAL", 156, 161], ["steatosis", "DISEASE", 179, 188], ["GluOC", "CHEMICAL", 57, 62], ["ACC", "CANCER", 15, 18], ["FAS", "GENE_OR_GENE_PRODUCT", 23, 26], ["GluOC", "SIMPLE_CHEMICAL", 57, 62], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 120, 127], ["GluOC", "SIMPLE_CHEMICAL", 156, 161], ["hepatic", "ORGAN", 171, 178], ["hepatic DNL", "MULTI-TISSUE_STRUCTURE", 204, 215], ["KKAy mice", "ORGANISM", 219, 228], ["FAS", "PROTEIN", 23, 26], ["SREBP1c", "PROTEIN", 120, 127], ["hepatic DNL", "PROTEIN", 204, 215], ["mice", "SPECIES", 224, 228], ["mice", "SPECIES", 224, 228], ["this study", "TEST", 3, 13], ["ACC and FAS expression", "PROBLEM", 15, 37], ["the decreased SREBP1c expression", "PROBLEM", 106, 138], ["GluOC improved hepatic steatosis", "PROBLEM", 156, 188], ["reduced", "OBSERVATION_MODIFIER", 42, 49], ["consistent with", "UNCERTAINTY", 90, 105], ["decreased", "OBSERVATION_MODIFIER", 110, 119], ["SREBP1c expression", "OBSERVATION", 120, 138], ["hepatic", "ANATOMY", 171, 178], ["steatosis", "OBSERVATION", 179, 188], ["hepatic", "ANATOMY", 204, 211], ["DNL", "OBSERVATION", 212, 215]]], ["Additionally, hepatic CPT1 and MCAD expression were both initially lower and then became significantly The immunoblot data were quantified by normalizing intensity of each protein to GAPDH or \u03b2actin.", [["hepatic", "ANATOMY", 14, 21], ["hepatic", "ORGAN", 14, 21], ["CPT1", "GENE_OR_GENE_PRODUCT", 22, 26], ["MCAD", "GENE_OR_GENE_PRODUCT", 31, 35], ["GAPDH", "GENE_OR_GENE_PRODUCT", 183, 188], ["\u03b2actin", "GENE_OR_GENE_PRODUCT", 192, 198], ["hepatic CPT1", "PROTEIN", 14, 26], ["MCAD", "PROTEIN", 31, 35], ["GAPDH", "PROTEIN", 183, 188], ["\u03b2actin", "PROTEIN", 192, 198], ["The immunoblot data", "TEST", 103, 122], ["\u03b2actin", "TREATMENT", 192, 198], ["hepatic", "ANATOMY", 14, 21], ["CPT1", "OBSERVATION", 22, 26], ["MCAD expression", "OBSERVATION", 31, 46]]], ["Data are expressed as mean \u00b1 SD (n = 3-4). # P < 0.05, ### P < 0.001 vs. C57; P < 0.001 vs. KKAy higher after GluOC treatment in KKAy mice compared to C57 mice (Fig. 6c, d) .", [["GluOC", "CHEMICAL", 110, 115], ["GluOC", "CHEMICAL", 110, 115], ["GluOC", "SIMPLE_CHEMICAL", 110, 115], ["KKAy mice", "ORGANISM", 129, 138], ["C57 mice", "ORGANISM", 151, 159], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 155, 159], ["mice", "SPECIES", 134, 138], ["mice", "SPECIES", 155, 159], ["C57", "TEST", 73, 76], ["P", "TEST", 78, 79], ["KKAy", "TEST", 92, 96], ["GluOC treatment", "TREATMENT", 110, 125]]], ["CPT1 is a regulatory enzyme in the mitochondria that transfers FAs from the cytosol to the mitochondria prior to \u03b2oxidation [46] .", [["mitochondria", "ANATOMY", 35, 47], ["cytosol", "ANATOMY", 76, 83], ["mitochondria", "ANATOMY", 91, 103], ["CPT1", "GENE_OR_GENE_PRODUCT", 0, 4], ["mitochondria", "CELLULAR_COMPONENT", 35, 47], ["FAs", "SIMPLE_CHEMICAL", 63, 66], ["cytosol", "CELLULAR_COMPONENT", 76, 83], ["mitochondria", "CELLULAR_COMPONENT", 91, 103], ["CPT1", "PROTEIN", 0, 4], ["regulatory enzyme", "PROTEIN", 10, 27], ["a regulatory enzyme", "TEST", 8, 27]]], ["Medium-chain acyl-CoA dehydrogenase (MCAD) participates in the first reaction of mitochondrial fatty-acid \u03b2oxidation, catalyzing C4 to C12 straight-chain acyl-CoAs [47] .", [["mitochondrial", "ANATOMY", 81, 94], ["fatty-acid", "CHEMICAL", 95, 105], ["acyl-CoAs", "CHEMICAL", 154, 163], ["acyl-CoA", "CHEMICAL", 13, 21], ["fatty-acid", "CHEMICAL", 95, 105], ["C12 straight-chain acyl-CoAs", "CHEMICAL", 135, 163], ["Medium-chain acyl-CoA dehydrogenase", "GENE_OR_GENE_PRODUCT", 0, 35], ["MCAD", "GENE_OR_GENE_PRODUCT", 37, 41], ["mitochondrial", "CELLULAR_COMPONENT", 81, 94], ["fatty-acid", "SIMPLE_CHEMICAL", 95, 105], ["C4", "SIMPLE_CHEMICAL", 129, 131], ["C12 straight-chain acyl-CoAs", "SIMPLE_CHEMICAL", 135, 163], ["Medium-chain acyl-CoA dehydrogenase", "PROTEIN", 0, 35], ["MCAD", "PROTEIN", 37, 41], ["Medium-chain acyl-CoA dehydrogenase (MCAD)", "PROBLEM", 0, 42], ["mitochondrial fatty-acid \u03b2oxidation", "PROBLEM", 81, 116], ["CoA", "ANATOMY", 18, 21]]], ["These results imply that GluOC treatment could augment fatty-acid \u03b2oxidation to mitigate steatosis.DISCUSSIONGluOC ameliorates dyslipidemia partly by suppressing hepatic DNL in KKAy mice Blood TG level is mainly affected by exogenous food intake and endogenous liver synthesis.", [["hepatic", "ANATOMY", 162, 169], ["Blood", "ANATOMY", 187, 192], ["liver", "ANATOMY", 261, 266], ["GluOC", "CHEMICAL", 25, 30], ["fatty-acid", "CHEMICAL", 55, 65], ["steatosis", "DISEASE", 89, 98], ["dyslipidemia", "DISEASE", 127, 139], ["GluOC", "CHEMICAL", 25, 30], ["fatty-acid", "CHEMICAL", 55, 65], ["GluOC", "SIMPLE_CHEMICAL", 25, 30], ["fatty-acid", "SIMPLE_CHEMICAL", 55, 65], ["hepatic DNL", "MULTI-TISSUE_STRUCTURE", 162, 173], ["KKAy mice", "ORGANISM", 177, 186], ["Blood", "ORGANISM_SUBSTANCE", 187, 192], ["TG", "SIMPLE_CHEMICAL", 193, 195], ["liver", "ORGAN", 261, 266], ["hepatic DNL", "PROTEIN", 162, 173], ["mice", "SPECIES", 182, 186], ["mice", "SPECIES", 182, 186], ["GluOC treatment", "TREATMENT", 25, 40], ["fatty-acid \u03b2oxidation", "TREATMENT", 55, 76], ["steatosis", "PROBLEM", 89, 98], ["dyslipidemia", "PROBLEM", 127, 139], ["Blood TG level", "TEST", 187, 201], ["endogenous liver synthesis", "PROBLEM", 250, 276], ["steatosis", "OBSERVATION", 89, 98], ["dyslipidemia", "OBSERVATION", 127, 139], ["hepatic", "ANATOMY", 162, 169], ["DNL", "OBSERVATION", 170, 173], ["exogenous food intake", "OBSERVATION", 224, 245], ["liver", "ANATOMY", 261, 266]]], ["As shown in Fig. 3 , the food intake remained unchanged during GluOC administration.", [["GluOC", "CHEMICAL", 63, 68], ["GluOC", "CHEMICAL", 63, 68], ["GluOC", "SIMPLE_CHEMICAL", 63, 68], ["GluOC administration", "TREATMENT", 63, 83], ["unchanged", "OBSERVATION_MODIFIER", 46, 55]]], ["The improved hypertriglyceridemia might be attributed to the suppressed DNL and the reduced hepatic TG synthesis and steatosis.", [["hepatic", "ANATOMY", 92, 99], ["hypertriglyceridemia", "DISEASE", 13, 33], ["steatosis", "DISEASE", 117, 126], ["DNL", "SIMPLE_CHEMICAL", 72, 75], ["TG", "SIMPLE_CHEMICAL", 100, 102], ["The improved hypertriglyceridemia", "PROBLEM", 0, 33], ["the suppressed DNL", "PROBLEM", 57, 75], ["the reduced hepatic TG synthesis", "PROBLEM", 80, 112], ["steatosis", "PROBLEM", 117, 126], ["improved", "OBSERVATION_MODIFIER", 4, 12], ["hypertriglyceridemia", "OBSERVATION", 13, 33], ["might be attributed to", "UNCERTAINTY", 34, 56], ["suppressed", "OBSERVATION_MODIFIER", 61, 71], ["DNL", "OBSERVATION", 72, 75], ["reduced", "OBSERVATION_MODIFIER", 84, 91], ["hepatic", "ANATOMY", 92, 99], ["TG synthesis", "OBSERVATION", 100, 112], ["steatosis", "OBSERVATION", 117, 126]]], ["Hypercholesterolemia in KKAy mice was also improved, though the mechanisms are unknown at this time.DISCUSSIONInterestingly, proteomic analysis indicated that GluOC downregulated MCAT expression MCAT is required for mitochondrial fatty-acid synthesis (FASII) and is implicated in insulin resistance and gestational diabetes mellitus [48] .", [["mitochondrial", "ANATOMY", 216, 229], ["Hypercholesterolemia", "DISEASE", 0, 20], ["fatty-acid", "CHEMICAL", 230, 240], ["gestational diabetes mellitus", "DISEASE", 303, 332], ["fatty-acid", "CHEMICAL", 230, 240], ["KKAy mice", "ORGANISM", 24, 33], ["GluOC", "GENE_OR_GENE_PRODUCT", 159, 164], ["MCAT", "GENE_OR_GENE_PRODUCT", 179, 183], ["MCAT", "GENE_OR_GENE_PRODUCT", 195, 199], ["mitochondrial", "CELLULAR_COMPONENT", 216, 229], ["fatty-acid", "SIMPLE_CHEMICAL", 230, 240], ["FASII", "SIMPLE_CHEMICAL", 252, 257], ["insulin", "GENE_OR_GENE_PRODUCT", 280, 287], ["GluOC", "PROTEIN", 159, 164], ["MCAT", "PROTEIN", 179, 183], ["MCAT", "PROTEIN", 195, 199], ["mice", "SPECIES", 29, 33], ["mice", "SPECIES", 29, 33], ["Hypercholesterolemia", "PROBLEM", 0, 20], ["proteomic analysis", "TEST", 125, 143], ["mitochondrial fatty-acid synthesis", "TREATMENT", 216, 250], ["gestational diabetes mellitus", "PROBLEM", 303, 332], ["improved", "OBSERVATION_MODIFIER", 43, 51], ["insulin resistance", "OBSERVATION", 280, 298]]], ["This protein is exclusively expressed in the mitochondrion, where the enzymatic function transfers a malonyl group from malonyl-CoA to mitochondrial acyl carrier protein [49] .", [["mitochondrion", "ANATOMY", 45, 58], ["mitochondrial", "ANATOMY", 135, 148], ["malonyl", "CHEMICAL", 101, 108], ["malonyl-CoA", "CHEMICAL", 120, 131], ["malonyl", "CHEMICAL", 101, 108], ["malonyl-CoA", "CHEMICAL", 120, 131], ["acyl", "CHEMICAL", 149, 153], ["mitochondrion", "CELLULAR_COMPONENT", 45, 58], ["malonyl", "SIMPLE_CHEMICAL", 101, 108], ["malonyl-CoA", "SIMPLE_CHEMICAL", 120, 131], ["mitochondrial", "CELLULAR_COMPONENT", 135, 148], ["mitochondrial acyl carrier protein", "PROTEIN", 135, 169], ["mitochondrial acyl carrier protein", "TEST", 135, 169]]], ["The LC-MS/ Fig. 7 GluOC treatment changes hepatic fatty-acid metabolic process in KKAy mice. a Comparison of the GO analysis of the proteins between the OC-treated mice and non-OC-treated KKAy mice.", [["hepatic", "ANATOMY", 42, 49], ["GluOC", "CHEMICAL", 18, 23], ["OC", "CHEMICAL", 153, 155], ["non-OC", "CHEMICAL", 173, 179], ["fatty-acid", "CHEMICAL", 50, 60], ["GluOC", "SIMPLE_CHEMICAL", 18, 23], ["hepatic fatty-acid", "SIMPLE_CHEMICAL", 42, 60], ["KKAy mice", "ORGANISM", 82, 91], ["OC", "SIMPLE_CHEMICAL", 153, 155], ["mice", "ORGANISM", 164, 168], ["non-OC", "SIMPLE_CHEMICAL", 173, 179], ["KKAy mice", "ORGANISM", 188, 197], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 164, 168], ["mice", "SPECIES", 193, 197], ["mice", "SPECIES", 87, 91], ["mice", "SPECIES", 193, 197], ["The LC", "TEST", 0, 6], ["MS/ Fig.", "TEST", 7, 15], ["GluOC treatment", "TREATMENT", 18, 33], ["hepatic fatty", "TEST", 42, 55], ["MS", "OBSERVATION", 7, 9], ["hepatic", "ANATOMY", 42, 49], ["fatty", "OBSERVATION", 50, 55]]], ["Comparison is summarized as the following three GO terms: Biological processes (BP), cellular compartments (CC), and molecular functions (MF); b Changes in the representative fatty-acid metabolic process-associated proteins (OC-L vs. KKAy); c Hepatic expression of MCAT by immunoblot.", [["cellular compartments", "ANATOMY", 85, 106], ["fatty-acid", "CHEMICAL", 175, 185], ["cellular", "CELL", 85, 93], ["OC-L", "GENE_OR_GENE_PRODUCT", 225, 229], ["MCAT", "GENE_OR_GENE_PRODUCT", 265, 269], ["associated proteins", "PROTEIN", 204, 223], ["OC", "PROTEIN", 225, 227], ["L", "PROTEIN", 228, 229], ["KKAy", "PROTEIN", 234, 238], ["MCAT", "PROTEIN", 265, 269], ["BP", "TEST", 80, 82], ["cellular compartments (CC)", "TEST", 85, 111], ["b Changes in the representative fatty-acid metabolic process", "PROBLEM", 143, 203], ["associated proteins", "PROBLEM", 204, 223], ["OC", "TEST", 225, 227], ["immunoblot", "TEST", 273, 283], ["Hepatic", "ANATOMY", 243, 250]]], ["Data are expressed as mean \u00b1 SD (n = 3-5). *P < 0.05, **P < 0.01 vs. KKAy MS analysis of mouse liver samples suggested that GluOC treatment significantly reduced MCAT expression, affecting the fatty-acid metabolic process (Fig. 7) and contributing to the decreased DNL and the ameliorated steatosis.", [["liver samples", "ANATOMY", 95, 108], ["GluOC", "CHEMICAL", 124, 129], ["steatosis", "DISEASE", 289, 298], ["GluOC", "CHEMICAL", 124, 129], ["fatty-acid", "CHEMICAL", 193, 203], ["mouse", "ORGANISM", 89, 94], ["liver samples", "CANCER", 95, 108], ["GluOC", "SIMPLE_CHEMICAL", 124, 129], ["MCAT", "GENE_OR_GENE_PRODUCT", 162, 166], ["DNL", "SIMPLE_CHEMICAL", 265, 268], ["MCAT", "PROTEIN", 162, 166], ["mouse", "SPECIES", 89, 94], ["mouse", "SPECIES", 89, 94], ["KKAy MS analysis", "TEST", 69, 85], ["mouse liver samples", "TEST", 89, 108], ["GluOC treatment", "TREATMENT", 124, 139], ["reduced MCAT expression", "PROBLEM", 154, 177], ["the fatty-acid metabolic process", "PROBLEM", 189, 221], ["the decreased DNL", "PROBLEM", 251, 268], ["the ameliorated steatosis", "PROBLEM", 273, 298], ["liver", "ANATOMY", 95, 100], ["decreased", "OBSERVATION_MODIFIER", 255, 264], ["DNL", "OBSERVATION", 265, 268], ["ameliorated", "OBSERVATION_MODIFIER", 277, 288], ["steatosis", "OBSERVATION", 289, 298]]], ["According to the literature and our experimental results, oral administration is safe, effective, and convenient.", [["oral", "ANATOMY", 58, 62], ["oral", "ORGANISM_SUBDIVISION", 58, 62], ["oral administration", "TREATMENT", 58, 77]]], ["Previous studies reported that oral osteocalcin could enter the circulation.", [["oral", "ANATOMY", 31, 35], ["oral", "ORGANISM_SUBDIVISION", 31, 35], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 36, 47], ["osteocalcin", "PROTEIN", 36, 47], ["Previous studies", "TEST", 0, 16], ["oral osteocalcin", "PROBLEM", 31, 47], ["osteocalcin", "OBSERVATION", 36, 47], ["circulation", "ANATOMY", 64, 75]]], ["Mizokami et al. [50] showed that oral administration of osteocalcin was as effective as the intraperitoneal route in increasing the serum concentration of insulin in mice.", [["oral", "ANATOMY", 33, 37], ["intraperitoneal", "ANATOMY", 92, 107], ["serum", "ANATOMY", 132, 137], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 56, 67], ["intraperitoneal", "IMMATERIAL_ANATOMICAL_ENTITY", 92, 107], ["serum", "ORGANISM_SUBSTANCE", 132, 137], ["insulin", "GENE_OR_GENE_PRODUCT", 155, 162], ["mice", "ORGANISM", 166, 170], ["osteocalcin", "PROTEIN", 56, 67], ["insulin", "PROTEIN", 155, 162], ["mice", "SPECIES", 166, 170], ["mice", "SPECIES", 166, 170], ["oral administration of osteocalcin", "TREATMENT", 33, 67], ["the intraperitoneal route", "TREATMENT", 88, 113], ["increasing the serum concentration of insulin", "TREATMENT", 117, 162]]], ["Another study [17] showed that 4 weeks of daily oral administration of osteocalcin (10 ng/g) significantly increased the serum OC.", [["oral", "ANATOMY", 48, 52], ["serum", "ANATOMY", 121, 126], ["osteocalcin", "CHEMICAL", 71, 82], ["OC", "CHEMICAL", 127, 129], ["oral", "ORGANISM_SUBDIVISION", 48, 52], ["osteocalcin", "GENE_OR_GENE_PRODUCT", 71, 82], ["serum", "ORGANISM_SUBSTANCE", 121, 126], ["OC", "SIMPLE_CHEMICAL", 127, 129], ["osteocalcin", "PROTEIN", 71, 82], ["Another study", "TEST", 0, 13], ["daily oral administration of osteocalcin", "TREATMENT", 42, 82], ["the serum OC", "TEST", 117, 129]]], ["In our study, the blood uncarboxylated OC levels were elevated after a 14-day OC administration (Fig. 1a) .", [["blood", "ANATOMY", 18, 23], ["OC", "CHEMICAL", 39, 41], ["OC", "CHEMICAL", 78, 80], ["blood", "ORGANISM_SUBSTANCE", 18, 23], ["OC", "SIMPLE_CHEMICAL", 39, 41], ["our study", "TEST", 3, 12], ["the blood uncarboxylated OC levels", "TEST", 14, 48], ["a 14-day OC administration", "TREATMENT", 69, 95]]], ["Some studies also suggested that oral administration of OC might exert metabolic regulation by stimulating the release of GLP-1 from the intestine.", [["oral", "ANATOMY", 33, 37], ["intestine", "ANATOMY", 137, 146], ["OC", "CHEMICAL", 56, 58], ["oral", "ORGANISM_SUBDIVISION", 33, 37], ["OC", "SIMPLE_CHEMICAL", 56, 58], ["GLP-1", "GENE_OR_GENE_PRODUCT", 122, 127], ["intestine", "ORGAN", 137, 146], ["GLP-1", "PROTEIN", 122, 127], ["Some studies", "TEST", 0, 12], ["oral administration of OC", "TREATMENT", 33, 58], ["intestine", "ANATOMY", 137, 146]]], ["However, no side effects of GLP-1 analogs were observed in this study, such as appetite suppression or body weight decrease (as shown in Fig. 3) .", [["body", "ANATOMY", 103, 107], ["GLP-1", "GENE_OR_GENE_PRODUCT", 28, 33], ["body", "ORGANISM_SUBDIVISION", 103, 107], ["GLP", "TEST", 28, 31], ["this study", "TEST", 59, 69], ["body weight decrease", "PROBLEM", 103, 123]]], ["Therefore, we speculate that GluOC may play a direct role in hepatic glucose and lipid metabolism by being absorbed into the blood circulation.", [["hepatic", "ANATOMY", 61, 68], ["blood", "ANATOMY", 125, 130], ["GluOC", "CHEMICAL", 29, 34], ["glucose", "CHEMICAL", 69, 76], ["glucose", "CHEMICAL", 69, 76], ["GluOC", "GENE_OR_GENE_PRODUCT", 29, 34], ["hepatic", "MULTI-TISSUE_STRUCTURE", 61, 68], ["glucose", "SIMPLE_CHEMICAL", 69, 76], ["lipid", "SIMPLE_CHEMICAL", 81, 86], ["blood", "ORGANISM_SUBSTANCE", 125, 130], ["GluOC", "PROTEIN", 29, 34], ["hepatic glucose", "TEST", 61, 76], ["hepatic", "ANATOMY", 61, 68], ["blood", "ANATOMY", 125, 130]]], ["The in-depth mechanism needs to be further studied.DISCUSSIONIn conclusion, this study provides preliminary but encouraging evidence that GluOC treatment improved hyperglycemia, hepatic steatosis, and dyslipidemia in KKAy mice and suggests that GluOC is a promising drug candidate for metabolic syndrome treatment.", [["hepatic", "ANATOMY", 178, 185], ["GluOC", "CHEMICAL", 138, 143], ["hyperglycemia", "DISEASE", 163, 176], ["hepatic steatosis", "DISEASE", 178, 195], ["dyslipidemia", "DISEASE", 201, 213], ["GluOC", "CHEMICAL", 245, 250], ["metabolic syndrome", "DISEASE", 285, 303], ["GluOC", "CHEMICAL", 138, 143], ["GluOC", "SIMPLE_CHEMICAL", 138, 143], ["hepatic", "ORGAN", 178, 185], ["KKAy mice", "ORGANISM", 217, 226], ["GluOC", "GENE_OR_GENE_PRODUCT", 245, 250], ["mice", "SPECIES", 222, 226], ["mice", "SPECIES", 222, 226], ["this study", "TEST", 76, 86], ["GluOC treatment", "TREATMENT", 138, 153], ["hyperglycemia", "PROBLEM", 163, 176], ["hepatic steatosis", "PROBLEM", 178, 195], ["dyslipidemia", "PROBLEM", 201, 213], ["GluOC", "PROBLEM", 245, 250], ["metabolic syndrome treatment", "TREATMENT", 285, 313], ["hyperglycemia", "OBSERVATION", 163, 176], ["hepatic", "ANATOMY", 178, 185], ["steatosis", "OBSERVATION", 186, 195], ["dyslipidemia", "OBSERVATION", 201, 213]]], ["The uncovered GluOC hypoglycemic mechanisms included enhancing the insulin signaling pathway, increasing hepatic Foxo1/GSK3\u03b2 phosphorylation and regulating hepatic glucose metabolism.", [["hepatic", "ANATOMY", 105, 112], ["hepatic", "ANATOMY", 156, 163], ["hypoglycemic", "DISEASE", 20, 32], ["glucose", "CHEMICAL", 164, 171], ["glucose", "CHEMICAL", 164, 171], ["GluOC", "SIMPLE_CHEMICAL", 14, 19], ["insulin", "GENE_OR_GENE_PRODUCT", 67, 74], ["hepatic", "MULTI-TISSUE_STRUCTURE", 105, 112], ["Foxo1", "GENE_OR_GENE_PRODUCT", 113, 118], ["GSK3\u03b2", "GENE_OR_GENE_PRODUCT", 119, 124], ["hepatic", "MULTI-TISSUE_STRUCTURE", 156, 163], ["glucose", "SIMPLE_CHEMICAL", 164, 171], ["hepatic Foxo1", "PROTEIN", 105, 118], ["GSK3\u03b2", "PROTEIN", 119, 124], ["The uncovered GluOC hypoglycemic mechanisms", "PROBLEM", 0, 43], ["enhancing the insulin signaling pathway", "TREATMENT", 53, 92], ["increasing hepatic Foxo1", "PROBLEM", 94, 118], ["GSK3\u03b2 phosphorylation", "TREATMENT", 119, 140], ["regulating hepatic glucose metabolism", "PROBLEM", 145, 182], ["hepatic", "ANATOMY", 105, 112], ["Foxo1", "OBSERVATION", 113, 118], ["hepatic", "ANATOMY", 156, 163], ["glucose metabolism", "OBSERVATION", 164, 182]]], ["The reduced blood insulin level and hepatic SREBP1c/ ACC/FAS and MCAT expression likely contributed to hepatic lipid reduction by inhibiting de novo lipogenesis, together with the elevated fatty-acid \u03b2-oxidation, as evidenced by the ameliorated hyperlipidemia in KKAy mice (Fig. 8) .", [["blood", "ANATOMY", 12, 17], ["hepatic", "ANATOMY", 36, 43], ["hepatic", "ANATOMY", 103, 110], ["fatty-acid", "CHEMICAL", 189, 199], ["hyperlipidemia", "DISEASE", 245, 259], ["fatty-acid", "CHEMICAL", 189, 199], ["blood", "ORGANISM_SUBSTANCE", 12, 17], ["insulin", "GENE_OR_GENE_PRODUCT", 18, 25], ["hepatic", "ORGAN", 36, 43], ["SREBP1c", "GENE_OR_GENE_PRODUCT", 44, 51], ["ACC", "GENE_OR_GENE_PRODUCT", 53, 56], ["FAS", "GENE_OR_GENE_PRODUCT", 57, 60], ["MCAT", "GENE_OR_GENE_PRODUCT", 65, 69], ["hepatic", "ORGAN", 103, 110], ["lipid", "SIMPLE_CHEMICAL", 111, 116], ["fatty-acid", "SIMPLE_CHEMICAL", 189, 199], ["KKAy mice", "ORGANISM", 263, 272], ["hepatic SREBP1c", "PROTEIN", 36, 51], ["ACC", "PROTEIN", 53, 56], ["FAS", "PROTEIN", 57, 60], ["MCAT", "PROTEIN", 65, 69], ["mice", "SPECIES", 268, 272], ["mice", "SPECIES", 268, 272], ["The reduced blood insulin level", "TEST", 0, 31], ["hepatic SREBP1c", "TEST", 36, 51], ["ACC/FAS", "TEST", 53, 60], ["MCAT expression", "TEST", 65, 80], ["hepatic lipid reduction", "TREATMENT", 103, 126], ["novo lipogenesis", "PROBLEM", 144, 160], ["the elevated fatty-acid \u03b2-oxidation", "PROBLEM", 176, 211], ["the ameliorated hyperlipidemia", "PROBLEM", 229, 259], ["hepatic", "ANATOMY", 36, 43], ["hepatic", "ANATOMY", 103, 110], ["lipid reduction", "OBSERVATION", 111, 126], ["novo lipogenesis", "OBSERVATION", 144, 160], ["ameliorated", "OBSERVATION_MODIFIER", 233, 244], ["hyperlipidemia", "OBSERVATION", 245, 259]]]], "PMC7302789": [["IntroductionThe Pamoja Tulinde Maisha (Swahili for together save lives; PALM) study1 was a randomised, controlled trial (RCT) of three investigational agents (mAb114,2, 3 REGN-EB3,4, 5 and remdesivir6) compared with a control group that included ZMapp7 for the treatment of patients with Ebola virus disease, caused by Ebola virus (Filoviridae: Ebolavirus).8 This trial was part of the emergency response to the ongoing Ebola virus disease outbreak in the Democratic Republic of the Congo (DR Congo) that started in August, 2018,9 and has included at least 3463 cases and 2280 deaths (as of May 28, 2020).10 The overall outbreak case fatality rate (CFR; number of deaths per number of infected patients) has steadily approximated 66%, although this number has consistently included large numbers of community deaths\u2014ie, patients with Ebola virus disease who never arrived at the treatment centres.IntroductionOn Aug 12, 2019, a year after the outbreak was initially declared, the Institut National de la Recherche Biom\u00e9dicale (DR Congo), WHO, and the US National Institutes of Health announced that an independent data and safety monitoring board reviewed interim data from the PALM study and recommended early termination of the trial on the basis of observed survival benefit in patients treated with either of the investigational agents mAb114 or REGN-EB3.", [["mAb114,2, 3 REGN-EB3,4, 5 and remdesivir6", "CHEMICAL", 159, 200], ["ZMapp7", "CHEMICAL", 246, 252], ["Ebola virus disease", "DISEASE", 288, 307], ["Ebola virus", "DISEASE", 319, 330], ["Ebola virus disease", "DISEASE", 420, 439], ["deaths", "DISEASE", 577, 583], ["deaths", "DISEASE", 664, 670], ["Ebola virus disease", "DISEASE", 834, 853], ["REGN-EB3", "CHEMICAL", 1350, 1358], ["3 REGN-EB3", "SIMPLE_CHEMICAL", 169, 179], ["5", "ORGANISM", 183, 184], ["remdesivir6", "SIMPLE_CHEMICAL", 189, 200], ["ZMapp7", "SIMPLE_CHEMICAL", 246, 252], ["patients", "ORGANISM", 274, 282], ["Ebola virus", "ORGANISM", 288, 299], ["Ebola virus", "ORGANISM", 319, 330], ["Ebola virus", "ORGANISM", 420, 431], ["patients", "ORGANISM", 694, 702], ["patients", "ORGANISM", 820, 828], ["Ebola virus", "ORGANISM", 834, 845], ["patients", "ORGANISM", 1281, 1289], ["REGN-EB3", "SIMPLE_CHEMICAL", 1350, 1358], ["patients", "SPECIES", 274, 282], ["Ebola virus", "SPECIES", 288, 299], ["Ebola virus", "SPECIES", 319, 330], ["Ebola virus", "SPECIES", 420, 431], ["patients", "SPECIES", 694, 702], ["patients", "SPECIES", 820, 828], ["Ebola virus", "SPECIES", 834, 845], ["patients", "SPECIES", 1281, 1289], ["Ebola virus", "SPECIES", 288, 299], ["Ebola virus", "SPECIES", 319, 330], ["Ebola virus", "SPECIES", 420, 431], ["Ebola virus", "SPECIES", 834, 845], ["a randomised, controlled trial (RCT)", "TREATMENT", 89, 125], ["three investigational agents", "TREATMENT", 129, 157], ["remdesivir6", "TREATMENT", 189, 200], ["ZMapp7", "TREATMENT", 246, 252], ["the treatment", "TREATMENT", 257, 270], ["Ebola virus disease", "PROBLEM", 288, 307], ["Ebola virus", "PROBLEM", 319, 330], ["the ongoing Ebola virus disease", "PROBLEM", 408, 439], ["Ebola virus disease", "PROBLEM", 834, 853], ["the PALM study", "TEST", 1174, 1188], ["the investigational agents", "TREATMENT", 1313, 1339], ["Ebola virus", "OBSERVATION", 288, 299], ["Ebola virus", "OBSERVATION", 420, 431], ["overall", "OBSERVATION_MODIFIER", 612, 619], ["outbreak", "OBSERVATION_MODIFIER", 620, 628], ["large", "OBSERVATION_MODIFIER", 782, 787], ["numbers", "OBSERVATION_MODIFIER", 788, 795], ["Ebola virus", "OBSERVATION", 834, 845]]], ["The Board further recommended that all future patients with Ebola virus disease at the study sites should be randomised in an extension phase to receive either mAb114 or REGN-EB3, while terminating the remdesivir experimental and ZMapp control groups.11 The PALM study results, published in 2019, support a statistically significant survival benefit in patients treated with mAb114 or REGN-EB3, with the greatest benefit seen in patients receiving early therapy or those with higher Ebola virus RT-PCR nucleoprotein gene (NP) cycle threshold (CT) values (an inverse proxy for higher Ebola virus load) at admission.1", [["Ebola virus disease", "DISEASE", 60, 79], ["REGN-EB3", "CHEMICAL", 170, 178], ["REGN-EB3", "CHEMICAL", 385, 393], ["patients", "ORGANISM", 46, 54], ["Ebola virus", "ORGANISM", 60, 71], ["REGN-EB3", "SIMPLE_CHEMICAL", 170, 178], ["patients", "ORGANISM", 353, 361], ["REGN-EB3", "GENE_OR_GENE_PRODUCT", 385, 393], ["patients", "ORGANISM", 429, 437], ["Ebola virus", "ORGANISM", 483, 494], ["Ebola virus", "ORGANISM", 583, 594], ["PCR nucleoprotein gene", "DNA", 498, 520], ["patients", "SPECIES", 46, 54], ["Ebola virus", "SPECIES", 60, 71], ["patients", "SPECIES", 353, 361], ["patients", "SPECIES", 429, 437], ["Ebola virus", "SPECIES", 483, 494], ["Ebola virus", "SPECIES", 60, 71], ["Ebola virus", "SPECIES", 483, 494], ["Ebola virus", "SPECIES", 583, 594], ["Ebola virus disease", "PROBLEM", 60, 79], ["the study sites", "TEST", 83, 98], ["ZMapp control groups", "TREATMENT", 230, 250], ["The PALM study", "TEST", 254, 268], ["early therapy", "TREATMENT", 448, 461], ["higher Ebola virus RT", "TREATMENT", 476, 497], ["PCR nucleoprotein gene (NP) cycle threshold", "TREATMENT", 498, 541], ["CT) values", "TEST", 543, 553], ["higher Ebola virus load", "TREATMENT", 576, 599]]]], "PMC7121829": [["Von der akuten Entz\u00fcndung zur Restitution ad integrumAkute entz\u00fcndliche Reaktionen bzw. der akute Infekt mit Restitutio ad integrum laufen in einer perfekt modulierten Kaskade ab, bei der eine akute inflammatorische Einleitungsphase von einer antiinflammatorischen Phase und einer Entz\u00fcndungsaufl\u00f6sungsphase abgel\u00f6st wird.Von der akuten Entz\u00fcndung zur Restitution ad integrumDamit ein inflammatorischer Prozess keinen gro\u00dfen Schaden hinterl\u00e4sst, sollte dieser selbstlimitierend sein.", [["Von der akuten Entz\u00fcndung zur Restitution ad integrumAkute entz\u00fcndliche Reaktionen bzw", "SPECIES", 0, 86], ["Phase", "TEST", 265, 270]]], ["Diese Selbstregulation ist kein passiver Prozess, wie man fr\u00fcher immer dachte, sondern erfordert die Aktivierung von antiinflammatorischen Mechanismen, wie Hemmung der proinflammatorischen Kaskaden, Sekretion von antiinflammatorischer Mediatoren und Aktivierung von Treg-Zellen.", [["man", "SPECIES", 54, 57], ["Diese Selbstregulation ist kein passiver Prozess, wie man fr\u00fcher immer dachte, sondern erfordert die Aktivierung von antiinflammatorischen Mechanismen, wie Hemmung der proinflammatorischen Kaskaden, Sekretion von antiinflammatorischer Mediatoren und Aktivierung von Treg-Zellen", "SPECIES", 0, 277]]], ["All diese Prozesse werden durch das komplexe Zusammenspiel und Regulationspotenzial der verschiedenen Lipidmediatoren gesteuert.Von der akuten Entz\u00fcndung zur Restitution ad integrumRezente Forschungsergebnisse legen offen, wie komplex sich die Lipidmediatoren-Biosynthese und die Signalgebung auf zellul\u00e4rer und multizellul\u00e4rer Gewebsebene darstellen und dass eine Vielzahl von Lipidmediatoren gro\u00dfe Bedeutung bei der Erhaltung der Hom\u00f6ostase haben.Von der akuten Entz\u00fcndung zur Restitution ad integrumIn der initialen proinflammatorischen Phase werden klassische Eicosanoide wie Prostaglandine und Leukotriene mittels COX und LOX aus Arachidons\u00e4ure gebildet, die zun\u00e4chst Leukozyten aus dem Blut zum Ort der Entz\u00fcndung locken.", [["Von der akuten Entz\u00fcndung zur Restitution ad integrumRezente Forschungsergebnisse legen offen, wie komplex sich die Lipidmediatoren-Biosynthese und die Signalgebung auf zellul\u00e4rer und multizellul\u00e4rer Gewebsebene darstellen und dass eine Vielzahl von Lipidmediatoren gro\u00dfe Bedeutung bei der Erhaltung der Hom\u00f6ostase haben", "SPECIES", 128, 448], ["Von der akuten Entz\u00fcndung zur Restitution ad integrumIn der initialen proinflammatorischen", "SPECIES", 449, 539], ["Phase werden klassische Eicosanoide wie Prostaglandine und Leukotriene mittels COX und LOX aus Arachidons\u00e4ure gebildet, die zun\u00e4chst Leukozyten aus dem Blut zum Ort der Entz\u00fcndung locken", "SPECIES", 540, 726], ["Lipidmediatoren", "TREATMENT", 244, 259], ["Phase werden klassische Eicosanoide", "TREATMENT", 540, 575], ["Prostaglandine und Leukotriene mittels COX und LOX aus Arachidons\u00e4ure gebildet", "TREATMENT", 580, 658]]], ["\u00dcber PGD2, PGE2 und PGI2 werden die Venolen erweitert und Cys-LT sowie LT B4 erh\u00f6hen die Durchblutung und die Gef\u00e4\u00dfpermeabilit\u00e4t.", [["PGD2", "CHEMICAL", 5, 9], ["PGE2", "CHEMICAL", 11, 15], ["PGI2", "CHEMICAL", 20, 24], ["PGE2", "CHEMICAL", 11, 15], ["PGI2", "CHEMICAL", 20, 24], ["PGE2 und PGI2", "TREATMENT", 11, 24], ["LT", "ANATOMY", 62, 64]]], ["Wie Bienen schw\u00e4rmen daraufhin Neutrophile, aber auch Basophile, Eosinophile, Makrophagen und Mastzellen aus den postkapill\u00e4ren Venolen an den Ort des entz\u00fcndlichen Geschehens, um den Wirt zu verteidigen.", [["Makrophagen und Mastzellen aus den postkapill\u00e4ren Venolen an den Ort des entz\u00fcndlichen Geschehens, um den Wirt zu verteidigen", "SPECIES", 78, 203], ["Eosinophile", "TREATMENT", 65, 76], ["Makrophagen", "TREATMENT", 78, 89]]], ["Gemeinsam mit Zytokinen und dem Komplementsystem (C5a, C3b) werden chemotaktisch noch mehr Leukozyten und Makrophagen angezogen, die die eingedrungenen Pathogene phagozytieren und neutralisieren (Serhan et al. 2015) (s. \u25d8 Abb.", [["C5a", "TEST", 50, 53], ["C3b)", "TREATMENT", 55, 59], ["chemotaktisch", "TEST", 67, 80], ["Leukozyten und Makrophagen angezogen", "TREATMENT", 91, 127], ["Pathogene phagozytieren", "TREATMENT", 152, 175]]]]}